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clinical/genetics  knowledge to promote and achieve optimal health in fetal medicine. 




orphology Scan and Invasive M
ethods
PRENATAL DIAGNOSIS – 
MORPHOLOGY SCAN AND 
INVASIVE METHODS 
 
Edited by Richard Kwong Wai Choy and  
Tak Yeung Leung 
 
  
PRENATAL DIAGNOSIS – 
MORPHOLOGY SCAN AND 
INVASIVE METHODS 
 
Edited by Richard Kwong Wai Choy and  
Tak Yeung Leung 
 
  
Prenatal Diagnosis - Morphology Scan and Invasive Methods
http://dx.doi.org/10.5772/1283
Edited by Richard Kwong Wai Choy and Tak Yeung Leung
Contributors
Inés Velasco, Federico Soriguer, Pere Berbel, Tuba Gunel, Hayri Ermis, Kılıc Aydınlı, Maria Luis Cardoso, Mafalda 
Barbosa, Ana Maria Fortuna, Franklim Marques, Shangzhi Huang, Atsushi Watanabe, Anastasia Konstantinidou, 
Hande Yagmur, Sonja Pop-Trajkovic, Funda Gungor Ugurlucan, Atil Yuksel, Hulya Kayserili, Sebastián Illanes, Javier 
Caradeux, Israel Goldstein
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Prenatal Diagnosis - Morphology Scan and Invasive Methods
Edited by Richard Kwong Wai Choy and Tak Yeung Leung
p. cm.
ISBN 978-953-51-0614-2
eBook (PDF) ISBN 978-953-51-6997-0
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr Richard K. W. Choy obtained his BSc degree in Bio-
medical Sciences from the University of Bradford and 
M(Med)Sc in Immunology at University of Birmingham, 
UK. He received postgraduate training in research and 
was awarded Doctor of Philosophy by The Chinese Uni-
versity of Hong Kong in 1999. Dr Choy’s main research 
interests include the development of novel molecular 
diagnostic strategies and innovative applications of molecular analysis 
tools in prenatal diagnosis. His current research focuses on the develop-
ment of the microarray based Comparative Genomic Hybridization (array 
CGH) and massive parallel sequencing for prenatal diagnosis. In terms of 
professional service, Dr Choy is an Honorary Scientific Officer (medical) 
at the New Territories East Cluster of Hospitals, Hong Kong, where he is 
involved in the delivery of the laboratory diagnostic service. He is also the 
board member of the Hong Kong Society of Medical Genetics since 2009.
Tak Yeung Leung is Professor in the Maternal Fetal 
Medicine unit in the Department of Obstetrics and 
Gynaecology of The Chinese University of Hong Kong. 
His special interest is in perinatal medicine, prenatal 
screening and diagnosis of fetal abnormalities, with 
advanced genetic and ultrasound technology, includ-
ing the non-invasive prenatal diagnosis using maternal 
cell-free fetal DNA and array comparative genomic hybirdisation. He has 
published more than 150 papers in international peer reviewed journals. 
He is also invited into the editorial board of international journals su-
chas American Journal of Perinatology and Pediatric Research (Fetus & 
Pregnancy Section). Besides, Professor Leung has strong international 
and Asian-Pacific connection with appointments in several international 
professional bodies including: Chairman of the Prenatal Maternal Screen-
ing Special Interest Group of International Society for Prenatal Diagnosis, 
Foundation Broad member of Global Obstetric Network (GONet), Foun-
dation Secretary of The Chinese Fetal Medicine Foundation. He is also the 
Vice-president of Obstetrical and Gynaecolgical Society of Hong Kong, 
and co-opt council member of Hong Kong College of Obstetricians and 
Gynaecologists. Professor Leung is enthusiastic in teaching and training 
and is the organizer as well as trainer in many traning courses such as first 











Chapter 1 Invasive Prenatal Diagnosis 1 
Sonja Pop-Trajković, Vladimir Antić and Vesna Kopitović 
Chapter 2 Prenatal Diagnosis of Severe Perinatal (Lethal) 
Hypophosphatasia 27 
Atsushi Watanabe, Hideo Orimo,  
Toshiyuki Takeshita and Takashi Shimada 
Chapter 3 Skeletal Dysplasias of the Human Fetus:  
Postmortem Diagnosis 33 
Anastasia Konstantinidou 
Chapter 4 Prenatal Sonographic Diagnosis and Evaluation of  
Isolated Macrodactyly 59 
Hande Yağmur, Atıl Yüksel and Hülya Kayserili 
Chapter 5 Prenatal Evaluation of Fetuses Presenting with  
Short Femurs 71 
Funda Gungor Ugurlucan, Hülya Kayserili and Atil Yuksel 
Chapter 6 Normal and Abnormal Fetal Face 85 
Israel Goldstein and Zeev Wiener 
Chapter 7 Current Issues Regarding Prenatal Diagnosis of  
Inborn Errors of Cholesterol Biosynthesis 111 
Maria Luís Cardoso, Mafalda Barbosa,  
Ana Maria Fortuna and Franklim Marques 
Chapter 8 Understanding Prenatal Iodine Deficiency 137 
Inés Velasco, Federico Soriguer and P. Pere Berbel 
Chapter 9 Real-Time Quantitative PCR for  
Detection Cell Free Fetal DNA 163 
Tuba Gunel, Hayri Ermis and Kilic Aydinli 
Contents 
Preface XI 
Chapter 1 Invasive Prenatal Diagnosis 1 
Sonja Pop-Trajković, Vladimir Antić and Vesna Kopitović 
Chapter 2 Prenatal Diagnosis of Severe Perinatal (Lethal) 
Hypophosphatasia 27 
Atsushi Watanabe, Hideo Orimo,  
Toshiyuki Takeshita and Takashi Shimada 
Chapter 3 Skeletal Dysplasias of the Human Fetus: 
Postmortem Diagnosis 33 
Anastasia Konstantinidou 
Chapter 4 Prenatal Sonographic Diagnosis and Evaluation of 
Isolated Macrodactyly 59 
Hande Yağmur, Atıl Yüksel and Hülya Kayserili 
Chapter 5 Prenatal Evaluation of Fetuses Presenting with 
Short Femurs 71 
Funda Gungor Ugurlucan, Hülya Kayserili and Atil Yuksel 
Chapter 6 Normal and Abnormal Fetal Face 85 
Israel Goldstein and Zeev Wiener 
Chapter 7 Current Issues Regarding Prenatal Diagnosis of 
Inborn Errors of Cholesterol Biosynthesis 111 
Maria Luís Cardoso, Mafalda Barbosa,  
Ana Maria Fortuna and Franklim Marques 
Chapter 8 Understanding Prenatal Iodine Deficiency 137 
Inés Velasco, Federico Soriguer and P. Pere Berbel 
Chapter 9 Real-Time Quantitative PCR for 
Detection Cell Free Fetal DNA 163 
Tuba Gunel, Hayri Ermis and Kilic Aydinli 
X Contents
Chapter 10 The Experiences of Prenatal Diagnosis in China 171 
Shangzhi Huang 
Chapter 11 Fetal Therapy: Where Do We Stand 193 









As new technological innovations arise, clinical medicine must also adapt and 
assimilate these advances into clinical practice. Prenatal diagnosis is no exception. 
When amniocentesis was introduced into practice, study of the unbanded 
chromosomes was the standard. With the introduction of G-banded analysis, 
duplications, deletions, and gross chromosomal translocations were detectable. By 
comparing the phenotypic to the genotypic findings, most of the detected 
chromosomal aberrations were quickly found to be clinically relevant. Integrating this 
new information into patient care and counseling required years of data gathering and 
analysis. As clinical and molecular technologies continued to evolve, similar questions 
concerning the appropriate clinical use of these technologies in prenatal diagnosis 
have also arisen. 
Prenatal Diagnosis: Morphology Scan and Invasive Methods brings together distinguished 
contributors with extensive experience in the fetal ultrasound and prenatal diagnosis 
fields. Emphasis has been paid to the inclusion of molecular and sonographic 
techniques used in fetal medicine that are relevant to obstetricians and scientists 
performing prenatal diagnosis. These include how to diagnose iodine deficiency, 
skeletal dysplasisa; methods for molecular diagnosis of fetal diseases and treatment by 
fetal therapy. We hope that this book will be an invaluable reference for obstetricians 
and scientists in the process of prenatal diagnosis. 
 
Richard Kwong Wai Choy and Tak Yeung Leung 
The Chinese University of Hong Kong, 
Prince of Wales Hospital, 
Hong Kong, China 
1 
Invasive Prenatal Diagnosis 
Sonja Pop-Trajković1, Vladimir Antić1 and Vesna Kopitović2 
1Clinic for Gynecology and Obstetrics, Clinical center of Niš 
2Clinic for Gynecology and Obstetrics, Clinical Center of Vojvodina 
Serbia 
1. Introduction 
Prenatal diagnosis, traditionally used as a synonymous for invasive fetal testing and 
evaluation of chromosomal constellation, presently encompasses many other issues like 
pedigree analyses, fetal risk assessment, population screening, genetic counseling and fetal 
diagnostic testing as well. Ultrasound guided chorionic villus samling (CVS), amniocentesis 
and, to a lesser extent, fetal blood sampling are used routinely in fetal medicine units. Other 
fetal tissue biopsies such as skin, liver and muscle biopsy are used only rarely. In this 
chapter we discuss the invasive diagnostic procedures in maternal fetal medicine with 
specific interest of showing the list of indications basic principles used for choosing the 
particular invasive technique, linkage of non invasive with invasive diagnostic procedures, 
precise description of techniques, list of complications and their prevention and 
management, all of these based on the recent scientific results and clinical experiences 
publicized in the available literature.  
2. Chorionic villus sampling 
The ability to sample and analyse  villus tissue was demonstrated in China, in 1975 
(Department of Obstetrics and Gynecology THoAIaSCA, 1975). Trying to develop a technique 
for fetal sex determination, Chinese inserted a thin catheter into the uterus guided only by the 
tactile sensation and small pieces of villi were aspirated. By today’s standards of ultrasonically 
guided invasive procedures this approach seems crude, but their diagnostic accuracy and low 
miscarriage rate demonstrated the feasibility of first-trimester sampling. Major advancements 
have occurred since that time in instrumentation, techniques for direct kariotyping, faster 
culturing of cells and in the molecular and biochemical assay of chorionic villi. Today in 
experienced centers, chorionic villus sampling (CVS) as a method of obtaining chorionic villi 
using transcervical or transabdominal approach, can be utilized as a primary prenatal 
diagnostic tool. Although CVS has the advantage of being carried out very early in pregnancy 
to the widespread amniocentesis, due to, more likely, the more technically demanding aspects 
of sampling, CVS has still not replaced amniocentesis in many centers. 
2.1 Timing and technique 
CVS is usually performed between 10 and 12 weeks of pregnancy. The risk and severity of 
limb deficiency appear to be associated with the timing of CVS: the risk before the end of 10 
1 
Invasive Prenatal Diagnosis 
Sonja Pop-Trajković1, Vladimir Antić1 and Vesna Kopitović2 
1Clinic for Gynecology and Obstetrics, Clinical center of Niš 
2Clinic for Gynecology and Obstetrics, Clinical Center of Vojvodina 
Serbia 
1. Introduction 
Prenatal diagnosis, traditionally used as a synonymous for invasive fetal testing and 
evaluation of chromosomal constellation, presently encompasses many other issues like 
pedigree analyses, fetal risk assessment, population screening, genetic counseling and fetal 
diagnostic testing as well. Ultrasound guided chorionic villus samling (CVS), amniocentesis 
and, to a lesser extent, fetal blood sampling are used routinely in fetal medicine units. Other 
fetal tissue biopsies such as skin, liver and muscle biopsy are used only rarely. In this 
chapter we discuss the invasive diagnostic procedures in maternal fetal medicine with 
specific interest of showing the list of indications basic principles used for choosing the 
particular invasive technique, linkage of non invasive with invasive diagnostic procedures, 
precise description of techniques, list of complications and their prevention and 
management, all of these based on the recent scientific results and clinical experiences 
publicized in the available literature.  
2. Chorionic villus sampling 
The ability to sample and analyse  villus tissue was demonstrated in China, in 1975 
(Department of Obstetrics and Gynecology THoAIaSCA, 1975). Trying to develop a technique 
for fetal sex determination, Chinese inserted a thin catheter into the uterus guided only by the 
tactile sensation and small pieces of villi were aspirated. By today’s standards of ultrasonically 
guided invasive procedures this approach seems crude, but their diagnostic accuracy and low 
miscarriage rate demonstrated the feasibility of first-trimester sampling. Major advancements 
have occurred since that time in instrumentation, techniques for direct kariotyping, faster 
culturing of cells and in the molecular and biochemical assay of chorionic villi. Today in 
experienced centers, chorionic villus sampling (CVS) as a method of obtaining chorionic villi 
using transcervical or transabdominal approach, can be utilized as a primary prenatal 
diagnostic tool. Although CVS has the advantage of being carried out very early in pregnancy 
to the widespread amniocentesis, due to, more likely, the more technically demanding aspects 
of sampling, CVS has still not replaced amniocentesis in many centers. 
2.1 Timing and technique 
CVS is usually performed between 10 and 12 weeks of pregnancy. The risk and severity of 
limb deficiency appear to be associated with the timing of CVS: the risk before the end of 10 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
2 
weeks  gestation  is higher than the risk from CVS done before that time. The upper limit for 
transcervical sampling has been suggested to be 12–13 weeks. Indeed, by the end of the first 
trimester, the gestational sac becomes attached to the decidual wall. Thereafter, any attempt 
to insert either a catheter or a biopsy forceps entails a higher risk of indenting and damaging 
the membranes .There are two paths for approaching placenta: through the maternal 
abdomen using a needle or through  the cervical canal by catheter or biopsy forceps. For 
transcervical  CVS, after ultrasound examination and determination of placental location, 
position of uterus and cervix is determined and a catheter path is mapped. (Vaughan & 
Rodeck,2001). The distal 3 to 5 cm of the sampling catheter is molded into a slightly curved 
shape and the catheter gently passed under ultrasound guidance through the cervix to the 
distal edge of the placenta under the ulatrasound visualization. The stylet is removed and a 
syringe with nutrient medium is attached. After obtaining negative pressure by a syringe 
the catheter is gently removed. In most cases chorionic villi are seen with naked eye in the 
syring (Dadelszen et al.,2005). For transabdominal approach the skin surface is treated with 
antiseptic solution. Trajectory of the needle should be chosen as much as parallel to the long 
axis of the trophoblast. The 20-gauge needle is inserted into chorionic villi (single needle 
technique). In some centers double needle technique is used. With this technique, 18-gauge 
needle is inserted into chorionic villi and the stylet is removed, then a smaller, 20-gauge 
needle with the aspirating syringe is inserted through this needle. Therefore if the sample is 
not adequate, sampling procedure with this smaller needle through 18-gauge needle can be 
repeated as necessary. Each technique (single or double needle) can be either free-hand or 
with needle-guide (alfirevic et al.,2003). 
2.2 Counseling before CVS 
Individualized counseling, by the obstetrician or an expert in genetics should always 
precede the procedure and support the couple in coming to a decision. Adequate time and 
personnel should be available to conduct a high-quality informed consent process in order 
to enhance the woman’s decision making about prenatal testing. Counseling patients before 
CVS  should emphasize some issues. First, the indication for invasive diagnosis in general 
and for CVS in particular. CVS is recommended for patients with very high risk of single 
gene disorder or chromosomal translocations in offspring. Although CVS should be also 
available to lower risk patients who wish karyotyping, the amniocentesis as an alternative 
should be offered. Second, specific data should be given to parents about failure, false-
negative and false-positive results of the procedure and the need of amniocentesis in cases 
with confined placental mosaicism which occurs in approximately 1-2%. At the end, the 
risks of CVS should be discussed, especially the risk of fetal loss. The risk of other 
complications is low and should not be discussed routinely, unless the patient asks. Written 
material about CVS might also be given to the couple. It is good clinical practice to obtain 
formal written consent for CVS before the procedure and it is mandatory in most centers. 
2.3 Indications 
Prenatal diagnosis in the first trimester has advantages over midtrimester diagnosis for a 
number of reasons. The first one is the advantage of an earlier procedure which brings relief 
to the patient when the results are normal and on the other hand allows an easier and more 
private pregnancy termination when necessary. Earliest time for having the chromosome 
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results is the 14th week with CVS and the 19th week with amniocentesis. First trimester 
abortion is followed by significantly lower rate of clinical complications. Speaking of 
emotional effect on patient, it is less stressful than labor induction and delivery at about 20 
weeks. Also, by that time maternal-fetal bonding is not clearly established and the 
pregnancy is generally not visible to the environment. Additionally, early diagnosis is 
essential when there is a need for in utero gene or stem cell therapy for the correction a 
genetic defect. The earliest applications of CVS were fetal sex determination and prenatal 
diagnosis of hemoglobinonopathies by DNA analysis ( Monni et al.,1993) Since then, 
advances in cytogenetic and DNA analysis techniques have remarkably expanded the 
number and types of genetic conditions detectable in the prenatal period. Currently, CVS is 
primarily indicated for chromosomal studies, DNA analysis of genetic disorders and 
prenatal diagnosis of inborn errors of metabolism. For chromosomal studies, the main 
indications for CVS are: maternal age over 35 years, previous pregnancy with a 
chromosomal abnormality or multiple anomalies, parents with proved chromosome 
translocations, inversions and aneuploidies, X-linked diseases, history of recurrent 
miscarriage, abnormal ultrasound scan and decrease or the absence of amniotic fluid  in the 
first trimester. The development of first-trimester screening methods for the detection of 
fetal chromosomal anomalies has increased the demand for CVS. In fact, although maternal-
related risk for fetal aneuploidy remains a common indication for CVS, the indication for 
CVS has evolved to become one of quick confirmation of an abnormal karyotype  whenever 
chromosomal abnormality is suspected based on ultrasound scan or biochemical screening 
in the first trimester. Less common indications for fetal karyotyping are multiple 
miscarriages and pregnancies after assisted reproductive techniques. First trimester 
ultrasound screening for Down syndrome can occasionally bring to light a number of fetal 
abnormalities. Holoprosencephaly, omphalocele, cystic hygroma, diaphragmatic hernia and 
megacystis are well known features of either aneuploidies or other genetic syndromes. 
When they are detected in the first trimester, CVS is indicated for fetal karyotyping or 
molecular studies. DNA-based diagnoses of single-gene disorders, such as cystic fibrosis, 
hemophilia, muscular dystrophy and hemoglobinopathies, continue to expand with 
advancing technologies and the discovery of the additional disease-causing  genes. Single 
gene disorders, which affect about 1% of livebirths, carry a high risk of recurrence and have 
unsatisfactory treatment so that prenatal diagnosis with termination of affected pregnancies 
is an important option for at-risk couples. Prenatal diagnosis of genetic disorders is based on 
the carrier detection procedures and genetic counseling of the couples at risk. Inborn errors 
of metabolism represent a vast group of disorders that are individually rare but together are 
a significant cause of human disease. Chorionic villi provide large amounts of metabolically 
active cytoplasm, therefore for many inherited metabolic diseases direct assay is possible, 
yielding diagnostic results within hours or a few days. Moreover, the amount of DNA 
obtained from a conventional sampling allows reliable analysis by recombinant DNA 
technologies. This is not the case with amniotic fluid cells, which provide too little DNA, 
which is frequently fragmented. Majority of these disease are very rare and new detection 
methods for specific disorders are constantly being reported so it is advisable to check with 
a specialists referral center on the current availability and preferred method for prenatal 
diagnosis. Some congenital infections such as rubella, toxoplasmosis, cytomegalovirus and 
parvovirus can also be detected by CVS. 
CVS in multiple pregnancies require more experience, ability and an accurate planning of 
the procedure. The procedure is not complicated in cases with clearly separated placentas 
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but it becomes a challenge in cases of fused or joined placentas, because in contrast to 
amniocentesis when one amniotic cavity can be marked with a dye, with CVS there is no 
technique to ensure that each sample has been obtained from a distinct placenta. To be sure 
to sample all fetuses one by one, and to reduce the risk of contamination, separate forceps 
and needles are inserted in succession and different samples are collected in close proximity 
to each cord insertion. A high level of expertise in technique of CVS is crucial. However, 
CVS can generally offer several technical advantages over midtrimester amniocentesis 
(Antsaklis et al.,2002). The easy evaluation of the membranes by ultrasound  makes both the 
prediction of chorionicity and amnionicity and the identification of the affected twin(s) more 
reliable, the use of rapid analytical methods makes substantial changes in the uterine 
topography very unlikely, and if same-sex dichorionic twins are diagnosed, DNA 
polymorphism markers may be easily checked to assure retrieval of villi from the individual 
placentas. In the hands of experienced operators, CVS has the same efficacy as mid-trimester 
amniocentesis for genetic diagnosis of multiple gestations: diagnostic error, probably due to 
incorrect sampling, is between 0,3% and 1,5%. Speaking of safety, carried out by expert 
physician, CVS appears at least as safe as amniocentesis (Brambati et al.,2001). Postprocedural 
loss rate after CVS in multiple pregnancies is somewhat higher than in singleton pregnancies 
but comparable to midtrimester amniocentesis. In cases where selective reduction is indicated 
the advantages of the first-trimester approach include a significantly lower emotional impact 
and a lower risk of clinical complications (Brambati et al.,2004) 
2.4 Laboratory considerations for chorionic villus sampling 
In the early development of CVS  there was a high rate of incorrect results due to maternal 
cell contamination and misinterpretation due to placental mosaicism. In the early 1990s the 
laboratory failure rate was 2,3%, which was significantly higher compared to amniocentesis. 
Nowadays CVS is considered to be a reliable method of prenatal diagnosis with a high rate 
of sucess and accuracy. Most centers report near 99% CVS sucess rate with only 1 % of the 
patients requiring a second diagnostic test ( amniocenteses or cordocenetsis) to clarify the 
results (Brun et al., 2003). Maternal cell contamination is the first cause of potential 
diagnostic errors which can occur after CVS.Obtained samples after CVS typically contain 
two cell lines: fetal i.e.placental villi and maternal i.e. decidua. It is posible that maternal cell 
line completely overgrow the culture and lead to incorect sex determination ans potentially 
to false- negative diagnosis. However, today, maternal cell contamination occurs in less then 
1% of cases and usually does not limit the possibilities of accurate diagnosis. Contamination 
of samples with significant amounts of maternal decidual tissue is almost always due to 
small sampling size. In experienced centers in which adequate quantities of villi are avilable, 
this problem has disappeared. The second major cause of potential diagnostic error 
associated with CVS is placental mosaicism (Kalousek et al.,2000). The rate of placental 
mosaicism in the frst trimester CVS is 1-2%. Although the fetus and placenta have a 
common ancestry, chorionic villus tissue will not always reflect fetal genotype. While 
initially placental mosaicism was considered as the main disadvantige of CVS in prenatal 
diagnosis, today it is an important marker for pregnancies at increased risk for growth 
retardation or genetic abnormalities. Two mechanisms can explain the occurance of 
placental mosaicism: mitotic error originally confined to the placenta and trisomic conceptus 
loosing of chromososme in the embryonic cell line. The most significant complication of 
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placental mosaicism is uniparental disomy which is the case when both chromosomes 
originate from the same parent (Kotzot et al.,2001). The clinical concequence of uniparental 
disomy occurs when the involved chromososme carries an imprinted gene in which 
expression is dependent on the patern of origin. For example, Prader-Willi syndrome may 
result from uniparental maternal disomy for chromosome 15. Because of this, all cases in 
which trisomy 15 is confined to the placenta should be evaluated for uniparental disomyy 
by amniotic fluid analysis. There is also evidence that placental mosaicism might alter 
placental function leading to the fetal growth restriction. This is especially relevant to 
chromosome 16 where placental trisomy affects growth of both uniparental and biparental 
disomy fetuses in a similar manner. A decision of termination of pregnancy should not be 
done on the basis  of mosaicism found on CVS. In such cases an amniocentesis should be 
offer to elucidate the extent of fetal involvement. Amniocentesis correlates perfectly with 
fetal genotype when mosaicism is limited to the direct preparation. When a mosaicism is 
observed in tissue culture, amniocentesis  is associated with a false negative rate of about 6% 
and mosaic fetuses were reported to be born after normal amniotic fluid analysis (Los et 
al.,2001). Follow-up may include fetal blood sampling or fetal skin biopsy. However, the 
predictive accuracy of these additional tests is still uncertain. 
2.5 Transcervical versus transabdominal chorionic villus sampling 
In most cases, operator or patient choice will determine the sampling route, but the choice of 
the route is usually decided on a case-by-case depending on placental site. Anterior and 
fundal placentas are usually easily accessed transabdominally while lower, posterior located 
placentas are more accessible transcervically. However, operators must be skilled in both 
methods. Both  techniques appear to be comparably efficient between 8 and 12 weeks, when 
the overall success rate after two sampling device insertions is considered to be very near to 
100% (Philip et al.,2004).This efficiency has been confirmed in three national randomized 
trials of transabdominal vs.transcervical CVS (Brambati et al.,1991; Jackson et al.,1992; 
Smidt-Jensen et al.,1992). Although the data appear to confirm that the two techniques are 
equally effective in obtaining adequate amounts of chorionic tissue, transabdominal 
needling entailed a significantly smaller proportion of repeated device insertions (3.3 vs. 
10.3%) and of low weight specimens (3.2 vs. 4.9%). Moreover, the complications due to 
undetected vaginal or cervical infection were much higher in the transcervical group. 
Additionally, speaking of safety, the Cochrane review showed that the transcervical CVS is 
more technically demanding than transabdominal CVS with more failures to obtain sample 
and more multiple insertions (Alfirevic et al.,2003). There are no differences in birth weight , 
gestational age at delivery, or congenital malformations with either method (Cederholm et 
al.,2003). Because of the specificity of the sampling route, transabdominal and transcervical 
sampling techniques are expected to have different types of contraindications. Vaginismus 
and stenotic or tortuous cervical canal, as well as myomas of the lower uterine segment, 
may severely hamper the introduction of either catheter or forceps. Active vaginal infection 
may also be an absolute contraindication to the cervical route. In the latter condition, vaginal 
and cervical culture and specific treatment do not seem sufficient to remove any risk of 
ascending infection. Transabdominal sampling may be relatively or absolutely 
contraindicated when obstacles such as intestines, large myomas or the gestational sac 
cannot be avoided. If olygohydramnios is present, transabdominal CVS may be the only 
approach available. 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
4 
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Transabdominal sampling, in our experience, has definitely become the method of choice, 
and our preference for this approach is based on the shorter learning time, the lower rate of 
immediate complications, the higher practicality and success rates at the first device 
insertion, the lower hazard of intrauterine infection, the opportunity to extend sampling 
beyond the first trimester, and the wider range of diagnostic indications.  
2.6 Complications 
The benefits of earlier diagnosis of fetal genetic abnormalities by chorionic villus sampling 
(CVS) or early amniocentesis must be set against higher risks of pregnancy loss and possibly 
diagnostic inaccuracies of these tests when compared with second trimester amniocentesis. 
The overall pregnancy loss rate following CVS has been reported in a number of relatively 
large clinical studies, and the values range from 2.2% to 5.4% (Odibo et al.,2008). The date 
used for determining the associated risks of fetal loss due to CVS are presented in the 
literature as case series with detailed outcome and comparative studies of CVS group versus 
amniocentesis and transabdominal versus transcervical CVS. Data evaluating the safety of 
CVS compares amniocentesis comes primarily from three collaborative reports ( Canadian 
Collaborative group, 1989; Medical Research Council, 1977; Rhoads et al.,1989). The results 
of Canadian Collaborative group demonstrated equivalent safety of CVS compared to 
midtrimester amniocentesis There was a 7,6% loss rate in the CVS group and a 7% loss rate 
in the amniocentesis group. A multicentric U.S. (Rhoads et al.,1989) study found slightly 
higher fetal loss rate following CVS (7,2%) compared to the one following midtrimester 
amniocentesis (5,7%). A prospective, randomized, collaborative comparison of more than 
3200 pregnancies, sponsored by the European Medical Council reported CVS having a 4,6% 
greater pregnancy loss rate than amniocenetesis.Based on the presented data, CVS is 
associated with a slightly increased risk of fetal loss when compared to amniocentesis. 
Noteworthy, that excluding the results of the MRC study, CVS is associated with no more 
then 1 % extra risk of fetal loss when compared to midtrimester amniocentesis. Also, the 
risks of fetal loss rate should not be compared between the studies since each study had its 
own criteria for total fetal loss (although most have described fetal loss  before 28 weeks 
gestation). Moreover, while some have included only cytogenetically normal fetuses, others 
have evaluated a mixed population. The risk of fetal loss after CVS can also be obtained 
from the studies comparing CVS with early amniocentesis (Caughey et al.,2006). Most of these 
studies point to a relatively small risk of fetal loss ( 2-3%) associated with CVS on the one hand 
and a significantly increased risk of fetal loss in the early amniocentesis gropu on the other 
hand. Logistic regression analysis of the procedure-related variables showed a significant 
association between fetal loss rate and maternal age, the lowest rates occurring in the youngest 
women (1.22%) and the highest in the women of 40 years and over, while gestational age 
affected the abortion rate only at 8 weeks (3.78%), no differences in the odds ratio being 
present at 9 to 12 weeks. Moreover, procedure related risk remained low later in pregnancy, 
and total fetal loss rates for CVS cases performed at 13–14 weeks and at least 15 weeks 
compared favorably with early and midtrimester amniocentesis respectively. Single-operator 
experience presents an estimated fetal loss after CVS of about 2-3%. Although, single operator 
experience shows that the results ( fetal loss rate) of early procedures are better in the hands of 
skilled operators, this remains controversial. Transabdominal CVS is considered by many to be 
safer than the transcervical approach.However, this observation is heavily influenced by the 
data from the Danish study (Smidt-Jansen,1992).Moreover no significant difference found 
 
Invasive Prenatal Diagnosis 
 
7 
between those two approaches from two of three randomized trials comparing 
techniques.Based on these studies, as well as myny single center reports, we believe that the 
poor results from the Danish study ( where the Portex cannula was used) would not be 
repeated if the operators were equally good at the techniques being compared. Unfortunately, 
no study has randomly evaluated CVS versus non-sampled (with same risk) patients. 
Among early post-procedural complications, spotting within a few hours has been more 
frequently observed in patients undergoing transcervical rather than transabdominal CVS 
(Brambati et al.1991). Other sequelae due to injury to the placental circulation include retro-
placental hematomas and subchorionic hemorrhage. Significant amniotic fluid leakage after 
CVS is about 2-4 times less frequent when compared to early amniocentesis.  
Localized peritonitis immediately after sampling occurs in very few cases, and only after 
transabdominal sampling, with an overall rate of 0.04%. Intrauterine infection (acute 
chorionamnionitis) should be considered a potential, although very rare, complication of 
transcervical CVS, having been reported in 0.1–0.5% of cases, and in some large series no 
cases at all were observed (Paz et al.,2001). However, there is some concern about the role of 
less serious infection in women who experience fetal loss after transcervical CVS. Because 
transcervical CVS involves passage of a cannula or forceps through the cervical canal from 
the perineum and vagina, microbial colonization and infection, with consequent morbidity 
for both mother and fetus, may result (Cederholm et al.,2003). 
Feto-maternal hemorrhage following CVS has been demonstrated by a significant increase 
in maternal serum a-fetoprotein in 40–72% of cases, and in 6–18% of these the amount of 
blood transfused was calculated to exceed 0.1ml. Fetal hemorrhage should therefore be 
capable of initiating an immune response in RhD-negative women bearing an RhD-positive 
fetus. Moreover, an association between maternal serum a-fetoprotein increase and 
frequency of spontaneous fetal death has been suggested for the cases with the highest 
maternal serum a-fetoprotein levels (Mariona et al.,1986). 
In general, the rate of fetal abnormalities after CVS is not different than in general 
population. Several case reports and cohort studies in the early 1990s have suggested a 
possible association between  CVS and a cluster of limb defects and oromandibular 
hypogenesis. However, these findings were not repeated in other studies. The background 
risk of limb reduction defects (LRD) in the general population is low and varies between 1.6 
and 4/10000. In an evaluation of CVS safety presented by WHO, LRD cases were observed 
in 5.3/10000. The possible mechanisms of LRD following CVS are unknown. However, 
there are three principal theories: 
1. Vascular disruption caused by hemodynamic disturbances, vasoactive peptides or 
embolism 
2. Amnion puncture with subsequent compression and entanglement of the fetus. 
3. Immunological mechanisms causing increased apoptotic cell death 
It is speculated that technical aspects of the procedure may have a bearing on the amount of 
placental trauma associated with the sampling procedure and the risk of limb deficiency. 
However, the rarity of limb deficiency following CVS means that none of the existing trials 
have the power to clarify the effect of technical factors on the risk. It also remains unresolved 
whether the risk of limb deficiency differs for transabbominal versus transcervical sampling ( 
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Froster et al., 1996). Given the weight of current evidence supporting an association between 
early sampling and limb deficiency, it would be unethical to conduct a trial to investigate this 
prospectively. 
No increased frequency of perinatal complications, i.e. preterm birth, small-for-dates 
neonates, perinatal mortality and congenital malformations, have been observed both in 
randomized and clinical control studies (MRC Working Party, 1992). 
3. Amniocentesis 
Amniocentesis is the invasive diagnostic procedure by which amniotic fluid is aspirated 
from pregnant uterus using transabdominal approach. This method was first performed as 
therapeutic procedure more than 100 years ago for decompression of polyhydramnios. 
Amniocentesis became a diagnostic procedure in 1950s when Bevis first used amniotic fluid 
for measurement of bilirubin concetration and prediction of the severity of Rhesus 
immunisation. Today amniocentesis is a significant diagnostic tool for prenatal detection of 
chromosomal as well as metabolic disorder. Tests performed on fetal cells found in the 
sample can reveal the presence of many types of genetic disorders, thus allowing doctors 
and prospective parents to make important decisions about early treatment and intervention 
(Wilson, 2005). 
3.1 Timing and technique 
For karyotyping  amniocentesis is generally performed between 15 and 18 weeks of 
gestation with results usually available within three weeks. At this time, the amount of fluid 
is adequate (approximately 150ml), and the ratio of viable to nonviable cells is greatest. With  
the current technology amniocentesis is technically possible from 8 weeks of gestation  but 
this is not usually recommended because there appears to be an increased risk of 
miscarriage when done at this time (Allen & Wilson,2006). The advantage of early 
amniocentesis and speedy results lies in the extra time for decision making if a problem is 
detected. Potential treatment of the fetus can begin earlier. Important, also, is the fact that 
elective abortions are safer and less controversial the earlier they are performed. For 
assessment of the fetal lung maturity the amniocentesis can be used until term (Hanson  et 
al.,1990). Before the procedure, genetic couceling is mandatory and a detailed family history 
should be obtained. The parents should be informed about the complications and limitations 
of the procedure same as for CVS. After genetic counseling, a "level two" ultrasound is then 
done to check for any signs of fetal abnormalities, to check the fetal viability, to determine 
the position of the fetus and of the placenta, to examine closely the main fetal structures, and 
to double check the gestational age (Hanson  et al.,1990). Ultrasound is used  also to 
determine the best location for placing the needle-a pocket of substantial amniotic fluid well 
away from the baby and umbilical cord. When amniocentesis  first came into use, they were 
done "blind" (without continuous ultrasound guidance during the procedure), and this 
resulted in a number of disastrous outcomes, including occasional cases of horrifying fetal 
damage and death(Gratacos et al.,2000) .Modern amniocentesis is done with continuous 
ultrasound and is much less dangerous. For the amniocentesis, the mother lies flat on her 
back on a table. Iodine solution is swabbed onto her belly in order to cleanse the area 
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thoroughly, and sterile drapes are placed around the area. After  an appropriate sampling 
path has been chosen , a 20 to 22-gauge needle is introduced into a pocket of amniotic fluid 
free of fetal parts and a umbilical cord. The pocket should be large enough to allow 
advancement of the needle tip through the free-floating amniotic membrane that  may 
occasionally obstruct the flow of fluid. The first 2ml of amniotic fluid are discarded to 
reduce the risk of contamination  of  the sample with maternal cells which could 
occasionally lead to false-negative diagnosis. The amount of  withdrawn amniotic  fluid 
should not exceed 20 to 30ml (Blessed et al.,2001).There is confirmed relationship between 
higher fetal loss and aspiration of 40ml of amniotic fluid and more. Continuous ultrasound 
during an amniocentesis allows the doctor to see a constant view of the needle's path, the 
location of fetus and to identify uterine contractions that occasionally retract the needle tip 
back into the myometrium. If the fetus moves near the needle's path at any point, the doctor 
can then reposition the needle, or if necessary, withdraw the needle and try again in a 
different location. Continuous ultrasound has eliminated a great deal of the risk formerly 
associated with amniocentesis (Johnson  al.,1999). The procedure should be performed 
either free-hand or with the needle guide. The free-hand  technique allows easier 
manipulation  of  the needle if the position of the  target is altered by a fetal  movement or 
uterine contraction. Alternatively, a needle guide allows more certain  ascertainment of the 
needle entry point and a more precise entry determination of the sampling path. A needle 
guide technique is helpful for obese patients, in cases of oligohydramnios  and  for  
relatively inexperienced sonographer (Welch et al.,2006). After the fluid sample is taken, the 
doctor immediately  checks the viability of the fetus. Both uterine and maternal abdominal 
wall puncture sites should be observed for bleeding and anti-D should be given to Rh 
negative women. In experienced hands  and after 11 completed weeks of gestation the pure 
amniotic fluid aspiration has a success rate of 100%. If the initial attempt to obtain fluid is 
unsuccessful, a second attempt in another location should be performed after reevaluation 
of the fetal and placental positions. If unsuccessful after two attempts, the patient should be 
rescheduled in several days. The technique of early amniocentesis is similar to 
amniocentesis performed at later gestational ages. However, in the first trimester there are 
two sacs, the amniotic cavity and the extra-embryonic coelome. The incomplete fusion of the 
amnion and chorion in early gestation may result in tenting of the membranes, which may 
necessitate more needle insertions. It is important to distinguish the two sacs 
ultrasonographically at the time of the amniocentesis, as the fluid in the extraembryonic 
coelome is jelly-like, difficult to aspirate, and has a different alpha-fetoprotein concentration 
than amniotic fluid. Retrieval of fluid from this sac should be avoided, as it will only rarely 
produce enough cells to allow a cytogenetic diagnosis (Sundberg  et al.,1991). In order to 
assess whether amniotic fluid has been retrieved from both sacs in twin pregnancies, a 
marker (a dye or a biochemical substance) may be injected into the first sac. When the 
second sac is punctured, the absence of the marker in the amniotic fluid indicates that both 
sacs have been sampled. However, real-time ultrasound allows visually guided amniotic 
fluid sampling from both sacs, thus making dye-injection obsolete (Pijpers et al.,1988). 
Whether amniocentesis in twin pregnancies should be performed by using one or two 
needle insertions remains to be shown. A single needle insertion could reduce the abortion 
risk, but may on the other hand create the problems of amniotic band syndrome or a mono-
amniotic twin pregnancy, or give rise to cytogenetic problems (Millaire et al.,2006).  
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Since the mid-1970s, amniocentesis has been used routinely to test for Down syndrome by 
far the most common, nonhereditary, genetic birth defect, affecting about one in every 1,000 
babies. By 1997, approximately 800 different diagnostic tests were available, most of them 
for hereditary genetic disorders such as Tay-Sachs disease, sickle cell anemia, hemophilia, 
muscular dystrophy and cystic fibrosis (Summers et al.,2007). 
Amniocentesis is recommended for women who will be older than 35 on their due-date. It is 
also recommended for women who have already borne children with birth defects, or when 
either of the parents has a family history of a birth defect for which a diagnostic test is 
available. Another reason for the procedure is to confirm indications of Down syndrome 
and certain other defects which may have shown up previously during routine maternal 
blood screening (Fergal  et al.,2005). The risk of bearing a child with a nonhereditary genetic 
defect such as Down syndrome is directly related to a woman's age—the older the woman, 
the greater the risk. Thirty-five is the recommended age to begin amniocentesis  testing 
because that is the age at which the risk of carrying a fetus with such a defect roughly equals 
the risk of miscarriage caused by the procedure-about one in 200. At age 25, the risk of 
giving birth to a child with this type of defect is about one in 1,400; by age 45 it increases to 
about one in 20. Nearly half of all pregnant women over 35 in the United States undergo 
amniocentesis and many younger women also decide to have the procedure. Notably, some 
75% of all Down syndrome infants born in the United States each year are to women 
younger than 35 (Jacobson et al.,2004). 
One of the most common reasons for performing amniocentesis is an abnormal alpha-
fetoprotein (AFP) test. Because this test has a high false-positive rate, another test such as 
amniocentesis is recommended whenever the AFP levels fall outside the normal range 
(Sepulveda et al.,1995). 
3.3 Laboratory considerations for amniocentesis 
The cells within the amniotic fluid arise from fetal skin, respiratory tract, urinary tract, 
gastrointestinal tract and placenta. After obtained fetal cells, they are put into tissue culture, 
either in flasks or more often on coverslips. After 3 to 7 days of growth, sufficient mitoses 
are present for staining and karyotype analysis. Viable cells in the amniotic fluid are 
cultured and used for karyotyping, and investigation of metabolic and biochemical 
disorders. Uncultured cells may now be used to detect specific chromosome aberrations by 
using chromosome specific probes and fluorescent in situ hybridization (FISH) on 
interphase cells, but complete karyotyping is not yet possible on uncultured cells 
(Pergament,2000). Amniocyte  culture is quite reliable, with failure occurring in less than 1% 
of cases. The culture failure rate increase with falling  gestational age and it seems to occur 
more often in fetal aneuploidy. Chromosomal mosaicism most frequently results from 
postzygotic  nondisjunction but can also occur from meiotic errors with trisomic rescue. The 
most common etiology is pseudomosaicism where the abnormality is evident in only one of 
several flasks or confined to a single colony on a coverslip. In this case the abnormal cells 
have arisen in vitro, are not present in the fetus, and are not clinically important. 
Alternatively, true fetal mosaicism is rare, occurring in 0,25% of amniocentesis but can be 
clinically important, leading to phenotypic or developmental abnormalities. Maternal cell 
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contamination may cause misdiagnosis, if only maternal cells are examined or mosaicism is 
suspected. The rate of maternal cell contamination is 1-3 per 1000 cases, but this figure 
should probably be doubled as maternal cell contamination is only detected when the fetus 
is male (Tepperberg  et al.,2001). A large study (Welch et al.,2006) sought to relate the 
frequency of maternal cell contamination in amniotic fluid samples that were submitted to a 
single laboratory for cytogenetic analysis to the experience and training of the physician 
who performed the amniocentesis.  
Fluorescence in situ hybridization (FISH) probes are relatively short fluorescently labeled DNA  
sequences that are hybridized to a known location on a specific chromosome and allow for 
determination of the number and location of specific DNA sequences. Presently, it is suggested 
that FISH analysis not be used as a primary screening test on all genetic amniocenteses because 
of its inability to detect structural rearrangements, mosaicism, markers, and uncommon 
trisomies. Because all abnormalities would be detectable by tissue culture, FISH analysis is not 
cost effective. Presently, most laboratories use FISH to offer quick reassurance to patients with 
an unusually high degree of anxiety or to test fetuses at the highest risk, such as those with 
ultrasound anomalies. It is also beneficial in cases where rapid results are crucial to subsequent 
management, such as advanced gestational age (Sawa et al., 2001). 
3.4 Complications 
Amniocentesis is not without maternal and fetal complications and should be undertaken 
with due regard to the risks involved. 
3.4.1 Maternal 
The risk of intervention for the mother is minimal. The risk of an amnionitis after 
amniocentesis is less than 0,1% and the risk of a severe maternal infection reaches 0.03%-0.09% 
(Wurster et al.,1982). In a retrospective survey of 358 consecutive amniocentesis ( Pergament, 
2000) there were two patients who developed amniotic fluid peritonism and one with minor 
intraperitoneal bleeding. Amniocentesis is not associated with severe pregnancy complications 
such as placental abruption or placenta praevia. On the other hand after amniocentesis there is 
an increased risk of complications related to amniotic cavity, membranes and hypotonic 
uterine dysfunction (Cederholm et al.,2003).Feto-maternal hemorrhage  occurs during 
amniocentesis in one out of six women, and may therefore theoretically give rise to subsequent 
isoimmunisation. In a prospective cohort study (Tabor et al.,1987) the immunization rate was 
1.4%. The observed 1.4% immunization rate is not different from the spontaneous 
immunization rate. In spite of these findings, and since Rh-immune serum globulin is 
apparently harmless to the fetus and mother, its use is recommended in nonsensitized Rh-
negative mothers after amniocentesis Practice differs between countries regarding whether 
this recommendation is followed or not. In American  controlled study anxiety and depression 
varied similarly in women having amniocentesis and in control women. However, among 
women having amniocentesis due to advanced maternal age, the anxiety level was increased 
while awaiting the results of the test (Phipps et al.,2005). 
3.4.2 Fetal 
The major risk of mid-trimester amniocentesis is fetal loss. Two types of loss should be 
considered: (1) total pregnancy loss rate postprocedure, which includes both background 
 




Since the mid-1970s, amniocentesis has been used routinely to test for Down syndrome by 
far the most common, nonhereditary, genetic birth defect, affecting about one in every 1,000 
babies. By 1997, approximately 800 different diagnostic tests were available, most of them 
for hereditary genetic disorders such as Tay-Sachs disease, sickle cell anemia, hemophilia, 
muscular dystrophy and cystic fibrosis (Summers et al.,2007). 
Amniocentesis is recommended for women who will be older than 35 on their due-date. It is 
also recommended for women who have already borne children with birth defects, or when 
either of the parents has a family history of a birth defect for which a diagnostic test is 
available. Another reason for the procedure is to confirm indications of Down syndrome 
and certain other defects which may have shown up previously during routine maternal 
blood screening (Fergal  et al.,2005). The risk of bearing a child with a nonhereditary genetic 
defect such as Down syndrome is directly related to a woman's age—the older the woman, 
the greater the risk. Thirty-five is the recommended age to begin amniocentesis  testing 
because that is the age at which the risk of carrying a fetus with such a defect roughly equals 
the risk of miscarriage caused by the procedure-about one in 200. At age 25, the risk of 
giving birth to a child with this type of defect is about one in 1,400; by age 45 it increases to 
about one in 20. Nearly half of all pregnant women over 35 in the United States undergo 
amniocentesis and many younger women also decide to have the procedure. Notably, some 
75% of all Down syndrome infants born in the United States each year are to women 
younger than 35 (Jacobson et al.,2004). 
One of the most common reasons for performing amniocentesis is an abnormal alpha-
fetoprotein (AFP) test. Because this test has a high false-positive rate, another test such as 
amniocentesis is recommended whenever the AFP levels fall outside the normal range 
(Sepulveda et al.,1995). 
3.3 Laboratory considerations for amniocentesis 
The cells within the amniotic fluid arise from fetal skin, respiratory tract, urinary tract, 
gastrointestinal tract and placenta. After obtained fetal cells, they are put into tissue culture, 
either in flasks or more often on coverslips. After 3 to 7 days of growth, sufficient mitoses 
are present for staining and karyotype analysis. Viable cells in the amniotic fluid are 
cultured and used for karyotyping, and investigation of metabolic and biochemical 
disorders. Uncultured cells may now be used to detect specific chromosome aberrations by 
using chromosome specific probes and fluorescent in situ hybridization (FISH) on 
interphase cells, but complete karyotyping is not yet possible on uncultured cells 
(Pergament,2000). Amniocyte  culture is quite reliable, with failure occurring in less than 1% 
of cases. The culture failure rate increase with falling  gestational age and it seems to occur 
more often in fetal aneuploidy. Chromosomal mosaicism most frequently results from 
postzygotic  nondisjunction but can also occur from meiotic errors with trisomic rescue. The 
most common etiology is pseudomosaicism where the abnormality is evident in only one of 
several flasks or confined to a single colony on a coverslip. In this case the abnormal cells 
have arisen in vitro, are not present in the fetus, and are not clinically important. 
Alternatively, true fetal mosaicism is rare, occurring in 0,25% of amniocentesis but can be 
clinically important, leading to phenotypic or developmental abnormalities. Maternal cell 
 
Invasive Prenatal Diagnosis 
 
11 
contamination may cause misdiagnosis, if only maternal cells are examined or mosaicism is 
suspected. The rate of maternal cell contamination is 1-3 per 1000 cases, but this figure 
should probably be doubled as maternal cell contamination is only detected when the fetus 
is male (Tepperberg  et al.,2001). A large study (Welch et al.,2006) sought to relate the 
frequency of maternal cell contamination in amniotic fluid samples that were submitted to a 
single laboratory for cytogenetic analysis to the experience and training of the physician 
who performed the amniocentesis.  
Fluorescence in situ hybridization (FISH) probes are relatively short fluorescently labeled DNA  
sequences that are hybridized to a known location on a specific chromosome and allow for 
determination of the number and location of specific DNA sequences. Presently, it is suggested 
that FISH analysis not be used as a primary screening test on all genetic amniocenteses because 
of its inability to detect structural rearrangements, mosaicism, markers, and uncommon 
trisomies. Because all abnormalities would be detectable by tissue culture, FISH analysis is not 
cost effective. Presently, most laboratories use FISH to offer quick reassurance to patients with 
an unusually high degree of anxiety or to test fetuses at the highest risk, such as those with 
ultrasound anomalies. It is also beneficial in cases where rapid results are crucial to subsequent 
management, such as advanced gestational age (Sawa et al., 2001). 
3.4 Complications 
Amniocentesis is not without maternal and fetal complications and should be undertaken 
with due regard to the risks involved. 
3.4.1 Maternal 
The risk of intervention for the mother is minimal. The risk of an amnionitis after 
amniocentesis is less than 0,1% and the risk of a severe maternal infection reaches 0.03%-0.09% 
(Wurster et al.,1982). In a retrospective survey of 358 consecutive amniocentesis ( Pergament, 
2000) there were two patients who developed amniotic fluid peritonism and one with minor 
intraperitoneal bleeding. Amniocentesis is not associated with severe pregnancy complications 
such as placental abruption or placenta praevia. On the other hand after amniocentesis there is 
an increased risk of complications related to amniotic cavity, membranes and hypotonic 
uterine dysfunction (Cederholm et al.,2003).Feto-maternal hemorrhage  occurs during 
amniocentesis in one out of six women, and may therefore theoretically give rise to subsequent 
isoimmunisation. In a prospective cohort study (Tabor et al.,1987) the immunization rate was 
1.4%. The observed 1.4% immunization rate is not different from the spontaneous 
immunization rate. In spite of these findings, and since Rh-immune serum globulin is 
apparently harmless to the fetus and mother, its use is recommended in nonsensitized Rh-
negative mothers after amniocentesis Practice differs between countries regarding whether 
this recommendation is followed or not. In American  controlled study anxiety and depression 
varied similarly in women having amniocentesis and in control women. However, among 
women having amniocentesis due to advanced maternal age, the anxiety level was increased 
while awaiting the results of the test (Phipps et al.,2005). 
3.4.2 Fetal 
The major risk of mid-trimester amniocentesis is fetal loss. Two types of loss should be 
considered: (1) total pregnancy loss rate postprocedure, which includes both background 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
12
pregnancy loss for that gestational age and procedure-related loss, and (2) procedure related 
pregnancy loss. The total post-amniocentesis loss rates are derived from studies of 
populations of pregnant women who underwent amniocentesis, with a control group 
consisting of populations of pregnant women who had another procedure. The 
amniocentesis-related pregnancy loss rates are derived from studies of pregnant women 
who had amniocentesis compared with a “no procedure” control group. A  study published 
by Eddleman et al. suggests that the procedural loss rate of amniocentesis may be much 
smaller than previously reported, further challenging the indications for invasive testing in 
the context of a traditional “risk-benefit” ratio (Eddleman et al.,2006). Although the 
committee agrees that it is timely to re-evaluate this issue, it is believed Eddleman’s 
conclusion that the rate of miscarriage due to amniocentesis of 0.06% (1/1600) is misleading 
and should be interpreted with caution. The study is based on a secondary analysis of data 
from the “First and Second Trimester Evaluation of Risk for Aneuploidy” (FASTER) trial, 
the primary goal of which was to compare first and second trimester noninvasive prenatal 
genetic screening methods. Among the 35 003 women enrolled the rate of spontaneous fetal 
loss prior to 24 weeks’ gestation in the study group was 1%, not statistically different from 
the control group rate of 0.94%. The risk of miscarriage due to amniocentesis was reported 
to be the difference between these two rates, which was 0.06%. Letters to the editor have 
criticized the FASTER conclusion. Nadel (Nadel,2007) concluded that the likelihood of 
amniocentesis resulting in the loss of a euploid fetus is less than 0.5% .Smith (Smith,2007) 
commented that the methods used to include or exclude pregnancy termination patients 
resulted in the paradox of a statistically significant increase in spontaneous abortion for 
women not having amniocentesis with a positive screen and women who were aged 35 
years or over. The lowest rate of risk for genetic amniocentesis derived from the literature is 
about 1 in 300 (Wilson,2007). In counseling patients prior to amniocentesis, it is important to 
convey to patients that at their stage of pregnancy there is still a background pregnancy loss 
rate, and that amniocentesis will contribute an additional procedure related loss rate. The 
notion of background population or individual loss rate is important, as the patient will not 
be able to determine whether her pregnancy loss was “background” or 
“procedural.”Counselling should provide a woman with the total pregnancy loss rate to 
enable her to fully understand the possible sequelae of her decision. Individual procedural 
risks may be required for counseling because of the real variables that contribute to the 
population or individual background risk. 
A. Patient factors 
1. Maternal age/ paternal age (Kleinhaus et al.,2006) 
2. Past reproductive history 
3. Pre-existing maternal conditions (diabetes, hypertension, infertility, autoimmune)  
4. Pregnancy/uterine (assisted reproductive techniques, vaginal bleeding, uterine 
fibroids, placental location, amniotic fluid loss, oligohydramnios, retro chorionic 
hematoma, single vs. multiple gestations) 
5. Screening methodology 
i. timing (first trimester, second trimester, first and second trimester) 
ii. technique (ultrasound alone, biochemistry, biochemistry and ultrasound, nuchal 
translucency +/- biochemistry, single or multiple soft markers or congenital 
anomalies) 
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B. Procedure factors  
1. Amniocentesis needle size variation 
2. Operator experience 
3. Ultrasound guided (freehand; needle guide) 
4. Uterine/placental location 
5. Maternal BMI 
C. Postprocedure factors 
1. Rest for 24 hours or normal activity (no evidence-based comparisons available) 
2. Complications (ruptured membranes, infection) 
Increasing maternal and paternal age are significantly associated with spontaneous 
abortion, independent of amniocentesis and multiple other factors (Kleinhaus et al.,2006). 
Also pre-existing maternal conditions, as well as assisted reproductive techniques and 
multiple gestations are “per se“ risk factors for increase fetal loss (Bianco et al.,2006). 
Amniocentesis before 14 weeks gestation has an adverse effect on fetal loss (Alfirević et 
al.,2007). Rupture of membranes is an uncommon complication of genetic amniocentesis. 
Theoretically, a thin needle may have both advantages and disadvantages for fetal loss. One 
would expect a thin needle to cause a smaller hole in the membranes and to be less 
traumatic, thereby decreasing the risk of amniotic fluid leakage and feto-maternal 
hemorrhage. On the other hand, a thin needle increases the procedure time, and increased 
sampling time might be associated with an increased risk of chorio-amnionitis and fetal loss 
(Weiner,1991). It seems reasonable to assume the fetal loss to be lower if the operator has 
performed a large number of invasive procedures than if he/she is inexperienced. 
(Milunsky,2010). The number of annual procedures needed for amniocentesis to be safe is 
not known, and the recommendation of at least 150 amniocenteses per year is not based on 
scientific evidence. There is indirect evidence from nonrandomized studies that ultrasound 
guided amniocentesis is safer than blind amniocentesis, because feto-maternal hemorrhage 
occurs less often if the procedure is performed under ultrasound guidance than if it is done 
blindly  and feto-maternal hemorrhage may be associated with an increased risk of fetal loss 
(Papantoniou et al.,2001). In the study by Weiner and colleagues, there was some evidence 
that the rate of fetal loss after amniocentesis increased with the number of needle insertions. 
On the other hand they did not find increased fetal  loss after transplacental passage of the 
amniocentesis needle than after non-transplacental passage. Possibly, the most important 
thing is to perform the procedure as atraumatically as possible. Therefore, the puncture site 
that gives easiest access to a pocket of free fluid should be chosen. If the placenta can be 
easily avoided, it is probably wise to avoid it. Whether the amount of amniotic fluid 
removed has any effect on fetal loss rates is not known, but it is probably wise to remove as 
little as possible (usually 15-20 ml is enough to obtain a diagnosis). Spontaneous reseal of 
ruptured membranes after genetic amniocentesis can occur with conservative management 
and end with a favorable pregnancy outcome (Phupong & Ultchaswadi,2006). 
The Table 1 summarizes the recent published reports (randomized controlled trials and 
cohort studies with or without a control group; the control group may have no procedure or 
an alternative procedure), showing a range of post mid-trimester amniocentesis losses of 
0.75 to 2,1% .The FASTER study pregnancy loss difference (amniocentesis; no 
amniocentesis) is a clear outlier within these controlled study groups and reflects that this 
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B. Procedure factors  
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3. Ultrasound guided (freehand; needle guide) 
4. Uterine/placental location 
5. Maternal BMI 
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amniocentesis) is a clear outlier within these controlled study groups and reflects that this 
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study’s method of analysis underestimated the procedure-related pregnancy loss rate 
following mid-trimester amniocentesis by excluding the terminated pregnancies in the 
amniocentesis group, resulting in a lower intrinsic rate of pregnancy loss for this group than 
for the control group. 
In conclusion there is no single percentage (or odds ratio) that can be quoted as the risk of 
pregnancy loss following midtrimester amniocentesis in singleton pregnancies. The risks 
unique to the individual and is  based on multiple variables, as summarized in this opinion. 
The best estimate range to consider for the increased rate of pregnancy loss attributable to 
amniocentesis is 0.6% to 1.0% but may be as low as 0.19% or as high as 1.53% on the basis of 
the confidence intervals  seen in the various studies.  
The fetal loss rate in multiple gestations has not been estimated in a controlled trial and is 
difficult to determine due to the increased miscarriage rate per se in twin pregnancies. An 
increased post-amniocentesis abortion rate in multiple gestations may be expected, since 
most operators use more than one needle insertion, a variable associated with an increased 
fetal loss rate (Toth-Pal et al., 2004). In the largest Israel study fetal loss among bichorionic 
twin gestations undergoing genetic amniocentesis was compare with singletons undergoing 
the procedure and untested twins. Fetal loss was 2,73% in the first group, compared to 0,6% 
and 0,63% in the other two groups. It may thus be concluded  that the risk of early fetal loss 
is apparently higher in twins undergoing amniocentesis than in untested twins or tested 
singletons. These data can be of value in counseling parents of twins because of the 
increased number of gestations resulting from fertility programs and the elevated risk of 
chromosomal abnormalities in twin pregnancies (Yukobowich et al.,2001). Whether 
amniocentesis in twin pregnancies should be performed by using one or two needle 
insertions remains to be shown. A single needle insertion could reduce the abortion risk, but 
may on the other hand create the problems of amniotic band syndrome or a mono-amniotic 
twin pregnancy, or give rise to cytogenetic problems (Wapner et al.,1993). 
Considering perinatal mortality et morbidity, amniocentesis does not affect the preterm 
birth rate, the stillbirth rate or the perinatal mortality rate. This procedure does not affect 
neither the mean birth weight. In early experience with amniocentesis, needle puncture of 
the fetus was reported in 0,1% to 0,3% of cases (Karp & Hayden, 1977) and was associated 
with fetal exsanguinations (Young et al., 1977), intestinal atresia (Swift et al., 1979), 
uniocular blindess, porencephalic cysts, peripheral nerve damage and intestinal atresia 
(Karp & Hayden,1977) Continuous use of ultrasound to guide the needle minimizes needle 
puncture of the fetus and in the hands of experienced operators those are extremely rare 
complications. The British study ( Medical Research Study, 1978) also found an increase in 
postural deformities such as talipes and congenital dislocation of the hip. The possible 
mechanism of this deformity is compression due to olygohydramnios or tissue injury from 
the amniocentesis needle. This study was criticized for biases in the selection of the control 
patients who were younger, had less parity, entered later in the gestation in the study and 
some of the matched controls were replaced with other controls.No long-term adverse 
effects have been demonstrated in children undergoing amniocentesis. Finegan and 
colleagues (Baird et al.,1994) showed that  the offspring of women who had had 
amniocentesis were no more likely than controls to have a registrable disability (such as 
hearing disabilities, learning difficulties, visual problems, and limb anomalies) during 
childhood and adolescence. At the ages of 4 and 7 years, there was no difference between 
the two groups regarding child social competence, behaviour, growth and health. The 
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results suggest that the wide range of developmental and behavioural variables studied is 
not influenced by removal of amniotic fluid in the mid-trimester.  
 
 
RCT: Randomized controlled trial; C: cohort/case–control study; CVS: chorionic villus sampling (TA: 
transabdominal; TC: transcervical); EA: early amniocentesis; 
RR: relative risk; CI: confidence interval; NS: non-significant difference. 
* Study group: women 20–34 years of age having amniocentesis for increased risk of aneuploidy or 
maternal infection; control group: women 20–34 years of age at 
low risk but having amniocentesis 
 
Table 1. Summary of studies with mid-trimester amniocentesis population 
3.5 Early amniocentesis 
The desire for a first-trimester diagnosis stimulated interest in the feasibility of performing 
amniocentesis under 15 weeks gestation including first trimester. The major advantage of 
early amniocentesis (9 to 14 weeks’ gestation) is that results are known much more earlier. 
This procedure which was introduced in the late 1980s, is technically the same as a ’late’ 
procedure except that less amniotic uid is removed. The 15ml amniotic fluid  at this week 
of pregnancy is a significant amount, while the extremities are in a critical period for the 
development. Ultrasound needle guidance is considered to be an essential part of the 
procedure because of the relatively small target area. The presence of two separate 
membranes (amnion and chorion) until 15 weeks’ gestation creates an additional technical 
difculty. Only the amniotic (inner) sac should be aspirated, because the outer sac does not 
contain sufcient numbers of living fetal cells. It has been reported that there is a culture 
failure ranging from o,5-2,5%. The karyotyping success rate may be increased by using lter 
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techniques in which amniotic cells are retained on a lter after aspiration while the rest of 
the amniotic uid (cell free) is reinjected into the amniotic cavity (Alfirević et al.,2007). 
Fetal complications related to early amniocentesis were expected to be higher than those 
related to mid-trimester amniocentesis because of the higher amount of removed amniotic 
fluid (Johnson et al., 1999). Since a controlled trial has not yet been done, the complications 
following early amniocentesis has been compared to that following chorionic villus 
sampling (CVS) or amniocentesis in week 16-18. To determine the safety and accuracy of 
early amniocentesis, a randomized, multicenter Canadian study (Meier et al.,2005) 
compared the procedure to second-trimester amniocentesis.Among the women in the early 
amniocentesis group, 1% gave birth to infants with a foot anomaly. By comparison, only 
0.1% of those in the second-trimester group gave birth to infants with this deformity a 
proportion similar to that found within the general population.Both the U.K. and Danish 
studies (Tabor et al., 1986) found an increase in respiratory distress syndrome and 
pneumonia in neonates from the mothers who underwent early amniocentesis. It may be 
that altered amniotic fluid volume after amniocentesis or subsequent chronic amniotic 
fluid leakage interferes with normal lung development and lung structure at term, thus 
giving rise to pulmonary hypoplasia and consequently to RDS in the newborn. Whether 
these antenatal and neonatal changes have any longterm impact on lung development 
remains to be shown. The study, funded by the National Institute of Child Health and 
Human Development (Philip et al.,2004) compared the rate of fetal loss between early 
amniocentesis and CVS. The combined outcome of spontaneous loss before 20 weeks and 
procedure-related termination occurred slightly more often after amniocentesis than after 
CVS, with risk most increased when amniocentesis was performed during week 13. In 
addition, incidence of talipes equinovarus (clubfoot) was fourfold higher after 
amniocentesis than after CVS , again, most cases occurred when amniocentesis was 
performed during week 13..  
Early amniocentesis appears to be as accurate as CVS and mid-trimester amniocentesis. 
Amniocentesis at 13 weeks gestation carries a significantly increase risk of talipes 
equinovarus and respiratory illness compared with CVS and mid-trimester amniocentesis 
and also suggests an increase in early, unintended pregnancy loss. The safety of 
amniocentesis before 14 weeks gestation is uncertain. Until its safety can be ensured, it is 
best to delay routine sampling until week 15 or 16 of pregnancy. 
4. Cordocentesis 
Cordocentesis is an invasive method of obtaining fetal blood from umbilical cord  using 
transabdominal approach. This method first described in 1983 by Daffos and coworkers 
offers advantage in efficacy and safety over the fetoscopic methods previously used to 
obtain fetal blood and nowdays almost completely abandoned  (Daffos et al.,1985). The 
main target for obtaining fetal blood is the umbilical vein. Other possible targets for fetal 
blood sampling are fetal heart ventricles and the intrahepatic tract of the umbilical vein 
(Antsaklis et al., 1992) 
4.1 Timing and technique 
Depending on the indication, cordocentesis can be performed from about 18 completed 
weeks of gestation until the end of the pregnancy. When imaging and placental conditions 
 
Invasive Prenatal Diagnosis 
 
17 
are optimal, it can be done as early as 15 completed weeks. It is usually performed on an 
ambulatory basis. It requires a high-resolution ultrasound scanner, an experienced team and 
a laboratory specializing in fetal blood analysis (Sirirchotiyakul et al.,2000). The most 
favorable puncture site is the placental insertion of the umbilical cord, as the cord is the least 
mobile at that location. A 20-22 gauge needle is used. A stable needle is important, 
especially with the posterior placenta, so that the needle will not bend on the relatively long 
path to the umbilical cord insertion (Ghezzi et al.,2001). Blood is drawn from the umbilical 
vein with a 1ml syringe. Blood samples must be immediately examined to identify to purity 
of the sample and the results of the analysis can be significantly altered in case it has been 
contamined by maternal blood or amniotic fluid. A free loop of umbilical cord or the fetal 
insertion of the cord can also be used for puncture. Intra-abdominal puncture of the 
umbilical vein is yet another option. It is most difficult to puncture a free loop of umbilical 
cord. Attempts to puncture free loops often result in the cord being pushed away by the 
needle (Liaou et al.,2006). Besides the large-caliber vein, it is also possible to sample blood 
from one of the two smaller-caliber umbilical arteries. This procedure, however, carries a 
risk of vasospasm with subsequent fetal bradycardia and/or profuse afterbleedind and 
therefore puncture of the umbilical vein is always preferred. Fetal heart is an alternative 
sampling site and this technique can be used when access to the fetal circulation  must be 
obtained at gestational age less than 17-18 weeks gestation or if an emergency blood 
transfusion is required. 
4.2 Indications 
Indications for cordocentesis have changed regarded to past decade. In fact the list is shorter 
than a decade ago because the noninvasive methods have rendered  cordocentesis less 
important. However, some specific metabolic, hematologic or gene disorders are still 
testable only by fetal blood sampling. Cordocentesis is most commonly used for rapid fetal 
karyotyping (Shah et al., 1990). This is done in cases with ambiguous chromosomal findings 
from amniotic cell culture or CVS. The results can be obtained in 48-72 hours by leukocyte 
culture of the fetal sampled blood. This advantage of rapid karyotyping can also be used 
when ultrasound reveals an abnormality that is associated with chromosome disorders or in 
cases of an abnormal triple test. On the other hand some essentials blood tests are replaced 
by amniocentesis due to PCR techniques for gene amplification and the emergence of many 
new genetic markers. Various fetal infections can be diagnosed in the fetal blood: rubella, 
cytomegalovirus, toxoplasmosis, varicella and parvovirus B19 (Valente et al., 1994). For 
detection a fetal infection cordocentesis is not performed before 22 weeks of gestation 
because IgM antibodies occur in fetal blood after 20 weeks of gestation. Various blood 
diseases can be diagnosed using cordocentesis: hemoglobinopathies, coagulopathies, 
immune deficiencies and trombocytopenias (Burrows and Kelton, 1993). Determination of 
the platelet count in congenital thrombocytopenias provides important information on the 
intrauterine risk to the fetus which is particularly applies to alloimune thrombocytopenia. If 
this disease is confirmed intrauterine therapy with platelets should be performed to avoid 
fetal cerebral hemorrhage. In disorders that can lead to severe fetal anemia as a result of 
hemolysis (Rh or Kell alloimmunisation, parvovirus B19 infection) cordocentesis can 
directly determine the degree of anemia and provide a specific basis for planning an 
intrauterine transfusion (Bowman, 1991). The use of Doppler  peak velocity to assess the 
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degree of fetal anemia reduce the need for fetal blood sampling. However, cordocentesis is 
always indicated when history, maternal titers or MCA Doppler  show a risk of anemia. 
Correlation between biophysical profile scoring (BPS) and fetal PH on cordocentesis, reduce 
percentage of fetal blood sampling in the determination of fetal blood gases and acid-base 
status, because BPS can be safely use to indicate fetal PH without invasive method. But 
because neither the BPS patterns nor Doppler findings provide clear-cut evidence of fetal 
compromise in all cases, cordocentesis can be a useful adjunct to the noninvasive tests, 
especially in cases of severe growth retardation. In cases with abnormal Doppler flow with a 
normal BPS score, cordocentesis can confirm or exclude chronic fetal asphyxia. 
4.3 Complications 
The overall complication rate of cordocentesis is slightly higher than that of amniocentesis. 
Besides the risk that are the same as for amniocentesis such as: abortion,  membrane rupture 
and chorioamnionitis, there are additional risks that are specific for cordocentesis. Fetal loss 
rate related to cordocentesis  reported to be as high as 6-7% in centers with low experience, 
but in experienced hands the rate is as low as 1-2%. Overall pregnancy loss rate depends 
largely on the fetal condition for which cordocentesis is done. The rate of pregnancy loss is 
worse in cases of fetal anomalies and abnormal karyotype (Tongsong et 
al.,2001).Unfortunately no controlled trials are yet available and it is not quite clear what is 
the fetal loss rate to quote to patients, because most clinical series contain many high risk 
cases such as stated before. The most common complication of cordocentesis is fetal 
bradycardia. The rate of fetal bradycardia reported in literature is 6,6%. In most cases it is 
transient, self-limited and with no long-term concequences. It is related to uterine 
contraction directly at the cord insertion or  fetal movement against the umbilical cord by 
the contraction. Profound or prolonged bradycardia occurs in less than 3% of cases and it is 
associated with umbilical artery vasospasm after puncture of the umbilical cord or tetanic 
uterine contraction, which is rar. Early gestational age and hydrops fetalis correlated 
significantly with the development of bradycardia at cordocentesis. The other risk groups, 
including fetuses with intrauterine growth retardation, the puncture site, and the number of 
puncture attempts did not correlate with fetal bradycardia  (Preis et al.,2004). Transient 
bleeding from the umbilical cord puncture, called the “jet phenomenon” is a relatively 
common, innocuous finding after cordocentesis and it lasts no more than 2 minutes.The 
bleeding from the artery is reported to be longer than that from the vein. Differences among 
centers with respect to bleeding may relate to the size of the needle used and the technique 
employed.Bleeding over 300 seconds or massive hemorrhage occurs less than once per 200 
cordocentesis. When this occurs a viable fetus should be delivered by emergency cesarean 
section. Hematomas of the cord have been observed in pathologic specimens with the 
freehand technique, although most are not associated with adverse sequelae (Kay et 
al.,2011). The incidence of symptomatic cord hematoma  causing significant fetal 
bradycardia is very low. The risk of amnionitis is approximately 1% when the freehand 
technique is used and less than 0.3% when the needle-guided technique is used. Rarely, 
chorioamnionitis can lead to the development of maternal sepsis and adult respiratory 
distress syndrome. 
Maternal complications are also seen. Cordocentesis lasts longer than amniocentesis, so 
the mother will more likely be anxious and have more discomfort. On the other hand, 
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cordocentesis is less uncomfortable than CVS, so the patients will less complain of pain 
and contractions.Acute rupture of membranes and preterm labor are very rare 
complications. 
Fetal-maternal transfusion has been reported after both cordocentesis and amniocentesis, 
especially when the placenta was anterior. It is imperative that Rh-negative women be given 
Rh immunoglobulin after a procedure unless the fetus is known to be Rh-negative or the 
patient is already sensitized (Rujiwetpongstorn et al.,2005) 
The safety of cordocentesis is believed to be both technique-dependent and experience-
dependent. Fewer punctures are reported with the freehand technique, but a lower 
fetal/neonatal loss rate is reported with the needle-guided technique. The rate of bleeding is 
reported to be reduced with the needle-guided technique and with the use of smaller gauge 
needles. Several investigators have found  a greater number of complications among their 
first 30 procedures. 
5. Other invasive diagnostic procedures 
On infrequent occasions, analysis of other fetal tissues may be required. Because they are 
only rarely required, their use is usually confined to only a few regional referral centers in 
hopes of limiting procedural risk. Fetal skin biopsy is indicated for diagnosis of some type of 
genodermatosis or congenital dermoepidermic disorders which is  expected to be lethal in 
short or medium terms. Those disorders are: bullous epidermolysis, anhidrotic ectodermic 
dysplasias, keratinization disorders and pigmentary atopies (Elias et al.,1994). It can also be 
helpful in the workup of fetal mosaicism for some chromosomes, such as 22 chromososme, 
which are known not to be manifest in fetal blood. Fetal muscle biopsy is used to diagnose 
Duchenne’s muscular dystrophy in a male fetus if DNA testing is not informative (Nevo et 
al.,1999). It can also be used to detect other hereditary myopathies as long as there is some 
clinical family history of these disorders. Fetal liver biopsy was the only means of 
diagnosing fetuses with inborn errors of the urea cycle such as ornithine transcarbamylase 
deficiency, carbamoylphosphate synthetase deficiency and other disorders expressed only 
in the liver such as von Gierke glycogen-storage disease type IA and primary hyperoxaluria 
type I (Haberle et al.,2004). However, most of these conditions are now diagnosable by DNA 
analysis (without the need for histology and enzymatic assays) of cells extracted from either 
chorionic villi or amniocytes. Direct genetic analysis of chorionic villi is feasible, fast and 
specific and can be regarded as the primary choice  for prenatal diagnosis of these rare 
conditions. The procedure which is used more frequent than the previous described is 
aspiration and biochemical analysis of fetal urine for the evaluation of fetal renal function. 
This evaluation is essential in determination of fetuses whose kidneys are not irreversible 
damaged and who will have the benefit from intrauterine derived therapy.The biochemical 
markers that have close relation with the renal function are defined by Na,Cl, beta-2 
microglobuline and osmotic urine (Troyano et al., 2002).Other punctures on fetal tumor 
formations such as teratomas or liquid collections such as pericardiocentesis do not have an 
acceptable justification from a diagnostic point of view, as the echographic evaluation and 
the present application of biophysical methods give an acceptable identification of their 
vascularisation and origin, including those of suspicious neoplasm. 
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More than 40-year history of invasive procedures has seen a rise and than a fall in the 
degree of invasiveness of the procedures. The decades of invasive diagnostic procedures  
have given us a unique opportunity to study the fetus. They have contributed to our 
understanding of human fetal physiology, metabolism, and disease. However, the 
introduction of non-invasive procedures has diminished the need for some invasive 
procedures, in the first place for cordocentesis. As molecular genetics shrinks the role of 
cordocentesis for prenatal diagnosis of hereditary disease and as cytogenetic techniques 
make inroads that supplant the need for fetal blood sampling to obtain a rapid karyotype, it 
is likely that there will be fewer indications for cordocentesis in the next decade. A 
diminished role for cordocentesis will demand further regionalization of care in order for 
some persons to maintain the skill and further the knowledge base of normal fetal 
physiology and fetal disease. On the other hand amniocentesis still remains the gold 
standard for karyotyping, especially now that rapid diagnostic methods are available. Will 
nowdays invasive proceduers suffer the same fate as fetoscopy—here one day, gone 
another—or will the indications for them gradually be refined, limiting its practice to 
situations not suitable for noninvasive fetal testing remains to be shown. Invasive 
procedures may become obsolete when reliable non-invasive prenatal diagnosis becomes 
available. 
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1. Introduction 
Hypophosphatasia (HPP) is an inherited disorder characterized by defective mineralization 
of the bone and low activity of alkaline phosphatase (ALP; EC 3.1.3.1) (Mornet, 2008). 
Screening for mutations in the ALPL gene allows genetic counseling and prenatal diagnosis 
of the disease in families with severe forms of HPP. 
2. Hypophosphatasia 
HPP is a clinically heterogeneous disease and classified into at least six forms according to 
severity and age of onset: perinatal (lethal), perinatal (benign), infantile (MIM [Mendelian 
Inheritance in Man] # 241500), childhood (MIM# 241510), adult (MIM# 146300), and 
odontohypophosphatasia (Mornet, 2008) (Table 1). All forms of HPP display reduced activity 
of unfractionated serum ALP and the presence of either one or two pathologic mutations in 
the liver/bone/kidney alkaline phosphatase gene (ALPL, MIM# 171760), the gene encoding 
ALP, the tissue-nonspecific isozyme (TNSALP). There is no curative treatment for HPP to date.  
2.1 ALPL gene 
ALPL is the only gene known to be associated with HPP. ALPL consists of 12 exons: 11 
coding exons and one untranslated exon. More than250 ALPL mutations have been 
described in persons from North America, Japan, and Europe (The Tissue Nonspecific 
Alkaline Phosphatase Gene Mutations Database). HPP is frequently caused by p.E191K and 
p.D378V in Caucasian, whereas p.F327L and c.1559delT are more common in Japanese(the 
first nucleotide (+1) corresponds to the A of the ATG initiation codon using the ALPL cDNA 
number of the standard nomenclature). This variety of mutations in ALPL results in highly 
variable clinical expression and in a great number of compound heterozygous genotypes. 
2.2 Perinatal (lethal) form of hypophosphatasia 
The perinatal (lethal) form of HPP (pl-HPP) is the most severe HPP with an autosomal 
recessive mode of inheritance (Gehring et al., 1999) In the lethal perinatal form, the patients 
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show markedly impaired mineralization in utero (Fig.1). Pregnancies may end in stillbirth. 
Some infants survive a few days with pulmonary complication due to hypoplastic lungs and 
rachitic deformities of the chest. Hypercalcemia is common and may be associated with 
apnea or seizures.  
 
Type Inheritance MIM Symptoms 
Perinatal  (lethal) AR Hypomineralization, 
osteochondral spurs 
Perinatal  (benign) AR or AD Long-bone bowing, benign 
postnatal course 
Infantile  AR 241500 Craniosynostosis, 
Hypomineralization, rachitic ribs, 
hypercalciuria, Premature loss, 
deciduous teeth
Childhood AR or AD 241510 Short stature, skeletal deformity, 
bone pain/fractures, Premature 
loss, deciduous teeth
Adult  AR or AD 146300 Stress fractures: metatarsal, tibia; 
chondrocalcinosis 
Odontohypophosphatasia AR or AD Exfoliation (incisors), dental caries 
, Alveolar bone loss
Table 1. Clinical Features of Hypophosphatasia by Type. AD; autosomal dominant, AR; 
autosomal recessive 
 
Fig. 1. Ultrasonography examination at 19 weeks’ gestation of pl-HPP fetus 
The upper limb(A) femur(B) at 19 weeks’ gestation was shortened with no evidence of 
fractures. The cranium(C) at 19 weeks’ gestation was thin with marked hypomineralization. 
pl-HPP is more common in Japan than in other countries (Satoh et al. 2009). Parents of pl-
HPP are heterozygous carriers of ALPL mutations. They show no clinical symptoms, but 
have reduced serum ALP activity and increased urinary phosphoethanolamine (PEA).  
2.3 c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of 
hypophosphatasia in Japan 
c.1559delT in ALPL is a common mutation resulting in pl-HPP in Japan and has only been 
found in Japanese to date (Orimo et al., 2002; Michigami et al., 2005). Symptoms caused by 
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deletions and insertions of nucleotides that change the reading frame will be highly 
deleterious. Some patients with pl-HPP are homozygous for c.1559delT, with parents who 
are heterozygous carriers for the mutation but with no evidence of consanguinity (Fig. 2) 
(Sawai et al. 2003). Patients who are homozygous for the c.1559delT mutation differed in the 
severity of HPP, including both their symptoms and serum ALP activity. In the c.1559delT 
mutation, the symptom in HPP of homozygous mutation is responsible for a severe 
phenotype, but that of compound hetero varies from severe to mild that depends on 
mutation position in other allele. 
 
Fig. 2. Direct sequencing results around 1559delT in ALPL from a pl-HPP patient both 
parents, and healthy control. The sequence of the parents could not be determined in 
progress at cDNA number 1559 of the ALPL and these results indicate both parents were 
heterogenous carriers for 1559delT. The sequence of the pl-HPP patient could be 
determined in progress containing the deletion of T at nucleotide 1559, which was 
different from that of a healthy control and indicates that the fetus is homozygous for a 
1559delT of the ALPL. 
c.1559delT, a deletion of T at 1559, which caused a frameshift downstream from leucine 
(Leu) at codon 503, resulted in the elimination of the termination codon at 508 and the 
addition of 80 amino acid residues at the C-terminus. The mutant protein caused by 
1559delT formed an aggregate, was polyubiquitinated, and was then degraded in the 
proteome (Komaru et al., 2005), thus allowing us to directly correlate the phenotype 
(perinatal type) and the genotype (1559delT). 
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The c.1559delT carrier frequency is 1/480 (95% confidence interval, 1/1,562-1/284) in Japanese 
(Watanabe et al. 2011). This indicates that approximately 1 in 900,000 individuals to have pl-
HPP caused by a homozygous c.1559delT mutation. The majority of c.1559delT carriers had 
normal values of HPP biochemical markers, such as serum ALP and urine PEA. The only way 
to reliably detect the pl-HPP carriers is to perform the ALPL mutation analysis. 
2.4 Prenatal diagnosis for perinatal (lethal) form of hypophosphatasia 
pl-HPP has been diagnosed in utero by ultrasonography performed with careful attention to 
marked hypomineralization of the limbs and the skull (Fig.1) (Tongsong & Pongsatha, 2000). 
The differential diagnosis of HPP depends on the age at which the diagnosis is considered. 
Ultrasonography examination in prenatal stage may lead to a consideration of osteogenesis 
imperfecta type II, campomelic dysplasia, and chondrodysplasias with defects in bone 
mineralization, as well as pl-HPP. Experienced sonographers usually have little difficulty in 
distinguishing among these disorders. However, pl-HPP is occasionally not diagnosed with 
sonographic examination in the first trimester because incomplete ossification is a normal 
finding at this stage of development (Zankl, 2008).  
Prenatal assessment for pregnancies at increased risk of severe HPP by mutation analysis is 
possible if two HPP causing ALPL mutations of an affected family member are identified 
(Watanabe et al., 2007). Most of pl-HPPs are related to c.1559delT in Japan (Watanabe et al., 
2011), but to usually compound heterozygotes, carrying two distinct mutations in US and 
France (Simon-Bouy et al., 2008). In Japan,screeing of c.1559delT is important to diagnose pl-
HPPs. In out of Japan, mutations occur throughout the entire gene without hot spots. To detect 
different mutations, all exon screening of ALPL is needed. In prenatal genetic diagnosis, fetal 
genomic DNA was extracted from chorionic villus at approximately ten to 12 weeks' gestation 
or cultured cells of amniotic fluid at approximately 15 to 18 weeks' gestation. 
A prenatal genetic diagnosis for HPP gives a couple important information about the fetus. 
Prenatal genetic diagnosis for HPP in combination with ultrasonography is thus considered 
useful for confirming a diagnosis of HPP, which presents with a wide variety of phenotypes. 
2.5 Genetic counseling for perinatal (lethal) form of hypophosphatasia 
Genetic counseling for pl-HPP has two situations, family with an affected first child (index 
case) or fortuitous prenatal skeletal dysplasia in a family without history of HP (no index 
case) (Fig. 3) (Simon-Bouy et al., 2008). First, a couple with an index case with recessive form 
of pl-HPP will have in subsequent pregnancies affected children similar to the index case 
with a 25% chance of recurrence. However, the severity of symptoms in HPP may differ 
from one child to another even in the same mutation (Nakamura-Utsunomiya, 2010). 
Second, in pl-HPP, pregnancies with clinical symptoms could be detected by ultrasound 
with no familial history of pl-HPP (no index case). The screening for c.1559delT in ALPL 
may be useful for diagnosis of pl-HPP in Japanese. Detection of 1559delT mutation confirms 
the diagnosis of severe HPP, and an attempt to predict the severity of the disease. Postnatal 
molecular genetic analysis using the cord tissue can provide a diagnosis of pl-HPP allows 
time for parental counseling and delivery planning. In addition, Enzyme replacement 
therapy (Millán JL et al., 2008) and gene therapy (Yamamoto et al., 2011) will be certainly the 
most promising challenge. Confirmation of the diagnosis of HPP by ALPL genetic testing 
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will be indispensable before starting the treatment, and perhaps the characterization of the 
mutations will orient and personalize the treatment in future.  
 
Fig. 3. Pedigree examples of two situations in genetic counseling for pl-HPP: A) family with 
an affected first child (index case) or B) fortuitous prenatal skeletal dysplasia in a family 
without history of HP (no index case) 
A prenatal diagnosis should be provided in a supportive, noncoercive atmosphere that 
allows the couple to make informed choices regarding what is are best for them in view of 
their values and parenting goals. Genetic counseling is particularly important before 
prenatal diagnosis to enable parents to make an informed choice. Counseling before testing 
makes counseling after testing (for those with an affected fetus) less difficult because 
prospective parents are better prepared. Careful counseling regarding if and how to inform 
the parents about the child can help to overcome this potential problem. A prenatal genetic 
diagnosis may also help the professional team to prepare for a difficult delivery.  
3. Conclusion 
To diagnose pl-HPP in prenatal stage, collaborations between obstetricians and clinical 
geneticists are important and could provide support for parents of prenatal patients 
suspected of having skeletal dysplasia. 
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approach. The chapter will summarize the principal postnatal diagnostic features of the 
more common subgroups of fetal genetic skeletal disorders to be used as diagnostic tools by 
the fetal pathologist at autopsy.  
2. Current knowledge 
General information on the definitions, frequency, classification, as well as the possibilities 
and restrictions of prenatal sonographic and genetic molecular diagnosis is given below. 
2.1 Definitions  
All the entities included in the latest classification of genetic skeletal disorders present a 
significant skeletal involvement corresponding to the definition of osteochondrodysplasias, 
dysostoses, metabolic bone disorders, and skeletal malformation and/or reduction 
syndromes.  
The osteochondrodysplasias are disorders in the development and/or growth of cartilage 
and/or bone. The long bones are affected in a generalized manner with or without 
involvement of the membranous bone of the skull. The abnormalities are usually symmetric, 
and dwarfism is common and often disproportionate (Kornak & Mundlos, 2003). 
A dysostosis is a disturbance in the pattern of the chondroid anlage as an organ. A 
dysostosis affects one or a few skeletal elements while the other bones remain normal. 
Dysostoses are caused by defects in signalling during organogenesis. These disorders can be 
asymmetric, there is usually no dwarfism and chondro-osseous histology is often normal.  
2.2 Incidence – Frequency 
The overall incidence of genetic skeletal disorders has been estimated to approximately 2 in 
10,000 births (range according to the literature 2-5/10,000) (Rasmussen et al., 1996). Of those, 
the frequency of lethal skeletal dysplasias among stillborn and liveborn infants is 1 in 4,000 - 
6,000 (Nikkels, 2009). A percentage of 23% of affected fetuses are stillborn, while a 32% die 
during the first week of life. The perinatal mortality rate due to skeletal dysplasias is 
estimated to 0.9% (Goncalves & Jeanty, 1994). The frequency among perinatal autopsies 
ranges from 1 in 50 to 1 in 100 (Konstantinidou, 2009; Nikkels, 2009). Overall, the skeletal 
dysplasias that are more frequently encountered are Thanatophoric dysplasia, 
Achondroplasia, Osteogenesis Imperfecta, Achondrogenesis, and the Short-Rib with or 
without Polydactyly syndromes (Jeanty et al., 2003, Konstantinidou et al., 2009). 
Thanatophoric dysplasia, Osteogenesis Imperfecta and Achondrogenesis constitute the 
majority of lethal skeletal dysplasias (Konstantinidou et al., 2009). Achondroplasia is the 
more frequent nonlethal skeletal dysplasia.  
2.3 Classification  
Since the mid-1960s the knowledge of skeletal dysplasias has significantly expanded and 
numerous new entities have been identified (Gilbert-Barness, 2007). Before then, a 
disproportionately short stature was called without any distinction by clinicians as 
“achondroplasia” (attributed to short limbs) or “Morquio disease” (attributed to a short 
trunk). The lack of knowledge and the scarcity of individual skeletal dysplasias, in 
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association with the large heterogeneity, phenotypic variability and overlapping features of 
skeletal dysplasias led to a significant diagnostic controversy surrounding the skeletal 
dysplasias. The terminology has been basically descriptive, based on the clinical evolution 
(e.g. thanatophoric dysplasia - greek thanatos = death, phero = to bear: the dysplasia that 
bears death), the clinical description (e.g. campomelic dysplasia - greek campsis = curving, 
benting / meli = limbs: the dysplasia with curved or bent limbs), the assumed pathogenesis 
(e.g. osteogenesis imperfecta, achondrogenesis), or the name of investigators that first 
described the disease (e.g. Ellis-van Creveld syndrome).  
With time, acquired knowledge in the field of molecular and clinical genetics has 
significantly contributed to the distinction and classification of skeletal disorders. A first 
significant classification was created in 1970 in Paris, and was subsequently revised in 1978 
and 1983, while a substantial classification took place in 1998 and was revised in 2002, 2006 
and 2010 (INCO, 1998; Hall, 2002; Superti-Furga & Unger, 2007; Warman et al., 2011). 
However, in the recent years, the number of recognized genetic disorders with a significant 
skeletal component is growing and the distinction between dysplasias, metabolic bone 
disorders, dysostoses and malformation syndromes is blurring. Molecular evidence leads to 
confirmation of individual entities and to the constitution of new groups but also allows for 
delineation of related but distinct entities and indicates a previously unexpected 
heterogeneity of molecular mechanisms. Thus, accumulating molecular evidence does not 
necessarily simplify the Nosology, and a further increase in the number of entities and 
growing complexity is expected. For classification purposes, in the latest revision, the 456 
genetic skeletal disorders included are placed in 40 groups defined by molecular, 
biochemical and/or radiographic criteria. For classification purposes, pathogenetic and 
molecular criteria are integrating with morphological ones, but disorders are still identified 
by clinical and radiographic criteria (Warman et al., 2011).  
According to our experience in diagnosing fetal skeletal dysplasias, the latest Revisions of the 
Nosology and Classification placing the genetic skeletal disorders in groups, have proved 
most useful in providing a list of conditions entering the differential diagnosis, once the main 
group has been recognized. In our cases of fetal autopsy, the diagnostic approach is still based 
on morphological features, radiographic appearance, pathological and histological findings. 
2.4 Prenatal ultrasonography in skeletal dysplasias  
Prenatal diagnosis is initially based on the sonographic detection, most commonly during 
the second gestational trimester. Several previously published series have emphasized on 
the diagnostic and prognostic implications of prenatal ultrasonography in fetal skeletal 
disorders (Doray et al., 2000; Parilla et al., 2003; Krakow et al., 2008; Witters et al., 2008). 
Two-dimensional ultrasonography may detect the majority of skeletal dysplasias, however, 
difficulties in the diagnosis as well as in the differential diagnosis are frequently arising. The 
use of further imaging modalities or invasive procedures is sometimes necessary in order to 
detect or exclude an underlying chromosomal or singe gene disorder. An accurate diagnosis 
is essential to allow adequate genetic counseling as well as further management of the case. 
For this approach, the three-dimensional ultrasonography and three-dimensional computed 
tomography may provide more detailed imaging results, whereas the role of fetal MRI may 
prove to be useful in the future. Despite the indisputable progress that has been achieved in 
the last years, in some cases the antenatal detection delays and is feasible only at the late 
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second or even at the third gestational trimester. This may generate serious bioethical 
concern as well as difficulties in the management and the genetic counseling, particularly in 
cases of lethal skeletal dysplasias. 
Prenatal ultrasound can detect cases of dwarfism and several other skeletal malformations, 
while there are sonographic measurements that serve as good predictors of lethality (Parilla 
et al., 2003). Lethality is usually due to thoracic underdevelopment and lung hypoplasia. 
Sonographic markers of lethality are mainly based on the assessment of lung biometry, 
measurements of chest circumference (CC) and its relation to the abdominal circumference 
(AC), femur length (FL), and finally assessment of the pulmonary arteries by Doppler 
ultrasonography. Thus, measurements of CC lower than the 5th centile, CC/AC <5th centile,  
chest/trunk length ratio <0.32, lung area <5th centile, right lung area/thoracic area ratio 
<0.11, and FL/AC <0.16, are considered as markers of lethality of high predictive value 
(Parilla et al., 2003). The presence of curved or bent femora should be taken into 
consideration when estimating the femur length in order to assess lethality, as in such 
conditions the bone may be longer than it appears. In the lethal skeletal dysplasias, the 
femur length is shorter with a deviation of 6.7 weeks from the 50th centile during the second 
trimester of gestation, whereas in those compatible with life the deviation is of 4.2 weeks 
(Parilla et al., 2003). The discordance between lethal and non lethal dysplasias is raised with 
advancing gestation. In achondrogenesis, the femur length is 30% of the normal mean, in 
osteogenesis imperfecta type 2 and thanatophoric dysplasia type 1 it measures 40-60% of the 
normal mean, while in the nonlethal achondroplasia and hypochondroplasia is as high as 
80% (Goncalves et al., 1994). 
Despite the accuracy in predicting lethality, however, in cases of skeletal malformations, as 
in all cases of fetal malformations, a specific diagnosis is necessary not only for the 
prognosis of the current pregnancy, but also to assess recurrence risk in subsequent 
pregnancies and enable genetic counseling and future prenatal diagnosis. Given that 
prenatal ultrasound accuracy in the final diagnosis of genetic skeletal disorders remains 
relatively low, ranging from 18% to 65% in published series (Doray et al., 2000; Parilla et al., 
2003; Krakow et al., 2008; Witters et al., 2008; Konstantinidou et al., 2009; Hatzaki, et al., 
2011), the impact of the specific diagnosis is still dependent on the molecular genetic or 
postmortem examination. 
2.5 Prenatal molecular genetic control in skeletal dysplasias  
Out of 456 entities included in the latest Revision of the Nosology (Warman et al., 2011), 215 
are associated with one or more of 226 different genes. The nosologic status has been 
classified as final (mutations or locus identified), probable (pedigree evidence), or bona fide 
(multible observations and clear diagnostic criteria, but no pedigree or locus evidence yet). 
Among the skeletal dysplasias that can be encountered in the fetus at autopsy, several have 
a known underlying molecular defect. Examples include type 1 collagenopathies (e.g. 
osteogenesis imperfecta type 1, 2 and 3 with COL1A defects), type 2 collagenopathies (e.g. 
achondrogenesis type 2 and hypochondrogenesis with COL2A defects) and the group of 
fibroblast growth factor receptor defects (e.g. thanatophoric dysplasia, achondroplasia and 
hypochondroplasia with FGFR3 mutations). This last group comprises practically the vast 
majority of the cases that are prenatally diagnosed by molecular genetic method (Hatzaki et 
al., 2011). The possibility of molecular analysis for mutations in selected exons of the FGFR3 
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gene by PCR amplification of fetal DNA extracted from amniotic fluid cells has led to an 
increased demand for FGFR3 testing. This has become part of a routine prenatal control 
when a preliminary diagnosis of “skeletal dysplasia” is set by ultrasonography, regardless 
of the phenotypic relevance to the FGFR3 group of skeletal disorders. Thus, in many 
instances, the prenatal FGFR3 molecular control proves to be irrelevant with the case, and 
should be substituted by molecular confirmation of other underlying defects, as indicated 
by the postmortem diagnosis.     
3. Postmortem examination: The role of the pathologist  
More than 50 skeletal dysplasias are identifiable at birth, the list being rapidly expanding 
(Krakow et al., 2008). Fetuses with skeletal disorders are frequently subjected to postmortem 
examination following prenatal ultrasonographic pathological findings and interruption of 
pregnancy or after intrauterine fetal demise.  
Despite the scarcity of individual skeletal dysplasias, our experience is that the 
fetopathologist frequently deals with this group of disorders at fetal or perinatal autopsy 
and is responsible, in everyday practice, for the correct identification of such conditions. In 
the department of Pathology of Athens University, where consult cases of fetal autopsies are 
received from central and district hospitals in Greece, the frequency of fetal/perinatal 
skeletal dysplasias has raised to 1 in 40 over a 15-year period. Affected fetuses of the second 
trimester of gestation form the majority in the series of our patients. Liveborn infants 
affected with perinatally lethal skeletal dysplasias on the other hand are only a small 
minority, usually the offspring of families with a low socio-economic background that have 
not received prenatal follow-up. Increasing expertise in prenatal ultrasound has led to 
increased and more accurate early identification of fetal skeletal dysplasias. Prenatal 
identification of a presumably lethal skeletal dysplasia raises the option of termination of 
the pregnancy. Molecular characterization is often carried out prenatally, particularly for the 
family of FGFR3 gene mutations. In the case of positive results for a FGFR3 gene mutation, 
termination of pregnancy is often decided by the parents and the fetus is sent for autopsy. 
Postmortem examination in the context of a known molecular defect, apart from the 
confirmation of the diagnosis, may also be of scientific interest: the pathologist may observe 
and record phenotypic variability under the same molecularly defined entity with a single 
mutation, or contribute to a phenotype-genotype correlation in entities with mutational 
variability. When there is no molecular diagnosis preceding autopsy, the fetopathologist is 
responsible for the diagnostic approach, given that the prenatal ultrasonographic evaluation 
can usually predict lethality, but very often fails to identify the particular type of skeletal 
dysplasia, which is necessary for genetic counseling and future prenatal diagnosis. 
Significant phenotypic overlapping and relatively limited knowledge of the genetic 
background are the main sources of controversy in the diagnosis of these disorders. Thus, in 
everyday practice, the diagnosis and prognosis still depend on the postmortem 
radiographical, pathological and histopathological findings.  
Although the assistance of an experienced paediatric radiologist or clinical geneticist in the 
interpretation of the postmortem radiography is desirable, this is not always feasible in many 
countries, because of lack of expertise. Under these circumstances, the fetopathologist should 
be able to deal with the radiographic interpretation of, at least, the more common among 
skeletal dysplasias and refer the remaining cases to specialized referral centers. Radiological 
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second or even at the third gestational trimester. This may generate serious bioethical 
concern as well as difficulties in the management and the genetic counseling, particularly in 
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gene by PCR amplification of fetal DNA extracted from amniotic fluid cells has led to an 
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by the postmortem diagnosis.     
3. Postmortem examination: The role of the pathologist  
More than 50 skeletal dysplasias are identifiable at birth, the list being rapidly expanding 
(Krakow et al., 2008). Fetuses with skeletal disorders are frequently subjected to postmortem 
examination following prenatal ultrasonographic pathological findings and interruption of 
pregnancy or after intrauterine fetal demise.  
Despite the scarcity of individual skeletal dysplasias, our experience is that the 
fetopathologist frequently deals with this group of disorders at fetal or perinatal autopsy 
and is responsible, in everyday practice, for the correct identification of such conditions. In 
the department of Pathology of Athens University, where consult cases of fetal autopsies are 
received from central and district hospitals in Greece, the frequency of fetal/perinatal 
skeletal dysplasias has raised to 1 in 40 over a 15-year period. Affected fetuses of the second 
trimester of gestation form the majority in the series of our patients. Liveborn infants 
affected with perinatally lethal skeletal dysplasias on the other hand are only a small 
minority, usually the offspring of families with a low socio-economic background that have 
not received prenatal follow-up. Increasing expertise in prenatal ultrasound has led to 
increased and more accurate early identification of fetal skeletal dysplasias. Prenatal 
identification of a presumably lethal skeletal dysplasia raises the option of termination of 
the pregnancy. Molecular characterization is often carried out prenatally, particularly for the 
family of FGFR3 gene mutations. In the case of positive results for a FGFR3 gene mutation, 
termination of pregnancy is often decided by the parents and the fetus is sent for autopsy. 
Postmortem examination in the context of a known molecular defect, apart from the 
confirmation of the diagnosis, may also be of scientific interest: the pathologist may observe 
and record phenotypic variability under the same molecularly defined entity with a single 
mutation, or contribute to a phenotype-genotype correlation in entities with mutational 
variability. When there is no molecular diagnosis preceding autopsy, the fetopathologist is 
responsible for the diagnostic approach, given that the prenatal ultrasonographic evaluation 
can usually predict lethality, but very often fails to identify the particular type of skeletal 
dysplasia, which is necessary for genetic counseling and future prenatal diagnosis. 
Significant phenotypic overlapping and relatively limited knowledge of the genetic 
background are the main sources of controversy in the diagnosis of these disorders. Thus, in 
everyday practice, the diagnosis and prognosis still depend on the postmortem 
radiographical, pathological and histopathological findings.  
Although the assistance of an experienced paediatric radiologist or clinical geneticist in the 
interpretation of the postmortem radiography is desirable, this is not always feasible in many 
countries, because of lack of expertise. Under these circumstances, the fetopathologist should 
be able to deal with the radiographic interpretation of, at least, the more common among 
skeletal dysplasias and refer the remaining cases to specialized referral centers. Radiological 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
38
diagnosis in very young fetuses may occasionally be very difficult, as some bones are not yet 
mineralized and only the chondroid anlage is present. Genetic metabolic diseases and 
malformation syndromes involving the skeleton are also difficult to diagnose at autopsy, 
demanding from the pathologist knowledge and skills of clinical dysmorphology and clinical 
genetics. The diagnostic difficulties are obvious, such as the restricted or incomplete 
phenotype at an early gestational age and the eventual lack of typical morphological or clinical 
hallmarks of the syndrome in utero (e.g. mental retardation, hearing deficit, hair loss etc). 
Despite these restrictions, however, there are many examples where an alert and experienced 
fetopathologist has first provided the affected family with a correct diagnosis of a genetic 
syndrome, based on the postmortem examination of an affected fetus.  
4. Methods  
In a combined retrospective and prospective study, we have gathered radiological, physical, 
gross pathological and histopathological data on 50 cases of genetic skeletal disorders 
diagnosed among 2250 fetal and perinatal autopsies carried out at the Department of 
Pathology of the University of Athens over a 12-year period.   
The methodology for postmortem examination of the fetus with skeletal dysplasia included 
radiographic control, photographs, external inspection, gross inspection of all organs 
including the brain, organ dissection and sampling for microscopical examination, and, 
finally, sampling from the bones and cartilage for histological, histochemical and 
occasionally immunohistochemical staining.  
4.1 Radiography  
Χ-rays/babygram both anteroposterior and lateral, using a Faxitron Cabinet X-Ray System, 
were taken in the following instances: in all cases identified as possible “skeletal dysplasias” 
on prenatal ultrasonographic examination; in cases suspect of skeletal dysplasia on external 
inspection; in cases of external deformities. Measurements of the length of the long bones 
and spine on the X-ray were compared to normal values of fetal long bone growth and spine 
(van der Harten, 1990). 
4.2 Autopsy - Histopathology   
Detailed autopsy with histological sampling from various organs was performed in all 
cases. Bone samples included the head of the femur or humerus with the metaphysis and 
part of the diaphysis in all cases. A midsagittal section of lumbar vertebral bodies and the 
costochondral junction of the ribs were occasionally available. After fixation in 10% formalin 
and decalcification in 0,5M EDTA, paraffin sections were stained with Hematoxylin-Eosin, 
Periodic-acid-Schiff (PAS) and PAS after diastase predigestion, and occasionally additional 
Alcian blue and Masson trichrome stains were used. The bones were cut longitudinally to 
include the resting cartilage, growth plate, and primary spongiosa of the metaphysis .  
4.3 Molecular genetic analysis  
Molecular genetic control was available and confirmed the diagnosis in 12 cases. Of those, 6 
referred to mutations of the FGFR3 gene, prenatally or postnatally tested by PCR 
amplification analysis. The mutations tested included R248C and S249C for Thanatophoric 
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dysplasia, G380R for Achondroplasia and N540K for Hypochondroplasia, as previously 
published (Konstantinidou et al., 2009; Hatzaki et al., 2011). Molecular genetic control was 
also available in selective cases of Osteogenesis Imperfecta, Greenberg dysplasia and 
Cranioectodermal dysplasia (Konstantinidou et al., 2009). 
5. Results  
In our series of 2250 autopsied fetuses and infants, 50 cases could be identified as genetic 
skeletal disorders and were grouped under 13 of the 40 groups included in the 2010 
Revision of the Nosology (Warman et al., 2011). The various types of skeletal dysplasias 
included in our series are shown in Table 1. 
Among the overall group of fetal genetic skeletal disorders, the skeletal dysplasias 
(osteochondrodysplasias) were the more common (87.5%), followed by the limb 
hypoplasia/reduction group (12%) and the dysostoses (10%). The larger group of 
osteochondrodysplasias was the group of FGFR3 defects (20%). The more common types of 
osteochondrodysplasia were Thanatophoric dysplasia (16%), Osteogenesis Imperfecta 
(14%), and the group of Short-Rib dysplasia - with or without polydactyly (14%). 
Achondrogenesis/Hypochondrogenesis cases, although perinatally lethal, were not 
common in our series of autopsies (4%), in contrast with other published autopsy series 
(Nikkels et al., 2009). Fetal age at autopsy ranged from 12 to 37.4 weeks with a mean of 20.5 
weeks. There was a predilection for male gender among skeletal disorders (male to female 
ratio 3:1). Lethal osteochondrodysplasias represented a majority of 58% among the 
diagnosed genetic skeletal disorders. The remaining 42% belonged to groups that are known 
to be non lethal or not always lethal, presenting, however, severe morbidity in most cases. 
Lethality could be accurately predicted by prenatal ultrasonography, based on the 
identification of thoracic underdevelopment and severe limb shortening. 
The main ultrasonographic findings that led to a presumptive prenatal diagnosis of “skeletal 
dysplasia” were short limbs, curved femora, narrow thorax, fractures and acrania (lack of 
skull ossification). At postmortem examination, several cases of short femora were 
attributed to intrauterine growth restriction (IUGR), with no signs of a genetic skeletal 
disorder. Short and/or curved limbs were seen in a variety of skeletal dysplasias other than 
thanatophoric dysplasia. Fractures were seen in the context of osteogenesis imperfecta, 
achondrogenesis type 1A, hypophosphatasia and gracile bone dysplasia 
(osteocraniostenosis, osteocraniosplenic syndrome). Acrania was a feature of osteogenesis 
imperfecta type 2A, achondrogenesis type 2A and osteocraniostenosis. 
Correct typing coinciding with the final postmortem diagnosis was achieved in only 25% of 
cases by ultrasonography. Lack of knowledge of the large variety of the less common 
skeletal dysplasias was the main reason of prenatal ultrasonographic diagnostic failure. 
Curved or angular bent femora were occasionally mistaken for fractured limbs, misleading 
the presumptive prenatal diagnosis towards the conditions that appear with fractures, such 
as osteogenesis imperfecta. 
6. Description of the more common genetic skeletal disorders  
The more common among the fetal skeletal disorders encountered in our series will be 
presented briefly below. The group number refers to the order of the 2010 Revision of the 
Nosology and Classification of Genetic Disorders of Bone (Warman et al., 2011).  
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Revision of the Nosology (Warman et al., 2011). The various types of skeletal dysplasias 
included in our series are shown in Table 1. 
Among the overall group of fetal genetic skeletal disorders, the skeletal dysplasias 
(osteochondrodysplasias) were the more common (87.5%), followed by the limb 
hypoplasia/reduction group (12%) and the dysostoses (10%). The larger group of 
osteochondrodysplasias was the group of FGFR3 defects (20%). The more common types of 
osteochondrodysplasia were Thanatophoric dysplasia (16%), Osteogenesis Imperfecta 
(14%), and the group of Short-Rib dysplasia - with or without polydactyly (14%). 
Achondrogenesis/Hypochondrogenesis cases, although perinatally lethal, were not 
common in our series of autopsies (4%), in contrast with other published autopsy series 
(Nikkels et al., 2009). Fetal age at autopsy ranged from 12 to 37.4 weeks with a mean of 20.5 
weeks. There was a predilection for male gender among skeletal disorders (male to female 
ratio 3:1). Lethal osteochondrodysplasias represented a majority of 58% among the 
diagnosed genetic skeletal disorders. The remaining 42% belonged to groups that are known 
to be non lethal or not always lethal, presenting, however, severe morbidity in most cases. 
Lethality could be accurately predicted by prenatal ultrasonography, based on the 
identification of thoracic underdevelopment and severe limb shortening. 
The main ultrasonographic findings that led to a presumptive prenatal diagnosis of “skeletal 
dysplasia” were short limbs, curved femora, narrow thorax, fractures and acrania (lack of 
skull ossification). At postmortem examination, several cases of short femora were 
attributed to intrauterine growth restriction (IUGR), with no signs of a genetic skeletal 
disorder. Short and/or curved limbs were seen in a variety of skeletal dysplasias other than 
thanatophoric dysplasia. Fractures were seen in the context of osteogenesis imperfecta, 
achondrogenesis type 1A, hypophosphatasia and gracile bone dysplasia 
(osteocraniostenosis, osteocraniosplenic syndrome). Acrania was a feature of osteogenesis 
imperfecta type 2A, achondrogenesis type 2A and osteocraniostenosis. 
Correct typing coinciding with the final postmortem diagnosis was achieved in only 25% of 
cases by ultrasonography. Lack of knowledge of the large variety of the less common 
skeletal dysplasias was the main reason of prenatal ultrasonographic diagnostic failure. 
Curved or angular bent femora were occasionally mistaken for fractured limbs, misleading 
the presumptive prenatal diagnosis towards the conditions that appear with fractures, such 
as osteogenesis imperfecta. 
6. Description of the more common genetic skeletal disorders  
The more common among the fetal skeletal disorders encountered in our series will be 
presented briefly below. The group number refers to the order of the 2010 Revision of the 
Nosology and Classification of Genetic Disorders of Bone (Warman et al., 2011).  
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1. FGFR3 group  21. Chondrodysplasia punctata (CDP) group 
Thanatophoric dysplasia type 1 Chondrodysplasia punctata (CDPX2) 
Achondroplasia heterozygous HEM (Greenberg) dysplasia 
Hypochondroplasia 25. Dysplasias with decreased bone density 
2. Type 2 collagen group Osteogenesis Imperfecta type 2a 
Achondrogenesis  type 2              Osteogenesis Imperfecta type 2b 
Osteogenesis Imperfecta type 2c Spondyloepiphyseal dysplasia       
7. Filamin group 26. Abnormal mineralization group 
Atelosteogenesis type 1  Hypophosphatasia 
9. Short-rib dysplasia (with or without 
polydactyly) group:SR(P) 
27. Lysosomal storage diseases with skeletal 
involvement (dysostosis multiplex group) 
SR(P) 2 (Majewski) Mucopolysaccharidosis 
SR(P) 1/3 (Saldino-Noonan/Verma-
Naumoff) 
35. Dysostoses with predominant vertebral 
involvement, with and without costal involvement 
Chondroectodermal dysplasia (Ellis-van 
Creveld) 
Spondylocostal dysostosis /Jarcho-Levin 
syndrome 
15. Acromelic dysplasias 38. Limb hypoplasia-reduction defects group 
Cranioectodermal dysplasia 
(Sensenbrenner) 
Roberts syndrome  
18. Bent-bone dysplasia group De Lange syndrome 
Campomelic dysplasia Ectrodactyly-radial defect 
19. Slender bone dysplasia group Split Hand-Foot malformation with tibial 
hypoplasia 
Gracile bone dysplasia 
(Osteocraniostenosis) 
Femoral hypoplasia – Unusual facies  
IMAGE syndrome                          
Table 1. The various types of genetic skeletal disorders in our series 
6.1 Group 1: FGFR3 mutations group 
Index cases: Thanatophoric dysplasia type 1, Achondroplasia  
6.1.1 Thanatophoric dysplasia type 1 (TD1)  
This type of congenital skeletal dysplasia was the most common in our series (8/50 cases, 
16%). Prenatal ultrasonography detected all these cases as “skeletal dysplasias”, but the 
correct labelling of thanatophoric dysplasia was suggested by the ultrasonographic findings in 
four of them, all belonging to the latest chronological period of our series. As the name 
suggests, the condition is invariably lethal in the perinatal period. It is attributed to 
mutations in the gene encoding the Fibroblast Growth Factor Receptor (FGFR3). Most cases 
occur sporadically as a result of a de novo autosomal dominant mutation. Three of our cases 
were molecularly confirmed to host the 742C>T mutation, resulting in aminoacid change 
R248C within exon 7 of the FGFR3 gene (Konstantinidou et al., 2009; Hatzaki et al., 2011). 
The mean age at autopsy was 21.3 weeks, ranging from 20 to 24 weeks of gestation.  
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Fig. 1. Fetuses with Thanatophoric Dysplasia type 1 at 20 weeks (left) and 22.5 weeks (right) 
 
   
Fig. 2. Thanatophoric dysplasia type 1 at 20 and 32 weeks: Platyspondyly, short ribs, short 
tubular bones, curved femora with metaphyseal spikes, horizontally shortened ilia 
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All cases presented the following constant typical characteristics (Fig. 1): At external 
inspection the head was large with an increased fronto-occipital diameter. A flat nasal 
bridge and protruding tongue were typical facial characteristics. The thorax was narrow and 
bell-shaped and the abdomen distended. The upper and lower limbs were short in all 
respects (rhizomelic, mesomelic and acromelic shortening). All the linear somatometric 
measurements were affected in thanatophoric dysplasia, particularly the crown-heel and 
toe-heel lengths, as well as the cranial perimeter, chest and abdominal circumferences. 
X-rays (Fig. 2) show severe platyspondyly with H-shaped or U-shaped vertebral bodies, 
relatively short ribs, small horizontally shortened iliac bones with sacrosciatic notches and 
markedly shortened upper and lower limb bones. Short and curved “telephone receiver-
like” femora are a hallmark of type 1 thanatophoric dysplasia, but curving may be less 
pronounced in the younger fetuses. The femora show small metaphyseal spikes. 
At autopsy, fetuses with thanatophoric dysplasia type 1 have a large head with small cranial 
sutures and megalencephaly. The brain is heavy, the temporal lobe is enlarged and there are 
multiple transverse grooves along the inferomedial surface of the temporal and occipital 
lobes (Fig. 3). Hippocampal dysplasia is also part of the temporal lobe dysplasia in this 
condition. 
Temporal dysplasia was present in all the examined fetal brains in our sample of fetuses 
with thanatophoric dysplasia type 1. The finding could not be confirmed in severely 
macerated brains. 
  
Fig. 3. The brain in Thanatophoric dysplasia at 22 weeks: transverse sulci along the 
inferomedial surface of the temporal and occipital lobes (arrows) 
In one unique case of a fetus with otherwise typical TD1 findings, organ inspection and 
dissection revealed intestinal malrotation, renal tubular cysts and persisting ductal plate of 
the liver. These findings are frequent in other forms of skeletal dysplasias, particularly in the 
family of Short-Rib-Polydactyly dysplasias (referred to later in this chapter). The findings 
are unique in that they have never been reported in cases of TD1 to our knowledge. 
Molecular analysis in that case confirmed the presence of a typical R248C mutation in the 
FGFR3 gene. A possible explanation for this unusual association of abnormal findings could 
be the presence of a second mutation or microdeletion in a different part of the genome. 
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Histopathologic examination of the epiphyseal growth plate in TD1 shows retardation and 
disorganization of the growth plate with irregular borders of the periphysis. There is fibrous 
extension of the ossification groove of Ranvier and periosteal expansion of bone formation at 
this site. These alterations correspond to the metaphyseal spikes seen on radiography (Fig. 4).  
FGFR3 molecular genetic analysis showed the R248C mutation in four examined cases, 
while in the remaining cases the diagnosis of TD1 was based on the typical external, 
radiographic and histopathologic findings provided by the postmortem examination. 
 
 
Fig. 4. Epiphyseal growth plate from the femoral head of a fetus with Thanatophoric 
dysplasia type 1. TOP: The borders between the cartilage and the primary spongiosa are 
irregular. Extension of the ossification groove of Ranvier (corresponding to the metaphyseal 
spikes seen on radiography) are seen on the left. BOTTOM: The growth plate is 
disorganized, without column formation. 
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bridge and protruding tongue were typical facial characteristics. The thorax was narrow and 
bell-shaped and the abdomen distended. The upper and lower limbs were short in all 
respects (rhizomelic, mesomelic and acromelic shortening). All the linear somatometric 
measurements were affected in thanatophoric dysplasia, particularly the crown-heel and 
toe-heel lengths, as well as the cranial perimeter, chest and abdominal circumferences. 
X-rays (Fig. 2) show severe platyspondyly with H-shaped or U-shaped vertebral bodies, 
relatively short ribs, small horizontally shortened iliac bones with sacrosciatic notches and 
markedly shortened upper and lower limb bones. Short and curved “telephone receiver-
like” femora are a hallmark of type 1 thanatophoric dysplasia, but curving may be less 
pronounced in the younger fetuses. The femora show small metaphyseal spikes. 
At autopsy, fetuses with thanatophoric dysplasia type 1 have a large head with small cranial 
sutures and megalencephaly. The brain is heavy, the temporal lobe is enlarged and there are 
multiple transverse grooves along the inferomedial surface of the temporal and occipital 
lobes (Fig. 3). Hippocampal dysplasia is also part of the temporal lobe dysplasia in this 
condition. 
Temporal dysplasia was present in all the examined fetal brains in our sample of fetuses 
with thanatophoric dysplasia type 1. The finding could not be confirmed in severely 
macerated brains. 
  
Fig. 3. The brain in Thanatophoric dysplasia at 22 weeks: transverse sulci along the 
inferomedial surface of the temporal and occipital lobes (arrows) 
In one unique case of a fetus with otherwise typical TD1 findings, organ inspection and 
dissection revealed intestinal malrotation, renal tubular cysts and persisting ductal plate of 
the liver. These findings are frequent in other forms of skeletal dysplasias, particularly in the 
family of Short-Rib-Polydactyly dysplasias (referred to later in this chapter). The findings 
are unique in that they have never been reported in cases of TD1 to our knowledge. 
Molecular analysis in that case confirmed the presence of a typical R248C mutation in the 
FGFR3 gene. A possible explanation for this unusual association of abnormal findings could 
be the presence of a second mutation or microdeletion in a different part of the genome. 
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Histopathologic examination of the epiphyseal growth plate in TD1 shows retardation and 
disorganization of the growth plate with irregular borders of the periphysis. There is fibrous 
extension of the ossification groove of Ranvier and periosteal expansion of bone formation at 
this site. These alterations correspond to the metaphyseal spikes seen on radiography (Fig. 4).  
FGFR3 molecular genetic analysis showed the R248C mutation in four examined cases, 
while in the remaining cases the diagnosis of TD1 was based on the typical external, 
radiographic and histopathologic findings provided by the postmortem examination. 
 
 
Fig. 4. Epiphyseal growth plate from the femoral head of a fetus with Thanatophoric 
dysplasia type 1. TOP: The borders between the cartilage and the primary spongiosa are 
irregular. Extension of the ossification groove of Ranvier (corresponding to the metaphyseal 
spikes seen on radiography) are seen on the left. BOTTOM: The growth plate is 
disorganized, without column formation. 
 




This condition is the most common nonlethal osteochondroplasia. It is autosomal dominant 
due to mutations in the FGFR3 gene. In our case, there was a de novo heterozygous G380R 
mutation. The facial appearance is typical with a prominent forehead, small maxillary area 
and flat nasal bridge. The trunk is of almost normal length and there is rhizomelic 
shortening of limbs.  
Radiographic features include platyspondyly, short ribs, squared iliac wings with 
horizontal acetabular roofs and spurs (trident appearance), splayed upper femoral 
metaphyses, metaphyseal flaring and short metacarpals (Fig. 5). 
   
Fig. 5. Achondroplasia at 37 weeks: narrow thorax, rhizomelic limb shortening, splayed 
upper femoral metaphyses and trident appearance of iliac bones. 
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6.2 Group 2: Type II collagen group 
Index case: Achondrogenesis type II 
Achondrogenesis is the most severe lethal form of osteochondrodysplasia. This condition, 
commonly encountered in European published series of lethal skeletal dysplasias (Nikkels 
et al., 2009), was uncommon in our Greek series (1/50 cases). Achondrogenesis type II, as all 
type II collagenopathies, is an autosomal dominant disorder caused by mutations in the 
COL2A1 gene.  
Major radiographic features and clinical presentation are similar in achondrogenesis type I 
and type II (Fig. 6). Deficient skull ossification and rib fractures are present only in type Ia. 
Histologically, the growth plate is severely disorganized. The resting cartilage is cellular 
with many prominent blood vessels and perivascular fibrosis. The chondrocytes may appear 
ballooned.  
           
Fig. 6. Achondrogenesis: The trunk and extremities are extremely short. Hydrops is present. 
There is complete absence of ossification in the vertebrae, sacrum and pubis in the young 
fetus. The limb bones are extremely short and there are metaphyseal spike-like spurs. 
(Images kindly ceded by Dr. I. Scheimberg; Barts and The London NHS Trust) 
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6.3 Group 25: Osteogenesis Imperfecta and dysplasias with decreased bone density 
Index cases: Osteogenesis Imperfecta type IIa and type IIb 
6.3.1 Osteogenesis Imperfecta (O.I.) type II 
The lethal type 2 is the most commonly met in the fetus. It is mostly a dominantly inherited 
condition due to mutations in the COL1A1 and COL1A2 genes. Some severe cases of O.I. are 
caused by compound heterozygote mutations in the CRTAP and LERPE genes and follow 
recessive inheritance. Based on morphological features radiology or histology, it is not yet 
possible to discriminate between the O.I. cases caused by mutations in the collagen I gene 
and the autosomal recessive cases (Nikkels et al., 2009).  
Two index cases of Osteogenesis Imperfecta type IIa and IIb are shown below (Figure 7). 
Both cases had dominant mutations in the COL1A1 gene. The fetus with O.I. type IIa has a 
large membranous skull (acrania) (Figure 7, left). There is deficient ossification of the skull 
but not complete acrania in type IIb (Figure 7, right). The femora are bent and shortened as a 
result of multiple recurrent fractures. The characteristic “blue sclera” recognised in infancy 
or later are not a feature of the fetus at autopsy. Brain heterotopias have been described in 
O.I. and were present in both of these index cases with O.I type IIa and IIb.  
   
Fig. 7. Osteogenesis Imperfecta type IIa at 26 weeks (left) and type IIb at 20 weeks (right)   
Rib fractures are present in type IIa but there are hardly any in type IIb. The femora are 
deformed. The spine is normal. 
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Radiography (Fig. 7) of the 2nd trimester fetus shows multiple fractures with beaded ribs 
and crumbled femora in the more severe O.I. type IIa (Fig. 7, left) or bowed femora with 
fewer or no rib fractures in the less severe type IIb (Fig. 7, right). The humeri are usually 
straight without fractures, but they may appear bowed in severe forms of O.I. later in 
pregnancy. The spine is normal in the fetus.  
Histopathology of the bone and cartilage is comparable in types IIa and IIb of Osteogenesis 
Imperfecta (Fig. 8, 9). The bony spicules in the metaphysis are narrow, hypercellular, and 
covered by basophilic meager primitive woven bone. They are markedly reduced in number 
and size in the diaphysis. The osteocytes are closely arranged around the bony trabeculae 











Fig. 8. Histology is comparable in Osteogenesis Imperfecta type 2a (left) and type 2b (right). 
The bony spicules of the primary spongiosa are narrow and covered by meager basophilic 
woven bone. Part of the normal growth plate is seen on top left. Towards the diaphysis, the 
bone marrow predominates over the bony trabeculae (right). 
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 Fig. 9. Osteogenesis Imperfecta type 2b. There is increased number of osteocytes at the 
periphery of the bony spicules and at subperiosteal sites. 
6.4 Group 9: Short-rib dysplasia (with or without polydactyly) - SR(P) 
Index cases: SR(P) type II (Majewski), SR(P) type III (Verma-Naumoff), 
chondroectodermal dysplasia (Ellis-van Creveld) 
6.4.1 Short-rib-polydactyly syndromes 
There are at least 4 distinct types:  
 Type I   Saldino-Noonan 
 Type II  Majewski 
 Type III Verma-Naumoff 
 Type IV Beemer-Langer (polydactyly unlikely) 
Types I and III may represent a phenotypic spectrum of the same entity as may types II and 
IV. Indeed, there are overlapping characteristics between all 4 types and several cases are 
described that cannot fit in a particular type (Gilbert-Barness, 2007). 
All SRPs are autosomal recessive. Types I/III are caused by mutations in the DYNC2H1 
gene. The molecular background is not identified in the remaining ones. The association 
of SRP skeletal dysplasias with particular extraskeletal malformations, such as Dandy-
Walker malformation, cardiovascular, gastrointestinal and genitourinary abnormalities, 
renal cysts and ductal plate malformation of the liver indicates that these syndromes 
probably belong to the expanding group of ciliopathies (Badano et al., 2006; 
Konstantinidou et al., 2009b). 
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In our series, 4 fetuses were diagnosed with SRP at autopsy, one with type II/Majewski (Fig. 
10), two with type III/Verma-Naumoff, and one with SRP of undetermined type (aged 12 
weeks of gestation). 
External inspection in SRP dysplasias reveals a very narrow chest, very short limbs, and 
polydactyly (rare in type IV). The combination of these findings contributes to an early 
sonographic prenatal diagnosis, achieved as early as the 12th week of gestation in our series. 
 
Fig. 10. Short-Rib-Polydactyly type II (Majewski) at 22 weeks. There is a median cleft lip, the 
chest is very narrow and the limbs are short. Micropenis and combined preaxial and 
postaxial polysyndactyly of hands and feet are also seen.  
Radiographic features (Fig. 11): There is mild platyspondyly in types I/III, the ribs are very 
short and horizontal, and the long bones are short. Metaphyseal spurs are present in types I 
and III (Fig. 11 right), while in types II and IV the metaphyses are smooth. In our index case 
of type II (Majewski) the tibia is the shortest of all long bones (Fig. 11, left). Polydactyly is 
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postaxial (in types I, II, III), preaxial (type II) or combined preaxial and postaxial (type II) 
and is common in all types, except type IV. Fusion of metacarpals is seen in type II-
Majewski (Fig. 11 left), (as in chondroectodermal dysplasia Ellis-van Creveld).  
Jeune syndrome and Ellis-van Creveld syndrome are also classified under the group of 
Short-Rib (with or without Polydactyly) dysplasias. These may be indistinguishable in the 
fetus. 
   
Fig. 11. Short-Rib-Polydactyly type II at 22 weeks (left) and type III at 23 weeks (right). The 
ribs are short. The tibia is the shorter long bone in type II. Metaphyses are spiked in type III. 
Extraskeletal abnormalities noted in our index case of SRP type II (Majewski) consisted in a 
median cleft lip, micropenis and a Dandy-Walker malformation of the cerebellum. 
Microscopically, the kidneys showed renal tubular and glomerular cysts and in the liver 
persisting ductal plate was noted.  
In our index case of SRP type III (Verma-Naumoff) there was mild hydrops, moderately 
hypoplastic lungs, a complex cardiovascular defect with atrioventricular canal defect type I 
and interruption of the aortic arch, intestinal malrotation, small kidneys with tubular cysts 
and portal fibrosis with persisting ductal plate of the liver, and there was no polydactyly.  
6.4.2 Chondroectodermal dysplasia (Ellis-van Creveld) 
Two fetuses in our series were diagnosed with Ellis-van Creveld (EvC) syndrome at post-
mortem examination, both at 23 weeks of gestation (Fig. 12).   
 




   
 
Fig. 12. Ellis-van Creveld syndrome (chondroectodermal dysplasia) at 23 weeks. There is 
postaxial polydactyly of both hands (left) and postaxial polysyndactyly (right). The chest is 
narrow and the limbs are moderately short. 
At autopsy, organ dissection of the two female fetuses showed pulmonary hypoplasia, renal 
tubular cysts and persisting ductal plate in the liver. One fetus had postaxial hexadactyly 
and the other postaxial polysyndactyly of both hands (Fig. 12).  
Molecular genetic analysis was not performed in either case. The presence of postaxial 
polydactyly favored the diagnosis of EvC versus Jeune Asphyxiating Thoracic Dysplasia 
(ATD), which in the fetus may be indistinguishable from EvC or SRP type II. In childhood, 
the typical disorders of ectodermal dysplasia, i.e. hypoplastic nails, thin hair and abnormal 
teeth combined with postaxial polydactyly would suggest the diagnosis of EvC versus Jeune 
ATD. Ellis-van Creveld and Jeune ATD are compatible with life; SRP type II is invariably 
lethal in the perinatal period. 
Radiographic findings (Fig. 13) included short ribs, short long bones with rounded 
metaphyses, fibular hypoplasia in one case, vertically shortened ilia with notches and a V-
shaped 3rd metacarpal in one case.  
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Fig. 13. EvC (same cases as in Fig. 12): The ribs are short. The long bones are short with 
rounded metaphyses. The radiographic findings may be indistinguishable from Jeune ATD. 
Histology of the epiphyseal growth plate shows retardation and disorganization in the 
formation of columns (Fig. 14). 
 
Fig. 14. Retardation and focal disorganization of the femoral epiphyseal growth plate in 
Ellis-van Creveld syndrome at 23 weeks. 
 
Skeletal Dysplasias of the Human Fetus: Postmortem Diagnosis 
 
53 
6.5 Group 35: Dysostoses with predominant vertebral involvement with and without 
costal involvement 
Index case: Spondylocostal / Spondylothoracic dysostosis 
6.5.1 Spondylocostal / Spondylothoracic dysostosis  
Various genetically distinct axial dysostoses with predominant vertebral and costal 
involvement were previously named as Jarcho-Levin syndrome, a label that has been 
eliminated by the 2010 revision of the Nosology. This heterogeneous group of disorders 
characterized by multiple spinal malsegmentation may be autosomal recessive, autosomal 
dominant or sporadic. It has been suggested that thoracic asymmetry characterizes 
Spondylothoracic dysostosis, whereas a short but overall symmetric thorax is a feature of 
Spondylocostal dysostosis (Solomon, 1978; O’ Neill, 2011a). 
There were 5 cases of spondylocostal /spondylothoracic dysostosis in our series (10%). Fetal 
age ranged from 13 to 37 weeks of gestation. One case referred to a liveborn neonate born to 
a mother who had not received prenatal sonographic control. 
In all cases there were characteristic external, radiographic and pathological findings. The 
fetus with spondylocostal/spondylothoracic dysostosis has a short neck with low frontal 
and occipital hairline, short trunk in contrast to extremities of normal length, and scoliosis 
(Fig. 15).  
 
 
Fig. 15. Spondylothoracic / Spondylocostal dysostosis in two fetuses of 16.5 weeks (left - 
formalin-fixed) and 23.5 weeks (middle and right). Scoliosis, short neck, short deformed 
thorax and hirsutism in the older fetus are obvious. 
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Extraskeletal findings consisting in neural tube defects, hindbrain malformations, 
cardiovascular and genitourinary anomalies have been described in the former 
heterogeneous Jarcho-Levin syndrome. It is suggested that associated visceral anomalies are 
more common in sporadic cases of spinal malsegmentation than in the familial types of 
spondylocostal /spondylothoracic dysostosis (O’ Neill, 2011a). 
Our first index familial case is represented by a male fetus of 16.5 w, who was the second 
affected offspring of the family with features of spondylothoracic dysostosis (Fig. 15, left). 
At autopsy, we noted a Dandy-Walker variant of the cerebellum, asymmetry of thoracic and 
abdominal organs, hypospadias, and renal tubular microcysts.  
The second index case, a female fetus of 23.5 w, offspring to consanguineous parents, had an 
atrial septal defect, a retroesophageal right subclavian artery and ectopic pancreatic tissue in 
the spleen.  
Radiography shows the characteristic vertebral anomalies including vertebral segmentation 
with hemivertebrae and block vertebrae accompanied by deformity of the ribs. Fused ribs 
result in a typical 'crab-like' radiologic appearance of the thoracic skeleton (Fig. 16). The 
skeleton is otherwise normal. 
 
Fig. 16. Vertebral segmentation and deformity of the ribs with thoracic asymmetry in 
spondylothoracic dysostosis. Left: 23.5 w - Right: At term, crab-like appearance of the ribs  
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In the early lethal form of spondylocostal/spondylothoracic dysostosis patients die 
perinatally with respiratory complications; other forms of the syndrome allow survival to a 
later age. 
6.6 Group 38: Limb hypoplasia-reduction defects group 
Index cases: Roberts syndrome, Split Hand-Foot malformation with tibial hypoplasia 
6.6.1 Roberts syndrome  
Roberts syndrome is a rare autosomal recessive condition caused by mutation in the ESCO2 
gene, the protein product of which is required for the establishment of sister chromatid 
cohesion during S phase. In the fetus it is manifest with facial clefting and symmetrical limb 
defects, resulting in tetraphocomelia in most cases (Kniffin, 2010). Alternatively the 
syndrome is called “Long bone deficiencies associated with cleft lip-palate”. Hypertelorism, 
facial hemangioma and clitoral or penile enlargement are also features of the syndrome. 
Another name of this condition often found in literature is “Roberts phocomelia” or ‘‘the 
(SC) pseudothalidomide syndrome’’, because of the resemblance to malformations seen in 
the thalidomide embryopathy. “Phocomelia’’ is an old term for nearly total deficiency of the 
long bones of a limb, (Greek phoka = seal, melos = limb; phocomelia = seal limb).  
 
Fig. 17. Median cleft lip and palate, micrognathia, hypertelorism, upper limb phocomelia, 
ectrodactyly and syndactyly, hypoplastic femora, and penile enlargement in a 12.5-week 
male fetus with Roberts syndrome. 
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Karyotypic analysis shows in 50% of cases a characteristic centromeric abnormality of the 
chromosomes, namely, puffing and splitting of sister chromatides. The finding was present 
in one 25-week male fetus of our series, confirming the diagnosis of Roberts’ syndrome 
(Pavlopoulos et al., 1998), and was absent from a second male fetus of 12.5 weeks (Fig. 17). 
6.6.2 Split Hand-Foot malformation with tibial aplasia  
The Split Hand-Foot malformations are a group of genetically heterogeneous disorders, 
presenting as isolated forms (five genetically different forms) or in combination with tibial 
hypoplasia or aplasia. The latter condition [OMIM #1191OO] is autosomal dominant, with a 
recently determined molecular defect mapping on chromosome 1q42.2-q43 (O’ Neill, 2009b). 
   
Fig. 18. Cleft hand, tibial aplasia, and bifid femur in a 16.5-week male fetus 
Our index case refers to a male fetus of 16.5 weeks sent for autopsy after termination of 
pregnancy because of sonographically diagnosed limb reduction defects (Fig. 18). A possible 
secondary aetiology should be ruled out, given that limb defects are often sporadic, 
attributed to vascular disruptions or amniotic band syndrome. At autopsy, we noted a cleft 
hand, absent tibia, bifid femur and hypoplasia of other long bones. This led to the diagnosis 
of the genetic disorder Split hand/foot malformation with tibial aplasia, alternatively named 
Split-hand/foot malformation with long bone deficiency [OMIM #1191OO]. The postmortem 
diagnosis conducted the genetic investigation and enabled genetic counseling of the family. 
7. Conclusion  
The pathologist will perform the post-mortem examination of a fetus or infant affected by a 
genetic skeletal disorder in cases of intrauterine death caused by lethal skeletal dysplasias, or, 
more often nowadays, when the detection of skeletal abnormalities on prenatal ultrasound 
leads to the termination of pregnancy. The presence of skeletal abnormalities mandates an 
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extended study of the fetus. Pediatric radiologists who have experience in radiologic 
assessment of skeletal disorders of infants and children can provide expertise in this area. 
However, in many institutions it is the task of the pathologist to deal with the skeletal 
disorders at autopsy. It is important that pathologists carrying out fetal and perinatal autopsies 
should be familiar with the phenotypic manifestations of the more common skeletal disorders, 
including the interpretation of radiologic findings. The association with extraskeletal 
abnormalities in particular settings also contributes to the diagnostic approach. The histology 
of the cartilage and bone and of the epiphyseal growth plate proves very useful in a restricted 
number of skeletal dysplasias. As specific diagnosis and classification of genetic skeletal 
disorders is difficult, a collaborative approach among pathological, radiological and genetic 
services is optimal to provide the parents with all available information regarding the 
diagnosis and prognosis of fetal and perinatal genetic skeletal disorders.  
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1. Introduction 
Macrodactyly, defined as enlargement of one or several digits of the hands or feet, is a rare 
malformation. It may be due tumorous enlargement of a single tissue element, as in 
hemangioma, lymphangioma or enchondroma or it may be caused by overgrowth of all 
structures of the digit, including phalanges, subcutaneous tissue, nerves, vessels and skin as 
in ‘true macrodactyly’(Barsky, 1967). Furthermore, it may either be isolated or associated 
with other anomalies such as hemihypertrophy, vascular malformations, lipomas, 
cutaneous lesions or visceral anomalies as a feature of a syndrome.  
There is only one case report of prenatally diagnosed isolated macrodactyly till then by 
Yüksel et al. Macrodactyly of the second toe of the left foot was noted on a routine fetal 
anomaly scan at 24 weeks (Figure 1). The other toes were of normal size and there were no 
other associated anomalies on serial scans. The fetal karyotype was also normal. The baby 
was born at term and evaluations carried out at birth, 6 months and 2 years of age revealed 
no other additional abnormalities; neither hemihypertrophy, macrocephaly, lipomas nor 
vascular abnormalities were detected. Diagnosis of congenital isolated true macrodactyly 
was confirmed. Distal phalangectomy was performed at 6 months of age and due to 
progressive enlargement after the first operation, the digit had to be amputated at 9 months 
of age. Histopathological evaluation of the specimen was consistent with true macrodactyly, 
with enlargement of all mesenchymal tissues, mainly of fibroadipose tissue origin (Yüksel et 
al., 2009). 
Macrodactyly is an isolated finding without evidence of other systemic involvement in the 
majority of cases. However, there is a well-established association of macrodactyly with 
overgrowth syndromes such as Proteus syndrome, Bannayan-Riley-Ruvalcaba syndrome, 
CLOVES (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, and 
Skeletal/Spinal abnormalities) syndrome, Maffucci syndrome, Ollier’s disease, Klippel-
Trenaunay-Weber syndrome, neurofibromatosis, tuberous sclerosis and Milroy disease 
(Alomari, 2009; Norman-Taylor & Mayou, 1994; Yüksel et al., 2009). Therefore, prenatal 
diagnosis of macrodactyly necessitates thorough evaluation of all systems to differentiate 
between isolated and syndromic macrodactyly, which have different prognostic implications. 
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Macrodactyly is an isolated finding without evidence of other systemic involvement in the 
majority of cases. However, there is a well-established association of macrodactyly with 
overgrowth syndromes such as Proteus syndrome, Bannayan-Riley-Ruvalcaba syndrome, 
CLOVES (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, and 
Skeletal/Spinal abnormalities) syndrome, Maffucci syndrome, Ollier’s disease, Klippel-
Trenaunay-Weber syndrome, neurofibromatosis, tuberous sclerosis and Milroy disease 
(Alomari, 2009; Norman-Taylor & Mayou, 1994; Yüksel et al., 2009). Therefore, prenatal 
diagnosis of macrodactyly necessitates thorough evaluation of all systems to differentiate 
between isolated and syndromic macrodactyly, which have different prognostic implications. 
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Fig. 1. Ultrasonographic scan of the fetus at 24 gestational weeks demonstrating the 
difference in size between two second toes. Macrodactyly of the left second toe is confirmed 
by comparable measurements. This is another image of the same case presented in ‘Prenatal 
diagnosis of isolated macrodactyly’ in Ultrasound in Obstetrics and Gynecology 2009; 33: 
360-362.  
2. Macrodactyly 
2.1 True macrodactyly 
Congenital true macrodactyly is a rare, nonhereditary malformation and appears to be more 
common in the hands than in the feet  (Barsky, 1967). Overall, it constitutes around 1% of all 
congenital anomalies of the upper limb (Flatt, 1977, as cited in Kotwal & Farooque, 1998).  
The disease is almost always unilateral and a single digit or several, usually adjacent digits 
may be involved (D’Costa et al., 1996, as cited in Singla et al., 2008; Syed et al., 2005). The 
second or third digit of the hand or foot are frequently involved in the majority of cases, 
corresponding to the median nerve and medial plantar nerve distribution (Krengel et al., 
2000; Sone et al., 2000). The enlargement is most pronounced at the distal end of the digits 
on the volar side and therefore causes dorsal angulation (Singla et al., 2008). It may also be 
associated with syndactyly, polydactyly, or clinodactyly (Goldman & Kaye, 1977).  
Two subtypes of true macrodactyly, namely, static and progressive types, have been 
described (Barsky, 1967). In the static type, the growth rate of the involved digit is the same 
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as the normal digits whereas in the progressive type, growth is accelerated compared to the 
rest. The progressive type is less common and involvement of the metacarpal and metatarsal 
bones is more likely in the progressive type (Turkington & Grey, 2005). Abnormal 
accelerated growth usually ceases at puberty (Singla et al., 2008; Turkington & Grey, 2005).  
Marked increase in adipose tissue within a mesh of fibrous tissue that involves the bone 
marrow, periosteum, muscles, nerve sheaths and subcutaneous tissues is the characteristic 
pathological finding in true macrodactyly (Kelikian, 1974 and Thorne et al., 1968 as cited in 
Goldman & Kaye, 1977). The most striking difference between macrodactyly of the hand 
and foot is neural involvement. Hypertrophy and tortuosity of the digital nerve is a notable 
finding in macrodactyly of the hand whereas it is rarely seen in the foot (Syed et al., 2005; 
Dennyson et al., 1977 as cited in Syed et al., 2005). The etiology is unclear and proposed 
mechanisms include lipomatous degeneration, neurofibromatosis, disturbed fetal circulation 
and local deficiency of growth inhibiting or overexpression of growth promoting factors 
(Syed et al., 2005; Gupta et al., 1992, as cited in Singla et al. 2008). 
Macrodactyly causes cosmetic disfigurement and may also impair function due to secondary 
degenerative joint disease and nerve entrapment (Turkington & Grey, 2005). Treatment is 
usually not entirely satisfactory and may require several bulk reducing operations, carpal 
tunnel release, phalangectomy, and amputation (Kotwal & Farooque, 1998). 
2.2 Macrodactyly due to tumorous enlargement 
In contrast to true macrodactyly whereby all the structures of the digit are overgrown as a 
whole, there is tumourous enlargement of a single tissue element. Most of the tumors (95%) 
are benign and they may be classified according to the tissue of origin. Abnormal growth of 
vascular (hemangiomas, glomus tumors), osseous (enchondromas –multiple enchondromas 
as in Ollier disease-, osteoid osteomas, osteoblastomas, giant cell tumors, aneurysmal and 
unicameral bone cysts), neural (schwannomas, fibrolipomatous hamartomas, 
neurofibromas), cutaneous (mucous cysts, nodular fasciitis, pyogenic granulomas) and soft 
tissue (ganglions, lipomas, nodular tenosynovitis) elements cause localized masses of the 
hand and digits (Lin SJ et al., 2011). 
Fibrolipomatous hamartoma is a rare, intraneural tumor characterized by fibrofatty 
infiltration around the nerve fascicles (Razzaghi & Anastakis, 2005). It is associated with 
macrodactyly due to overgrowth of bone and subcutaneous fat in more than one-third of the 
patients and it presents early in childhood with macrodactyly or later with a volar forearm 
mass and compressive neuropathy (Silverman & Enzinger, 1985, as cited in Razzaghi & 
Anastakis, 2005; Razzaghi & Anastakis, 2005).   
Malignant tumors are rare. Primary malignant tumors may be of skin (most common site for 
malignant tumors), bone or soft tissue origin whereas metastatic tumors are mainly due to 
lung, kidney or head and neck cancers (Marrero IC et al., 2011). 
3. Syndromes associated with macrodactyly 
3.1 Proteus syndrome 
Proteus syndrome (MIM 176920) is a sporadic disorder that may be caused by a somatic 
alteration in a gene, that probably controls local production or regulation of tissue growth 
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difference in size between two second toes. Macrodactyly of the left second toe is confirmed 
by comparable measurements. This is another image of the same case presented in ‘Prenatal 
diagnosis of isolated macrodactyly’ in Ultrasound in Obstetrics and Gynecology 2009; 33: 
360-362.  
2. Macrodactyly 
2.1 True macrodactyly 
Congenital true macrodactyly is a rare, nonhereditary malformation and appears to be more 
common in the hands than in the feet  (Barsky, 1967). Overall, it constitutes around 1% of all 
congenital anomalies of the upper limb (Flatt, 1977, as cited in Kotwal & Farooque, 1998).  
The disease is almost always unilateral and a single digit or several, usually adjacent digits 
may be involved (D’Costa et al., 1996, as cited in Singla et al., 2008; Syed et al., 2005). The 
second or third digit of the hand or foot are frequently involved in the majority of cases, 
corresponding to the median nerve and medial plantar nerve distribution (Krengel et al., 
2000; Sone et al., 2000). The enlargement is most pronounced at the distal end of the digits 
on the volar side and therefore causes dorsal angulation (Singla et al., 2008). It may also be 
associated with syndactyly, polydactyly, or clinodactyly (Goldman & Kaye, 1977).  
Two subtypes of true macrodactyly, namely, static and progressive types, have been 
described (Barsky, 1967). In the static type, the growth rate of the involved digit is the same 
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as the normal digits whereas in the progressive type, growth is accelerated compared to the 
rest. The progressive type is less common and involvement of the metacarpal and metatarsal 
bones is more likely in the progressive type (Turkington & Grey, 2005). Abnormal 
accelerated growth usually ceases at puberty (Singla et al., 2008; Turkington & Grey, 2005).  
Marked increase in adipose tissue within a mesh of fibrous tissue that involves the bone 
marrow, periosteum, muscles, nerve sheaths and subcutaneous tissues is the characteristic 
pathological finding in true macrodactyly (Kelikian, 1974 and Thorne et al., 1968 as cited in 
Goldman & Kaye, 1977). The most striking difference between macrodactyly of the hand 
and foot is neural involvement. Hypertrophy and tortuosity of the digital nerve is a notable 
finding in macrodactyly of the hand whereas it is rarely seen in the foot (Syed et al., 2005; 
Dennyson et al., 1977 as cited in Syed et al., 2005). The etiology is unclear and proposed 
mechanisms include lipomatous degeneration, neurofibromatosis, disturbed fetal circulation 
and local deficiency of growth inhibiting or overexpression of growth promoting factors 
(Syed et al., 2005; Gupta et al., 1992, as cited in Singla et al. 2008). 
Macrodactyly causes cosmetic disfigurement and may also impair function due to secondary 
degenerative joint disease and nerve entrapment (Turkington & Grey, 2005). Treatment is 
usually not entirely satisfactory and may require several bulk reducing operations, carpal 
tunnel release, phalangectomy, and amputation (Kotwal & Farooque, 1998). 
2.2 Macrodactyly due to tumorous enlargement 
In contrast to true macrodactyly whereby all the structures of the digit are overgrown as a 
whole, there is tumourous enlargement of a single tissue element. Most of the tumors (95%) 
are benign and they may be classified according to the tissue of origin. Abnormal growth of 
vascular (hemangiomas, glomus tumors), osseous (enchondromas –multiple enchondromas 
as in Ollier disease-, osteoid osteomas, osteoblastomas, giant cell tumors, aneurysmal and 
unicameral bone cysts), neural (schwannomas, fibrolipomatous hamartomas, 
neurofibromas), cutaneous (mucous cysts, nodular fasciitis, pyogenic granulomas) and soft 
tissue (ganglions, lipomas, nodular tenosynovitis) elements cause localized masses of the 
hand and digits (Lin SJ et al., 2011). 
Fibrolipomatous hamartoma is a rare, intraneural tumor characterized by fibrofatty 
infiltration around the nerve fascicles (Razzaghi & Anastakis, 2005). It is associated with 
macrodactyly due to overgrowth of bone and subcutaneous fat in more than one-third of the 
patients and it presents early in childhood with macrodactyly or later with a volar forearm 
mass and compressive neuropathy (Silverman & Enzinger, 1985, as cited in Razzaghi & 
Anastakis, 2005; Razzaghi & Anastakis, 2005).   
Malignant tumors are rare. Primary malignant tumors may be of skin (most common site for 
malignant tumors), bone or soft tissue origin whereas metastatic tumors are mainly due to 
lung, kidney or head and neck cancers (Marrero IC et al., 2011). 
3. Syndromes associated with macrodactyly 
3.1 Proteus syndrome 
Proteus syndrome (MIM 176920) is a sporadic disorder that may be caused by a somatic 
alteration in a gene, that probably controls local production or regulation of tissue growth 
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factor receptors (Cohen MM Jr., 1993 and Samlaska et al., 1989, as cited in Jamis-Dow et al., 
2004). The infants affected by the disorder usually appear normal or show only mildly 
asymmetric development at birth, but progressively develop the characteristic features of 
the syndrome during childhood. As the manifestations are highly variable, standard 
diagnostic criteria have been developed to minimise misdiagnosis (Biesecker et al., 1999, as 
cited in Jamis-Dow et al., 2004 ). Skeletal abnormalities such as macrodactyly, scoliosis, 
asymmetric overgrowth and limb length discrepancy, soft tissue abnormalities such as 
lipomas or regional absence of fat, asymmetric muscle development, connective tissue nevi 
and vascular malformations are common manifestations of the disease wheareas visceral 
anomalies such as splenomegaly, asymmetric megalencephaly, white matter abnormalities, 
nephromegaly, and masses other than fatty, muscular or vascular masses are uncommon 
(Jamis-Dow et al., 2004). Macrodactyly was encountered in 16 of 21 (76%) patients with 
Proteus syndrome in whom the diagnosis was based on standardized criteria (Jamis-Dow et 
al., 2004). Isolated macrodactyly has also been proposed as an extremely localized form of 
Proteus syndrome (van Bever & Hennekam, 1994).  
Sigaudy et al. reported a prenatally diagnosed case of Proteus syndrome presenting with a 
large cystic mass on the right side of the abdomen and thorax and possible syndactyly of the 
fourth and fifth fingers at 26 weeks. The pregnancy was terminated at 28 weeks due to 
massive enlargement of the mass and autopsy revealed cystic lymphangioma on the right 
side, enlargement of the left arm, lateral deviation of the third to fifth fingers of the left hand 
with a large fixed gap between the second and the third finger, bilateral enlargement of the 
third toes, a small thymic cyst and left hemimegalencephaly confirming the diagnosis of 
Proteus syndrome (Sigaudy et al., 1998). Brasseur et al. reported a very similar case with 
antenatally diagnosed large, cervico-thoraco-brachial cystic lymphangioma at 22 weeks. 
After birth, macrodactyly of the first and second toes were noted and Proteus syndrome was 
diagnosed (Brasseur et al., 2009). Another prenatally diagnosed case with Proteus syndrome 
had a cystic enlargement of one limb and abnormal positioning of the toes (Richards et al., 
1991, as cited in Sigaudy et al., 1998). These case reports show that severe cases of Proteus 
syndrome with early manifestations can be detected in utero. Most of the cases show at least 
one manifestation at birth and this finding can be either strongly suggestive of Proteus 
syndrome or more subtle (Sigaudy et al., 1998). Furthermore, as the phenotype develops 
over time, cases with apparently isolated findings such as macrodactyly may ultimately be 
diagnosed with Proteus syndrome (Lacombe & Battin, 1996, as cited in Sigaudy et al., 1998). 
3.2 Bannayan-Riley-Ruvalcaba syndrome 
Bannayan-Riley-Ruvalcaba (MIM 153480) syndrome is an autosomal dominant disorder, 
associated with mutations of the PTEN gene. Macrocephaly, lipomas, vascular 
malformations, intestinal polyps, and pigmented macules of the penis are the characteristic 
features of this syndrome. Macrodactyly of the right index finger along with a hamartoma of 
the small bowel mesentery with angiomatous, lipomatous and lymphangiomatous 
components has been reported by Zonana et al (Zonana et al., 1976). 
There have been no reports regarding the prenatal diagnosis of Bannayan-Riley-Ruvalcaba 
syndrome; however, as it is characterized by hamartomatous changes leading to localized 
overgrowth, it may be included in the differential diagnosis of overgrowth syndromes like 
Proteus syndrome and macrodactyly (Jamis-Dow et al., 2004). 
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3.3 CLOVES syndrome  
CLOVES syndrome (MIM 612918) is a disorder with complex truncal lipomatous mass, 
vascular malformations, epidermal nevi, acral deformities including large, wide feet and 
hands, macrodactyly and wide sandal gap and scoliosis and other musculoskeletal, 
neurologic, renal and cutaneous malformations (Alomari, 2009). Sapp et al. described 7 
patients with progressive, primarily truncal vascular malformations, dysregulated 
adipose tissue, scoliosis and enlarged, but not severely distorted, bony structures without 
progressive overgrowth and designated the condition as a distinct entity, namely, CLOVE 
(Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi) syndrome 
(Sapp et al., 2007). They stated that bony distortion in these patients was limited to areas 
of the body that had undergone major surgery in contrast to patients with Proteus 
syndrome. Later in 2009, the acronym CLOVES syndrome was proposed to emphasize the 
association of Skeletal/Scoliosis and Spinal abnormalities with this syndrome (Alomari, 
2009). Spinal-paraspinal fast-flow lesions within or adjacent to the truncal overgrowth or 
a cutaneous birthmark in 6 patients with CLOVES syndrome were also reported (Alomari 
et al., 2011).  
There is one case report regarding antenatal findings of a multicystic abdominal wall mass, 
asymmetry of the cerebral hemispheres and face in a fetus, where postnatal clinical and 
imaging findings led to the diagnosis of CLOVES syndrome (Fernandez-Pineda et al., 2010).  
3.4 Klippel-Trenaunay-Weber syndrome  
Klippel-Trenaunay-Weber (KTW) (MIM 149000) syndrome is a rare disorder associated with 
large cutaneous capillary and venous malformations with hypertrophy of the related bones 
and soft tissues. The cutaneous lesions include one or several port-wine stains over the 
affected limb and large venous ectatic vessels and vesicular lymphatic lesions. The lower 
extremity is more commonly involved. The enlargement of the limb is due to muscle 
hypertrophy, thickened skin, excessive subcutaneous fat, abnormal vascular tissue and 
occasionally lymphedema (Requena & Sangueza, 1997, as cited in Gonçalves et al., 2000). 
Hypoplasia or aplasia of the venous system is also a feature of the syndrome although it is 
less commonly encountered (Jacob et al., 1998, as cited in Coombs at al., 2009).  
The mosaic pattern and occasional familial cases of KTW syndrome have been explained 
by paradominant inheritance, whereby heterozygous individuals for the single gene 
defect are phenotypically normal and the trait is expressed when a somatic mutation 
occurs in the normal allele at an early stage of embryogenesis (Happle, 1993, as cited in 
Gonçalves et al., 2000).  
Peng et al. have reviewed the prenatal findings of 21 cases with Klippel-Trenaunay-Weber 
syndrome involving the thigh until 2006. Asymmetric limb hypertrophy was the prominent 
prenatal finding and extensive involvement of other parts of the body such as the pelvis, 
abdomen, retroperitoneum or thorax was noted in around 70% of cases (Peng et al., 2006). 
Signs of high cardiac output probably due to the rapid development of numerous 
arteriovenous fistulas, such as cardiomegaly, polyhydramnios, non-immune hydrops fetalis 
and thick placenta have also been reported (Paladini et al., 1998; Peng et al., 2006).  
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factor receptors (Cohen MM Jr., 1993 and Samlaska et al., 1989, as cited in Jamis-Dow et al., 
2004). The infants affected by the disorder usually appear normal or show only mildly 
asymmetric development at birth, but progressively develop the characteristic features of 
the syndrome during childhood. As the manifestations are highly variable, standard 
diagnostic criteria have been developed to minimise misdiagnosis (Biesecker et al., 1999, as 
cited in Jamis-Dow et al., 2004 ). Skeletal abnormalities such as macrodactyly, scoliosis, 
asymmetric overgrowth and limb length discrepancy, soft tissue abnormalities such as 
lipomas or regional absence of fat, asymmetric muscle development, connective tissue nevi 
and vascular malformations are common manifestations of the disease wheareas visceral 
anomalies such as splenomegaly, asymmetric megalencephaly, white matter abnormalities, 
nephromegaly, and masses other than fatty, muscular or vascular masses are uncommon 
(Jamis-Dow et al., 2004). Macrodactyly was encountered in 16 of 21 (76%) patients with 
Proteus syndrome in whom the diagnosis was based on standardized criteria (Jamis-Dow et 
al., 2004). Isolated macrodactyly has also been proposed as an extremely localized form of 
Proteus syndrome (van Bever & Hennekam, 1994).  
Sigaudy et al. reported a prenatally diagnosed case of Proteus syndrome presenting with a 
large cystic mass on the right side of the abdomen and thorax and possible syndactyly of the 
fourth and fifth fingers at 26 weeks. The pregnancy was terminated at 28 weeks due to 
massive enlargement of the mass and autopsy revealed cystic lymphangioma on the right 
side, enlargement of the left arm, lateral deviation of the third to fifth fingers of the left hand 
with a large fixed gap between the second and the third finger, bilateral enlargement of the 
third toes, a small thymic cyst and left hemimegalencephaly confirming the diagnosis of 
Proteus syndrome (Sigaudy et al., 1998). Brasseur et al. reported a very similar case with 
antenatally diagnosed large, cervico-thoraco-brachial cystic lymphangioma at 22 weeks. 
After birth, macrodactyly of the first and second toes were noted and Proteus syndrome was 
diagnosed (Brasseur et al., 2009). Another prenatally diagnosed case with Proteus syndrome 
had a cystic enlargement of one limb and abnormal positioning of the toes (Richards et al., 
1991, as cited in Sigaudy et al., 1998). These case reports show that severe cases of Proteus 
syndrome with early manifestations can be detected in utero. Most of the cases show at least 
one manifestation at birth and this finding can be either strongly suggestive of Proteus 
syndrome or more subtle (Sigaudy et al., 1998). Furthermore, as the phenotype develops 
over time, cases with apparently isolated findings such as macrodactyly may ultimately be 
diagnosed with Proteus syndrome (Lacombe & Battin, 1996, as cited in Sigaudy et al., 1998). 
3.2 Bannayan-Riley-Ruvalcaba syndrome 
Bannayan-Riley-Ruvalcaba (MIM 153480) syndrome is an autosomal dominant disorder, 
associated with mutations of the PTEN gene. Macrocephaly, lipomas, vascular 
malformations, intestinal polyps, and pigmented macules of the penis are the characteristic 
features of this syndrome. Macrodactyly of the right index finger along with a hamartoma of 
the small bowel mesentery with angiomatous, lipomatous and lymphangiomatous 
components has been reported by Zonana et al (Zonana et al., 1976). 
There have been no reports regarding the prenatal diagnosis of Bannayan-Riley-Ruvalcaba 
syndrome; however, as it is characterized by hamartomatous changes leading to localized 
overgrowth, it may be included in the differential diagnosis of overgrowth syndromes like 
Proteus syndrome and macrodactyly (Jamis-Dow et al., 2004). 
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3.3 CLOVES syndrome  
CLOVES syndrome (MIM 612918) is a disorder with complex truncal lipomatous mass, 
vascular malformations, epidermal nevi, acral deformities including large, wide feet and 
hands, macrodactyly and wide sandal gap and scoliosis and other musculoskeletal, 
neurologic, renal and cutaneous malformations (Alomari, 2009). Sapp et al. described 7 
patients with progressive, primarily truncal vascular malformations, dysregulated 
adipose tissue, scoliosis and enlarged, but not severely distorted, bony structures without 
progressive overgrowth and designated the condition as a distinct entity, namely, CLOVE 
(Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi) syndrome 
(Sapp et al., 2007). They stated that bony distortion in these patients was limited to areas 
of the body that had undergone major surgery in contrast to patients with Proteus 
syndrome. Later in 2009, the acronym CLOVES syndrome was proposed to emphasize the 
association of Skeletal/Scoliosis and Spinal abnormalities with this syndrome (Alomari, 
2009). Spinal-paraspinal fast-flow lesions within or adjacent to the truncal overgrowth or 
a cutaneous birthmark in 6 patients with CLOVES syndrome were also reported (Alomari 
et al., 2011).  
There is one case report regarding antenatal findings of a multicystic abdominal wall mass, 
asymmetry of the cerebral hemispheres and face in a fetus, where postnatal clinical and 
imaging findings led to the diagnosis of CLOVES syndrome (Fernandez-Pineda et al., 2010).  
3.4 Klippel-Trenaunay-Weber syndrome  
Klippel-Trenaunay-Weber (KTW) (MIM 149000) syndrome is a rare disorder associated with 
large cutaneous capillary and venous malformations with hypertrophy of the related bones 
and soft tissues. The cutaneous lesions include one or several port-wine stains over the 
affected limb and large venous ectatic vessels and vesicular lymphatic lesions. The lower 
extremity is more commonly involved. The enlargement of the limb is due to muscle 
hypertrophy, thickened skin, excessive subcutaneous fat, abnormal vascular tissue and 
occasionally lymphedema (Requena & Sangueza, 1997, as cited in Gonçalves et al., 2000). 
Hypoplasia or aplasia of the venous system is also a feature of the syndrome although it is 
less commonly encountered (Jacob et al., 1998, as cited in Coombs at al., 2009).  
The mosaic pattern and occasional familial cases of KTW syndrome have been explained 
by paradominant inheritance, whereby heterozygous individuals for the single gene 
defect are phenotypically normal and the trait is expressed when a somatic mutation 
occurs in the normal allele at an early stage of embryogenesis (Happle, 1993, as cited in 
Gonçalves et al., 2000).  
Peng et al. have reviewed the prenatal findings of 21 cases with Klippel-Trenaunay-Weber 
syndrome involving the thigh until 2006. Asymmetric limb hypertrophy was the prominent 
prenatal finding and extensive involvement of other parts of the body such as the pelvis, 
abdomen, retroperitoneum or thorax was noted in around 70% of cases (Peng et al., 2006). 
Signs of high cardiac output probably due to the rapid development of numerous 
arteriovenous fistulas, such as cardiomegaly, polyhydramnios, non-immune hydrops fetalis 
and thick placenta have also been reported (Paladini et al., 1998; Peng et al., 2006).  
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There are two case reports demonstrating the association of Klippel-Trenaunay syndrome 
with macrodactyly. The first one presented antenatally with multiple distorted cystic areas 
involving the right leg and abdomen and cardiomegaly with early fetal heart failure who 
was found to have bilateral macrodactyly of the second toe as well after birth (Zoppi et al., 
2001). The second one is a fetus with marked lower limb edema, cystic areas in the 
abdomen/pelvis/lower limbs and abnormal development of the feet demonstrating 
bilateral hypoplasia of the femoral and popliteal veins in whom postnatal clinical evaluation 
also revealed right foot hemihypertrophy/syndactyly and left hallux hypertrophy (Coombs 
at al., 2009). 
3.5 Neurofibromatosis type 1 
Neurofibromatosis type 1 (NF1) (MIM 162200) is a relatively common, autosomal dominant 
multisystem disorder that affects around one in 3500 individuals. Nearly half of the cases 
occur as a result of a new mutation (Freidman, 1998, as cited in McEwing et al., 2006) and 
expressivity is highly variable even among family members who carry  the same mutation 
(Korf & Rubenstein, 2005, and Riccardi & Lewis, 1998, as cited in Boyd et al., 2009). It is 
characterized by cafe-au-lait macules, neurofibromas (plexiform neurofibroma being 
pathognomonic), axillary or inguinal freckling, optic glioma, iris hamartomas (Lisch 
nodules), and osseus lesions such as sphenoid dysplasia or thinning of long bone cortex. 
Macrodactyly in patients with neurofibromatosis is due to plexiform neurofibroma; it may 
be bilateral and involvement of the distal phalanx may not be as prominent as in true 
macrodactyly (Goldman & Kaye, 1977).  
The prenatal diagnosis is very unlikely as the neonatal clinical features are usually 
solitary and cutaneous such as cafe-au-lait macules (McEwing et al., 2006) and spesific 
clinical findings increase in frequency with age (Freidman, 1998, as cited in McEwing et 
al., 2006). Nevertheless, there are a few cases with early and severe prenatal 
manifestations proven to be associated with neurofibromatosis postnatally. McEwing et 
al. reported a case presenting with a large oropharyngeal tumor, macrocephaly, 
ventriculomegaly, cardiomegaly, pleural and pericardial effusion, ascites and 
polyhydramnios. There was a positive paternal history of NF1 and after termination of 
pregnancy at 32 weeks, postmortem histologic evaluation was consistent with plexiform 
neurofibroma, confirming the diagnosis (McEwing et al., 2006). Another similar fetus with 
an oral tumor was also found to have NF1 postnatally (Hoyme et al., 1987, as cited in 
McEwing et al., 2006). Lastly, Drouin et al. reported a fetus with ambiguous genitalia, 
macrocephaly, shortened long bones and polyhydramnios in whom postnatal evaluation 
demonstrated a large abdominopelvic tumor and skeletal abnormalities consistent with 
NF1 (Drouin et al, 1997, as cited in McEwing et al., 2006).  
3.6 Tuberous sclerosis 
Tuberous sclerosis (MIM 191100/191092) is an autosomal dominant, hamartomatous 
disorder with variable expressivity. It affects about 1/6000 to 1/10000 live births and two 
thirds of the cases are considered to result from de novo mutations. It is associated with skin 
abnormalities such as hypomelanotic macules, facial angiofibromas, shagreen patches, 
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fibrous facial plaques, and ungual fibromas, brain abnormalities like cortical tubers, 
subependymal nodules, astrocytomas causing seizures, intellectual disability, and mental 
retardation, renal anomalies such as angiomyolipomas and cysts, and cardiac 
rhabdomyomas (Northrup & Au, 1999). Bone changes also occur and macrodactyly has been 
reported in 11 patients with tuberous sclerosis complex (Aldrich et al., 2010; Ghalli, 2001; 
Norman-Taylor & Mayou, 1994; Sahoo et al., 2000; Sharma et al., 2011; Shin & Garay,1997; 
Tung & Shih, 2009; Kousseff, 1989, and Ortonne et al., 1982 and Wallis & Beighton, 1989, and 
Zaremba, 1968, as cited in Norman-Taylor & Mayou, 1994). Mesodermal dysplasia as a 
component of tuberous sclerosis complex is postulated to be responsible for the 
macrodactyly (Sahoo et al., 2000) and overgrowth of the tissues and bones of the forearm 
and wrist has also been reported (Webb et al., 1996, as cited in Sahoo et al., 2000 ). 
The cases of tuberous sclerosis complex with macrodactyly were mainly in the infancy and 
childhood age group and in most of them the diagnosis of tuberous sclerosis was clinically 
obvious (Norman-Taylor & Mayou, 1994). The case reported by Sharma et al. developed 
macrodactyly of the index and middle finger of the right hand at 9 nine months of age along 
with a fibrous hamartoma at his right wrist whereas in Ghalli’s case macrodactyly of the 
second left toe was present at birth. 
Cardiac rhabdomyomas, arrhythmias, cerebral lesions such as cortical tubers and 
subependymal nodules, hydrops, and stillbirth are the most prevalent findings in the fetus 
(Isaacs, 2009). Although there are no reports of prenatal diagnosis of macrodactyly 
associated with tuberous sclerosis, regarding the highly variable phenotypic expression of 
the disease, it may be considered in the differential diagnosis.  
3.7 Ollier disease and Maffucci syndrome  
Ollier disease and Maffucci syndrome (MIM 166000) are rare, sporadic disorders 
characterized by multiple enchondromas of primarily small bones of the hands and feet, 
the long tubular bones, and also the flat bones like the pelvis. Maffucci syndrome is also 
associated with hemangiomas of the skin, mucosa and internal organs (Casal et al., 
2010).  
These two entities usually become manifest during childhood and adolescence and prenatal 
diagnosis has not been reported.  
3.8 Milroy disease 
Milroy disease (MIM 153100) is a rare, autosomal dominant disorder characterized by 
lymphedema of the lower extremities, either of the whole leg or limited to the feet or toes 
(Lev-Sagie et al., 2003). Although the associated localized overgrowth may mimic the 
clinical picture of macrodactyly, it is differentiated easily from true macrodactyly since the 
bony structures are of normal size in Milroy disease . 
Prenatal diagnosis of Milroy disease has previously been reported; with edema of the 
dorsum of both feet in two cases, bilateral leg edema and hydrothorax in one case and 
bilateral edema of the lower extremities most marked in the calves and feet in another case 
(Lev-Sagie et al., 2003; Makhoul et al., 2002; Franceschini et al., 2001). Lymphedema has been  
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There are two case reports demonstrating the association of Klippel-Trenaunay syndrome 
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Proteus syndrome Sporadic Macrodactyly, asymmetric   overgrowth 
and limb length discrepancy, vertebral 
abnormalities, soft tissue abnormalities, 
connective tissue nevi, vascular 
malformations, visceral anomalies such 
as splenomegaly, asymmetric 
megalencephaly, white matter 






Macrocephaly, lipomas, vascular 
malformations, intestinal polyps,  
pigmented macules of the penis 
CLOVES syndrome Sporadic Complex truncal lipomatous mass, 
vascular malformations, epidermal nevi, 
acral deformities including large, wide 
feet and hands, macrodactyly, and wide 
sandal gap, scoliosis and other 






Cutaneous capillary and venous 
malformations with hypertrophy of the 
related bones and soft tissues, 







Cafe-au-lait macules, neurofibromas, 
axillary or inguinal freckling, optic 
glioma, iris hamartomas (Lisch nodules), 
osseus lesions such as sphenoid 
dysplasia or thinning of long bone cortex 
Tuberous sclerosis Autosomal 
dominant/de novo 
mutation 
Hypomelanotic macules, facial 
angiofibromas, shagreen patches, fibrous 
facial plaques, ungual fibromas, brain 
abnormalities like cortical tubers, 
subependymal nodules, and 
astrocytomas, renal anomalies such as 
angiomyolipomas and cysts, cardiac 
rhabdomyomas
Ollier disease Sporadic Enchondromas, cerebral tumors 
Maffucci syndrome Sporadic Enchondromas, vascular malformations 
Milroy disease Autosomal 
dominant/de novo 
mutation
Lymphedema of the lower extremities 
Table 1. Characteristics of syndromes associated with macrodactyly. 
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associated with several other syndromes in early childhood such as lymphedema-distichiasis, 
Cholestasis-Lymphedema Syndrome (Aagenaes Syndromes) and Hennekam syndrome. 
The main features of above named syndromes associated with macrodactyly are 
summarized in Table 1. 
In addition to these syndromes which are well-known and more frequent, macrodactyly as a 
feature of several other rare conditions has also been observed. In this context, macrodactyly 
has been reported in association with minor tibial duplication (Adamsbaum et al., 1991), 
benign lipoblastomatosis with the relationship of this condition to Proteus syndrome being 
unclear (Colot et al., 1984), terminal osseous dysplasia with pigmentary defects (Brunetti-
Pieri et al., 2010), macrocephaly-capillary malformation syndrome (reported as enlarged 
hands in one case) (Barnicoat et al., 1996), segmentary fibrous dysplasia (Keymolen et al., 
1999) and a lethal skeletal dysplasia associated with ectopic digits (Morton et al., 1998). 
These conditions have overlapping features such as overgrowth and vascular malformations 
with well defined syndromes like Proteus syndrome and therefore, they should be kept in 
mind for the differential diagnosis of syndromic macrodactyly. 
 
4. Conclusion 
Although the majority of cases with macrodactyly are isolated, prenatal recognition of an 
enlarged digit mandates thorough evaluation of all systems in search for associated 
anomalies which may indicate syndromic involvement. Moreover, serial scans are 
recommended as some of the features such as hemihypertrophy may develop over time and 
indirect signs such as cardiac overload or hydrops fetalis may lead to recognition of an 
additional finding. In addition, fetal magnetic resonance imaging may be considered in 
cases with associated anomalies, although its contribution is controversial. As macrodactyly 
can be a clinical finding in several autosomal dominantly inherited disorders such as 
neurofibromatosis, tuberous sclerosis, Bannayan-Riley-Ruvalcaba syndrome and Milroy 
disease, family history and examination of further family members, prospect mother and 
father being the first ones to be evaluated, are mandatory to reveal the familial occurrence of 
a further case (Yüksel et al., 2009). Amniotic band syndrome, which causes swelling and 
edema distal to the point of constriction, should also be included in the differential 
diagnosis of prenatally diagnosed macrodactyly (Yüksel et al., 2009). 
A practical algorythym for the prenatal evaluation of macrodactyly is depicted in Fig. 2. 
Further case reports/series and information on the outcome of isolated and syndromic 
macrodactyly cases will help to improve the evaluation and management of this entity.  
It could be speculated that the most critical aspect in the management of isolated 
macrodactyly is its possible association with a syndrome which could become evident later 
in childhood, and emphasizing this possibility is mandatory when counselling the parents. 
Knowing that there is a significant clinical overlap between the overgrowth syndromes and 
that the phenotype may well develop in time, postnatal follow-up of the newborn during 
the first decade on a yearly basis by a multidisciplinary team consisting of a geneticist, 
dermatologist and orthopedic surgeon should be considered and the parents should be 
counselled accordingly.   
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* Associated anomalies may become overt postnatally and may ultimately lead to the diagnosis of a 
specific syndrome associated with macrodactyly 
** Prenatal diagnosis has not been reported previously. 
Fig. 2. Algorythym for the management and work-up for differential diagnosis of prenatal 
finding of macrodactyly.  
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Short FL is defined as below the 5th percentile or – 2 standard deviations (SD) appropriate 
for gestational age  at the ultrasound examination. FL measurement is one of the easiest fetal 
biometry measurements. However; careful ultrasonographic measurement of only the 
ossified portions of the diaphysis is needed to obtain accurate measurements. The ossified 
portion of the femur is measured from the major trochanter to the distal end of the femoral 
shaft; the distal and proximal epiphyses are not included in the measurement. Oblique 
planes must be avoided and the femur closer to the transducer must be measured while the 
transducer is aligned parallel to the long axis of the bone. (Figure 1) 
In most cases, short FL may be measured inaccurately or may be a variant of normal, 
especially if present as an isolated finding. However; short FL might be a diagnostic 
challenge for the examiner with various differential diagnoses. Short FL may be a part of a 
malformation such as a skeletal dysplasia or aneuploidies such as Trisomy 21 (Down 
Syndrome) or Monosomy X, and metabolic syndromes. (Kurtz et al.1990; Vergani et al. 2000; 
Bromley et al. 2002) Some studies have also suggested that a short FL is a feature of 
intrauterine growth restriction (IUGR) and small-for-gestational age (SGA) babies. (Todros 
et al. 1996; Zalel et al. 2002) Short FL may be associated with uteroplacental insufficiency 
and altered biochemical markers. (Weisz et al. 2008) 
In this chapter, the abnormalities that might present with a short FL will be described in 
detail and then the management of short FL will be discussed.  
2. Femur length and aneuplodies 
The antepartum detection of fetal aneuploidy is one of the major goals of prenatal screening 
programs and aneuploidies are the most common genetic abnormalities detected by 
prenatal diagnosis. (Nyberg et al. 2008) The major screening method for aneuploidies in the 
antenatal period is detection of abnormalities during ultrasonography in addition to 
biochemical markers, maternal age, and genetic risk. However, for definitive diagnosis, 
karyotype analysis by amniocentesis or chorionic villus biopsy is needed.  
Trisomy 21 (Down’s syndrome) is an aneuploidy characterized by presence of an extra 
chromosome 21. It is named after John Langdon Down who first described the syndrome in 
1866. (Down JLH; 1866)  The condition was identified as an extra chromosome 21 in 1959 by 
Jerome Lejeune. (Lejeune et al. 1959) Characteristic dysmorphic features of trisomy 21 
predominantly affect the head and neck and the extremities. Changes in the extremities 
include short broad hands, hypoplastic mid phalanx of fifth finger, incurved fifth finger, 
transverse palmar crease, space between the first and second toes (sandal gap deformity), 
hyperflexibility of joints. In addition, fetuses with trisomy 21 have slightly shorter long-
bones than their normal counterparts. Actually, the mean length at birth is approximately 
0.5 standard deviations (SD) less than normal babies in addition to decrease in birthweight 
and head circumference are less in babies with trisomy 21 when compared with normal 
counterparts. (Cronk CE; 1978) 
In 1987, Lockwood et al and Benacerraf et al were the first ones to show that short FL was 
associated with increased risk of trisomy 21. (Lockwood et al. 1987; Benacerraf et al. 1987) 
The other biometric parameters were also evaluated, but the most significant changes were 
observed in the length of the extremities. (Barr Jr M.; 1994) Various criteria have been 
described for the determination of short FL. Lockwood and Brumsfield used the biparietal 
 
Prenatal Evaluation of Fetuses Presenting with Short Femurs 
 
73 
diameter (BPD) to FL ratio in order to evaluate the risk of Down syndrome. (Lockwood et al. 
1987; Brumsfield et al. 1989) Lockwood chose an upper limit of 1.5 standard deviations 
above the mean. This led to a sensitivity of 50% and false- positive rate of 7% for identifying 
fetuses with Down syndrome. Brumsfield suggested a sensitivity of 40% and false positive 
rate of 2.2% using a BPD: FL ratio of ≥ 1.8 in the second trimester. (Brumsfield et al. 1989) 
But, it must be kept in mind that the BPD: FL ratio might differ depending on the gestational 
age of the fetus; second trimester seems to be the best time for evaluation. On the other 
hand, Grist used the measured-to-expected FL ratio and identified fetuses with Down 
syndrome with a sensitivity of 50% and false positive rate of 6.5%. ( Grist et al. 1990) 
It seems that most of the studies suggest that fetuses with trisomy 21 have slightly short FL. 
However the change in FL is only slight and therefore it is regarded as a soft marker for 
trisomy 21. Soft markers of trisomy 21 are ultrasonographic findings with the possibility of 
association with chromosomal abnormalities such as choroid plexus cysts, echogenic bowel, 
short FL, short humerus length (HL), pyelectasis. They are insufficient to be used as an 
isolated marker, but rather they are more likely to be useful when combined with each 
other. (Bethune, 2007) It must be remembered that isolated soft markers are identified in 11-
17% of normal fetuses; however the prevalence is much higher in trisomy 21 and the risk of 
trisomy 21 increases more especially of there is more than one marker. (Breathnach et al., 2007) 
So a detailed fetal anatomy scanning should be performed to search for other markers when a 
short FL is encountered and if there is more than one marker a karyotype analysis should be 
obtained. Increased nuchal fold thickness, hypoplastic nasal bone and aberrant right 
subclavian artery are more powerful markers for Down Syndrome, and fetal chromosomal 
analysis might be offered in most cases with these findings even if they were isolated. 
Short HL is also associated with trisomy 21 and it is suggested that the risk of trisomy 21 is 
higher with a short HL than a short FL. (Bethune, 2007) Therefore measurement of HL 
should be part of the routine whenever a short FL is measured.  
Turner Syndrome (Monosomy X) is the only monosomy that is compatible with life. Turner 
syndrome was first described by Henry Turner in 1938 and was recognized to be secondary 
to karyotypic variation of 45,X in 1959. (Turner, 1938; Ford et al., 1959; Wiedemann & Glatzl, 
1991)  Although most conceptions with Turner syndrome die, 1% survive until term. 
(Cockwell et al., 1991) Its incidence is 1 in 2500 to 3000 live-born girls. Approximately half 
have monosomy X (45,X), and 5 to 10% have a duplication (isochromosome) of the long arm 
of one X (46,X,i(Xq)). (Sybert & McCauley, 2004) It is characterized by large cystic hygromata 
and fetal hydrops at the early stages of gestation in addition to short FL and short HL. (Chen & 
Chien, 2007) Live born fetuses may have minor problems such as short stature, widely spaced 
nipples, congenital lymphedema, webbed neck, and minor bone and cartilage abnormalities. 
Prenatal sonographic diagnosis is usually established in the late first and early second 
trimesters, secondary to cystic hygroma formation. (Weisz et al., 2008) One study evaluated 
the clustered ultrasonography findings in fetuses with Turner syndrome. (FitzSimmons et al., 
1994) Thirteen fetuses with Turner syndrome were observed among 9348 early pregnancies 
(1/3086). Huge septated cystic hygroma, subcutaneous edema, and hydrops were observed in 
all cases. Short FL was detected in 12 of the 13 (92%) fetuses. Papp et al reported seven fetuses 
(10.1%) with short FL in 69 fetuses with Turner syndrome. The authors concluded that the 
addition of the soft marker of short FL to the second-trimester sonographic survey may 
increase the detection rate of Turner syndrome. (Papp et al.,2006) 
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all cases. Short FL was detected in 12 of the 13 (92%) fetuses. Papp et al reported seven fetuses 
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Todros et al evaluated the outcome of pregnancy in 86 fetuses diagnosed with short FL in 
the second trimester ultrasonography scanning. (Todros et al., 2004) Twenty-eight of the 
fetuses (32.5%) were normal, 40 (46.5%) were structurally abnormal and 18 (21%) were small 
for gestational age. Of the 40 malformed fetuses, 16 (40%) were aneuploid. The structural 
malformations associated with aneuploidy included 10 cases of congenital heart disease 
with trisomy 21, three cases of multiple malformations with trisomy 18, one case of multiple 
malformations with trisomy 13 and two cases of Turner syndrome with aortic coarctation. 
None of the fetuses with isolated short FL was aneuploid. Therefore the authors suggested 
that short FL is not considered as an indication for karyotype analysis unless associated with 
other sonographic markers.  
3. Femur length, skeletal dysplasias and other malformations 
The skeletal dysplasias account for about 5% of the genetic disorders seen in the newborn 
period. (Orioli et al.,1986) They represent a significant burden to many families because of 
potential lethality, and short- and long-term medical complications, and recurrence risk. The 
fetal skeleton is easily visualized by ultrasound, however most series note a diagnostic 
accuracy for the skeletal dysplasias at less than 50%. (Doray et al., 2000; Parilla et al., 2003; 
Krakow et al., 2008) 
Shortening of the FL is referred to as rhizomelia. When a short FL is identified before 24 
weeks gestation, skeletal dysplasias must be considered and all long bones (each femur, 
humerus, radius, ulna, tibia, and fibula) must be measured to determine the relative length 
against normal values. In addition to measurement of the length, the long bones should be 
evaluated regarding changes in shape, mineralization, bowing, angulation, and metaphyseal 
flare. Although there is severe shortening of all limbs in the majority of skeletal dysplasias, 
the foot length is relatively normal. The normal FL: foot length ratio is 1.0 throughout the 
pregnancy, thus a ratio of less than 1 is useful in distinguishing skeletal dysplasia from other 
causes of short FL, such as IUGR or aneuploidy. (Campbell et al., 32)  
Many skeletal dysplasias and specific syndromes are associated with short FL. These are 
listed in Table 1; however in most of these, it is possible to detect several additional 
ultrasonographic markers in a detailed ultrasonography scan.  
Achondroplasia (OMIM Entry # 100800) is the most frequent form of short-limb dwarfism 
and most common form of skeletal dysplasia. (Horton et al., 2007) It occurs in one in 15,000 
to one in 40,000 live births. 
It is caused by mutation in the fibroblast growth factor receptor-3 gene (FGFR3), which is 
located at chromosome 4p16.3 and is inherited as an autosomal dominant fashion with 
essentially complete penetrance. (Superti-Furga & Unger, 2007) More than 99% of individuals 
with achondroplasia have one of two mutations in FGFR3. Over 80% of individuals with 
achondroplasia have parents with normal stature and have achondroplasia as the result of a de 
novo gene mutation. Affected individuals exhibit short stature caused by rhizomelic shortening 
of the limbs, characteristic face with frontal bossing and midface hypoplasia, exaggerated 
lumbar lordosis, limitation of elbow extension, bowed legs, and trident hand. (Nyberg, 2003) 
Head and abdominal circumference may be normal, but are often enlarged. But these signs are 
not specific. Prenatal sonographic diagnosis is often not possible as the length of long bones is 
well  preserved until around 22 weeks’ gestation, the time of the routine fetal anomaly scan. 
(Goncalves & Jeanty, 1994; Chitty et al., 2011)  The FL is at the fifth percentile at this time and 
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then below the first percentile at about 30 weeks. (Nyberg, 2003) Presentation and diagnosis of 
de novo cases often occurs at this period when the short limbs, frontal bossing and trident hand 
may be evident. Even then, misdiagnosis is common. (Modaff et al., 1996)  
 
 
Table 1. The list of skeletal dysplasias  and syndromes  that might present prenatally with 
isolated short FL 
Bowing of the femora have been reported in some cases. One study suggested that all the 
fetuses with achondroplasia had rounded metaphyseal–epiphyseal interface, with an angle 
connexion to diaphysis wider than expected at the ultrasonography scan. (Boulet et al., 2009) 
Routine prenatal ultrasound examination may identify short FL and raise the possibility of 
achondroplasia in a fetus not known to be at increased risk. Krakow et al described the use 
of 3D ultrasonography in pregnancies from 16 to 28 weeks' gestation to enhance 
appreciation of the facial features and relative proportions of the appendicular skeleton and 
limbs for the diagnosis of achondroplasia. (Krakow et al., 2009) Ruano et al used a 
combination of 3D ultrasonography and intrauterine 3D helical computer tomography to 
enhance the diagnostic accuracy for intrauterine skeletal dysplasias. (Ruano et al., 2004) 
Molecular testing can confirm the diagnosis in achondroplasia. DNA extracted from fetal 
cells obtained by amniocentesis or fetal cord blood sampling can be analyzed for FGFR3 
mutations if achondroplasia is suspected. (Francomano et al., 1993a) 
Alkyldihydroxacetonephosphate synthase deficiency 
Atelosteogenesis type III 
Barrow (1984)- short-limbed dwarfism; congenital heart defect 
Baxova (1993)- micromelic bone dysplasia-humerus, femur, tibia type 
Brachydactyl-type A1 
Chondrodysplasia punctata-tibia metacarpal type 
De la Chapelle-neonatal osseous dysplasia 
Dysspondylochondromatosis 
Gracile bone dysplasia 
Hypochondroplasia 
Hypochondroplasia (autosomal recessive) 
Kyphomelic dysplasia 
Metaphyseal acroscyphodysplasia 
Metaphyseal chondrodysplasia- cone-shaped epiphyses 
Omodysplasia 
Omodysplasia type II 
Patterson (1975)-rhizomelic dysplasia 
Proximal femoral focal deficiency 
Pseudoacondroplasia-like syndrome 
Slaney (1999)- spondyloepimetaphyseal dysplasia-hypogammaglobulinaemia 
Spondyloepimetaphyseal dysplasia-type Genevieve 
Spondylometaphyseal dysplasia-type Borochowitz 
Spondylometaphyseal dysplasia-type Sutcliffe 
Silver-Russell syndrome 
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Todros et al evaluated the outcome of pregnancy in 86 fetuses diagnosed with short FL in 
the second trimester ultrasonography scanning. (Todros et al., 2004) Twenty-eight of the 
fetuses (32.5%) were normal, 40 (46.5%) were structurally abnormal and 18 (21%) were small 
for gestational age. Of the 40 malformed fetuses, 16 (40%) were aneuploid. The structural 
malformations associated with aneuploidy included 10 cases of congenital heart disease 
with trisomy 21, three cases of multiple malformations with trisomy 18, one case of multiple 
malformations with trisomy 13 and two cases of Turner syndrome with aortic coarctation. 
None of the fetuses with isolated short FL was aneuploid. Therefore the authors suggested 
that short FL is not considered as an indication for karyotype analysis unless associated with 
other sonographic markers.  
3. Femur length, skeletal dysplasias and other malformations 
The skeletal dysplasias account for about 5% of the genetic disorders seen in the newborn 
period. (Orioli et al.,1986) They represent a significant burden to many families because of 
potential lethality, and short- and long-term medical complications, and recurrence risk. The 
fetal skeleton is easily visualized by ultrasound, however most series note a diagnostic 
accuracy for the skeletal dysplasias at less than 50%. (Doray et al., 2000; Parilla et al., 2003; 
Krakow et al., 2008) 
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Achondroplasia (OMIM Entry # 100800) is the most frequent form of short-limb dwarfism 
and most common form of skeletal dysplasia. (Horton et al., 2007) It occurs in one in 15,000 
to one in 40,000 live births. 
It is caused by mutation in the fibroblast growth factor receptor-3 gene (FGFR3), which is 
located at chromosome 4p16.3 and is inherited as an autosomal dominant fashion with 
essentially complete penetrance. (Superti-Furga & Unger, 2007) More than 99% of individuals 
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of the limbs, characteristic face with frontal bossing and midface hypoplasia, exaggerated 
lumbar lordosis, limitation of elbow extension, bowed legs, and trident hand. (Nyberg, 2003) 
Head and abdominal circumference may be normal, but are often enlarged. But these signs are 
not specific. Prenatal sonographic diagnosis is often not possible as the length of long bones is 
well  preserved until around 22 weeks’ gestation, the time of the routine fetal anomaly scan. 
(Goncalves & Jeanty, 1994; Chitty et al., 2011)  The FL is at the fifth percentile at this time and 
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then below the first percentile at about 30 weeks. (Nyberg, 2003) Presentation and diagnosis of 
de novo cases often occurs at this period when the short limbs, frontal bossing and trident hand 
may be evident. Even then, misdiagnosis is common. (Modaff et al., 1996)  
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Hypochondroplasia (OMIM Entry #146000) is also inherited in an autosomal dominant pattern 
and caused by mutation in the gene for FGFR3 located on 4p, which is 98-99% mutated in 
achondroplasia. (Francomano et al., 1993b) The majority of the cases result from 
spontaneous mutations and that the unaffected parents of a child with hypochondroplasia 
have an extremely low risk (<0.01%) of having another affected child. Its prevalence is 1 in 
50.000 births. (Hicks, 2003) The molecular testing strategies can detect only % 70 of the cases. 
Not all patients with presumed hypochondroplasia have demonstrable mutations in the 
FGFR3 gene, suggesting genetic heterogeneity. It is characterized by short stature, short 
arms and legs, and macrocephaly. The skeletal features are very similar to achondroplasia 
but usually tend to be milder. (Spranger, 1988) Shortening of long bones with mild 
metaphyseal flare is observed. The hands are relatively short but do not exhibit the "trident" 
appearance that is typical in achondroplasia. Facial features are usually normal and the 
classic facial features of achondroplasia (e.g., midface hypoplasia, frontal bossing) are not 
generally seen. Head size may be large without significant disproportion.  
Hypochondroplasia shows some resemblance to achondroplasia, but is much milder and 
can be distinguished on clinical and radiographic grounds. Unlike achondroplasia, motor 
milestones are usually not significantly delayed and symptoms resulting from spinal cord 
compression (e.g., apnea, neuropathy) are less common. (Wyne-Davies et al., 1981) 
The antenatal  diagnosis is difficult  as skeletal disproportion tends to be mild and the 
ultrasonography findings nonspecific. Prenatal molecular genetic testing is available if the 
mutations in the parents with hypochondroplasia have been identified. If the mutation causing 
hypochondroplasia cannot be identified, ultrasound examination is the only method of prenatal 
testing. It is often possible to detect an affected fetus early in the pregnancy if the fetus is at risk 
of being a heterozygote with another dominantly inherited skeletal dysplasia. (Francomano et 
al., 1993b) However, it is currently difficult to detect heterozygous hypochondroplasia or other 
milder phenotypes using ultrasonography. Signs of disproportionate growth may suggest the 
diagnosis of hypochondroplasia, but a "normal" third trimester ultrasound examination is not 
sufficient to rule out a diagnosis of hypochondroplasia. DNA banking may be offered to the 
family for future analysis. DNA-based diagnosis (FGFR3 N540K and G380R mutation analysis) 
via chorion villus sampling, amniocentesis or fetal cord blood sampling  may be helpful in 
ruling out lethal forms of skeletal dysplasia and establishing a more favorable prognosis for the 
fetus. (Francomano et al., 1993b)  
Leroy I-cell disease is an autosomal recessive disorder first described in 1967 by Leroy and 
Demars and called I-cell disease due to the presence of phase dense intracytoplasmic 
inclusions in fibroblasts which were termed I cells. (Leroy et al., 1969) There is a biochemical 
defect in uridine diphospho-N-acetylglucosamine-1-phosphotransferase, which is the 
enzyme that catalyses addition of a mannose phosphate residue for lysosomal trafficking. 
(Wenger et al., 2002) Death from pneumonia or congestive heart failure usually occurs 
within the first decade of life. The most severely affected system is the skeletal system. Bone 
changes are similar to those observed in mucopolysaccharidoses. The classic finding is 
dysostosis multiplex, with a cloaking appearance of the long tubular bones due to periosteal 
new bone formation, anterior beaking and wedging of the vertebral bodies, widening of the 
ribs, proximal pointing of the metacarpals, and bullet shaped phalanges. Other findings are 
coarse facial features, developmental delay, growth failure, umbilical and inguinal hernias, 
hepatomegaly, and hypotonia. (Benacerraf, 1998)  Lees et al have described polyhydramnios 
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and short femurs in a case of Leroy I-cell disease that was diagnosed in the postnatal period. 
(Lees et al., 2001) The family had a history of Leroy I-cell disease. Yuksel et al reported two 
cases that both had short femurs and in one femoral bowing was additionally detected in 
the late second trimester and both were diagnosed as Leroy I-cell disease by enzyme 
analysis in the postnatal period. (Yuksel et al., 2007) None of the two families had a history 
of Leroy I-cell disease. Invasive prenatal diagnosis is possible by analysis of enzyme activity 
in chorionic villi or cultured amniocytes, but it is offered to families only known to be at risk 
for  the metabolic disease. 
For most of the other skeletal dysplasias presenting with short FL, other associated 
ultrasound findings such as bell-shaped thorax, protuberant abdomen, and polydactyl are 
present. (Nyberg, 2003) 
Femoral-facial syndrome (FFS), also known as femoral hypoplasia-unusual facies syndrome 
(FHUFS) (MIM 134780), first described by Daentl et al, is a rare and sporadic multiple 
congenital anomaly syndrome comprising bilateral femoral hypoplasia and characteristic 
facial features, such as long philtrum, thin upper lip, micrognathia with or without cleft 
palate, and a short nose with broad tip. (Daentl et al., 1975; Nowaczyk et al., 2003)  
Nowaczyk et al reported an infant born with the disorder whose ultrasonography scan  at 19 
weeks was reported as normal. Review of the prenatal radiographs showed no diagnostic 
features in this child. These authors underlined the difficulties in identifying femoral 
abnormalities on 2D imaging and suggested that 3D imaging would be more effective for 
prenatal diagnosis. (Nowaczyk et al., 2003) 
Acampomelic campomelic dysplasia (MIM 114290) is referred to cases without campomelia 
which is the bowing of the legs, especially the tibias. (Macpherson et al., 1989) However the 
other features of the syndrome such as ovarian dysgenesis, craniofacial changes, and 
defective tracheal bronchial cartilage are observed. (Rodriguez, 1993) Mutations in SOX-9 
gene have been observed, 46, XY sex reversal is common. (Kwok et al., 1995) 
Shprintzen syndrome (MIM 182212) is also associated with short FL. It is characterized by 
short stature, mild mental retardation, ear and hearing abnormalities, microcephaly, 
micrognathia, and cardiac and limb defects. The syndrome is autosomal dominantly  
inherited and is  caused by mutations in the fibrillin 1 gene, which cannot be tested easily in 
the antenatal period due to its size. (Biery et al., 1999) 
The most important point in the antenatal diagnosis of skeletal dysplasias is the prediction 
of lethal disorders. It is crucial to measure the thoracic circumference and warn the parents 
when the thoracic circumference is well below the fifth centile. Multidisciplinary approach 
is necessary in the diagnosis and counselling of these cases. After delivery or termination of 
the pregnancy, the diagnosis should be confirmed by clinical, radiographic, and 
histopathological analysis and also by molecular testing strategies when available. Cell 
cultures  and DNA should be banked to be used for future diagnostic  molecular testing.  
4. Femur length and intrauterine growth restriction 
Several case series have shown an association between short FL and  IUGR. Bromley et al, 
reported four fetuses with  short femurs  measuring more than 2 SD below the mean 
compared with the biparietal diameter. (Bromley et al., 1993) These fetuses were 
subsequently found to have severe IUGR with no evidence of skeletal dysplasia. Two other 
studies have described a short FL in cases with  IUGR. (O’Brien et al., 1982)  
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Hypochondroplasia (OMIM Entry #146000) is also inherited in an autosomal dominant pattern 
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and short femurs in a case of Leroy I-cell disease that was diagnosed in the postnatal period. 
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facial features, such as long philtrum, thin upper lip, micrognathia with or without cleft 
palate, and a short nose with broad tip. (Daentl et al., 1975; Nowaczyk et al., 2003)  
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In one study, 18 of the 86 fetuses (21%) referred for FL below the 10th percentile had SGA. 
(Todros et al., 2004) The diagnosis of SGA in fetuses was confirmed about 9 weeks after the 
initial finding of short FL. In another study short FL was associated with low birth weight 
and SGA, but not with gestational hypertension. These cases of isolated short FL were 
associated with significantly lower levels of pregnancy associated plasma protein- A (PAPP-
A), but similar β-hCG, inhibin-A, and alpha-fetoprotein (AFP) when compared to fetuses 
with normal FL. (Qin et al., 2006)  
Fetuses with short FL at the second trimester scanning might be considered as having an 
increased risk of IUGR. Maternal evaluation regarding blood pressure monitorization and 
follow-up for development of preeclampsia, ultrasonographic evaluation of the placenta, and 
Doppler analysis should be offered in this situation. In one study 50% of the women developed 
preeclampsia while undergoing follow-up for short FL and IUGR. (Todros et al., 2004)   
The association between short FL and IUGR is unclear. It might be explained by the brain 
sparing effect with decreased flow to the lower body. It is likely that IUGR and short FL are 
linked to preeclampsia by the common mechanism of placental insufficiency. (Weisz et al., 2008)  
Silver-Russell syndrome (SRS, MIM 180860) is a syndrome characterized by severe 
asymmetric IUGR, poor postnatal growth, craniofacial features such as a triangular shaped 
face and a broad forehead, body asymmetry, and a variety of minor malformations. It was 
reported independently by Silver et al. and Russell. (Silver et al., 1953; Russell, 1954) The 
long bones are short whereas the head measurements are within the normal range. The 
hallmark for the diagnosis of Silver-Russell  syndrome is the demonstration of limb length 
asymmetry, which is unusual in other conditions. Yet there is no specific testing to confirm 
the diagnosis in the prenatal period. (Nyberg, 2003) In very near future testing strategies like 
chip-based next generation sequencing and methylation testing assays will be available for 
definitive diagnosis of SRS cases and many other sydromes having  short femurs  as the  
only clinical sign will be thoroughly evaluated during the antenatal period.  
5. Femur length and normal variants 
It must be considered that most of the fetuses presenting with isolated short FL are clinically  
normal. A short FL is defined as below the 5th percentile or below two standard deviations 
from the mean for the gestational age. That results in a pickup rate that exceeds the expected 
frequency of skeletal dysplasias. Various criteria have been published for the determination 
of short FL and HL. (Lockwood et al., 1987; Benacerraf et al., 1992) These criteria overlap the 
range observed in unaffected fetuses and vary widely among different populations; 
therefore, it would be prudent to develop standards for each population. Some authors have 
advocated the use of ethnic-specific FL growth charts. FL is observed to be shorter in Asian 
and oriental populations. (Nyberg, 2003; Down, 1866; Bromley et al., 1993; Shipp et al., 2001; 
Kovac et al., 2002a; Drooger et al., 2005)  A significant difference in the mean expected FL 
among fetuses in the second trimester with regard to ethnicity was observed. It was stated 
that using ethnic-specific formulas for expected FL can have a considerable impact on the 
use of sonographic risk factors for trisomy 21 screening. (Kovac et al., 2002b) In another 
study, it was reported that short stature increased a woman's risk of having an abnormal 
BPD:FL ratio at the second trimester. They indicated that risk assessment for fetal trisomy 21 
for such patients might be inaccurate. (Drooger et al., 2005) At 18 and 19 weeks' gestation, 
women shorter than one SD below the mean were twice as likely to have an abnormal BPD: 
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FL ratio compared with women taller than one SD above the mean (relative risk 2.38; 95% 
confidence interval 1.21, 4.69). (Drooger et al., 2005) 
6. Management of short femur length 
The differential diagnoses of short FL include normal variation, a false-positive 
measurement, IUGR, aneuploidy, and skeletal dysplasias. Very short FL is suggestive for 
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Table 2. Differential Diagnosis of short femur length 
Detailed ultrasonography scanning should be performed in patients presenting with short FL 
to exclude fetal malformations. Other tubular bones should be evaluated in addition to FL.  
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FL ratio compared with women taller than one SD above the mean (relative risk 2.38; 95% 
confidence interval 1.21, 4.69). (Drooger et al., 2005) 
6. Management of short femur length 
The differential diagnoses of short FL include normal variation, a false-positive 
measurement, IUGR, aneuploidy, and skeletal dysplasias. Very short FL is suggestive for 
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Table 2. Differential Diagnosis of short femur length 
Detailed ultrasonography scanning should be performed in patients presenting with short FL 
to exclude fetal malformations. Other tubular bones should be evaluated in addition to FL.  
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It must be remembered that the majority of isolated short FL are normal or constitutionally 
short and 13-61% of the fetuses diagnosed with isolated short FL at the second trimester 
scanning are classified as normal eventually on the follow-up. (Todros et al., 2004; 
Papageorghiou et al., 2008) In contrast, severely shortened (<5th percentile) or abnormal 
appearing long bones may be a sign of a skeletal dysplasia or early onset fetal growth 
restriction. (Weisz et al., 2008) 
Counselling should be given to cases with isolated short FL; however a more conservative 
approach is more appropriate. Serial ultrasonography examinations should be performed in 
order to exclude skeletal dysplasias, IUGR, and uteroplacental insufficieny. Karyotype 
analysis should be offered if there are other sonographic markers suggesting aneuploidies. 
In cases where the karyotype analysis is normal, it is wise to store the DNA for future 
analysis in cases of sporadic skeletal dysplasias and syndromes. Isolated short FL cases  
should be followed up. Short FL due to IUGR should be suspected if during follow-up a 
small abdominal circumference, or abnormal Doppler parameters develop. If the FL falls 
further from the mean in the three-four weeks of follow-up skeletal dysplasia or severe 
IUGR should be suspected. (Kurtz et al., 1990) 
Mild shortening of FL may suggest chromosomal abnormality or a syndrome. (Benacerraf et 
al., 1987; LaFollette et al., 1989; Perella et al., 1988; Nyberg et al., 1990)  If mildly short FL 
(defined as length < 90% of the predicted FL) is present, there is a 1% risk of trisomy 21 in a 
high risk population (1/250 trisomy 21) and 3% risk of trisomy 21 in a low risk population 
(1/700 trisomy 21). (Nyberg et al., 1990) Short HL is even more specific than short FL in 
predicting trisomy 21. If short HL (defined as length < 90% of the predicted HL) is 
identified, there is a 3% risk of trisomy 21 in a high-risk population and a 1-2% risk of 
trisomy 21 in a low-risk population. (Benacerraf et al., 2001) 
In the third trimester, one should remember that the FL is subject to the same ‘biologic 
variability’ as other biometric markers. It is not unusual for the FL measurement to be 
slightly less than other biometric markers in the absence of morphologic abnormality. This is 
particularly true if the remainder of the sonographic evaluation of the fetus is normal.  
Evaluation of fetal posture and fetal movements are very important in prenatal ultrasound. 
Abnormal posture or movement may be the first clues to either focal or generalized 
musculoskeletal abnormality. Some skeletal dysplasias may develop additional features 
during the follow-up. The family must be clarified about the fact that some of the sydromes 
cannot be ruled out despite detailed sonographic evaluation.  
7. Key points 
1. Most of the fetuses with isolated short FL are normal or constitutionally short. 
2. Detailed sonographic evaluation regarding additional markers for aneuploidy, 
measurement of other tubular bones, Doppler analysis should be performed. 
3. If there are additional markers, karyotype analysis should be performed. The DNA may 
be banked for future analysis.  
4. If the fetal karyotype analysis is normal, serial follow-up scans should be scheduled. 
5. If, during follow-up the FL falls more from the mean, skeletal dysplasias or severe 
IUGR should be suspected. Molecular analysis must be performed  for the diagnosis of 
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skeletal dysplasias with known molecular teiology, such as achondroplasia and 
hypochondroplasia . Preeclampsia must be ruled out.  
6. Findings more suggestive for skeletal dysplasias include FL 2 SD below the mean for 
gestational age; FL/ foot length <1; and FL/ abdominal circumference < 0.16 . 
7. Despite detailed sonographic evaluation, some of the syndromes cannot be ruled out 
and postnatal clinical genetic  evaluation of fetuses or newborns should be considered.  
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1. Introduction 
During the early stages of embryogenesis, genetic factors play the predominant role in the 
development of the fetal face. In later stages, environmental influences increase in 
importance. Facial malformation may be the result of chromosomal aberrations as well as 
teratogenic factors. Therefore, facial dysmorphism can provide important clues that suggest 
chromosomal or genetic abnormalities. The post-natal diagnosis of facial dysmorphism is a 
well-known pediatric diagnosis, primarily based on pattern diagnosis related to the 
appearance of one or a combination of facial features, such as low-set ears, hypo-
hypertelorism, small orbits, micrognathia, retrognatia, and more. Some of these features are 
detectable prenatally (Benacerraf, 1998). More than 250 syndromes are associated with 
disproportional growth of abnormal features of the fetal face (Smith & Jones, 1988). 
 
Indication N % 
Other fetal anomalies detected by US 118 52.8 
Familial history of craniofacial malformations 72 32.2 
Maternal drug intake 25 11.2 
Fetal chromosomal aberrations 8 3.6 
Total 223  
Table 1. Indications for ultrasound examination of the fetal face (Pilu et al., 1986) 
Sonographic assessment of the fetal face is part of the routine anatomic survey. Recently, 
three-dimensional ultrasound (3D) images of the fetus can be also obtained. However, two-
dimensional ultrasonographic images are more easily, rapidly, efficiently, and accurately 
obtained. Imaging of the fetal face is possible in most ultrasound examinations beyond 12 
weeks of gestation. 
This chapter describes normal structural development and the sonographic approach to 
evaluation of the fetal face. Clinical applications are discussed in relation to perinatal 
management. 
2. Fetal face profile 
Sonographic imaging of the fetal face can provide information for the antenatal diagnosis of 
fetuses with various congenital syndromes and chromosomal aberrations, many of which 
are known to be associated with facial malformations. Deviation from the normal 
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Sonographic imaging of the fetal face can provide information for the antenatal diagnosis of 
fetuses with various congenital syndromes and chromosomal aberrations, many of which 
are known to be associated with facial malformations. Deviation from the normal 
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proportions of the fetal face profile might be one of the 'soft sonographic signs' that can 
provide important clues that suggests congenital syndromes (Benacerraf, 1998). 
Visualization of the curvature of the forehead is important to rule out a flat forehead, such 
as microcephaly, or bossing of the forehead, such as craniosynostosis (Goldstein et al., 1988). 
Visualization of the bridge of the nose could rule out Apert or Carpenter syndromes (Smith 
& Jones, 1988). Visualization of normal prominent lips can rule out cleft lip (Benacerraf, 
1998). Finally, a normal jaw appearance is important to rule out microganthia or prognathia 
(Sivan et al., 1997). 
Evaluation of the fetal face structures is suggested on the coronal and mid-sagittal views. 
The fetal face profile appearance should be obtained, while an imaginary line is passed 
through the nasion (bridge of the nose) and the gnathion (lower protrusion of the chin). This 
imaginary line is vertical to the maxillary bone. In this view, the following structures can be 
identified: the bridge and tip of the nose, the philtrum (area between the nose and the upper 
lip), upper and lower lips, and chin (Goldstein et al., 2010). 
 
Fig. 1. A describes the distance from the tip of the nose to the mouth (line between the lips), 
B from the mouth to the chin, a describes the distances from the upper philtrum and the 
mouth, b from the mouth and the upper concavity of the chin. 
The ratios between the following distances are independent of the gestational age and are 
almost constant: the distances between the tip of the nose and the mouth, and the distance 
from the mouth to the gnathion. In addition, a constant ratio was found between the upper 
philtrum and the mouth and from the mouth to the upper concavity of the chin (Goldstein 
et al., 2010). 
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Fig. 2. Sonographic picture of the fetal face. Typical facial concavities and protrusions are 
presented. The calipers measured between the upper philtrum to the mouth (upper picture), 
and between the mouth to the chin (lower picture). 
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Fig. 3. 3D pictures of the fetal face. Mimics of face: a. kiss, b: open mouth and tongue, c: 
whistling, d: whistling, e: bye-bye 
3. The forehead 
Visualization of the curvature of the forehead is important to rule out a flat forehead (Figure 
4). Investigators agree that microcephaly is associated with a decreased size of the frontal 
fossa and flattening of the frontal bone. Therefore, determination of the normal dimensions 
of the anterior cranial fossa and the frontal lobe of the fetal brain can provide normative 
 
Fig. 4. Schematic picture of the anterior lobe on sagittal and axial planes 
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Fig. 5. A flat forehead in neonates with microcephaly 
GA [weeks] FLD [cm] mean±2SD TFLD [cm] mean±2SD 
15 1.4 0.4 3.2 0.4
16 1.4 0.4 3.2 0.4
17 1.6 0.2 3.6 0.6
18 1.6 0.2 3.7 0.6
19 1.7 0.2 3.8 0.4
20 1.7 0.2 4.1 0.4
21 1.8 0.4 4.1 0.4
22 1.8 0.4 4.6 0.4
23 1.8 0.4 4.6 0.4
24 1.9 0.2 4.7 0.4
25 2.2 0.4 5.1 0.6
26 2.3 0.4 5.2 0.6
27 2.5 0.6 5.6 0.8
28 2.8 0.2 5.7 0.4
29 2.7 0.2 6.1 0.4
30 2.8 0.6 6.2 1.2
31 2.9 0.4 6.2 0.8
32 3.0 0.6 6.4 0.8
33 3.1 0.6 6.5 0.6
34 3.2 0.2 6.7 0.6
35 3.2 0.4 6.9 0.6
36 3.2 0.4 7.0 0.4
37 3.4 0.4 7.2 0.6
38 3.5 0.4 7.3 0.8
39 3.7 0.6 7.5 0.8
40 4.0 0.6 7.7 0.8
Table 2. Measurements of the mean±2SD of the frontal lobe distance and thalamic frontal 
lobe distance versus gestational age (Goldstein et al., 1988) (GA = gestational age, FLD = 
frontal lobe distance, TFLD = thalamic frontal lobe distance) 
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Fig. 5. A flat forehead in neonates with microcephaly 
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data against which fetuses suspected to have microcephaly or any other lesion affecting the 
anterior fossa can be evaluated. A dysmorphic sign with a high frequency appears to be a 
flat facial profile in neonates with trisomy 21 (Smith & Jones, 1988). Table 2 describes the 
normal dimensions of the frontal lobe of the fetal brain (Goldstein et al., 1988). 
4. The nasal bone 
Smallness of the nose is a common finding at postnatal examination of fetuses or neonates 
with trisomy 21, but also with more than 40 other genetic conditions.  Measurements of the 
nasal bone were performed on a mid-sagittal profile in normal singleton fetuses at 14-34 
weeks’ gestation. It was found that the length of the nasal bones increased from 4 mm at 14 
weeks to 12 mm at 35 weeks’ gestation (Guis et al., 1995). Investigators examined the 












Table 3. Mean, standard deviation (SD), mean+2SD and mean-2SD for length of the nasal 
bones (mm) throughout gestation (Guis et al., 1995) 











Table 4. Fetal nasal bone length (mm), 11-20 weeks' gestation (Cuick et al., 2004) 





Table 5. Nomogram of fetal nasal bone length at 11-13 gestational weeks in fetuses (Sivri et 
al., 2006) 
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possible improvement in screening for trisomy 21 by examining the fetal nasal bone with 
ultrasound at 11-14 weeks of gestation (Cicero et al., 2001). The nasal bone was absent in 43 
of 59 (73%) trisomy 21 fetuses, and in three of 603 (0.5%) chromosomally normal fetuses. 
5. The nostrils 
Smallness of fetal nose, often attributed to hypoplasia, is a common finding during postnatal 
examination of fetuses or neonates with trisomy 21 (Smith & Jones, 1988) 
 
GA [weeks] Centiles10 25 50 75 90
14-15 5.5 7.2 7.6 8.3 10.2
16-17 6.5 7.3 7.9 8.5 10.5
18-19 8.5 8.9 10.0 10.5 11.0
20-21 10.2 11.0 12.0 12.0 13.0
22 13.0 13.0 14.0 15.0 15.0
23 13.0 13.0 14.0 15.0 15.0
24 13.0 14.1 15.0 16.0 16.0
25 14.2 15.0 16.3 17.0 17.0
26 14.1 15.0 16.3 17.4 18.4
27 13.4 15.4 17.2 18.4 19.0
28 15.1 16.9 17.6 18.2 20.2
29-30 16.5 17.4 18.1 19.2 20.6
31-32 16.6 17.9 19.6 20.7 21.4
33-34 17.4 19.1 20.5 21.4 23.1
35-37 17.6 20.0 20.5 22.0 23.3
38-40 17.4 17.9 18.9 20.5 23.4
Table 6. The fetal nose width (mm) (Goldstein et al., 1997) 
GA [weeks] Centiles10 25 50 75 90
14-15 3.3 3.6 4.2 4.7 5.4
16-17 3.5 3.9 4.4 4.8 5.9
18-19 4.0 4.4  .6 5.0 5.8
20-21 4.2 5.0 5.0 5.7 6.0
22 5.0 5.0 6.0 6.4 7.0
23 5.0 5.6 6.0 7.0 7.0
24 5.8 6.0 6.2 7.3 7.9
25 5.9 6.0 6.4 7.0 7.7
26 5.1 6.2 7.7 8.0 9.0
27 6.4 6.8 7.8 8.4 9.4
28 6.4 7.0 7.9 8.6 9.4
29-30 5.4 7.0 7.0 8.2 9.6
31-32 4.6 7.4 7.9 9.2 10.7
33-34 5.4 6.4 8.1 9.0 9.7
35-37 5.8 6.6 8.5 9.6 10.2
38-40 6.0 6.8 8.5 9.5 10.5
Table 7. The fetal nostril distance (mm) (Goldstein et al., 1997) 
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data against which fetuses suspected to have microcephaly or any other lesion affecting the 
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20-21 4.2 5.0 5.0 5.7 6.0
22 5.0 5.0 6.0 6.4 7.0
23 5.0 5.6 6.0 7.0 7.0
24 5.8 6.0 6.2 7.3 7.9
25 5.9 6.0 6.4 7.0 7.7
26 5.1 6.2 7.7 8.0 9.0
27 6.4 6.8 7.8 8.4 9.4
28 6.4 7.0 7.9 8.6 9.4
29-30 5.4 7.0 7.0 8.2 9.6
31-32 4.6 7.4 7.9 9.2 10.7
33-34 5.4 6.4 8.1 9.0 9.7
35-37 5.8 6.6 8.5 9.6 10.2
38-40 6.0 6.8 8.5 9.5 10.5
Table 7. The fetal nostril distance (mm) (Goldstein et al., 1997) 
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6. The fetal eyes 
The earliest sonographic visualization of the fetal orbit and lens has been considered to be in 
the beginning of the second trimester of pregnancy. On ultrasound, the orbits appear as 
echolucent circles in the face of the fetus, and the lens can be easily identified inside these 
structures. Imaging of these structures, which is possible on virtually all ultrasound 
examinations beyond the first trimester, is important because deviation in the relative size of 
the orbit and the lens can be associated with congenital malformations. The fetal orbits and 
lens eyes are best visualized by scanning the fetal face in coronal and axial planes. The fetal 
orbits should appear as two symmetrical structures on both sides of the fetal nose. Both 
lenses are depicted on the coronal or axial plane of the eye as circular hyperechogenic rings 
and with hypoechogenic areas inside the ring. 
The coronal planes of the fetal face are the most important in the evaluation of the fetal orbits. 
Figure 6a shows the the outer orbital distance small hands, and Fig 6b the inner orbital distace 
the small arrows. The calipers measuring the outer orbital from the lateral mid-echogenicity to 
the lateral mid-echogenicity, and the calipers measuring the inner orbital distace  from the 
middle mid-echogenicity to the middle mid-echogenicity of the orbits. 
 
Fig. 6a. Coronal plane of the fetal orbits – small hands showing the outer orbital diameter 
measurement 
 
Fig. 6b. Coronal plane of the fetal orbits – small arrows showing the inner orbital diameter 
measurement 
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GA 
[weeks] 
N Mean 95% CI Centiles 
10 25 50 75 90 
14 10 5.2 4.8-5.7 4.5 5.0 5.3 5.7 90 
15 26 6.1 5.9-6.3 5.4 5.5 6.2 6.5 6.7 
16 25 6.6 6.3-6.9 5.8 6.2 6.5 7.0 7.6 
17-18 19 7.3 6.7-7.8 6.2 6.5 6.7 9.0 9.0 
19-20 23 9.8 9.3-10.2 8.6 9.0 10.0 10.1 11.3 
21 19 10.5 10.0-10.9 9.4 9.9 10.0 11.0 12.0 
22 26 10.4 10.0-10.7 9.5 9.6 10.5 11.0 11.3 
23 21 10.7 10.4-11.1 9.6 10.0 10.5 11.4 11.5 
24 19 11.6 11.3-11.8 10.7 11.0 11.5 12.0 12.5. 
25 13 11.2 11.4-12.4 10.3 11.0 12.2 12.5 12.8 
26 16 12.7 12.0-13.4 11.0 11.0 12.7 13.8 14.5 
27 14 13.0 12.4-13.5 11.9 12.0 12.9 13.4 14.8 
28 21 13.0 12.7-13.3 21.1 12.0 13.1 13.3 14.1 
29 23 13.9 13.4-14.4 12.6 13.0 13.7 14.6 15.7 
30-31 24 14.2 13.8-14.5 13.3 13.0 13.9 14.7 15.4 
32-33 24 14.4 13.7-15.1 12.2 13.0 14.1 14.8 17.5 
34-36 26 15.8 15.4-16.2 14.6 15.0 15.7 16.5 16.9 




n Mean 95% CI Centiles 
10 25 50 75 90 
14 10 2.5 23.3-2.7 2.1 2.4 2.5 2.7 2.9 
15 26 2.9 2.9-3.0 2.7 2.8 2.9 3.1 3.2 
16 25 2.9 2.8-3.0 2.7 2.8 2.9 3.1 3.2 
17-18 19 3.3 3.0-3.6 2.8 2.9 3.0 3.3 5.0 
19-20 23 4.1 4.0-4.3 3.6 4.0 4.0 4.3 5.0 
21 19 4.4 4.1-4.6 3.7 3.9 4.0 5.0 5.0 
22 26 4.4 4.2-4.7 3.9 4.0 4.3 5.0 5.0 
23 21 4.6 4.3-4.8 3.8 4.0 5.0 5.0 5.0 
24 19 4.6 4.4-4.8 4.0 4.3 4.6 5.0 5.0 
25 13 4.8 4.6-5.0 4.2 4.6 5.0 5.1 5.2 
26 16 5.0 4.8-5.2 4.4 4.8 5.1 5.2 5.5 
27 14 5.0 5.0-5.2 4.5 5.0 5.2 5.2 5.5 
28 21 5.1 5.0-5.2 4.5 5.0 5.2 5.2 5.5 
29 23 5.3 5.1-5.5 4.6 5.2 5.2 5.5 5.9 
30-31 24 5.3 5.2-5.5 4.8 5.1 5.5 5.5 5.7 
32-33 24 5.6 5.4-5.8 4.8 5.2 5.5 5.9 6.2 
34-36 26 5.8 5.6-6.0 5.4 5.5 5.7 6.0 6.5 
Table 9. Diameter of orbital lens (mm) (Goldstein et al., 1998) GA = gestational age; CI = 
confidence interval) 
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26 16 5.0 4.8-5.2 4.4 4.8 5.1 5.2 5.5 
27 14 5.0 5.0-5.2 4.5 5.0 5.2 5.2 5.5 
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Table 9. Diameter of orbital lens (mm) (Goldstein et al., 1998) GA = gestational age; CI = 
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6.1 Hypotelorism 
Hypotelorism is a condition pertaining to abnormally close eyes. 
 
GA [weeks] 
OOD [mm] IOD [mm] 
5th 50th 95th 5th 50th 95th 
12 8 15 23 4 9 13 
13 10 18 25 5 9 14 
14 13 20 28 5 10 14 
15 15 22 30 6 10 14 
16 17 25 32 6 10 15 
17 19 27 34 6 11 15 
18 22 29 37 7 11 16 
19 24 31 39 7 12 16 
20 26 33 41 8 12 17 
21 28 35 43 8 13 17 
22 30 37 44 9 13 18 
23 31 39 46 9 14 18 
24 33 41 48 10 14 19 
25 35 42 50 10 15 19 
26 36 44 51 11 15 20 
27 38 45 53 11 16 20 
28 39 47 54 12 16 21 
29 41 48 56 12 17 21 
30 42 50 57 13 17 22 
31 43 51 56 13 18 22 
32 45 52 60 14 18 23 
33 46 53 61 14 19 23 
34 47 54 62 15 19 24 
35 48 55 63 15 20 24 
36 49 56 64 16 20 25 
37 50 57 65 16 21 25 
38 50 58 65 17 21 21 
39 51 58 66 17 22 26 
40 52 59 67 18 22 26 
Table 10. The outer orbital diameter (OOD) and inner orbital diameter (IOD), GA = 
gestational age (Jeanty et al., 1984) 
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Fig. 7. Axial scan of a fetus at 25.3 weeks of gestation showing severe hypotelorism 
BPD [cm] Weeks' gestation IOD [cm] OOD [cm] 
1.9 11.6 0.5 1.3 
2.0 11.6 0.5 1.4 
2.1 12.1 0.6 1.5 
2.2 12.6 0.6 1.6 
2.3 12.6 0.6 1.7 
2.4 13.1 0.7 1.7 
2.5 13.6 0.7 1.8 
2.6 13.6 0.7 1.9 
2.7 14.1 0.8 2.0 
2.8 14.6 0.8 2.1 
2.9 14.6 0.8 2.1 
3.0 15.0 0.9 2.2 
3.1 15.5 0.9 2.3 
3.2 15.5 0.9 2.4 
3.3 16.0 1.0 2.5 
3.4 16.5 1.0 2.5 
3.5 16.5 1.0 2.6 
3.6 17.0 1.0 2.7 
3.7 17.5 1.1 2.7 
3.8 17.9 1.1 2.8 
4.0 18.4 1.2 3.0 
4.2 18.9 1.2 3.1 
4.3 19.4 1.2 3.2 
4.4 19.4 1.3 3.2 
4.5 19.9 1.3 3.3 
4.6 20.4 1.3 3.4 
4.7 20.4 1.3 3.4 
4.8 20.9 1.4 3.5 
4.9 21.3 1.4 3.6 
5.0 21.3 1.4 3.6 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 94
6.1 Hypotelorism 
Hypotelorism is a condition pertaining to abnormally close eyes. 
 
GA [weeks] 
OOD [mm] IOD [mm] 
5th 50th 95th 5th 50th 95th 
12 8 15 23 4 9 13 
13 10 18 25 5 9 14 
14 13 20 28 5 10 14 
15 15 22 30 6 10 14 
16 17 25 32 6 10 15 
17 19 27 34 6 11 15 
18 22 29 37 7 11 16 
19 24 31 39 7 12 16 
20 26 33 41 8 12 17 
21 28 35 43 8 13 17 
22 30 37 44 9 13 18 
23 31 39 46 9 14 18 
24 33 41 48 10 14 19 
25 35 42 50 10 15 19 
26 36 44 51 11 15 20 
27 38 45 53 11 16 20 
28 39 47 54 12 16 21 
29 41 48 56 12 17 21 
30 42 50 57 13 17 22 
31 43 51 56 13 18 22 
32 45 52 60 14 18 23 
33 46 53 61 14 19 23 
34 47 54 62 15 19 24 
35 48 55 63 15 20 24 
36 49 56 64 16 20 25 
37 50 57 65 16 21 25 
38 50 58 65 17 21 21 
39 51 58 66 17 22 26 
40 52 59 67 18 22 26 
Table 10. The outer orbital diameter (OOD) and inner orbital diameter (IOD), GA = 
gestational age (Jeanty et al., 1984) 
 
Normal and Abnormal Fetal Face 95 
 
Fig. 7. Axial scan of a fetus at 25.3 weeks of gestation showing severe hypotelorism 
BPD [cm] Weeks' gestation IOD [cm] OOD [cm] 
1.9 11.6 0.5 1.3 
2.0 11.6 0.5 1.4 
2.1 12.1 0.6 1.5 
2.2 12.6 0.6 1.6 
2.3 12.6 0.6 1.7 
2.4 13.1 0.7 1.7 
2.5 13.6 0.7 1.8 
2.6 13.6 0.7 1.9 
2.7 14.1 0.8 2.0 
2.8 14.6 0.8 2.1 
2.9 14.6 0.8 2.1 
3.0 15.0 0.9 2.2 
3.1 15.5 0.9 2.3 
3.2 15.5 0.9 2.4 
3.3 16.0 1.0 2.5 
3.4 16.5 1.0 2.5 
3.5 16.5 1.0 2.6 
3.6 17.0 1.0 2.7 
3.7 17.5 1.1 2.7 
3.8 17.9 1.1 2.8 
4.0 18.4 1.2 3.0 
4.2 18.9 1.2 3.1 
4.3 19.4 1.2 3.2 
4.4 19.4 1.3 3.2 
4.5 19.9 1.3 3.3 
4.6 20.4 1.3 3.4 
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BPD [cm] Weeks' gestation IOD [cm] OOD [cm] 
5.1 21.8 1.4 3.7 
5.2 22.3 1.4 3.8 
5.3 22.3 1.5 3.8 
5.4 22.8 1.5 3.9 
5.5 23.9 1.5 4.0 
5.6 23.3 1.5 4.0 
5.7 23.8 1.5 4.1 
5.8 24.3 1.6 4.1 
5.9 24.3 1.6 4.2 
6.0 24.7 1.6 4.3 
6.1 25.2 1.6 4.3 
6.2 25.2 1.6 4.4 
6.3 25.7 1.7 4.4 
6.4 26.2 1.7 4.5 
6.5 26.2 1.7 4.5 
6.6 26.7 1.7 4.6 
6.7 27.2 1.7 4.6 
6.8 27.6 1.7 4.7 
6.9 28.1 1.7 4.7 
7.0 28.6 1.8 4.8 
7.1 29.1 1.8 4.8 
7.3 29.6 1.8 4.9 
7.4 30.0 1.8 5.0 
7.5 30.6 1..8 5.0 
7.6 31.0 1.8 5.1 
7.7 31.5 1.8 5.1 
7.8 32.0 1.8 5.2 
7.9 32.5 1.9 5.2 
8.0 33.0 1.9 5.3 
8.2 33.5 1.9 5.4 
8.3 34.0 1.9 5.4 
8.4 34.4 1.9 5.4 
8.5 35.0 1.9 5.5 
8.6 35.4 1.9 5.5 
8.8 35.9 1.9 5.6 
8.9 36.4 1.9 5.6 
9.0 36.9 1.9 5.7 
9.1 37.3 1.9 5.7 
9.2 37.8 1.9 5.8 
9.3 38.3 1.9 5.8 
9.4 38.8 1.9 5.8 
9.6 39.3 1.9 5.8 
9.7 39.8 1.9 5.9 
Table 11. Predicted BPD and weeks' gestation from the inner orbital diameter (IOD) and 
outer orbital diameter (OOD) (Mayden et al., 1982) 
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6.2 Hypertelorism 
Hypertelorism is an abnormally increased distance between two organs or body parts, 
usually referring to an increased distance between the eyes (orbital hypertelorism), seen in a 
variety of syndromes (Table 12). 
 
Malformation Syndromes 
Anophthalmus Trisomy 13 
Vilaret, Weyers-Tier, ocular vertebral syndrome 





Associated with gingival fibromatosis 
Depigmentation 
Ocular hypotelorism Chromosome 5 p-syndrome 
Chromosome 15-p-proximal partial trisomy syndrome 
Chromosome 13 trisomy 
Craniosynostosis-medical aplasia syndrome 
Holoprosencephaly 
Meckel syndrome 
Ocular hypetelorism Aarshog syndrome 
Acrocephalosyndactyly 
Acrodystasis 
Auditory canal  atresia 
Basal nevus syndrome 
Branchio-skeleto-genital syndrome 
Broad thumb-hallux syndrome 
Campomelic dysplasia 
Cerebro-hepato-renal syndrome 
Chromosome 18 p- syndrome 
Chromosome 5 p- syndrome 
Chromosome 4 p- syndrome 
Chromosome 14 p-proximal partial trisomy syndrome 
Coffin-Lowry syndrome 
Cranio-carpo tarsal dysplasia 
Cranio-facial dysostosis 
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BPD [cm] Weeks' gestation IOD [cm] OOD [cm] 
5.1 21.8 1.4 3.7 
5.2 22.3 1.4 3.8 
5.3 22.3 1.5 3.8 
5.4 22.8 1.5 3.9 
5.5 23.9 1.5 4.0 
5.6 23.3 1.5 4.0 
5.7 23.8 1.5 4.1 
5.8 24.3 1.6 4.1 
5.9 24.3 1.6 4.2 
6.0 24.7 1.6 4.3 
6.1 25.2 1.6 4.3 
6.2 25.2 1.6 4.4 
6.3 25.7 1.7 4.4 
6.4 26.2 1.7 4.5 
6.5 26.2 1.7 4.5 
6.6 26.7 1.7 4.6 
6.7 27.2 1.7 4.6 
6.8 27.6 1.7 4.7 
6.9 28.1 1.7 4.7 
7.0 28.6 1.8 4.8 
7.1 29.1 1.8 4.8 
7.3 29.6 1.8 4.9 
7.4 30.0 1.8 5.0 
7.5 30.6 1..8 5.0 
7.6 31.0 1.8 5.1 
7.7 31.5 1.8 5.1 
7.8 32.0 1.8 5.2 
7.9 32.5 1.9 5.2 
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Deafness myopia cataract and saddle nose 
Ehlers-Danlos syndrome 
Fetal hydantoin syndrome 
Fetal warfarin syndrome 
G syndrome 
Hypertelorism–hypospadias syndrome 
Hypertelorism microtia facial clefting and conductive deafness 
Iris coloboma and canal atresia syndrome 
Larsen syndrome 




Median cleft syndrome 
Noonan syndrome 
Nose and nasal septum defects 
Bifid nose 
Glioma of the nose 
Posterior atresia of the nose 
Ocular and facial anomalies with proteinuria and deafness 
Oculo-dento osseous dysplasia 
Opitz-Kaveggia FG syndrome 
Oto-palatodigital syndrome 










Cri du chat syndrome 
 DiGeorge syndrome 
Loeys-Dietz syndrome 
 Morquio syndrome 
Hurler's syndrome 
Deafness 
Table 12. Syndromes associated with fetal ocular malformation (Bergsma, 1979) 
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6.3 Cyclopia 
Cyclopia is an anomaly characterized by a single orbital fossa, with fusion of bulbs, eyelids 
and lacrimal apparatus to a variable degree. Usually there is a single eye or partially divided 
eye in a single orbit and arhinia with proboscis. A normal nose is absent and a proboscis 
structure originating from the nasal root may be seen (Bergsma, 1979). The differential 
diagnosis in these cases includes ethmocephaly (extreme hypotelorism, arhinia and blinded 
proboscis located between the eyes) and ceboephaly (hypotelorism and a single nostril nose, 
without midline cleft). In ethmocephaly, the nasal bones, maxilla and nasal septum and 
turbinate are missing and lacrimal and palatine bones are united (Goldstein et al., 2003; 
McGahan et al., 1990). 
  
Fig. 8. Axial and sagittal scans of a fetus at 25.3 weeks of gestation show prominent forehead 
and proboscis 
 
Fig. 9. Ethmocephaly – postmortem demonstrating hypotelorism and proboscis 
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6.4 Cataracts 
A cataract is an opacity of the lens and accounts for 10% of the blindness seen in preschool 
age children in Western countries. Fetal cataracts may occur in association with infectious 
diseases, chromosomal anomalies or systemic syndromes. 
 
   
   
 
Fig. 10. Sonographic pictures of fetal cataracts at 15 weeks of gestation. Coronal views of 
echogenic lens. 
7. The ear 
Abnormally small ears have been noted to be one of the findings in newborn and infants 
with trisomy 21 and other aneuploidies. Ears in these infants are often described as small, 
low-set, and malformed. Short ear length has been found to be the most consistent clinical 
characteristic in making the diagnosis of Downs' syndrome (Aase et al., 1973). 
Sonographically, a short fetal ear length may be a parameter in predicting fetal aneouploidy 
(Chitkara et al., 2002). Sonographic studies have suggested that short ear length 
measurements might be a useful predictor of fetal anomalies (Awwad et al., 1994; Lettieri et 
al., 1993; Shimizu et al., 1997; Yeo et al., 1998). 
Investigators had suggested that the fetal ear length may be a useful measurement in 
prediction of aneuploidy in patients at high risk for fetal chromosomal abnormalities 
(Awwad et al., 1994; Lettieri et al., 1993; Shimizu et al., 1997; Yeo et al., 1998). However, it 
remains to be determined whether this measurement alone, or in combination with other 
aneuploidy markers, will prove to be a useful predictor of aneuploidy in a population of 
women at low risk for fetal chromosomal abnormalty. 
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GA (Weeks) Mean [mm] SD [mm] 
14 8 0.7 
15 9 1.8 
16 10 0.9 
17 11 1.0 
18 13 0.7 
19 14 1.1 
20 15 1.1 
21 17 1.0 
22 18 1.5 
23 19 1.4 
24 20 1.1 
25 22 1.7 
26 23 2.1 
27 25 1.7 
28 26 1.8 
29 26 1.6 
30 27 2.3 
31 29 2.6 
32 29 1.9 
33 30 1.8 
34 31 1.6 
35 31 2.1 
36 33 2.6 
37 33 2.0 
38 33 4.1 
39 34 4.3 
40 37 2.1 
41 38 1.9 
Table 13. Fetal ear length (Yeo et al., 1998) 
8. The maxillary bone 
Imaging of the maxillary bone is possible in most ultrasound examinations and is important, 
because deviations in maxillary bone development can also be associated with a malformed 
face. The relationship between the maxillary, zygomatic and palatine bones provides a 
capacity for rapid movement of the fetal face. The etiology of hypoplasia of the maxillary 
bone may, in some cases, form part of well-established structural abnormalities in the fetus 
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such as choanal atresia, or genetic syndromes such as Marfan's syndrome.  Sonographically, 
early prenatal detection of the maxillary bone is possible at 14 week of gestation. Hypoplasia 
of the maxillary bone can appear as an incidental finding. Table 14 depicts nomograms of 
the maxillary bone length. 
 
Fig. 11. Sonographic picture of the maxillary bone 
 
 
Table 14. Maxillary bone length across gestational age (Goldstein et al., 2005) 
The frontomaxillary facial (FMF) angle was studied in the first trimester in a Chinese 
population, demonstrating that the FMF angle decreases with fetal CRL increases. Similarity 
in the normal values of the FMF angle was found between the Chinese and Caucasian 
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populations (Chen et al., 2011). These authors previously studied the FMF angle in fetuses 
with trisomy 21 in the first trimester and found significant differences in the FMF angle 
between normal fetuses and fetuses with trisomy 21 in the Chinese population (Chen et al., 
2009). 
9. The tongue 
Fetal macroglossia and microglossia are associated with several chromosomal defects. Table 
15 describes the tongue circumference between 14 and 26 weeks of gestation. 
 
 
Table 15. Tongue circumference (mm) by gestational age (weeks) and the 95% confidence 
interval (Achiron et al., 1997) 
10. Cleft lips & palate 
Cleft lip and palate is a common facial anomaly, with an incidence of 1 in 1000 live births. 
The incidence in fetuses is much higher, and many of these also have other malformations. 
Cleft palate alone occurs in about 1 of 2,500 white births. Cleft lip is more common in males, 
and cleft palate is more common in females. Cleft lip is one or more splits (clefts) in the 
upper lip. Cleft lip can range from a small indentation in the lip to a split in the lip that may 
extend up into one or both nostrils. Cleft lip develops in about the sixth to eighth week of 
gestation, when structures in the upper jaw do not fuse properly and the upper lip does not 
completely merge. Sometimes the nasal cavity, palate, and upper teeth are also affected in 
an opening in the roof of the mouth that develops when the cleft palate bones and tissues do 
not completely join during fetal growth, sometime between the 7th and 12th weeks of 
gestation. The severity and type of cleft palate vary according to where the cleft occurs on 
the palate and whether all the layers of the palate are affected. A mild form of cleft palate 
may not be visible because tissue covers the cleft. A complete cleft palate involves all layers 
of tissue of the soft palate, extends to and includes the hard palate, and may continue to the 
lip and nose. Sometimes problems associated with cleft palate also include deformities of the 
nasal cavities and/or the partition separating them (septum). 
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An ultrasound detection of cleft lip and palate may be seen as early as 14 to 16 weeks of 
gestation. Cleft palate and cleft lip may occur independent of each other or at the same time. 
The hard palate is the front part of the roof of the mouth, and the soft palate is the back part 
of the roof of the mouth. This description may include whether the uvulais affected. The 
latter is impossible to detect prenatally. Cleft lip is classified according to its location and 
severity. Unilateral cleft lip affects one side of the mouth; bilateral cleft lip affects both sides 
of the mouth. A complete cleft lip is a deep split in the upper lip extending into one or both 
sides of the nose; an incomplete cleft lip affects only one side of the upper lip. It may appear 
as a slight indentation or as a deep notch. 
   
Fig. 12. Sonographic picture of normal primary palate (The alveolar ridge) 
    
    
Fig. 13. Sonographic pictures of cleft lip 
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Ultrasonography can be used to identify clefting in the lip and primary palate (alveolar 
ridge). The ultrasound detecting rates of facial clefting have been reported as low as 21-30% 
using two-dimensional ultrasound (Crane et al., 1994). Accurate characterization of the fetal 
clefting is an important aspect of ultrasound diagnosis. Three-dimensional ultrasound may 
be useful in defining the location and extent of facial clefting in utero (Johnson et al., 2000). 
Although three-dimensional images of the fetal alveolar ridge can be obtained, two-
dimensional sonographic images are obtained more easily, rapidly and accurately 
(Goldstein et al., 1999). 
  
Fig. 14. Sonographic pictures of cleft palate (15 & 23 weeks of gestation) 
 
Gestation [weeks] Mean [mm] ±SD [mm]

















Table 16. Normal values of the fetal alveolar ridge width (Goldstein et al., 1999) 
11. The chin: Microganthia-retroganthia or prognathia 
Abnormal size of the chin, micrognathia and macrognathia, and abnormal length of the 
philtrum (short or long) are morphological features in numerous syndromes. Micrognathia 
is a common finding in many chromosome aberrations and dysmorphic syndromes (Gulla 
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et al., 2005). Investigators have reported a series with subjective micrognathia, 66% of whom 
had chromosomal abnormalities (Nicolaides et al., 1993). Others reported that micrognathia 
was associated with aneuploidy in 25% and 38% of cases (Benacerraf et al., 1984; Turner & 
Twining, 1993). Sivan et al. (1997) established normative dimensions for objective chin 
length. Measurements of the chin length, was performed between the lower lip and the apex 
of the chin in mid-sagittal plane. 
 
Fig. 15. Chin length measured between the lower lip and the apex of the chin (Sivan et al., 1977) 
 
 
Table 17. Chin length (Sivan et al., 1997) 
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Fig. 16. Sagittal scan and postmortem of a fetus at 16 weeks of gestation shows prominent 
forehead and retrognathia 
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1. Introduction 
It has long been established that there is a relationship between hypercholesterolemia and 
cardiovascular disease in adulthood. However, only in the 90s, the biological consequence of 
low levels of cholesterol for mitotic cells was highlighted, with the description of the 
devastating effect of hypocholesterolemia on fetal development. This was supported by the 
discovery of a group of metabolic diseases caused by mutations in genes coding for 
enzymes involved in endogenous synthesis of cholesterol. This group is still growing as new 
diseases, phenotypes and mutated genes are being described by researchers. Despite the fact 
that they share some common clinical features - including abnormal morphogenesis and 
growth retardation - these inherited metabolic diseases are still poorly recognized in daily 
obstetric clinical practice.  
Cholesterol is an essential lipid found in all mammalian cells. It can modulate the activity of 
the Hedgehog proteins, which act as morphogens that regulate the precise patterning of 
many embryonic structures [Gofflot et al., 2003]. Furthermore, cholesterol is a key 
component of lipid-rafts, which have a structural role in cellular membranes and myelin 
sheets and it is a precursor molecule for sterol-based compounds, including bile acids, 
oxysterols, neurosteroids, glucocorticoids, mineralocorticoids, and sex hormones like 
estrogen and testosterone [Correa-Cerro et al., 2005]. Due to the panoply of biological 
functions of the sterols, a decrease of its availability during pregnancy has major 
consequences to the fetus, severely impairing his development [Cardoso et al., 2005a].  
2. Intestinal cholesterol absorption, transport and metabolism  
Dietary cholesterol is absorbed from bile salt micelles, with fatty acids and phospholipids, at 
the proximal part of the small intestine, in a process which involves Nieman-Pick C1-Like1 
protein (NPC1L1). This protein contains a sterol sensing domain (SSD) and is located in the 
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brush-border membrane of enterocytes where it plays a critical role in the intestinal uptake 
of cholesterol and phytosterols [Ikonen, 2006]. Once inside the enterocyte cholesterol is 
esterified by acyl-CoA: cholesterol acyltransferase (ACAT) whereas sterols other than 
cholesterol, are transported back into the intestinal lumen by an heterodimer transporter 
G5/G8 ATP binding cassette (ABCG5, ABCG8)1. Such mechanism prevents phytosterols 
molecules from passing to the blood to any significant extent [Charlton-Menys & 
Durrington, 2007].  
In order to enter in blood circulation cholesterol from enterocytes should be incorporated in 
lipoproteins named chylomicron. Chylomicrons assembly begins with the formation of 
primordial, phospholipid-rich particles in the membrane, taking together apolipoprotein 
B48 (ApoB-48)2 and cholesterol. Later in the lumen of the smooth endoplasmic reticulum 
(ER) these particles are converted into large chylomicrons. After that, they are transported 
(via specialized vesicles) from the ER to the Golgi3, for secretion into the lacteals of the 
intestine, and then they finally pass from linfa to blood (via thoracic duct) [Hussain et al., 
2005; Charlton-Menys & Durrington, 2007; Kindel, et al., 2010]. Once chilomicrons are in 
blood circulation they became smaller due to the action of lipoprotein lipase (LPL)4, which is 
anchored to the vascular endothelium of several organs, and hydrolyses the trigliceride 
from chilomicrons. Subsequently the circulating cholesterol-rich chylomicron remnant 
particles are uptaked by the liver in a process which involves the LDL-receptor like protein 
(LRP) [Charlton-Menys & Durrington, 2007].  
Liver, exports exogenous and endogenous cholesterol, to tisues by VLDL lipoproteins. The 
biosynthesis of VLDL consists of a number of distinct stages [Hebbachi & Gibbons, 2001; 
Shelness et al., 2001]. Briefly, the assembly of hepatic VLDL begins inside the rough ER, 
where, the peptide ApoB-100 2 is synthesized at membrane bound ribosomes and then sent 
through a protein channel into the cytoplasm. Additionally, microsomal triglyceride transfer 
protein (MTP)5 binds the precursor peptide and joins some triglycerides, phospholipids, and 
cholesteryl esters, allowing ApoB-100 to fold around a small lipid core. Then a higher 
amount of triglycerides are transferred into the precursor VLDL particle, and it sorts to the 
Golgi apparatus where additional lipids are recruited in order to form the mature VLDL 
lipoprotein [Daniels et al., 2009]. Finally VLDLs enter in circulation and distribute free fatty 
acids to muscle and adipose tissues expressing LPL and become intermediary density 
lipopoteins (IDLs) that can either be removed from circulation by the liver or they can lose 
further free fatty acids becoming low density lipoproteins (LDLs) which are important 
cholesterol transporters [Daniels et al., 2009].  
Therefore, low density lipoprotein receptor (LDLR)6, a transmembrane glicoprotein 
responsible for uptake of cholesterol-carrying lipoproteins from blood circulation, binds 
lipoprotein particles at the cell surface, which are internalized by endocytosis and later in 
the low-pH environment of the endosome, acid-induced dissociation of ligand and receptor 
occurs. LDLR peptide is recycled back to the membrane and LDL particles are released into 
the lysosomes whose enzymes degradate the lipoproteine into amino acids and lipid 
components. Cholesteryl esters are hydrolyzed by lysosomal acid lipase (LAL)7 to free 
cholesterol [Daniels et al., 2009; Jeon & Blacklow, 2005]. Therefore cholesterol can be re-
esterified by ACAT (a membrane-bound enzyme residing in the ER) and stored as lipid 
droplets [Zhang et al., 2003; Liu et al., 2005]. The mechanisms by which free and esterified 
cholesterol ingress and egress endosomes and lipid droplets, are not fully clarified. 
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Neverthless proteins NPC18 and NPC2 are involved in such process and other proteins like 
MLN64 (STARD3) and MENTHO (STARD3NL), are still under evaluation [Miller & Bose, 
2011; Vanier, 2010]. 
At steady state most cholesterol is in plasma membrane, but it must move inside the cell in 
order to be presented to the enzymes encharged of its metabolization, and it is transported 
between membrane organelles (as a component of lipid bilayers) in transport vesicles, as 
well as by non-vesicular means [Liscum et al., 1995; Maxfield & Wüstner, 2002].  
Meanwhile, the liver is consistently manufacturing high density lipoproteins (HDL) which 
have the critical task of removing excess cholesterol and serve as transport particles by 
which peripheral cell cholesterol is collected and delivered to the liver for catabolism in a 
process named reverse cholesterol transport [Ikonen, 2006]. The rate limiting step in this 
process is cholesterol efflux mediated by ABCA19 [Daniels et al., 2010].  
Cells inside the brain are cut off from this circuit by the blood-brain barrier and must 
regulate their cholesterol content in a different manner [Pfrieger & Ungerer, 2011].  
As cholesterol cannot be degraded by cells into noncyclic hydrocarbon products, 
hepatocytes excrete it into the bile, either directly, as free cholesterol, as well as transformed 
in bile salts. Bile salts are synthesized via two routes, the classic or neutral pathway and the 
alternative or acidic one [Kosters et al., 2003]. Cholesterol 7α-hydroxylase (CYP7A1) is a 
hepatic microsomal cytochrome P450 enzyme that catalyzes the first step of bile acid 
synthesis in the classical pathway, whereas sterol 27-hydroxylase (CYP27A1) is the first 
enzyme of the alternative one. It is a mitochondrial cytochrome P450 ubiquitous enzyme 
with a much broader biologic role; it is involved in the 27-hydroxylation of a variety of 
sterols (cholesterol included) and in the formation of potentially important regulatory 
sterols [Dias & Ribeiro, 2011]. 
All major classes of biologically active steroid hormones are also synthesized from 
cholesterol by a complex array of enzymes located both in the mitochondria and ER 
[Miller, 2011; White, 1994]. Adrenals and gonads receive cholesterol from low-density 
lipoproteins, store it as cholesterol esters, and transport cholesterol to mitochondria by ill-
defined but critical mechanisms [Miller, 2011]. Effectively, the acute quantitative 
regulation of steroidogenesis is determined by cholesterol import into mitochondria by 
the steroidogenic acute regulatory protein (STAR) which undergoes conformational 
changes for accept ing and discharge cholesterol molecules [Miller & Auchus, 2011]. Then 
P450scc /CYP11A1 enzyme, located in the inner mitochondrial membrane catalyses the 
conversion of cholesterol to pregnenolone, the first step of steroidogenesis [Miller & 
Auchus, 2011]. 
Control of cholesterol homeostasis is a highly regulated process, consistent with the overall 
importance of this lipid for normal cellular function, with several transcription factors and 
functioning proteins playing important roles and regulating intracellular cholesterol levels 
[Tarling & Eduards, 2011]. Mutations in genes codifying for proteins involved in the above 
referred pathways (and signalised with small numbers), alter sterol homeostasis and results 
in specific diseases. Table 1 resumes the most commum phenotypes associated to deficient 
cholesterol intra and extracelular transport and metabolism which was construct based on 
OMIM (http://www.ncbi.nlm.nih.gov/omim) available data.  
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AR. Characterized by unrestricted intestinal 
absorption of phytosterols. Patients show very 
high levels of plant sterols in the plasma with 
accumulation in tendons (tuberous 









Apolipoprotein B, occurs in the plasma in 2 
main forms, apoB48 (synthesized exclusively 
by the gut) and apoB100 (synthesized by the 
liver) resulting from differential splicing of the 
same primary mRNA transcript. 
Heterozygous show reduced plasma 
concentrations of LDL cholesterol, total 
triglycerides, and APOB less than 50% of 










AR. It is a disease of severe fat malabsorption 
and steatorrhea, associated with failure to 
thrive in infancy. Patients show low fasting 
plasma concentrations of plasma total, HDL, 
and LDL cholesterol. Electron microscopy 
studies of jejunal biopsy specimens showed 
severe steatosis, and an apparent block of 





































AR. Massive hyperchylomicronemia occurs 
when the patient is on a normal diet and 
disappears completely in a few days on fat-
free feeding. Caused by low tissue activity of 
lipoprotein lipase (a defect in removal of 
chylomicrons and of other triglyceride-rich 
lipoproteins). Characterized by attacks of 
abdominal pain, hepatosplenomegaly, 
eruptive xanthomas, and lactescence of the 
plasma.  
Deficiency of apolipoprotein C-II the activator 
of lipoprotein lipase. Clinically and 









Caused by mutations in the microsomal 
triglyceride transfer protein. Features are 
celiac syndrome, pigmentary degeneration of 
the retina, progressive ataxic neuropathy and 
acanthocytosis. Intestinal absorption of lipids 
is defective, serum cholesterol very low, and 
serum beta lipoprotein absent. 
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AD. Caused by mutations in the low density 
lipoprotein receptor gene. Heterozygotes 
develop tendinous xanthomas, corneal arcus, 
and coronary artery disease (fourth or fifth 
decade). Homozygotes develop these features 
at an accelerated rate in addition to planar 
xanthomas, which may be evident at birth in 
the web between the first 2 digits. 
7. 
Wolman disease #278000 LIPA 
It is caused by lysosomal LAL deficiency. 
Homozygous present liver failure, 
hypercholesterolemia, hypertriglyceridaemia, 
liver fibrosis, early atherosclerosis and early 
death. Heterozygous show a milder phenotype 
named cholesteryl ester storage disease. 
8. 
Niemann-Pick 
disease type C 
#257220 NPC1 
AR. Neurodegenerative lipid storage disorder 
characterized by a highly variable clinical 
phenotype. In the classic form symptoms 
appearing between 2 and 4 years and patients 
develop neurologic abnormalities (ataxia, grand 
mal seizures, and loss of previously learned 
speech). Diagnosis relies on detection of delayed 
LDL-derived cholesterol esterification on skin 
fibroblasts as well as in filipin staining. 
9. 
Tangier disease #205400 ABCA1 
AR disorder characterized by markedly reduced 
levels of HDL resulting in tissue accumulation of 
cholesterol esters. Clinical features include very 
large, yellow-orange tonsils, enlarged liver, 
spleen and lymph nodes, hypocholesterolemia, 
and abnormal chylomicron remnants. Coronary 






Hypercholesterolemia (high LDL), 
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3. The cholesterol biosynthesis pathway 
Cholesterol is a 27-carbon tetracyclic compound synthesised by all nucleated mammalian 
cells [Kelly & Herman, 2001] by a metabolic process involving approximately 30 enzymatic 
reactions [Ikonen, 2006] which take place in several cellular compartments: cytoplasm, ER 
(or its extensions), nuclear envelope and peroxisomes [Ikonen, 2006; Thompson et al., 1987]. 
The substrate for cholesterol synthesis is acetyl-CoA which is derived largely from glucose 
in the brain, and from fatty acids and other fuels in other tissues [Clayton, 1998].  
Although complex, the biosynthesis of cholesterol is only one element of the larger 
isoprenoid biosynthetic system, which incorporates the de novo synthesis of important 
biomolecules as diverse as dolichol, ubiquinone, heme A or farnesyl pyrophosphate [Kelly 
& Herman, 2001].  
For simplification one can considerer five major steps on the metabolic pathway of 
cholesterol synthesis [Figure 1].  
 
Fig. 1. Simplified schematic representation of cholesterol biosynthesis pathway. 
Steps one to four catalyze the transformation of acetyl-CoA into the first sterol of the 
cascade: lanosterol. The fifth step includes all the reactions needed to transform this sterol 
into cholesterol [http://themedicalbiochemistrypage.org/cholesterol.html]. The biologically 
significant details of each step are: 
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1. Conversion of acetyl-CoAs to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), an organic 
acid conjugate of intermediate metabolism that is also important for ketogenesis. 
2. HMG-CoA conversion to mevalonate by HMG-CoA reductase, the limitating step of 
cholesterol biosynthesis. In fact, HMG-CoA reductase is subject to complex regulatory 
control by four distinct mechanisms (i) feed-back inhibition, (ii) control of gene 
expression, (iii) rate of enzyme degradation and (iv) phosphorylation-dephos- 
phorylation (the first three are exerted by the cholesterol molecule itself).  
3. 3. Mevalonate conversion to the isoprene based molecule, isopentenyl pyrophosphate 
with the concomitant loss of CO2. 
4. Isopentenyl pyrophosphate conversion to lanosterol. The reactions of this stage are also 
required for the synthesis of other important compounds as previously referred: (i) 
isopentenyl-tRNAs (the isopentenyl groups in tRNAs are thought to be important in 
stabilizing codon-anti-codon interaction, thus preventing misreading of the genetic 
code during protein synthesis), (ii) dolichol which is required for protein N-
glycosylation, (iii) farnesyl and geranylgeranyl pyrophosphate essential for protein 
prenylation which is a post-translational modification required to commit proteins to 
cellular membranes and (iv) ubiquinone, which is an important component of 
mitochondrial respiratory chain [Clayton, 1998, Ikonen, 2006].  
5. Lanosterol conversion to cholesterol [Figure 2].  
 
Fig. 2. The distal part of cholesterol biosyntesis pathway: from lanosterol to cholesterol 
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This stage constitutes the post-lanosterol part of cholesterol biosynthesis pathway. It 
includes a series of enzymatic reactions namely (i) three demethylations at C4, C4 and 
C14, which converts the 30-carbon molecule of lanosterol into the 27-carbon cholesterol ; (ii) 
the isomerization of the 8(9) double bond to 7 double bond, (iii) one reaction of 
desaturation to form a 5 double bond; (iv) and finally the reduction of three double bonds 
14,24,7 [Porter, 2003]. 
4. Sterols and development 
Cholesterol is indispensable for embryogenesis and fetal development in higher vertebrates. 
The fetus obtains most cholesterol from de novo synthesis, with fetal sterols synthesis rates 
being greater than those observed in other extra hepatic tissues. This happens, most likely, 
because of the large cholesterol fetal requirements, in order to sustain the rapid intra-uterine 
growth [Woollett, 2005]. Nevertheless, the fetus appears to have an exogeneous source of 
cholesterol as well. In fact, some studies have suggested that maternal cholesterol may also 
contribute to the cholesterol accrued in the fetus [Lindegaard et al., 2008; McConihay et al., 
2001; Yoshida & Wada, 2005]. Reinforcing this hypothesis, a strong association with preterm 
delivery in caucasian mothers with low serum cholesterol during pregnancy was found, and 
smaller birth weight in term babies from such mothers [Edison et al., 2007]. Thus, two layers 
of cells must be crossed by maternal cholesterol to reach the fetal circulation (i) the 
trophoblasts (which form the layer closest to the maternal circulation) and (ii) the 
endothelium (locate between the trophoblast and fetal circulation) [Woollett, 2011]. 
According to some experiments, the modulation of maternal-fetal cholesterol transport has 
potential for in uterus therapy of fetuses that lack the ability to synthesize cholesterol 
[Lindegaard et al., 2008; Woollett, 2005]. 
Distal inhibitors of cholesterol biosynthesis have been studied for more than 30 years as 
potent teratogens capable of inducing cyclopia and other birth defects. These compounds 
specifically block the Sonic hedgehog (Shh) signaling pathway [Cooper et al., 1998]. 
Hedgehog (Hh) proteins comprise a group of secreted embryonic signaling molecules that 
are essential for embryonic patterning [Kolejáková et al., 2010]. In higher vertebrates, 
including humans, they are implicated in an increasing number of different developmental 
processes. In fact, Shh proteins were implicated in neural tube development, lung and 
kidney morphogenesis and hair development, Shh and Indian hedgehog were related with 
skeletal morphogenesis and gastrointestinal development and Desert hedgehog with male 
differentiation, spermatogenesis and development of peripheral nerve sheaths [Waterman & 
Wanders, 2000]. Cholesterol has an important role in regulation and modification of 
Hedgehog proteins, what links cholesterol to early embryonic development. [Kolejáková et 
al., 2010]. Decreasing levels of cellular sterols correlate with diminished response of the Hh 
signal and sterol depletion affects the activity of Smoothened, an essential component of the 
Hh signal transduction apparatus [Cooper et al., 2003]. 
Mutations in the Sonic Hedgehog gene cause holoprosencephaly and this cerebral 
malformation has also been associated with perturbations of cholesterol synthesis and 
metabolism in mammalian embryos [Gofflot et al., 2001]. Furthermore, in rodents, triparanol 
treatment reproduces limb defects observed in human syndromes of cholesterol 
biosynthesis defects by a modification of Shh signaling in the limb resulting in an imbalance 
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of Indian Hedgehog expression in the forming cartilage leading to reduced interdigital 
apoptosis and syndactyly [Gollof et al., 2003]. 
5. Inborn errors of post-squalene cholesterol biosynthesis 
Genetic defects in enzymes responsible for cholesterol biosynthesis have recently emerged 
as important causes of congenital anomalies. Patients with these metabolic diseases present 
with complex malformation syndromes involving different organs and systems [Yu & Patel, 
2005]. So far, nine polimalformative disorders due to enzymatic defects in post-squalene 
cholesterol biosynthesis have been identified:  
a. Smith-Lemli-Opitz syndrome (SLOS),  
b. X-linked dominant chondrodysplasia punctata type 2 (CDPX2),  
c. Congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome 
(CHILD)  
d. CK syndrome  
e. Greenberg dysplasia,  
f. Antley-Bixler syndrome with ambiguous genitalia (POR deficiency) 
g. Desmosterolosis,  
h. Lathosterolosis,  
i. Sterol-C4-methyloxidase–like deficiency. 
6. Prenatal diagnosis of cholesterol biosynthesis disorders 
For most inborn errors of metabolism, before attempting to perform prenatal diagnosis, it is 
essential to establish, or confirm the diagnosis of the disorder under consideration in the 
proband, or affected relatives. Nevertheless as inborn errors of cholesterol biosynthesis have 
been associated to a gestational biochemical marker (low maternal estriol) and abnormal 
ultrasound features, in many cases one can suspect of this spectrum of disorders in the 
course of a pregnancy, even without a previous index case in the family. 
6.1 Smith-Lemli-Opitz syndrome 
The Smith-Lemli-Opitz syndrome (SLOS, MIM #270400), is the most frequent disease of this 
group of inherited metabolic disorders, with a prevalence that varies between 1: 22.000 and 
1: 60.000, depending on the population. Nevertheless, a higher prevalence (between 1: 2.500 
and 1: 4.444) - close to that of cystic fibrosis and higher than phenylketonuria - would be 
expected based on carriers frequency studies [Porter et al., 2003].  
SLOS is caused by a deficit of the enzyme 7-dehydrocholesterol reductase (3--
hydroxysterol-7-reductase, E.C.1.3.1.21), encoded by the DHCR7 gene located on 11q13. 
This enzyme catalyses the conversion of 7-dehydrocholesterol to cholesterol [Waterham &, 
Wanders, 2000]. 
Since most of the cholesterol required for fetal growth and development is synthesized by 
the fetus, enzymatic deficiency affecting endogenous cholesterol biosynthesis leads to 
intrauterine growth restriction and aberrant organogenesis. Surveys of large series of 
patients with SLOS showed a constellation of severe abnormalities including intellectual 
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disability, microcephaly, failure to thrive, dysmorphic face, limb abnormalities and genital 
abnormalities in males [Cardoso et al., 2005b]. 
Prenatal diagnosis of SLOS has been performed in many pregnancies both retrospectively 
and prospectively. The prenatal diagnosis of this autosomal recessive metabolic disorder is 
based on a conjugation of methods that detect the dual aspects of the pathology: the 
polimalformative syndrome and the metabolic abnormalities [Cardoso et al., 2005a].  
6.1.1 Ultrasound findings 
A number of fetuses have been so far signalized as suspected of SLOS due to the 
identification, by ultrasound, of suggestive fetal abnormalities, such as: nuchal edema, 
microcephaly, cleft palate, polidactyly, cystic kidneys, ambiguous genitalia or a 46, XY 
karyotype in a phenotypically female fetus [Johnson et al., 1994, Kelley & Hennekam, 2001]. 
Nevertheless there is no pathognomonic ultrasound pattern associated with SLOS [Irons & 
Tint, 1998]. 
Concerning the detection of malformations in SLOS fetus, Goldenberg and collaborators 
evaluated the main abnormalities identified. Their results are as follows i) in the first 
trimester [11-13 weeks of gestational age]: increased nuchal translucency (26%); ii) in the 
second trimester [20-22 weeks of gestational age]: nuchal edema (26%), kidney 
malformation (26%), polydactyly (10%) [Figure 3], ambiguous genitalia (6%) [Figure 3], 
cerebral malformation (10%), heart malformation (10%), intrauterine growth restriction 
(20%); iii) in the third trimester [30-34 weeks of gestational age]: intrauterine growth 
restriction (46%) [Goldenberg et al., 2004]. However one should be aware that prenatal US 
examination of affected fetuses can also be normal [Irons & Tint, 1998].  
  
Fig. 3. Two ultrasound images of a male fetus with SLO. The white arrows are pointing a left 
foot with postaxial polydactyly (on the left) and a penis with large root and hypospadias (on 
the right).  
6.1.2 Serum maternal markers 
The fetoplacental biosynthesis of free estriol (E3) requires cholesterol as substrate 
[Palomaki et al., 2002]. Thus unconjugated estriol is produced by the fetus and then crosses 
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the placental barrier entering into mother’s blood circulation. By consequence fetal 
hypocholesterolemia can be suspected, if the pregnant woman shows low levels of this 
compound in serum. Low or undetectable unconjugated estriol levels in maternal serum 
and amniotic fluid have been reported in pregnancies of fetus affected with SLO [Hyett et 
al., 1995; Rossiter et al., 1995; Kratz & Kelley,1999; Cardoso et al., 2005a; Craig et al., 2006].  
Free estriol is not a specific marker of SLO and several other causes of low unconjugated 
estriol are known, namely intrauterine fetal demise and steroid sulphatase deficiency [Irons 
& Tint, 1998]. Meanwhile algorithms were proposed based on available values of maternal 
serum -fetoprotein and human chorionic gonadotrophin together with free estriol 
(obtained on the second-trimester screening program, for Down syndrome and open neural 
tube defects) which provide a more accurate estimation of individual risk for SLOS 
[Palomaki et al., 2002; Craig et al., 2006; Craig et al., 2007].  
According to our and others experience [Cardoso et al., 2005a; Dubuisson et al., 2008] a low 
level of free estriol alone is not a robust indicator for testing a pregnancy for SLOS. However 
the association of i) abnormal fetal US with ii) normal fetal karyotype and iii) low levels of 
unconjugated estriol on maternal blood are highly suggestive [Cardoso et al., 2005a; Shinawi 
et al., 2005; Dubuisson et al., 2008]. 
6.1.3 Biochemical approach  
The first report concerning prenatal diagnosis SLOS based on biochemical profile of sterols 
in amniotic fluid was performed in 1995 by Abuelo and collaborators [Abuelo et al., 1995]. 
Since then several cases referring the quantification of 7-dehydrocholesterol in amniotic 
fluid as well as in chorionic villus either by gas chromatography or gas chromatography-
mass spectrometry have been published [Irons & Tint, 1998; Chevy et al., 2005; Cardoso et 
al., 2005a]. The diagnosis can also be made based on the detection of low enzymatic 7-
dehydrocholesterol reductase activity on cultivated amniocytes or chorionic villus [Linck et 
al., 2000; Ginat et al., 2004]. 
Nowadays liquid chromatography-tandem mass spectrometry (LC-MS-MS) is available in 
many clinical biochemistry laboratories and efforts have been made in order to apply this 
highly sensitive technology to the diagnosis of inborn errors of cholesterol biosynthesis. 
Recently a protocol for prenatal diagnosis of SLOS by LC-MS-MS became available [Griffiths 
et al., 2008]. Another promising approach concerns the non-invasive SLOS biochemical 
prenatal diagnosis based on identification and measurement of abnormal steroids in 
maternal urine [Jezela-Stanek et al., 2006; Shackleton et al., 2007].  
6.1.4 Mutation analysis of DHCR7 gene 
Prenatal diagnosis of SLOS by mutation analysis of DHCR7 gene on DNA extracted directly 
from amniotic fluid, chorionic villus or the respective cell cultures is widespread used at this 
time [Yu & Patel, 2005]. This approach is accurate and reliable [Loeffler et al., 2002]. 
Moreover molecular prenatal diagnosis should be considered an option: (i) in laboratories 
without facilities for biochemical analysis, (ii) in families with known mutations who are 
interested in early and rapid testing and (iii) in cases with ambiguous biochemical results 
[Nowaczyk et al., 2001; Löffler et al., 2009; Waye et al., 2007].  
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the placental barrier entering into mother’s blood circulation. By consequence fetal 
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6.2 X-linked dominant chondrodysplasia punctata type 2, CHILD Syndrome and CK 
Syndrome  
X-linked dominant chondrodysplasia punctata type 2 (CDPX2 or Conradi-Hunermann-
Happle syndrome, MIM #302960) and Congenital hemidysplasia with ichthyosiform 
erythroderma and limb defects syndrome (CHILD syndrome, MIM #308050), are two X-
linked dominant skeletal dysplasias caused by hypocholesterolemia, which affect almost 
exclusively females, as they are typically lethal in hemizygous males. In both diseases 
affected females usually present at birth with skeletal and skin abnormalities [Herman et al., 
2000]. In CDPX2 these include epiphyseal stippling and asymmetric rhizomelic shortening 
of the limbs, follicular atrophoderma, ichthyosiform erythroderma (following the Blaschko’s 
lines), asymmetrical cataracts and accumulation in plasma and body tissues of cholesterol 
precursors: 8-dehydrocholesterol and cholest-8(9)-en-3-ol. The disorder is caused by a 
deficiency of the enzyme 3-hydroxysterol-8,7-isomerase encoded by EBP gene 
[Braverman et al., 1999]. In most severe cases ultrasound during pregnancy can show 
polyhydramnios, intra-uterine growth restriction or both [Kelley et al., 1999].Only a few 
prenatal diagnosis have been reported and they were based on the identification of 
mutations on EBP gene.  
Both CHILD syndrome and CK syndrome are caused by mutations in NSDHL gene 
encoding a 3-hydroxysterol dehydrogenase [Konig et al., 2000, McLaren et al., 2010]. 
CHILD is associated with an inflammatory nevus with unique lateralization, ipsilateral 
hypoplasia of the body that affects all skeletal structures including shortness or absence of 
limbs and viscera such as lungs, heart or kidneys [Happle et al., 1980]. CK syndrome is an X-
linked recessive intellectual disability syndrome characterized by dysmorphism, cortical 
brain malformations, asthenic build, increased methyl-sterol levels and it is associated to 
hypomorphic temperature-sensitive alleles [McLaren et al., 2010]. As far as we know, there 
are no reports on prenatal diagnosis of these two syndromes in literature. 
6.3 Greenberg dysplasia 
The Greenberg dysplasia (MIM #215140), is a rare and lethal autosomal recessive skeletal 
dysplasia characterized by hydrops fetalis, ectopic calcifications, "moth-eaten" skeletal 
dysplasia, short limbs, and abnormal chondro-osseous calcification [Madazli et al., 2001]. In 
2003, Waterham and collaborators found elevated levels of a cholesterol precursor (cholesta-
8,14-dien-3-ol) in cultured skin fibroblasts of a fetus with Greenberg dysplasia, that were 
compatible with a deficiency of the enzyme 3--hydroxysterol-14reductase from the 
cholesterol biosynthesis pathway. Sequencing analysis of two candidate genes encoding 
putative human sterol-14reductases allow the identification of an homozygous mutation 
(resulting in a truncated protein) in LBR gene (which encodes a bifunctional protein – lamin 
B receptor – with both lamin B binding and sterol-14reductase domain) [Waterham et al., 
2003]. After the publication of these results it was acknowledged that Greenberg dysplasia 
was a disorder of cholesterol biosynthesis. Nevertheless, recent studies with mice models 
raised some doubts about this classification and proposed that Greenberg dysplasia should 
be classified as a laminopathy rather than an inborn error of cholesterol synthesis [Wassif et 
al., 2007]. Despite this controversy i) ultrasound, ii) biochemical analysis of sterols on 
cultivated skin fibroblasts and iii) mutation analysis of LBR remain available to diagnose 
Greenberg dysplasia prenatally.  
 




Antley-Bixler syndrome (ABS) is a very rare congenital multiple malformation disorder 
characterized by craniofacial anomalies, skeletal defects and, in a subset of patients, 
ambiguous genitalia. The craniofacial anomalies include brachycephaly due to severe 
craniosynostosis. The typical facial dysmorphism include: depressed nasal bridge with 
very short upturned nose, small mouth and dysplastic ears. Skeletal features include 
radiohumeral or other forearm synostoses, arachnodactyly, bowing of femurs, multiple 
contractures and neonatal fractures. A variety of congenital heart defects and 
gastrointestinal malformations have also been reported. Urogenital anomalies include 
absent, dysplastic, ectopic, or horseshoe kidneys, abnormal ureters and abnormalities of 
the external genitalia, including cryptorchidism. [Porter et al., 2011]. Recently it has been 
considered that the minimum criteria to establish the diagnosis of ABS are the presence, 
from the prenatal period, of craniosynostosis and radiohumeral synostosis [McGlaughlin, 
et al., 2010]. 
ABS is genetically heterogeneous and there has been some debate about the definition of the 
disease: by the clinical phenotype versus according to the genetic etiology [Cragun & 
Hopkin, 2005; Huang et al., 2005]. In fact, some patients present ABS without disordered 
steroidogenesis (MIM #207410) due to one gain-of-function mutation in the FGFR2 gene 
(hence following autosomal dominant inheritance) while others present ABS with disorderd 
steroidogenesis (MIM #201750) due to two loss of function mutations in the POR gene 
(therefore, following autosomal recessive inheritance) [Flück et al., 2004]. ABS patients with 
mutations in POR are included in the spectrum of metabolic disorders due to abnormal 
cholesterol pathway. The POR gene encodes a cytochrome P450 oxidoreductase. The POR 
protein is an electron donor to many cytoplasmic P450 enzymes, including the cholesterol 
C14-lanosterol demethylase encoded by the CYP51 gene and several other enzymes 
involved in steroid hormone synthesis.  
ABS patients due to POR deficiency usually present with abnormal genitalia 
(underdeveloped genitalia and cryptorchidism in affected 46,XY males and external 
virilization, with clitoromegaly and fused labia, in 46,XX females) but a much wider 
spectrum of the remaining phenotype (milder craniofacial and skeletal malformations and 
normal cognitive function). The mildest end of the POR spectrum presents as individual 
with only steroidogenesis defects (amenorrhea, polycystic ovarian syndrome and infertility) 
[Fukami et al., 2009]. 
Independently of the severity, all POR deficient patients demonstrate biochemical evidence 
of partial blocks at multiple steps in the conversion of cholesterol to cortisol, estrogens, and 
androgens and biochemical diagnosis of POR deficiency can be made by GC-MS of urinary 
steroids, which reveals a characteristic profile of elevated pregnenolone and 17-OH- 
progesterone and other progesterone metabolites, in the presence of low androgens. 
Mineralocorticoid synthesis and metabolism are normal. Mild abnormalities of serum 
steroids are often, but not always, present. The steroid metabolites that accumulate in POR 
deficiency are consistent with partial deficiencies of 21-hydroxylase (CYP21A2) and 17α-
hydroxylase (CYP17A1). The biochemical findings are explained by the fact that the POR 
enzyme serves as an electron donor for all cytoplasmic P450 enzymes, including CYP17A1 
and CYP21A2. 
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A POR deficient fetus can be referred to prenatal diagnosis due to common abnormalities 
such as oligohydramnios or two vessel cord, to fetus with full blown ABS (multiple 
craniofacial, skeletal and urogenital abnormalities as described in detail above) on the 
ultrasound. Moreover, the diagnosis of ABS due to POR deficiency should be considered in 
pregnancies with low or undetectable serum uE3, like in SLOS [Cragun et al., 2004; 
Williamson et al., 2006]. Likewise, maternal virilization (e.g. acne, facial edema) shouldn’t be 
overlooked as it may comprise an important clue for the diagnosis of POR deficiency 
[Cragun et al., 2004].  
There should be an effort towards the confirmation of the diagnosis through molecular 
analysis since it is clinically relevant to distinguish ABS patients with disordered 
steroidogenesis from ABS patients with normal steroidogenesis, not only because of 
differences in inheritance patterns, but also because patients with POR deficiency are 
vulnerable to different risk factors and require different management. 
6.5 Possible approaches for prenatal diagnosis of Desmosterolosis, Lathostherolosis 
and Sterol-C4-methyloxidase–like deficiency 
Desmosterolosis (MIM #602398) and Lathostherolosis (MIM #607330) and Sterol-C4-
methyloxidase–like deficiency are additional autosomal recessive polimalformative 
syndromes due to defective cholesterol biosynthesis. Desmosterolosis is associated to 
mutations in DHCR24 gene and 3-hydroxysterol-24-reductase deficiency [Clayton et al. 
1996, Waterham et al., 2001] whereas mutations on SC5D gene, that encodes lathosterol-5-
desaturase, cause lathostherolosis [Krakowiak et al., 2003, Brunnetti-Pierri et al., 2002]. Both 
diseases are still poorly characterized due to the small number of cases identified. They both 
share some phenotypic characteristics with SLOS and the diagnosis of new cases will 
contribute for a better phenotypic characterization of these metabolic disorders. In order to 
contribute for the recognition of these entities, we have recently established reference values 
for several sterols in amniotic fluid at different gestational ages (lathostherol and 
desmosterol included) [Amaral et al., 2010].  
A patient with psoriasiform dermatitis, arthralgias, congenital cataracts, microcephaly, and 
developmental delay was recently identified as harboring mutations in sterol-C4-methyl 
oxidase–like gene (SC4MOL), which encodes a sterol-C4-methyl oxidase. This enzyme also 
belongs to the cholesterol biosynthesis pathway and catalyses the demethylation of C4-
methylsterols. Sterol-C4-methyl oxidase deficiency is a novel disease of inborn errors of 
cholesterol biosynthesis, which clinical spectrum remains to be defined [He et al., 2011].  
No prenatal diagnosis of these three disorders has so far been reported. However, in theory, 
it can be performed based on sterols profile of amniotic fluid or through the identification of 
mutations in the above mentioned genes. 
7. The teratogenic effect of drugs that interfere with cholesterol biosynthesis 
Many women on reproductive age take medicines on a regular basis. However, most drugs 
presently available on the market are not licensed for use in pregnancy. Therefore, these 
women may conceive on medication, leading to a large number of early pregnancies being 
exposed to a wide range of drugs. Moreover, fetuses have been increasingly exposed to new 
 
Current Issues Regarding Prenatal Diagnosis of Inborn Errors of Cholesterol Biosynthesis 
 
125 
classes of compounds, as these compounds have been shown to be effective and well 
tolerated outside pregnancy [Kyle, 2006].  
Drugs that block crucial steps of cholesterol biosynthesis exert a teratogenic effect on the 
fetus, mimicking the genetically determined enzymatic defects. These phenocopies have 
features that resemble the phenotype of the corresponding inherited metabolic disease. 
Drugs with such properties are identified among antifungal, hipocholesterolemic and some 
antineoplastic agents. 
7.1 Antifungals 
A variety of antimycotic compounds are currently available to treat systemic or 
mucocutaneous fungal infections and some of them are capable of penetrating the placental 
barrier [Moudgal & Sobel, 2003]. Azoles antifungals act by competitive inhibition of CYP51 
(lanosterol 14-demethylase) decreasing the synthesis of ergosterol, the main sterol in 
fungal cell membrane. Apart from ergosterol depletion, selective inhibition of CYP51 also 
leads to accumulation of lanosterol and other 14-methylsterols, resulting in alterations of 
fungal wall, cell growth, cell replication and inhibition of morphogenic transformation of 
yeasts into mycelia [Giavini & Menegola, 2010, Pursley et al., 1996 ]. The inhibitory potential 
of these compounds is not limited to fungi; it has also been seen in a number of mammalian 
cytochrom P450-dependent activities, including microsomial enzymes [Sheets & Mason, 
1984] and studies carried out in pregnant animals taking high doses of azole fungicides 
revealed their teratogenic potential. Malformations were found at branchial apparatus 
(related with facial structures), axial skeleton and limbs [Giavini & Menegola, 2010, 
Menegola et al., 2003].  
Fluconazole, a bis-triazole anti-fungal agent is commonly used to treat human mycosis. It 
shows excellent oral absorption, low plasma protein affinity, long half-life, high 
concentrations in urine and CSF, minimal adverse reactions, wide spectrum of anti-fungal 
activity and it has high specificity for fungal cytochrome P450 system [Agrawal et al., 1996]. 
Nevertheless, at least five cases reporting children with a multiple malformation syndrome 
due to first-trimester fluconazole exposure were published. In all cases, high doses (400-800 
mg/day) of fluconazole were administrated during several weeks (in order to treat a severe 
systemic mycotic infection) before women were aware that they were pregnant [Aleck & 
Bartley, 1997; Lopez-Rangel & Van Allen, 2005; Pursley et al., 1996]. The newborns showed 
anomalies analogous to those seen in experimental animals [Aleck & Bartley, 1997] and the 
phenotype identified resembled that of Antley-Bixler syndrome (thoroughly described 
above) [Lopez-Rangel & Van Allen, 2005]. A possible explanation for the similarity between 
this embriopathy and Antley-Bixler phenotype is a compromised cytochrome P450 system 
in both situations. 
In contrast to the above described teratogenicity of fluconazole, the use of topical azoles for 
treatment of superficial fungal infections in pregnancy seems safe and efficient [Moudgal & 
Sobel, 2003] and there are several epidemiologic reports of tens of women who took 
sporadically low doses (50 -150mg/day) of fluconazole during first trimester of pregnancy 
and did not show increased overall risk of birth defects, compared with a control group 
(fluconazole free during pregnancy) [Giavini & Menegola, 2010; Inman et al., 1994; 
Mastroiacovo et al., 1996; Nørgaard et al., 2008]. Hence, as it has been previously 
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demonstrated for other drugs [Polifka et al., 2002], dosage seems to be a critical factor on the 
teratogeneticity potential of fluconzazole given that apparently the exposure is harmful only 
if it is chronic or exceeds a certain threshold.  
7.2 Statins  
Another group of compounds that strongly interferes with cholesterol biosynthesis pathway 
are the hypocholesterolemic drugs: statins. These compounds inhibit the enzyme 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA) reductase that catalyses a limitating step of cholesterol 
biosynthesis: the conversion of HMG-CoA to mevalonate. Because this key compound is 
also required for the synthesis of several other biologically important molecules, levels of 
HMG-CoA reductase may regulate many cellular processes and functions in cell. In fact, 
knock out embryos for HMG-CoA reductase died prematurely suggesting that the loss of 
HMG-CoA reductase activity leads to implantation failure or to embryonic death prior to 
implantation [Ohashi, 2003].  
The use of statins for treatment of hyperlipidemia is increasingly common [Taguchi et al., 
2008] and the effectiveness of these agents in reducing mortality and morbidity associated 
with coronary artery disease is well established [Kusters et al., 2010]. However, when 
pregnancy is considered, lipid-lowering drugs are often discontinued because of the fear of 
teratogenic effects [Kusters et al., 2010].  
There is scarce and conflicting evidence on the teratogenic potential of statins and most of 
the information on drug safety for the fetus is limited to animal studies, a few case reports 
and retrospective uncontrolled data [Avis et al., 2009]. A study focusing on the toxicity of 
atorvastatin in pregnant rats and rabbits has shown that only the hightest doses tested - 
which were also toxic for the mothers - had harmful effects in pregnancy by increasing 
postimplantation loss and decreasing fetal body weight [Dostal et al., 1994]. Later, studies 
evaluating in vitro effects of statins in a human placental model have demonstrated that 
simvastatin (i) inhibited half of the proliferative events in the villi, (ii) increased apoptosis of 
cytotrophoblast cells and (iii) significantly decreased secretion of progesterone from the 
placental explants. These effects may contribute to the failure of implantation and be 
deleterious to the growth of the placental tissues which could explain the higher abortion 
rate and teratogenicity observed in animals exposed to statins during pregnancy [Kenis et 
al., 2005].  
Moreover, due to the occurrence of unplanned pregnancies, there are a number of cases in 
which statins were inadvertently taken during the first trimester of pregnancy, some of 
them resulting in newborns with birth defects [Edison & Muenke, 2004, 2005; Petersen et al., 
2008; Trakadis et al., 2009]. Nevertheless, these studies are not conclusive due to 
ascertainment bias: (i) in some cases pregnant women took potentially teratogenic drugs 
other than statins [Trakadis et al., 2009] or (ii) previous maternal health disorders like pre-
pregnancy diabetes, obesity or both [Petersen et al., 2008] or (iii) the small number of cases 
identified enables the validation of a stastically significant conclusion [Edison & Muenke, 
2004, 2005; Petersen et al., 2008]. Furthermore, none of the studies evaluated the possibility 
of decreased fertility, increased pre-implantation or peri-implantation losses that could be 
increased as shown in animal experiments [Elkin & Yan , 1999; Lee et al., 2007; Ohashi et al., 
2003; Richards & Cole, 2006; Zapata et al., 2003]. 
 




Another interesting compound is tamoxifen, a nonsteroidal selective estrogen receptor 
modulator, used for the treatment and prevention of breast cancer [de Medina et al., 2004]. 
This drug is currently used as adjuvant treatment in premenopausal women affected or at 
risk for breast cancer [Berger & Clericuzio, 2008]. Tamoxifen has also been reported to 
protect against the progression of coronary artery diseases in human and animal models [de 
Medina et al., 2004]. Such property can be related to the capacity of tamoxifen to inibit 
several enzymes related with cholesterol metabolism namely acyl-CoA cholesterol 
acyltransferase which catalyses cholesterol esterification [de Medina et al., 2004] as well as 
with its hypocholesterolemic properties. As a matter of fact, tamoxifen inibits several 
cholesterogenic enzymes, namely: (i) sterol -8-isomerase, (ii) sterol -24-reductase, (iii) 
sterol -14-reductase, and the administration of such compound to humans and laboratory 
animals results in a drastic reduction in cholesterol and a marked accumulation of certain 
sterol intermediates in serum [Cho et al., 1998].  
Despite tamoxifen long use in clinical practice, its teratogenic potential remains 
inconclusive. Furthermore, while the evidence of effects of tamoxifen in humans in utero is 
minimal, animal studies have shown evidence of teratogenicity (abnormalities of genital 
tract and irregulary ossified ribs in rat pups) and delayed vaginal opening in female 
offspring of guinea pigs [Barthelmes & Gateley, 2004; Berger & Clericuzio, 2008]. According 
to a review of seven papers refering tamoxifen prenatal exposure there was (i) one case of 
ambious genitalia after 20 weeks exposure to a diary dose of 20 mg (ii) one case of 
Goldenhar’s syndrome after 26 weeks exposure to 20 mg/day (with simultaneous exposure 
to other teratogenig drugs during the first 6 weeks) [Barthelmes & Gateley, 2004]. Later, one 
case of Pierre Robin sequence (small mandible, cleft palate and glossoptosis) associated with 
first trimestre fetal exposure was also published in a pregnancy with gestational diabetes 
[Berger & Clericuzio, 2008].  
If we put together the fact that (i) this drug was initialy developed as a contraceptive agent 
[Barthelmes & Gateley, 2004], (ii) it inhibits several enzymes of cholesterol biosynthesis 
pathway, (iii) in most cases the exposure to tamoxifen occurs very early – sometimes even 
before women are aware of the pregnancy - and (iv) no adverse effects were observed in 85 
cases in which tamoxifen was taken as preventive drug of breast cancer (without association 
to other potentially teratogenic compounds exposure), we are lead to the conclusion that 
tamoxifen has a „all-or-none“ effect. In other words, exposure to tamoxifen may cause 
affected embryos that are lost very early (even before women are aware of the pregnancy) or 
fetal survival without any malformation.  
All in all, one should highlight the role of the medical appointements on the evaluation of 
the interation of drugs with the developing fetus. Ideally, pregnancies should be prepared in 
advance and, at that time, the potencially teratogenic drugs should be replaced by less 
harmfull medicines or, if possible, discontinued. After conception and when evaluating a 
fetus with malformations on the ultrasound, doctors should bear in mind the role of 
teratogenic drugs that can produce phenocopies of genetically determined disorders. 
8. Conclusion  
During the last two decades inborn errors of cholesterol biosynthesis have emerged as a 
group of metabolic disorders that should be included in the differential diagnosis of 
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intrauterine growth restriction and abnormal embryogenesis as well as in the investigation 
of the etiology of low levels of maternal estriol in the second trimester of pregnancy. 
Patients with these metabolic diseases present with complex malformation syndromes 
involving different organs and systems. As metabolic pathways are biological interactive 
networks, one specific blockage activates new routes for detoxication of accumulated 
products followed by excretion. For example, it was noticed that urine from pregnant 
women at risk for SLOS revealed abnormal steroids derived from 7-dehydrocholesterol. One 
can assume this as a general rule, and postulate that, in defective cholesterol biosynthesis 
accumulated sterols are metabolized originating “new” steroids. If quantification of 
abnormal steroids in maternal urine (which is non invasive and easy to perform) becomes 
widely available, one can envision a future in which prenatal diagnosis of inborn errors of 
cholesterol biosynthesis is extended to most fetuses with developmental abnormalities.  
Furthermore it is possible that, as it is being developed in other fields of medical genetics, 
high throughput technologies might also be used in the setting of metabolic disorders: for 
example, a microarray chip with oligonucleotide probes targeted to all the genes involved in 
metabolic pathways and the application of a next generation sequencing platform to 
perform sequencing analysis of those genes. This would allow for the identification of both 
copy number variants and point mutations of the genes implicated in the inborn errors of 
cholesterol biosynthesis pathway, thus promoting a global and thorough approach to these 
diseases, a better phenotype-genotype correlation and a more accurate knowledge of the 
spectrum of these disorders.  
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1. Introduction  
Iodine deficiency is a worldwide Public Health problem, mainly in pregnant women and 
infants, which causes permanent and irreversible sequels in the Central Nervous System 
(CNS) of the progeny when daily iodine intake does not reach optimal levels. 
Pharmacological iodine supplements have been recommended during pregnancy and 
lactation periods in regions with low iodine intake diet.  
In recent years, maternal hypothyroxinemia has been recognized as the biochemical 
condition responsible for the alterations in the processes of neural development in the 
embryo and fetus associated to iodine deficiency. 
Research Methods: The objective of this study was to review the available scientific evidence 
on the crucial role of iodine in early stages of neural development, to understand the 
international scheduling recommendations about an adequate iodine intake in vulnerable 
populations groups. 
Iodine is a micronutrient essential for the synthesis of thyroid hormones1. The thyroid gland 
takes iodine from the diet, stores it and subsequently incorporates it into other molecules, to 
produce two types of thyroid hormones as a final product: triiodothyronine (T3) and 
thyroxine (T4) containing three and four iodine atoms respectively. Both circulate in blood 
bound to proteins and act on specific receptors. The free T3 is metabolically more active, but 
the T4 is, as we shall see, indispensable at specific developmental stages.  
The thyroid hormones are involved in many metabolic and developmental processes, and 
they exert a broad range of actions on every tissue of the body: body temperature 
regulation, somatic growth. Further, it is essential for the proper development and function 
of the Central Nervous System.2  
Since the first epidemiological studies conducted by Pharoah3 and Thilly4 in the 70's, the 
association between iodine deficiency in pregnant women and fetal neurological damage 
has been extensively reviewed and proven in scientific literature. In fact, the need to provide 
iodine supplementation to pregnant women in iodine-deficient regions is considered as 
proven by scientific evidence.5 
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Many of these studies are focused on regions where severe iodine deficiency is endemic and 
coexisting with mixedematous cretinism.6 The understanding of the neurological effects of 
hypothyroidism on infants was partially obtained from mothers with clinically overt 
hypothyroidism.7.8 All these factors have contributed to a general awareness that iodine 
deficiency is a problem restricted to specific geographic areas and to well-defined at-risk 
populations (hypothyroidism, goiter and malnutrition)9 
For a long time, there has been a prevailing belief that the main factor responsible for 
alterations in fetal neurological development was maternal hypothyroidism (defined as 
elevated serum TSH levels) in the early stages of pregnancy.8,10 Thus, when a pregnant 
woman was found to have normal thyroid function, neurodevelopmental alterations in the 
fetus were systematically discarded. 11 
Along history, some contradictions have arisen from mixing different concepts as 
endemic cretinism, congenital hypothyroidism, iodine deficiency, etc12. Fortunately, such 
contradictions have been clarified by the advances in our understanding of thyroid 
physiology during pregnancy13,14 , the transfer of maternal thyroid hormones to the 
fetus15,16 and the increasingly complete characterization of thyroid hormone receptors in 
placental and embryo tissues.17 Nevertheless, only the most recent studies have given 
satisfactory explanation of the possible role of thyroid hormones (maternal and fetal) 
during critical stages of fetal neurological development.18 Basing on these recent works, 
the relevance of an adequate balance of iodine during the early stages of life is 
considered proven. 
2. Iodine deficiency and pregnancy 
Pregnancy is accompanied by dramatic changes in the thyroid function, which are the result 
of a complex combination of factors specific to pregnancy that altogether stimulate the 
maternal thyroid machinery.14 
During the first half of gestation the maternal thyroid undergoes some changes:  
 Progressive increase of thyroglobulin, which reduces free fraction of thyroxine.  
 The human chorionic gonadotropin has TSH-like effect and acts by directly stimulating 
the maternal thyroid.  
 Meanwhile, the fetal thyroid is kept inactive and will not be functioning until 20 weeks 
of gestation.  
 The only source of thyroid hormones in the fetus throughout the first half of pregnancy 
is thyroxine of maternal origin.  
In healthy pregnant women with adequate iodine levels, pregnancy mainly involves a 
higher demand of thyroid hormones. The thyroid gland regulates the release of hormones to 
achieve a new balance, and maintains this balance until the end of the gestation process19. In 
general, the higher hormone need can only be met by a proportional increase in hormone 
release, which directly depends on the intake of iodine through the diet. At present, we 
know that iodine nutritional needs increase in all pregnant women due both to the higher 
hormone need and to the higher glomerular filtration rate20. This adaptation is achieved 
without difficulty by the thyroid machinery21. 
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Conversely, when the thyroid gland fails –due, for example, to iodine deficiency–, such 
changes in thyroid parameters may not be adequately compensated and adaptation 
mechanisms fail13, 21   
 Obviously, the more severe iodine deficiency, the more serious fetal and maternal 
consequences are. However, it has been shown that such alterations can be found when 
pregnancy occurs in healthy women residing in moderately iodine-deficient areas22. 
3. Thyroid hormones and fetal brain development 
3.1 Background 
In 1888, the Clinical Society of London prepared a report which emphasized the key role of 
the thyroid gland for normal brain development23. The members of this committee reached 
this conclusion after observing that patients with both endemic and sporadic cretinism 
showed clear evidence of mental retardation.24 
Initially, endemic cretinism was thought to be a congenital disease25, 26. However, the 
prenatal origin of this syndrome was confirmed when a clinical trial with iodized oil 
showed that it could be successfully prevented exclusively when iodine was supplied to the 
mother before conception.3 
The classic works by Pharoah et al.3,27 in Papua New Guinea in the 70's, and later by Thilly 
et al4 in Ubangi (Zaire) and Malawi, provided a thorough description of the clinical 
symptoms of endemic cretinism (in its myxedema and neurological forms), which were 
characteristic of regions with severe endemic goiter. 
These early studies supported the idea that severe iodine deficiency in the mother produces 
irreversible neurological damage in the fetus during critical development stages12. Cases of 
intrauterine deaths, miscarriages, death in childhood and the birth of cretins to women with 
biochemical evidence of iodine deficiency (very low free T4 levels) without clinical signs of 
hypothyroidism were described.28, 29 
In 1976, Pharoah et al27 pointed out that iodine deficiency was different from untreated 
myxedema and from congenital hypothyroidism, which are usually associated with 
menstrual disorders, infertility or repeated miscarriage.  
Later, studies on iodine deficiency and its effects at the reproductive age and on progeny 
almost fell into oblivion in the scientific scene. It was believed that iodine deficiency had an 
impact only in certain geographic areas with severe endemic goiter, and that such dramatic 
consequences had been eradicated both in Europe and in the United States.30 
Thus, a misconception of the pathophysiology of neurological deficit caused by iodine 
deficiency was established. The placenta was thought to prevent the transfer of thyroid 
hormones.31 According to this theory, the fetal brain would develop in the absence of 
maternal transfer of these hormones32 and, therefore, neurological damage could be 
prevented by hormone supplementation therapy at birth.13 
In the following years in Europe, further clinical experience emphasized the significance of 
getting the diagnosis of congenital hypothyroidism, and initiating appropriate 
supplementation therapy as soon as possible after birth. The development of increasingly 
more precise33, 34 screening tests of thyroid function allowed to identify congenital 
hypothyroidism at birth and begin treatment without delay35. 
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release, which directly depends on the intake of iodine through the diet. At present, we 
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without difficulty by the thyroid machinery21. 
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However, clinical reports in regions with severe iodine deficiency suggested a different 
reality: there was a clear correlation between maternal hypothyroxinemia levels and the 
severity of neurological damage in the progeny. The lower the maternal FT4, the more 
serious the effects on the fetus, causing irreversible neurological and mental abnormalities at 
birth that could only be prevented by treating maternal hypothyroxinemia throughout the 
first half of gestation.36 Subsequent interventions could not prevent all disorders. 
But it was not until 1999 –when Haddow et al.37 published their classic article in the New 
England Journal of Medicine–  that iodine deficiency in pregnant women in developed 
countries was seen again as a problem also affecting populations that were so far thought to 
be safe from this endemic disease. Haddow et al.37 found that infants of women with 
undiagnosed hypothyroidism (TSH above the 98th percentile) during pregnancy had lower 
scores on tests related to intelligence, attention, language, reading skills, school and visual-
motor performance, and that such differences with the other infants were statistically 
significant in the 15 tests performed. 
That same year, Pop et al 38 published an article proving that fetal neural development is not 
only affected when the mother has subclinical hypothyroidism, but it is just enough that  
 
Fig. 1. Fetal and neonatal effects of iodine deficiency during pregnancy. The main advance is 
that maternal hormone transfer to the fetus during pregnancy has been definitely accepted, 
as well as the existence of damage in the progeny in absence of maternal hypothyroidism. 
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there is a previous stage of "maternal hypothyroxinemia" in the early stages of pregnancy. In 
their article, the authors showed that infants of mothers with T4 levels below the 10th 
percentile at the 12th week of gestation had significantly lower scores on the Bayley 
Psychomotor Development Scale at 10 months of age, compared with infants of mothers 
with higher free T4 levels. 
In 2000, Morreale de Escobar et al.36 presented epidemiological and experimental evidence 
strongly suggesting that first-trimester hypothyroxinemia (a low for gestational age 
circulating maternal free T4, whether or not TSH is increased) produces an increased risk for 
poor neuropsychological development of the fetus. The damage would be caused by 
decreased availability of maternal T4 to the developing brain. 
Further, poor brain development occurs both in regions with severe iodine deficiency, and 
in regions with slight or moderate deficiency.22, 28 
The identification of hypothyroxinemia  as a factor which causes neurological damage in 
progeny –regardless whether or not the mother has hypothyroidism– is a landmark for the 
study of iodine deficiency in Europe.32,36 
Figure 1 shows the differences between the classic and current understanding of the 
physiopathology of iodine deficiency.  
4. Thyroid hormones and fetal neurological development 
In humans, cerebral cortical development occurs between the 6th and the 24th week of 
gestation. The cortical plate begins to form around day 54 (8 weeks of gestation). Cortical 
neuronal migration mostly occurs between the week 8th and 24th (before the end of the 
second trimester), and generally before the onset of fetal thyroid hormone secretion occurs 
in the middle of gestation39. 
From a didactical perspective, fetal neurological development takes place in three stages 
relying on the thyroid hormone40 (Figure 2): 
1. The first stage takes place before the fetus starts producing thyroid hormones, and ends 
between the week 16th and 20th of gestation. During this period, thyroid hormone 
exposure comes only from maternally synthesized hormones, which influence neuronal 
proliferation and migration of neurons into the neocortex and hippocampus. 
2. The second stage occurs during the remainder of pregnancy after the onset of the fetal 
thyroid function, when the developing brain derives its supply of thyroid hormones 
from both the fetus and the mother. At this moment, thyroid hormones will trigger 
neurogenesis, neuronal migration, axonal outgrowth, dendritic branching and 
synaptogenesis, and the onset of glial cell differentiation and migration, and 
myelination. 
3. The third stage takes place during the neonatal and post-natal period when thyroid 
hormone supplies to the brain are entirely derived from the child and critical for 
continuing maturation. At this stage, thyroid hormones affect granule cell migration in 
the hippocampus and cerebellum, including the migration of cerebellar Purkinje cells. 
Gliogenesis and myelination continue during this stage. 
Thyroid hormone receptors (TR alpha and beta) bind T3 with very high affinity, and act as 
ligand-induced transcription factors modulating the expression of different T3-dependent 
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target genes18. Thus, although circulating levels of T4L are 4-fold higher than those of T3L, 
the thyroid hormone receptor has at least 15-fold more affinity for T340, which indicates 
that T4 is a prohormone that must be converted into T3 before the onset of thyroid 
hormone function. 
 
Fig. 2. Relationship between thyroid hormone action and brain development. In the first 
trimester of gestation, early neuronal proliferation and migration is dependent on maternal 
thyroxine (T4). In fetal tissues, deiodinase (ID-III, D3) enzyme expression falls and marks 
the onset of the fetal thyroid development. (D2: deiodinase ID-II). TRs: thyroid hormone 
receptors. From Williams GR. Neurodevelopmental and Neurophysiological Actions of thyroid 
hormones. J Neuroendocrinol 2008; 20: 784-794.  
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TR alpha and beta receptors express in most tissues, but their distribution varies from one 
tissue to another, which constitutes a control mechanism of T3 action that is specific in time 
and space.41,42 
Towards the end of the first trimester, development of the hypothalamic-pituitary axis has 
occurred and causes an increase in TSH secretion that marks the onset of fetal thyroid 
hormone production. Then starts the activating deiodinase enzyme ID-II expression and 
increases the occupation of thyroid hormone receptors by T3. 
Continuing development of the brain in the second and third trimesters relies increasingly 
on the T4 produced by both the fetus and mother. Continued post-natal development is 
entirely dependent on neonatal thyroid hormone secretion.  
Thyroid hormones intervene directly or indirectly in most of the neurodevelopmental 
processes of the embryo and the fetus. This would explain that thyroid deficiency in early 
pregnancy causes irreversible effects43,44.  
Thyroid hormone receptors have been proven to express profusely both in neurons and in 
glial cells (astrocytes and oligodendrocytes)45,46. 
At neuronal level, thyroid hormones would act as “cofactors”, favoring the expression of 
certain patterns of genes involved in axonal and dendrite outgrowth, and in the formation 
of synapses, myelination, cell migrations, and proliferation of specific cell populations39. 
For a proper neuronal function (synaptic transmission, laminar cytoarchitecture of the 
cerebral cortex) appropriate interaction with glial cells is required47. In this sense, thyroid 
hormones favor proliferation of oligodendrocyte precursor cells and their differentiation 
into mature oligodendrocytes (which make the myeline sheath)46. 
At the same time, thyroid hormones are involved in the maturation of radial glial cells, 
which are directly involved in neuronal migration into the different layers of the cerebral 
cortex.48 Finally, thyroid hormones are directly involved in the development and maturation 
of glial cells in specific brain areas, as the hippocampus or the cerebellum.44 
Thorough this sequence of events, it should be considered: 
- That fetal neurodevelopment follows a very precise and limited sequence of events47. 
The response period of the cell is what is called competence. The same cell will not 
respond before or after this period. 
- That the maturation sequence is not formed by a succession of independent events, but 
rather by cascading events where each anomaly.49,50 
5. Thyroid hormone transfer and maternal hypothyroxinemia  
In humans, maternal thyroid hormones are transferred to the fetus and the embryo during 
pregnancy. In fact, during the first half of gestation, the mother is the sole source of thyroid 
hormones51,52. 
Under normal conditions, embryonic tissues have a set of security mechanisms protecting 
their development. Some of these mechanisms are physical barriers (placenta and 
extraembryonic membranes) that avoid free transfer of maternal thyroid hormones into the 
fetus, and expose it to the same plasma fluctuations that occur in maternal blood serum53,54. 
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Another security mechanism is the presence of deiodinase enzymes in fetal cerebral 
tissues55,56. Deiodinase enzymes take maternal free thyroxine (T4L) and subsequently 
convert it into T3, but do not allow direct transfer of maternal T357. FNAs were made to 
obtain samples of fetal serum, and T4 concentrations in fetal serum were found to rely 
directly on maternal thyroxinemia58. 
In case of nutritional iodine deficiency, the organism activates self-regulating mechanisms 
where T3 is synthesized prevailingly over T4, as a way to save iodine15 (Figure 3). This leads 
to a situation of maternal hypothyroxinemia, which is the fall of T4L levels in plasma, but 
presenting normal circulating T3L and TSH levels36,57. 
Maternal hypothyroxinemia is defined as: 
- A “biochemical” status (low T4L levels with normal TSH values). 
- It appears in healthy pregnant women (without any clinical sign or underlying thyroid 
pathology). 
- It reflects a deficient nutritional status where the daily dietary intake of iodine is not 
adequate to meet iodine needs during pregnancy. 
- It indicates maternal inability to guarantee adequate T4 transfer to the embryo, which is 
required for proper neurological development36,38. 
At present there is solid evidence that maternal hypothyroxinemia (low T4L) during the first 
half of gestation is the main cause of neurological alterations in the embryo and the fetus57,59. 
Such alterations are permanent and irreversible. 
All levels of iodine deficiency (low, moderate or severe) affect the maternal and neonatal 
thyroid function, and infant’s mental development22. 
6. Hypothyroxinemia and neurodevelopment 
Animal models for iodine deficiency during pregnancy on development of the CNS have 
been developed for monkeys, sheep and rats.2 These studies have shown changes in 
cerebellum with reductions in weight and cell number, and delayed maturation. The 
influence of maternal hypothyroxinemia on neocortical development has been recently 
studied in rats and mice.60  
6.1 Altered migration during corticogenesis 
The cerebral cortex is composed of neuronal layers with specific functions.39 To form this 
cytoarchitecture, neurons undergo a Tangential migration from the basal epithelium into 
the upper layers of the cortex44. Neuronal migration is highest between the 11th and the 
14th week of gestation, coinciding with the T4 peak in maternal blood serum during 
gestation.32 
During this migration, neurons use glial cells like the steps of a stairway to climb into the 
upper layers39,47. This interaction between glial cells and neurons is enabled by thyroid 
hormones.50,60 
Studies on radial migration during corticogenesis have revealed that in cerebral cortex of 
hypothyroid rats, the radial positioning of migrating neurons is altered48,49, resulting in 
abnormally located Heterotopic neurons in the subcortical white matter (Figure 3)2.  
 






Fig. 3. (A—C) Low-magnification photomicrographs of coronal sections of the parietal 
cortex and hippocampus showing BrdU-immunoreactive cells after E17--20 injections in 
control, LMH þ T4, and LMH pups at P40. (D—F) Details (boxes in A, B, and C) showing 
that both in layers I—VI and white matter (wm) the neocortex and the alveus (al) and 
stratum oriens (or) of the hippocampus, the radial distribution of BrdU-immunoreactive 
cells is more widespread in LMH pups than in control and LMH þ T4 pups. Note the 
increased number of heterotopic BrdU-immunoreactive cells in wm, al, and or in LMH pups 
compared with that of control and LMH þ T4 pups. The borders between layers are 
indicated by horizontal lines. LMH= Late maternal hypothyroidism. (Berbel P et al. Cerebral 
Cortex 2010)60 
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6.2 Abnormal cortical cytoarchitecture and connectivity 
Any situation compromising maternal thyroid hormone transfer to the fetus will disturb the 
neuronal migration process. As a result, neurons will not reach their final destination in the 
upper layers and their abnormal positioning will cause alterations in the laminar 
architecture of the cerebral cortex.44 
In biopsies performed in experimental animals maternal thyroid hormone deficiency was 
found to cause permanent and irreversible lesions in the cerebral cortex cytoarchitecture. As 








Fig. 4. Left. Photomicrographs of S1 coronal sections from normal and hypothyroid rats, 
showing the distribution of BrdU-labelled cells at P40, following injections at E15 and E17. 
Cells are more widely distributed in hypothyroid rats. Note the increased number of 
labeled cells, with respect to normal, in the white matter (wm) of hypothyroid rats. 
Centre. Photomicrographs of cresyl violet-stained coronal sections showing the PMBSF 
cytoarchitecture and layer borders in normal and hypothyroid rats. In normal rats, 
borders between layers are clear cut, while in hypothyroid rats (dashed lines) they are 
blurred. Note that in layer IV of hypothyroid rats, instead of normal barrels, disperse 
patches of high cell density can be seen. Arrowheads point to two septae adjacent to the 
barrel indicated by the arrow. Right. Plots of retrograde-labeled callosal neurons are 
shown in normal and hypothyroid rats. In normal rats, an important proportion of labeled 
neurones are in supragranular layers II and III. On the contrary, in hypothyroid rats, 
almost all labeled neurones are between layers IV and VI (Berbel P. et al.  
Neuroscience 2001)62.  
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Fig. 5. Thyroid hormones play an important role in the neuronal migration process. 
Specifically, rats born to females with moderately low thyroid hormone levels have a 
disorganized cortical plate and many neurons do not migrate to their normal position. 
Furthermore, this action of thyroid hormones occurs during early fetal life. The figure shows 
the radial (blue arrow)  and tangential (red arrows) migratory pathways. Both are afected by 
maternal hypothyroxinemia resulting in abnormal cortical lamination. (Adapted from Berbel 
P. Mente y Cerebro 2003)63 
7. Physiopathology of fetal cerebral damage 
Within this broad framework, three different situations can be found, with different results: 
When maternal hormone transfer is deficient –as in cases of maternal hypothyroidism or 
hypothyroxinemia–, the hormone concentrations transferred to the embryo and the fetus are 
inadequate during early pregnancy. Later, at the onset of fetal thyroid function, there is 
increased secretion of T4 and T3 by the fetal thyroid gland, though it fails to meet 
successfully the early disruption of maternal hormone supply. Thus, T4 and T3 
concentrations in fetal tissues are fairly normal when the fetus reaches term, but its 
intrauterine development will have suffered alterations.38,64 
However, as the secretion of thyroid hormones increases, the fetal thyroid cannot store 
them. Therefore, neonates to mothers with thyroid malfunction have higher difficulty to 
meet the hormonal needs at birth than neonates to mother with normal thyroid function. 
This situation can lead to permanent neurological abnormalities38,40. 
When the maternal thyroid function is normal, but the fetal function is not –as it is the case in 
congenital hypothyroidism–, maternal T4 and T3 supply can partly mitigate fetal 
hypothyroidism. Although maternal T4 supply cannot replace completely the fetal thyroid 
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function, it is crucial for brain development, where it does maintain normal T3 concentrations. 
However, such concentrations are not maintained in other tissues at normal levels.65  
However, although maternal T3 levels are normal, this does not mitigate T3 deficiency in 
the fetus. The reason is that the fetal brain is totally dependent on the conversion of T4 into 
T3 by local action of 5'D-II, as T3 cannot be taken directly from plasma.38,66  
Thus, these findings prove that maintaining adequate T4 levels in the mother is crucial, as it 
protects the brain of fetuses with congenital hypothyroidism until birth. Conversely, 
although the mother has normal T3 concentrations maintaining maternal euthyroid status, 
this hormone does not protect the fetal brain in mothers with hypothyroxinemia38,40 . 
When both the maternal and the fetal thyroid function are abnormal –as in the case of 
chronic iodine deficiency– mothers have very low levels of T4, though T3 concentrations are 
normal. In this situation, embryos and fetuses have deficient T4 levels during gestation and 
become increasingly deficient in T3.64,67 
 
Fig. 6. In this table, the three clinical situations leading to altered maternal and/or fetal 
thyroid function are shown. It shows how the relative contributions of an altered maternal 
and/or fetal thyroid function can lead eventually to alterations in fetal thyroxine levels 
during intrauterine development. (From Glinoer D, Delange F. The potential repercussions of 
maternal, fetal and neonatal hypothyroxinemia on the progeny. Thyroid 2000, 10 (10): 871-887)64. 
When the fetal thyroid gland should start working, it cannot compensate for the disrupted 
maternal supply, since it does not have enough iodine for the synthesis and secretion of T4. 
At the same time, the fetal brain has not preferential protection from maternal T4, as this 
hormone cannot be biosynthesized due to the deficiency of iodine. As a result, fetal tissues –
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including the fetal brain– are very deficient in T4 and T3 during very important stages of 
cerebral neurogenesis and maturation.41,68 . 
These data suggest that the pathogenic mechanisms that lead to cretinism and severe 
hypothyroidism are multifactorial, and the effects of severe iodine deficiency can be 
amplified by the deleterious effects of thiocyanate overload, selenium deficiency, and 
glandular destruction and fibrosis occurring gradually during childhood69. By contrast, 
when iodine supplementation is given to women in regions with endemic iodine deficiency, 
cretinism can be eradicated, and neonatal hypothyroidism prevented70. 
8. Clinical effects of prenatal iodine deficiency 
Now that we know the "virtually universal" participation of thyroid hormones in the 
development and proliferation of fetal neural tissue, the complex clinical manifestations of 
thyroid hormone deficit in early pregnancy can be easily anticipated. 
Therefore, maternal and fetal hypothyroxinemia caused by iodine deficiency determines 
permanent lesions in the upper cortical areas, hippocampus and cerebellum48,64, which 
causes neurological abnormalities with relatively well-defined characteristics: 
- Brain stem or medullar elements are not affected, so there is no direct motor 
dysfunction, but abnormal motor coordination function39. 
- The lesions affect the integration areas of the cerebral cortex –including “silent” areas of 
the association areas of the cortex– showing poorly defined anatomical alterations. 
- They do not have perinatal clinical expression, although they express later during early 
years of life until school age.71,72 
- Therefore, these lesions cannot be detected by modern prenatal diagnosis techniques.30 
A number of research studies conducted in regions with moderate iodine deficiency have 
shown the presence of irreversible alterations in the intellectual and neuro-psycho-motor 
development of infants and adults that were clinically euthyroid and that did not exhibit 
other signs or symptoms of endemic cretinism, which is the most serious form of brain 
damage caused by iodine deficiency. 
In follow-up studies on infants of mothers with hypothyroxinemia identified in the first 
trimester of pregnancy, low scores were obtained on scales measuring psychomotor 
development (psychometric tests used to find evidence of these abnormalities are varied 
and include adapted intelligence tests, regardless of the subjects’ culture). Such results were 
especially significant in those tests that assess visual-motor coordination, object 
manipulation, understanding the relationship between objects, imitation and early language 
development38,73. The results showed low visual-motor performance, motor skills, 
perceptual and neuromotor skills, and low development and intelligence quotients (IQ)71,76. 
Bleichrodt and Born74 conducted a meta-analysis of 19 studies on neuromotor and cognitive 
functions in conditions of moderate to severe iodine deficiency, and concluded that iodine 
deficiency leads to a loss of 13.5 IQ points, as compared with the global population. Apart 
from goiter, brain damage and loss of intellectual potential caused by iodine deficiency are 
an obstacle to the socioeconomic development of people, and must be considered as a major 
public health problem. 
More recently, iodine deficiency –maternal hypothyroxinemia– has been identified as a 
causal factor of attention-deficit hyperactivity disorder75.  
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9. Fetal and neonatal effects of iodine deficiency27 
 
Reference Inclusion criteria Conclusions Comments 
 
Pharoah POD, Buttfield  
IH, Hetzel BS. 
 
Neurological damage to 
the fetus resulting from 
severe iodine deficiency 
during pregnancy 
 
Lancet 1971, 1: 308 
 
Type of participants: Total 
population from 27 
villages in Papua Nueva 
Guinea. 
 





Type of results: 
Changing incidence of 
endemic cretinism 
Controlled clinical trial in 
a city of 8,000 
inhabitants. 
 
Intramuscular iodized oil 
is effective for the 
prevention of endemic 
cretinism. To be effective, 











study on populations 
with severe iodine 
deficit. 
 
The cohort monitored is 
very small, as compared 
with the initial group. 
 
The results obtained are 
expressed in terms of 








and maternal thyroid 
status in severe endemic 
goiter 
 
J Clin Endocrinol Metab 
1978; 47: 354 
Type of participants:
A total of 109 pregnant 
women and 128 newborn 
babies from Ubangi, 
Zaire. 
 
Type of intervention: 
Administration of 
intramuscular iodized oil 
to a group of pregnant 
women. 
 
Type of results: 
Changing TSH, T4 and 
T3 concentrations in 
mothers and newborn 
babies.
Maternal thyroid 
function in regions with 
severe endemic goiter is a 
good indicator of the 
thyroid function in a 
neonate. 
 
The factors responsible 
for this hypothetical 
relationship seem to be 
environmental factors 
acting simultaneously in 
the mother and the fetus.
 
Pregnant women were 
grouped “randomly” 
into two groups. 
 
The results obtained are 
shown in thyroid 
function values of the 




Bleichrodt N, Born MP. 
 
A metaanalysis of 
research on iodine and 
its relationship to 
cognitive development. 
 
Nutr Rev 1996; 54 (4 Pt 





Type of intervention: 
Metaanalysis of 19 
studies on neuro-motor 
and cognitive functions 
under conditions of 
moderate to severe 
iodine deficiency. 
 
Type of results: 




Iodine deficiency causes 
a decrease of 13.5 IQ 
points as compared with 
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Reference Inclusion criteria Conclusions Comments 
 
 








development of the child
 
N Engl J Med 1999; 341: 
549.5556 
Type of participants:
62 pregnant women with 
TSH above the 98th 
percentile, and 124 
pregnant women with 
normal TSH levels. 
 
Type of intervention: 
Infants aged 7-9 
underwent 15 tests. 
 
Type of results: 





Infants of women with 
high TSH concentrations 
scored seven points 
lower than the infants of 
124 control women 
(p=0,005) in the 15 tests 
employed, and 19 









Retrospective study on a 
bank of pregnant women 
serum collected for a 
period of three years. 
 
The results are expressed 
in terms of the scores 
obtained in intelligence, 
attention, language, 




Pop VJ, Kuijpens JL y 
cols. 
 
Low maternal free 
thyroxine concentrations 
during early pregnancy 
are associated with 
impaired psychomotor 
development in infancy 
 




220 pregnant women and 
220 infants at 10 months.
 
Type of intervention: Study 
of maternal thyroid 
function and evaluation 
of the neurological 
development of infants at 
10 months of life. 
 
Type of results: 
Scores obtained by 
children on the Bayley 
Scale of Psycho-motor 
development. 
Low free T4 plasma 
concentrations during 
early pregnancy may be a 
relevant risk factor of 
mental retardation in the 
progeny. 
 
Free T4 concentrations 
are defined as an 
independent parameter 
for the neurological 
development of the 
progeny. 
This is the first study to 
prove that low free TSH 
levels in apparently 
healthy women during 
early pregnancy increase 




Maternal TSH, fT and 
TPO antibodies are 
analyzed at the 12th and 
32th week of gestation. 
 
Consequences at the 12th 
week and the rest of 
weeks of pregnancy. 
 
 
Morreale de Escobar G, 
Obregón MJ y Escobar 
del Rey F. 
 
Is neuropsychological 
development related to 
maternal 




J Clin Endocrinol Metab 




Type of participants: 
Previous articles 
 
Type of intervention: 
Systematic analysis of 
articles published on the 
effects of maternal 




Type of results: 
Relying on the study 
reviewed. 
Maternal 
hypothyroxinemia in the 
first trimester increases 




Maternal T4 is the sole 
source of thyroid 
hormone for the fetal 




concentrations in the 
mother do not prevent 
from potential damaged 
caused by a low T4 
supply 
Through analysis of the 
main findings made in 
regions with severe 
iodine deficiency, in 
regions without iodine 




Development of a 
unifying theory on the 
severity and frequency of 
neurological  
damage in the progeny 
of mothers with 
hypothyroxinemia, 
 in contrast with mothers 
with hypothyroidism. 
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10. Studies with potassium iodide supplementation 
Finally, supplementation with potassium iodide (KI) from the early stages of pregnancy in 
pregnant women has proven to be a safe and effective method for preventing cognitive 
impairment associated with nutritional iodine deficiency. 
 
Inclusion criteria Subjects Methods Conclusion Comments Reference 
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significant 
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Laurberg P and 
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Inclusion criteria Subjects Methods Conclusion Comments Reference 
Pregnant women 
enrolled from the 
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of iodine (group 
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Inclusion criteria Subjects Methods Conclusion Comments Reference 
Group 1 included 
infants of women 
with FT4 above 
the 20th percentile 
at 4-6 gestational 
weeks and at full-
term. 
Group 2 included 
neonates to 
women with mild 
hypothyroxinemia 
diagnosed during 
the first 12-14 
gestational weeks 
and with FT4 
above the 20th 
percentile at full-
term. 
Group 3 included 
infants born to 





Three groups of 
infants were 
compared. 




from the day of 
enrolment until 







Lézine Scale at 





















A delay of 6-10 
weeks in iodine 
Fortification of 
Hypothyroxine






mental delay in 
the progeny. 




(200 µg KI per 
day) from the 
day of enrollment 




No women were 
found to be 
Hypothyroxine-
mic at full-term 
after 
supplementation.
Berbel P, et al. 
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1. Introduction 
Basically, diagnosis inherited diseases in gestation is very important. But amplication of the 
progress in early stage of pregnance is the serious and great aim for rapid application of risk 
assesment for both and fetus. Fetal genetic tissues collected through techniques such as 
amniocentesis and chorionic villus sampling (CVS) for prenatal diagnosis of fetal genetic 
diseases. These procedures are associated with a risk of fetal loss (1%) and two week needed 
for cultivation (Chiu et al., 2010). Rapid methods for prenatal diagnosis of fetal 
chromosomal aneuploidies have been developed. This method is multicolor fluorescence in 
situ hybridization (FISH). FISH is very reliable but requires intact cells and it can only be 
used on fresh samples (Klinger et al.,1992) The other method is quantitative fluorescent 
polymerase chain reaction  PCR anaylsis (real-time PCR) (Lo et al., 1997). Real-time PCR is a 
powerful tool for quantifying gene expression combining both high sensitivity and 
specificity with efficient signal detection (Kubista, 2008). A major advantage of real-time 
PCR is that it can be used to determine the amount of initial temlates (Heidi et al., 1996). In 
addition, by making use of a closed whereby the samples are analyzed directly in PCR 
reaction vessel during the amplification. Furthermore, the assay is less prone contamination  
(Zimmerman, 2006). Real-time PCR has found wide spread applicability in the analysis of 
gene expression measurement and cell-free nucleic acids in body fluids. The assay is readily 
amenable to automation, and by making use of the current real-time PCR 96-384 well 
formats. The discovery of cff DNA in maternal plasma in 1997 has opened non-invasive 
prenatal diagnosis (NIPD). This research area is a rapidly developing and dynamic field. 
NIPD using cell-free fetal DNA (and RNA) is likely to become increasingly available within 
the next few years. There have been a lot of reported applications, including fetal rhesus-D 
genotyping (Bombard et al.,2011), fetal sexing for X-linked disorders (Costa et al., 2002), 
paternally inherited genetic diseases, and pregnancy-associated conditions such as 
preeclampsia (Zhong et al., 2001). Diagnosing by using free DNA a variety of limitations 
due to some of the features of this resource. CffDNA analyses would be applicable only 
when the involved target sequence is in the fetus but absent from mother, such as paternally 
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inherited disorders or “de novo” mutations (Gonzales et al., 2005). In this chapter, we 
focused on NIPD with real-time PCR via the use of cell-free fetal DNA  
2. The cell free fetal DNA  
The cffDNA circulate  freely in the peripheral blood during pregnancy and  derived from 
the placenta, the fetal hematopoietic system, or the amniotic fluid, it appears to be 
transferred as a naked molecule or very quickly assumes that form (Robert et al., 2003). The 
cffDNA  is most likely of placental origin (Bianchi&Lo, 2001). It rapidly disappears from the 
maternal circulation folowing chilbirth. Unlike fetal cells, which can persist for decades, 
cffNA are rapidly cleared from the maternal circulation and are undetectable 2 hours after 
delivery. PHG foundation group was summarized of key properties of fetal/placental 
elements in maternal blood, specifically cell-free fetal nucleic acids and intact fetal cells 
(table 1). Fetal DNA molecules are amount to just 3–6 % of the total DNA circulating in the 
maternal plasma (Lo et.al., 1998a). High levels of cffDNA in maternal plasma is associated 
with several pregnancy related disorders (Holzgre et al., 2001). The size of cffDNA have 
confirmed that it is of average size 300 bp or smaller than maternal free DNA (Chan et al., 
2004). Fetal DNA can be detected in maternal plasma between the fifth to seventh week 
gestation  (Gonzalez et al., 2005). The technical problem that cffDNA makes up a low 
proportion in maternal plasma in high background of maternal DNA.  
 
Properties cffNA Fetal Cells 
Earliest detection 4 weeks ~ 7 weeks 
Proportion 5-10% 0.0001 - 0.01% 
 
Persistence in maternal 
blood 




Short fragments Dense nucleus 
 
Table 1. Differences cell-free fetal nucleic acids and intact fetal cells (phg foundation, 2009) 
2.1 Isolation of cell fetal free DNA from maternal plasma 
The discovery of cffDNA in maternal plasma of pregnant women in 1997 by Lo et al (Lo et 
al., 1998b), many laboratories have shown that several protocols for isolating this material. 
The nucleic acid extraction procedure is most important for the detection of fetal nucleic 
acids in maternal plasma. To separate plasma from whole blood, parameters including 
multiple centrifugations at different speed, filtration to rmove contaminating intact or 
apoptotic cells, and removal of protein impurities have been explored (Jorgez et. al., 
2006).The critical point with techniques used is the avoidance of contamination from other 
blood components. The protocols for isolation of plasma were optimized to reduce cell lysis. 
The standard protocol for isolating plasma, which is commanly, involves two centrifugation 
steps. First step is high speed. This step is removal of cellular material from plasma layer. 
Store plasma samples in smaller aliquots (500 µL). The second step, different commercial 
kits have been used to isolate cell free fetal DNA. The free fetal DNA particles in maternal 
blood are promising as an important step for diagnosis of numerical and structural 
 
Real-Time Quantitative PCR for Detection Cell Free Fetal DNA 
 
165 
chromosome anomalies belonging to fetus without invasive procedures. The main problem 
is that extremely low concentration of fetal DNA is present in maternal plasma. Circulating 
fetal DNA concentration increases with progression of pregnancy and disappears from 
maternal plasma rapidly after delivery , with median half-life of 16.3 min ( Lo et al., 1999, 
Smid et al., 2003). However, methods have been optimized for the extraction of fetal DNA 
from maternal plasma. Although extracted DNA is generally stable for long periods, levels 
of fetal DNA have been shown to decrease over long storage periods. Our laboratories use 
of the QIAampDSP virus kit (QIAGEN). To extract DNA,  600 µL of plasma from maternal 
sample for method.  
3. Clinical applications of real-time PCR for non-invasive prenatal diagnosis 
For many years, scientisist has focused seperation of fetal cells and fetal DNA in maternal 
blood. The discovery of circulating cell-free fetal nucleic acids in maternal plasma has 
opened up new possibilities for non invasive prenatal diagnosis. Cff DNA is detectable in 
maternal blood as early as 5-7 weeks of gestation (Honda et al., 2002; Galbiati et al., 2005). 
CffDNA present has been used succesfully for non-invasive diagnosis of the fetal sex and 
fetal Rhd genotype in Rh negative women (Chen et al., 2004). Recent advances in molecular 
methods enable other applications of fetal DNA purified from maternal plasma samples 
(Vlkova et al., 2010). Studies put more emphasis on this area (Purvosunu et al., 2008). The 
sensivity of the studies that have been recently carried out by the devoleped PCR techniques 
has been increased, but the greatest difficulty encountered is the isolation of pure and high 
scale fetal DNA. By doing this isolation, the need of invasive procedures, such as 
amniocentesis will largely be eliminated (Hahn et al., 2008).  
3.1 Fetal RHD status 
Hemolytic disease of newborn (HDN) is a clinic phenomenon, which occurs during 
pregnancy due to the RhD alloimmunization between  Rh (-) pregnant woman, who has 
become sensitive with RhD antigens, and  her Rh (+) fetus. Unnecessary application of Anti 
D Ig can be prevented for pregnant women who carry Rh – fetus, also this results in a better 
follow-up of pregnant women who carry Rh+ fetus with the detection of RhD genotype of 
fetus in maternal plasma at the first trimester of pregnancy. RHD was used as a test-bed to 
prove the effectiveness of detecting a paternally inherited allele carried bty circulating free 
fetal DNA in maternal plasma (Lo et al., 1997). Maternal plasma-based RHD genotyping has 
been succesfully implemented in our laboratories for use as a non-invasive prenatal 
diagnosis where alloimmunization has occured (Gunel et al., 2010). Real-time PCR has been 
the choice diagnostic test used. Fetal RhD detection can be applied routinely to Rh (-) 
women and the use of human anti –D can be significantly reduced (Hahn et al., 2008). A 
reduction in anti-D administration also has economic implications. Rh locus is composed of 
two homologous genes RHD and RHCE (97% homology) closely linked on chromosome 
1p34-p36. Each of these genes consists of 10 exones, and they contain 69 kb of DNA. The 
regions of exone 7 and exone 10 within the RhD gene are the areas of focus. In all positive 
results, the RhD blood group has also been found positive (Huang, 1998, Wagner and Flegel, 
2000). In a white population, D-negative individuals are homozygous for a deletion of RHD. 
The D-negative phenotype, absence of the whole RhD protein from red cell membrane. 
Different mechanisms may explain rare phenotypes, including gene conversion events 
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become sensitive with RhD antigens, and  her Rh (+) fetus. Unnecessary application of Anti 
D Ig can be prevented for pregnant women who carry Rh – fetus, also this results in a better 
follow-up of pregnant women who carry Rh+ fetus with the detection of RhD genotype of 
fetus in maternal plasma at the first trimester of pregnancy. RHD was used as a test-bed to 
prove the effectiveness of detecting a paternally inherited allele carried bty circulating free 
fetal DNA in maternal plasma (Lo et al., 1997). Maternal plasma-based RHD genotyping has 
been succesfully implemented in our laboratories for use as a non-invasive prenatal 
diagnosis where alloimmunization has occured (Gunel et al., 2010). Real-time PCR has been 
the choice diagnostic test used. Fetal RhD detection can be applied routinely to Rh (-) 
women and the use of human anti –D can be significantly reduced (Hahn et al., 2008). A 
reduction in anti-D administration also has economic implications. Rh locus is composed of 
two homologous genes RHD and RHCE (97% homology) closely linked on chromosome 
1p34-p36. Each of these genes consists of 10 exones, and they contain 69 kb of DNA. The 
regions of exone 7 and exone 10 within the RhD gene are the areas of focus. In all positive 
results, the RhD blood group has also been found positive (Huang, 1998, Wagner and Flegel, 
2000). In a white population, D-negative individuals are homozygous for a deletion of RHD. 
The D-negative phenotype, absence of the whole RhD protein from red cell membrane. 
Different mechanisms may explain rare phenotypes, including gene conversion events 
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between homologous RHD and RHCE producing hybrid genes, nonsense mutations, and 
deletions or insertions interrupting the reading frame of the messenger RNA (Rouillac-Le 
Sciellour et al., 2004. Gunel et al., 2011).  
3.2 Fetal sexing 
Researchers had focused on the detection of fetal-derived paternally inherited DNA because 
Y chromosome of male fetus, which were absent in the genome of the pregnant women (Lo 
YMD, 2010). Most sex-linked disease are recessive X-linked disesae such as haemophilia and 
and Duchenne muscular dystrophy. To determine the sex of a fetus by real-time PCR using 
DYS14 and SRY genes on  and Y chromosome. The genotyping of these fetal loci helps 
preventing invasive procedures in the case of X-linked disorders (Rijinders et al., 2004). 
CffDNA technology has been used to identify babies at risk of congenital adrenal 
hyperplasia by identifying fetal sex at the requisite stage in pregnancy in 6-7 weeks 
(Rijinders et al., 2001). 
3.3 Determination of fetal aneuploidy by real-time PCR  
The free fetal DNA particles in maternal blood are promising as an important step for 
diagnosis of numerical and structural chromosome anomalies belonging to fetus without 
invasive procedures. The direct analysis of cff DNA for the NIPD of trisomies is mainly 
complicated. The most common chromosomal abnormalities in live births is trisomi 21 and 
other chromosomes 13, 18 trisomies has rapidly analysis with real-time PCR methods. The 
full fetal karyotype is usually determined using cultured cells and need two weeks for 
result. Real-time PCR has rapidly determination of template copy numbers. Tong et. al. had 
first demonstration of the direct detection of trisomi 18 from maternal serum (Tong et al., 
2006). They were achived with use of the epigenetic allelic ratio method. Enrich et.al., had 
used sequence-specific taq of known chromosomal location as a quantitative representation 
of individual chromosomes in maternal plasma. Trisomi 21 detection by massively parallel 
shotgun sequencing (MPSS) in high risk women is complicated. Their overall classification 
showed 100% sensitivity and 99.7% specificity of detection of fetal trisomi 21 (2011). Lo et 
al., described a novel method for the NIPD of Down syndrome. Candidate mRNA markers 
shoul be encoded from genes located on chromosome 21. The PLAC4 gene on chromosome 
21 and originating from fetal cells in the placenta and cleared following delivery of the fetus 
(Lo et al., 2007). If the fetus is euploid, that is containing two copies of the PLAC4 gene, 
because SNP (single nucleotide polymorphism) alleles would be 2:1. (Lo, 2009). The first 
large-scale noninvasive prenatal detection of trisomi 21 using multiplex sequencing to 
analyze fetal DNA from maternal plasma by Chiue et. al., (2011). They show that   100% 
sensitivity and 97.9% specificity of detection of fetal trisomi 21. They report a % 2.1 false-
positive rate. This method replace invasive procedures and would be eliminated unintended 
procedures fetal losses as well as better targeting of pregnancy-related interventions.  
3.4 Pre-eclampsia and cell free fetal nucleic acids 
Preeclampsia is a potentially dangerous disorder specific to the second half of pregnancy, 
affecting about 2.5–3% of women (Redman & Sargent, 2005). The etiology of this disease 
involves the placenta. Real-time PCR, it is now possible to measure DNA/RNA content 
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accuracy. The increased presence of cell-free fetal DNA indicates that preeclampsia is 
associated with damage to the placenta (Zhong et al., 2001) The cell-free fetal DNA levels in 
maternal blood in preeclamptic patients are significantly higher than those of normal 
pregnancies, and this elevation precedes the clinical occurrence of preeclampsia by 
approximately 1-2 weeks. The results of the studies in this area are important for pregnancy 
follow-up. The change of free fetal DNA levels in maternal blood in healthy pregnancies 
according to gestation week, was shown in various publications (Zhong et al.,2001, Ferina et 
al.,2004, Carty et al., 2008). By using real-time PCR technology was shown to be elevated ~ 
5-fold in samples obtained from pregnant women with preeclampsia when compared with 
an eual-sized cohort of normotensive, pregnant women ( Lo et al., 1999) All study subjects 
were pregnant women carrying male fetuses, and investigators amplified sequences from 
the SRY gene distinguish fetal from maternal DNA (Levine et al., 2004).  
4. Summary 
The discovery of cell-free fetal DNA (cffDNA) in maternal blood has exciting possibilities 
for non-invasive prenatal diagnosis (NIPD). Free fetal DNAs stemming from the destruction 
of fetal cells from seven weeks of gestation transport to the maternal blood via the bi-sidal 
flow through the placenta.The free fetal DNA particles in maternal blood are promising as 
an important step for diagnosis of numerical and structural chromosome anomalies 
belonging to fetus without invasive procedures. The detection and quantification of gene 
rearrangement, amplification, translocation or deletion is a significant problem, both in 
research and in a clinical diagnostic setting. Real-time PCR has become a well-established 
procedure for quantifying levels of gene expression. There are a number non-invasive 
prenatal diagnosis methods such as sex diagnosis or Rh blood type incompatibility and 
single-gene disorders have been reported. Different problems associated with placental 
growth and development result in changed levels of cffDNA. The cell-free fetal DNA levels 
in maternal blood in preeclamptic patients are significantly higher than those of normal 
pregnancies. It is possible the diagnostic utility of adding cffDNA concentration to the 
current panel of biomarkers. The test can be used very early of pregnancy, with no risk to 
the mother and child. 
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1. Introduction 
China is situated in the south-eastern part of the Eurasian continent and has a total land area 
of 9.6 million square kilometers. It is composed of 23 provinces, five autonomous regions 
(Inner Mongolia, Ningxia Hui, Guangxi Zhuang, Xinjiang Weiwuer, and Tibet), four 
municipalities directly under the central authorities (Beijing, Shanghai, Tianjin and 
Chongqing), and two Special Administrative Region(SAR)(Hong Kong and Macao). China is 
a unified, multinational country (56 nationalities), with a population of about 1.37billion, of 
which 1.34 billion live in mainland. According to a survey carried out in 1987, the birth 
defects were of 4% in China. It is a big burden for the population. The government has paid 
attention to this situation. In order to improve the public health, China government passed 
the “Maternal and Child Health Law” in 1994.  
Prenatal diagnosis for severe birth defects was implemented in China step by steps. 
2. The outlines of the development of prenatal diagnosis in China 
2.1 Prenatal diagnosis of central neural tube defects 
The earliest cases of prenatal diagnosis for central neural tube defects (NTD) were 
performed with measuring the level of alpa-fetal protein in maternal serum in 1976. This 
work was awarded by the MOH of China and WHO. Ultrasoundnography was used to 
diagnose NTD routinely after 1980’. 
2.2 Karyotyping 
Fetal chromosome karyotyping was performed in 1970’ on cultured amnion fluid cells to 
detect chromosomal diseases[1,2]. It became the major technique used for prenatal diagnosis 
in China in 1980’. The scale was once declined in the 1990’. After the prenatal diagnosis 
spreed in China, cytogenetics is the main field for prevention of hereditary diseases.  
2.3 Fetoscopy  
Usage of fetoscopy was reported in the late of 1980’. It was used for biopsy of the fetal 
material and for fetal therapy[3,4].  
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2.4 Maternal serum screening  
Maternal serum screening for chromosomal abnormalities and other abnormalities, such as 
NTD, started in the early of 1990’[5]. This procedure was adopted nationwide in the 21 
century. A standard operation protocol was formulated in 2010 by the National Committee 
of Exports on Prenatal Diagnosis.  
2.5 Biochemical genetics 
Electrophoresis analysis was perform on amnion fluid as the first technique in prenatal 
diagnosis of metabolic disease[6,7]. After the enzyme assay methods were established, 
prenatal diagnosis of lysosomal diseases was carried out by enzyme assay[8]. More than 20 
protocols were developed for diagnosis of lysosomal storage diseases.  
2.6 Techniques developed for sampling fetus material 
2.6.1 Amniocentesis  
Amniocentesis was the first procedure for fetal cell sampling. It was performed as early as in 
1970 in China. It became the major procedure in collection fetal material nationwide now. 
2.6.2 Chorionic villus sampling (CVS)  
At the early stage, chorionic villus sampling via the cervix under was invented by a Chinese 
obstetrician[9]. Transcervical chorionic villus sampling(TC-CVS) was reintroduced into 
China in the early of 1980’ and got popular afterward. It was performed blindly at the very 
beginning, e.g. without the guidance of ultrasonography as does later, for prenatal diagnosis 
at early pregnancy(first trimester)[10]. It was further improved. Transabdominal chorionic 
vilus sampling(TA-CVS) was established in 1994[11]. 
2.6.3 Fetal blood sampling 
Fetal blood sampling via abdominal cordocentesis was performed in the late 1980’ for cell 
culture or hemoglobin analysis[12]. It is used rather routinely in the area where there is a 
high prevalence of hemoglobinopathies, since the blood component can be analyzed with 
the fetal blood.  
2.7 Gene diagnosis 
The first prenatal gene diagnosis was performed in the early of 1980’ on thalassemia[30]. 
Then prenatal diagnosis was performed on more and more monogenic diseases, when the 
gene mutations had been characterized for the disease, such as DMD, PKU, and hemophilia 
A (see details in section 3). 
2.8 Regulations on prenatal diagnosis 
As the prenatal diagnosis was offered nationwide, there were more and more problems 
emerged. It was necessary to make a regulation on the practices of prenatal diagnosis. In the 
second national conference of prenatal diagnosis 2000, this issue was discussed and a 
proposal on the regulation for prenatal diagnosis was sent to the Ministry of Public Health 
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after the meeting. A special group was organized to investigate the demands on prenatal 
diagnosis and the diseases needed to be put on the list for prenatal diagnosis. In the third 
national conference of prenatal diagnosis 2001, the draft of the regulation was discussed. 
After revising, “the regulations on prenatal diagnosis and diagnosis of genetic diseases” was 
distributed nationwide for further discussion and for modification. After one year debating, 
“The Regulation on Management of Techniques for Prenatal Diagnosis” was published on 
Dec. 22, 2002 and was implemented after May 1, 2003 [http://www.china.com.cn/policy/ 
txt/2003-02/14/content_5276708.htm]. A National Committee of Exports on Prenatal 
Diagnosis was established in 2004 to assist the work of the Division of Women’s Health and 
Community Health Care, MOH in prenatal diagnosis. 
2.9 The current situation of the organizations for prenatal diagnosis 
The techniques applied in the practices of prenatal diagnosis are cytogenetics, maternal 
serum screening, and ultrasounography. The prenatal diagnosis centers were assigned by 
the authorities in charge of public health of the local government. Up to year 2009, there 
were 511 centers carrying out maternal serum screening for chromosomal diseases and 
neural tube defects; 169 centers performing karyotyping for pregnancy at high risk or with a 
positive result of serum screening, and ultrasoundography for malformations.  
A total of 93905 prenatal diagnoses were carried out for chromosomal diseases and 
monogenic diseases in 2009. Fetal sampling was mainly carried out via amniocentesis (80%), 
only a small section was by CVS (1.8%). 
There were only 76 centers offering gene diagnosis, of which the most were located in the 
developed areas, such as Beijing , Shanghai, Hunan, Henan, Guangdong, and Guangxi.  
Nineteen diseases were carried out in some of the prenatal diagnosis centers, most of which 
were α-thalssemia, β-thalassemia, DMD, PKU, SMA, achondroplasia, APKD, and hereditary 
non-syndromic deafness. 
3. Prenatal gene diagnosis, the strategies and experiences in several 
common diseases 
3.1 Thalassemias 
Thalassemia is one of the most common monogenic disorders in the world. The incidence 
for this disease is high in tropical and subtropical areas including southern China. 
In China, the carrier rate of α-thalassemia was 17.55% in Guangxi, 8.53% in Guangdong and 
1% to 4.2% in other province of southern China[13,14]. The frequencies of α-thalassemic 
allele in Li Monority was 0.347. Fortunately, most of the thalassemic alleles were α-thal-2 (-
α3.7/ or -α4.2/) , only 0.0058 for α-thal-1 allele (--SEA/)[15]. The estimated incidence of carriers 
of β-thalassemia is as high as 6.43% in Guangxi, and 1% to 2.54% in populations in the 
endemic areas of southern China[13,16]. 
3.1.1 Mutation characterization 
Researches on thalassemias started in the early of 1980’s in China.  
The organization of the α globin was analyzed with Southern blotting. Data collected in 
Guangxi showed the defects of α globin genes in α-thalassemia patients were mostly 
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deletion types, --SEA/,-α3. 7/, and -α4. 2/.[17] Three primers bridging the deletion breakpoints 
were designed to detect these three deletion mutations [18]. Abnormal hemoglobins of the α 
globin gene, HbαCS and HbαQS, were characterized as thalassemic mutation. After 
sequencing the non-deletion α thalassemic mutant HBA, 12 mutations were revealed 
responsible for α-thalassemia[http://globin.cse.psu.edu ]. Reverse dot blotting with ASO 
probes (RDB) for αCD30(-GAG), αCD31(G>A), αCD59(G>A), αWestmead (CD22, C>G), αQS(CD125, 
T>C) and αCS (CD142, T>C) were developed in detection of the non-deletion α-thalassemia 
alleles. [19]  
The mutations causing β-thalassemia were exclusively point mutations[20]. It used to be 
the strategy to use the RFLP haplotype to predict mutations since there was linkage 
disequilibrium between the haplotypes and certain mutations [21]. The -29 A>G mutation 
was revealed as it was associated with a new haplotype. The mutations were identified 
via cloning and sequencing, the routine procedure for identifying mutations at that time. 
It was the first mutation of β-thalassemia characterized by the scientist from mainland 
China on patients collected in Guangzhou, Guagndong Province[22]. In the 1990’, most of 
the mutations were characterized with direct sequencing the PCR products. Five 
mutations, CD41-42 (-CTTT), IVS2-654 (C>T), –28 (A>G), CD26 (G>A) and CD17 (A>T), 
account for 90% of the common mutations in south China. New mutation was revealed 
with the RDB and characterized by direct sequencing. To date, 46 single-nucleotide 
mutations and small deletions in HBB have been characterized in the Chinese patients 
with β-thalassemia [http://globin.cse.psu.edu]. The recently developed technique is the 
probe-based melting curve analysis (MeltPro HBB assay). It is a qualitative in vitro 
diagnostic method designed to genotype a panel of 24 single-nuclueotide mutations and 
small indels in the HBB gene that cause β-thalassemia or abnormal hemoglobin. The test 
kit is based on a proprietary, multicolored, self-quenched, probe-based melting curve 
analysis performed with a standard real-time PCR instrument, from which genotype 
information for each mutation is retrieved based on the melting temperature (Tm) or 
difference in Tm between wild-type and mutant DNA samples[16].  
3.1.2 The strategy in thalassemia prevention 
In the report on the middle term evaluation on the progress of the National Project on 
thalassemia during the Seventh Five-Year Developing Plan in 1988, Shangzhi Huang had 
made a proposal on performing a population prevention program on thalassemia by 
hematological screening, mutation detection, and prenatal gene diagnosis in certain areas. 
The trail of population screening carriers with thalassemias was carried out on the Li 
Minority in Hainan in 1990. It showed that it was feasible to screening thalassemias with 
hematological parameters [23]. In the Li Minority in Hainan the carrier rate of β-thalassemia 
was 8.6%, and the mutation c.124-127delTTCT accounted for 94.7% of the mutant alleles in 
this population [24]. In 1991, carrier screening for thalassemias was carried out for people in 
marriage registration in Fushan City, Guangdong Province [25]. In 1993, Xiangmin Xu et al. 
started the hospital-based screening program for pregnant women during their first prenatal 
checking up in Guangdong and Guangxi [26].  
In hematological screening, quantitative test of hemoglobin, erythrocyte osmotic fragility, 
mean corpuscular volume (MCV), and hemoglobin electrophoresis were performed. When 
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erythrocyte osmotic fragility <60%, MCH<27pg, and MCV <80 fl, hemoglobin 
electrophoresis was carried out on the positive subjects. When HbA2≥3.5% or HbA2 normal 
but HbF >3%, β-thalassemia was suspected, while if HbA2<3.5%, α-thalassemia would 
considered. Iron deficiency anemia should be ruled out with serum iron test. The DNA were 
isolated later and Gap-PCR[27] and RDB[28] methods were used for α-thalassemia 
genotyping. β-thalassemia genotyping were carried out using RDB analysis for 18 common 
types of point mutation[29]. In the RDB procedure two-step hybridization was designed: the 
first dot strip contained ASO probes specific for seven common mutations, e.g., -28A>G, 
CD17A>T, CD26G>A, IVS1 nt5G>C, CD41/42 del CTTT, CD71/72 +A, IVS2 nt654C>T, and 
IVS2 nt652C>T; the second dot strip contained 11 less common but not rare mutations in 
Chinese, e.g.,-32C>A. -30T>C, -29A>G, +40_43 del AAAC, initial CD ATG>ACG, 
CD14/15+G, CD27/28+C, IVS1 nt1G>T, CD31-C, CD43G>T, and CD71/72+T [29]. DNA 
sequencing was also performed if there was an unknown allele of no-deletion α mutation 
remained. Four common types of α-thalassemia mutations, -α3. 7/, -α4. 2/, --SEA/, and αCSα/ 
alleles, were tested for all the subjects with β-thalassemia trait to reveal possible situation of 
β/α-thalassemia double heterozygote [26]. If the woman was identified as a heterzygote of 
thalassemia, her spouse would be tested for the same type thalassemia. If the couple were 
both heterozygous for the same type of thalassemias, either β- or α-thalassemia, prenatal 
diagnosis will be suggested to the couple. 
3.1.3 Prenatal diagnosis 
Thalassemia is a severe disease, and its treatment requires life-long transfusion and iron 
chelating. While many cities in China have facilities for diagnosis and treatment of this 
disease, free medical services are not provided by the government in most rural areas. 
Treatment is available to only a potion of patients who can afford it, although this situation 
is more favorable in some regions with better economical development. So, there is still a 
demand for prenatal diagnosis of thalassemia. 
Prenatal gene diagnosis on α-thalassemia was carried out in the early stage by Southern 
blotting [30] or with a simple but not accurate method, dot blot hybridization with α globin 
probe[31]. When polymerase chain reaction (PCR) was established, gap-PCR became a 
major approach in prenatal diagnosis of α-thalassemia to detect the deletion mutation on 
fetus [32], or RDB was used to detect the point mutation of α-thalassemia [28].  
Haplotypes of the RFLP sites on the β-globin cluster were used for linkage analysis in the 
early stage for diagnosis of β-thalassemia. Prenatal diagnosis was mainly performed with 
ASO probes routinely now, also there were several modifications being made, such as 
labeled with non-radioactive material, RDB, primer extension, and probe-based melting 
curve analysis (MeltPro HBB assay) [16].  
The first prenatal diagnosis of β-thalassemia was carried out in 1985 with RFLP linkage 
analysis[33,34]. It was PCR technique that overcame the obstacle of the limited amount 
DNA from fetus available for RFLP analysis. Using PCR technique combined with the 
radioactive labeled allele specific oligonucleotide (ASO) probes, prenatal gene diagnosis for 
β-thalassemia become much easier, not only for less DNA was used but also for its simple 
and quick performance [35] . The non-radioactive labeling ASO probes and RDB made the 
prenatal diagnosis procedure even easier. This new techniques has been the routine 
approach for prenatal diagnosis of β thalassemia in China[36].  
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There were other techniques used in China for prenatal diagnosis, such as allele specific 
PCR(AS-PCR)[37], multiplex AS-PCR[38]. Another approach is RFLP analysis by 
introducing an artificial base substitution to create restriction sites. PCR products were cut 
by certain restrictive enzyme and then visualized the fragments after electrophoresis in 
agarose gel [39].  
3.2 Duchenne muscular dystrophy (DMD) 
3.2.1 Clinical aspect 
Duchenne and Becker muscular dystrophy (DMD/BMD) (MIM#300377 and 300376) are 
allelic disorders, caused by mutations in the DMD gene coding for dystrophin, which 
locates on Xp21. The term "pseudohypertrophic muscular dystrophy" was used in the past; 
however, it is not used currently because pseudohypertrophy is not unique to the DMD or 
BMD phenotype. DMD is the severe form and usually presents in early childhood with 
develop delayed, including delays in sitting and standing independently. Progressive 
symmetrical muscular weakness, proximal severer than distal, before age 5 years, with a 
waddling gait and difficulty climbing, often with calf hypertrophy. Serum creatine 
phosphokinase (CK) concentration elevated, generally 10 times the normal range. 
Electromyography (EMG) is useful in distinguishing a myopathic disease from a neurogenic 
disorder. The characteristics were demonstrating short-duration, low-amplitude, 
polyphasic, rapidly recruited motor unit potentials. Muscle histology early in the disease 
shows nonspecific dystrophic changes, including variation in fiber size, foci of necrosis and 
regeneration, hyalinization, and, later in the disease, deposition of fat and connective tissue. 
Immunohistochemistry with antibody against dystrophin showed no signal of the 
dystrophin. Western blot can be used to distinguish DMD from other muscular dystrophies, 
such as Limb-girdle muscular dystrophy (LGMD), which are clinically similar to DMD but 
were autosomal recessive or autosomal dominant inheritance. LGMDs are caused by 
mutations in genes that encode sarcoglycans and other proteins associated with the muscle 
cell membrane that interact with dystrophin [40]. Testing for deficiency of proteins from the 
transmembrane sarcoglycans complex is indicated in individuals with dystrophin-positive 
dystrophies. 
The affected children will loss their walking ability by age 12 years old. Few patients survive 
beyond the third decade, with respiratory complications and cardiomyopathy, which are the 
common causes of death. BMD is the mild form characterized by later-onset skeletal muscle 
weakness. Individuals with BMD remain ambulatory into their 20s and the lifespan is 
longer. Female carriers have clinical features of DMD were resulted in the situations either 
of X-Auto-chromosome crossing over involving DMD locus, or because of Turner syndrome 
or non-random X-chromosome inactivation (XCI), so called “unfortunate Lyonization”. 
3.2.2 Mutation analysis 
The size of DMD gene is over 2.3 Mb, and composes 79 exons. It is the largest known human 
gene. The cDNA is 14kb. Large fragment deletion or duplication were the most common 
mutations of DMD, 60% for deletion and 6% for duplication with some were indel type, e.g., 
deletion with addition of several base pairs at the same site. There were cases with two 
deletions or deletion plus duplication scattered in the same allele[41-43]. There are two 
 
The Experiences of Prenatal Diagnosis in China 
 
177 
hotspots of deletion/duplication, one located on the 5’ portion, harboring exons 2 to 20, the 
other in the 3’ portion involving exons 44 to 53. The remaining mutations were small 
deletion, insertion, point mutations and splicing mutations. 
There were several methods for deletion/duplication analysis. In the early stage, Southern 
blotting was used with either genomic probes or cDNA probes, both deletion and 
duplication mutations were detectable[44]. With multiplex PCR approximately 98% of 
deletions are detectable[45,46]. Multiplex ligation-dependent probes assay (MLPA) has been 
employed for deletion/duplication analysis of the DMD gene in probands and for carrier 
detection in recent years[42,43]. 
Array chips for deletion or duplication mutations were also developed, it had the same 
power in detection of large deletion/duplication as MLPA, but the strength on detection of 
alterations with small size is under evaluation[47].  
Mutation scanning with denaturing high performance liquid chromatography (DHPLC) or 
high resolution melting assay (HRM) followed by direct sequence analysis was performed, 
but the efficiency is low [48]. It might be a good choice to perform RT-PCR and then 
sequencing. It would much easier to detect the size changes of the mRNA just by agarose gel 
electrophoresis, which were caused by large deletion/duplication or splicing abnormalities. 
If there is no or reduced RT-PCR products, mutations occurred on the regulatory elements 
would be suspected and sequence analysis would be performed then using genomic DNA 
to detect the sequence change. It also facilitates detection of the point mutations since the 
size of cDNA is much shorter than the genomic DNA.  
A “one-step approach” was developed with multiplex PCR using 9 primer pairs to detect 
deletions and to perform linkage analysis simultaneously[49]. The primers amplified 3 
exons, exon 8, 17 and 19, in the 5’ hotsport[50], and 6 short tandem repeats, 5’CA at the brain 
specific promoter region [51]and MP1P[52] at 3’UTR, and STR markers in introns 44, 45, 49 
and 50[53]. The primers were grouped into three triplex PCR, Group A: 5’CA, MP1P and 
exon 8; Group B: exon 17, i44 and i49; Group C: exon 19, i45 and i50. The amplified 
fragments in the group can also serve as the internal control, since deletion is rarely spread 
all the gene, although one deletion gene had been detected, of which only one fragment was 
amplified with the primers for 5’CA site [Huang S, unpublished data]. The primers at both 
ends of the gene, 5’CA and MP1P, were used to detect the possible  recombination.  
3.2.3 Carrier - Testing 
DMD is an X-linked recessive disease. Female carriers were at the risk to give birth to an 
affected male infant. Performing carrier testing offered a favorable opportunity for the 
carrier to get prenatal diagnosis at the first pregnancy. For deletion/duplication mutations, 
dosage analysis can be performed with either real-time PCR or MLPA[42,43], no mater it 
was a familial case or sporadic case, even the proband deceased. For point mutation, it can 
be carried out by direct sequencing. 
For familial cases, linkage analysis can be performed[54], no mater what kind the mutation 
was. It would be offered with caution for the sporadic cases, especially the diagnosis of 
DMD was not confirmed. The markers used for linkage analysis should be highly 
polymorphic and informative, and lie both within and flanking the DMD locus[51-53].  
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The large size of the DMD gene leads to an appreciable risk of recombination. It has been 
estimated that the genetic distance was 12 centimorgans between the two ends of the 
gene[55]. Multiple recombination events may occur during meiosis and may not be detected 
when the marker was homozygous; thus, it might be aware in interpretation of the data 
generated from a linkage study.  
Males with DMD usually die before reproductive age or are too debilitated to reproduce. It 
would be convincible that there was a plenty of de novo mutations responsible for the 
sporadic cases. For sporadic cases, the proband may be resulted from: 1) the mutation 
occurred after conception and is thus present in some but not all cells of the proband's body 
(somatic mosaicism), the proband’s mother is not a carrier and the recurrence risk was very 
low; 2) germline mutation, passed from the mother. The later situation was completed, since 
the mutation could be one of the followings: a) a de novo mutation occurred in the egg, a 
meiosis mistake and the mother was normal; b) the mutation is resulted in mitosis in the 
ovary and partial of the cells carry the mutation, termed “germline mosaicism” or “gonad 
mosaicism”, the recurrence risk depends on the proportion of the mutant cell line; c) somatic 
mosaicism, the mutation presented in some but not all of the mother’s body including the 
ovary, the recurrence risk is high, up to 50%; d) a germline mutation, passed from one of 
grand-parents, or passed from ancestor on the grandmother side, the mother is the carrier. 
Put all these considerations together, carrier testing on the mother may be not informative, 
since the mutation could only be detectable in the last two situations. Since it is hard to tell 
at which level the mutations occurred, to provide carrier testing on the proband’s mother in 
the sporadic case is controversial. There might be a misleading for the family, since the 
negative result of the testing may be misunderstood even misinterpreted as the mother was 
not a carrier at all, and the prenatal diagnosis was not necessary. It would be dangerous. For 
these reasons, prenatal diagnosis must be suggested to all cases especially the mutation has 
been identified; just in case the mother had the mutant cell line. The carrier status of the 
patient’s sister can be performed if there was a detectable mutation in the proband. It should 
be aware that if the germline mutation is of the grandfather’s origin, the maternal aunts 
would be at risk for a carrier, since there was a possibility that the grandfather is of germline 
mosaicism. The origin of the mutation can be revealed with linkage analysis[54,56]. This 
information is important in genetic counseling for determining which branches of the family 
are at risk for the disease. The carrier detection can be performed with either mutation 
detection if the proband’s mutation was identified, or with linkage analysis. There is an 
ethics issue for carrier detection: the optimal time for determination of genetic risk, 
clarification of carrier status, and discussion of availability of prenatal testing, is before the 
person’s pregnancy. It is appropriate to offer genetic counseling to young adults female 
relatives who are at risk of being carriers[56]. 
3.2.4 Prenatal diagnosis 
In preventing birth of DMD fetus, prenatal test was carried out by sex selection in the early 
era, e.g., if the fetus was 46,XY, abortion would be induced. 
The first case of prenatal diagnosis was performed in 1987 in China, via pathology analysis 
of the fetus muscle biopsy taken at 20 week gestation[57]. CK measurement on amnion fluid 
was used for prenatal diagnosis of DMD before gene analysis was available[58]. This 
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approach is still used as the complementary or “rescue” procedure in prenatal diagnosis, 
when gene analysis is uninformative or linkage analysis has revealed that the fetus inherited 
the same haplotype as the proband in sporadic case. 
Prenatal diagnosis for at-risk pregnancies requires prior identification of the disease-causing 
mutation in the family. It can be offered with 50% exclusive detection if the small mutation 
detection can not be carried out. The fetal material is obtained either by chorionic villus 
sampling (CVS) at approximately ten to 12 weeks' gestation or by amniocentesis usually 
performed at approximately 15-18 weeks' gestation.  
The usual procedure in prenatal diagnosis is to determine fetal sex by PCR amplification of 
the male specific fragment, such as the ZFY gene. If the fetus is male, DNA from the fetus 
will be analyzed for the known causal mutation or tracking linkage established previously. 
If the fetus is a female, test will be stopped at this point, unless the mutation of the proband 
was identified. In this circumstance the carrier status of the female fetus might be tested. 
Prenatal testing is possible for the first pregnancy of woman in the family whose carrier 
status has been recognized by mutation detection or linkage analysis.  
The first gene diagnosis on DMD was carried out with restriction fragment length 
polymorphism (RFLP)[59]. With PCR method available, it is much easier to perform 
prenatal diagnosis for deletion cases using multiplex PCR[60,61], or with linkage analysis 
using STR markers[56,62,63], and recently MLPA method was used[56, 64].  
In our center, prenatal gene diagnosis on DMD was performed mainly with “one-step 
approach”, a linkage analysis protocol[49]. In reviewing the data of the cases analyzed with 
one-step approach since 1995, it was informative in almost all the families. After MLPA 
analysis on the remaining“non-deletion” cases screened by “one-step approach” , it revealed 
that 80% of the deletions were detected with linkage analysis [43,47]. For prenatal diagnosis, it 
was required that differentiation diagnosis and gene analysis should be performed prior to 
prenatal diagnosis with one-step approach. Since this approach can detect deletion and 
establish linkage phase simultaneously. Prenatal diagnosis was performed with the 
information collected from the pre-analysis. If it was uninformative with the linkage analysis, 
or the male fetus shared the same haplotype with the proband, or there was a chromosome 
recombination observed, MLPA analysis would be performed as a rescue procedure to see 
whether there was a deletion/duplication existed for the proband or not[56]. 
As for all X-linked genetic diseases, it should be aware that contamination with maternal DNA 
is a critical risk causing error in prenatal diagnosis. It should be incorporated the personal 
identification procedure in prenatal diagnosis. It was carried out with a set of multiplex PCR of 
unrelated markers, such as the STR markers on chromosome 21(please refer to the section of 
quality control, QC). We had the experiences that the material of CVS was from the mother 
and the amniocentesis cell grown up in the cell culture was of maternal origin. Fortunately, all 
these contamination events were revealed with the QC procedure. 
3.3 Phenylketonuria (PKU) 
3.3.1 Heterogeneity and prevalence of HPA 
Phenylketonuria (PKU) (MIM 261600), an autosomal recessive inherited metabolic disease, 
is caused by phenylalanine hydroxylase (PAH) deficiency. It was called classical PKU in 
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China before, for distinguishing it from BH4 deficiency, which was called un-classic PKU or 
malignant PKU. In China the newborn screening data showed that the incidence of 
hyperphenylalaninemia (HPA) is around 1 in 11000[65], with the highest prevalence of 1 in 
1666 in Gansu province[66]. Differentiated diagnosis was made by HPLC pterin analysis of 
the urine, measurement of RBC DHPR activity, and BH4 loading test. Classic PKU is 
diagnosed in individuals with plasma phenylalanine (Phe) concentrations higher than 1000 
μmol/L in the untreated state. PKU accounts for 80% to 94% of HPA cases in Chinese, with 
the remaining as BH4 deficiency[67]. Patients with PKU are intolerance to the dietary intake 
of phenylalanine, one of the essential amino acids. Without dietary restriction of 
phenylalanine in the early life, most children with PKU will develop irreversible profound 
intellectual disability. Newborn screening has been launched in the early of 1980’s in China 
[68]and free dietary treatment for the patients detected through the newborn screening 
program started in the early of 21 century, although the coverage of the newborn screening 
program varied from 100% in the developed area to 20% in developing areas, and no 
screening program at all in the remote areas, such as Tibetan and Qinghai province. 
3.3.2 Mutation spectrum of PAH in China 
PAH gene, located on 12q23.2, contains 13 exons and spans 90 kb, coding for a 2.4-kb mature 
mRNA. Mutation detection of the PAH gene in the PKU patients started in the late of 1987 
on Chinese patients[69]. More than 100 different mutations have been identified up to date 
in Chinese PKU patients, accounting for 94.3% of the mutant alleles [70,71]. Mutations 
observed in the PAH gene include missense, splice site, and nonsense mutations, small 
deletions, and insertions. Eight mutations, c.728G>A(p.R243Q), IVS4-1G>A(rs62514907), 
c.611A>G (p.Y204C), c.1238G>C(p.R413P), c.331C>T(p.R111X), c.1068C>A(p.Y356X), and 
c.1197A>T(pV399V), accounting for 66.2% of the mutant alleles, with the proportions of 
18.8%, 10%, 10%, 9.4%, 7%, 6%, and 5% of mutant alleles respectively [71].  
When a panel of samples was collected in a certain area, mutation scanning was carried out 
with either ASO hybridization, denaturing high-performance liquid chromatography, or 
multiple AS-PCR. In the clinical service, we use a two-step procedure to detect the 
mutations of the PAH gene. In the first step, six exons, exon 3, 5, 6, 7, 11 and 12, and their 
flanking intronic sequences were amplified by PCR and then sequenced. In a panel of the 
patients, mutations were identified in 83% of the mutant alleles in the first step. If there was 
unknown allele remained in an individual, the second step of mutation scanning was 
carried out by sequencing the other seven exons. The total detection rate was 92.3%[71].  
3.3.3 The strategy of prenatal diagnosis of PKU 
Although there has been a good newborn screening program in China for decades and 
efficient early dietary treatment was available in the country[72], there is still a demand for 
prenatal diagnosis on the second pregnancy in the family. Prenatal diagnosis of PKU may be 
controversial if the testing is for the termination of the affected fetus. But it is the alternative 
choice of the families. The reasons for the parents seeking for prenatal diagnosis are: the 
first, the cost of the dietary treatment is high, beyond the economic capacity for the families 
with an average income, although there is a free treatment in some province, and the second 
is that in the families the parents had the bit experience already in managing the first child 
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and would not want to risk the further baby bearing with the condition. It was not 
convenience in bring up the affected child and it is hard for them to make the child adhered 
to the dietary. 
The first prenatal diagnosis on PKU was performed with RFLP linkage analysis in 
1987[73]. There were other centers offering prenatal diagnosis, of which the centers at 
Peking Union Medical College[74,75] and Shanghai Xinhua Children’s Hospital[76] 
played the main roles now.  
In the beginning, linkage analysis with RFLP was tried. But unfortunately it was not as 
informative with RFLP markers as in the Caucasians, since 80% of the chromosomes were 
with haplotype 4 in Chinese [77]. Prenatal diagnosis got into service until mutation 
detection was carried out by PCR amplification and hybridized with ASO probes labeled 
with isotope [78]. The mutations of PAH gene could also be detected by methods of AS-
PCR[79], single strand conformation polymorphism(SSCP)[80], or RFLP[81] 
The limitation for all these procedures was that the two mutant alleles in the family must be 
characterized. But not in all of the cases the two mutant alleles could be identified, especially 
there was no time for detecting the mutations as the pregnant women came to clinic asking 
for prenatal diagnosis without any previous gene analysis. In addition, as more and more 
mutations being characterized in Chinese, it was hard and inconvenient for any diagnostic 
center to have all the probes ready for use. The quick procedure needed to be deveoped to 
perform prenatal diagnosis. The linkage analysis with short tandem repeats (STR), (ACAT)n 
in the intron 3 of PAH gene, emerged in 1992[82]. This marker was introduced into China in 
the same year [83]and a “quick approach” for prenatal diagnosis of PKU was proposed by 
combining this STR maker with a novel SNP (IVS3 nt-11A/C)in the PAH gene[84]. It was 
further expanded with additional STR markers incorporated. Three markers, PAH-STR, 
PAH-26 and PAH32, were used for haplotype analysis. They are highly informative and are 
both intragenic and flanking to the PAH locus. Linkage phase of mutant alleles and the 
haplotype of the markers could be established in almost all the cases[85]. For families in 
which only one PAH mutation was identified, or there is a urgent case for prenatal 
diagnosis, linkage analysis would be an option for prenatal diagnosis. But it should be kept 
in mind that the diagnosis of phenylketonuria should be confirmed (e.g. it is caused by 
mutation of phenylalanine hydroxylase gene). The shortage for using linkage strategy is that 
there is genetic heterogeneity of the HPA and not all the HPA were caused by mutation in 
PAH gene. If the differentiation diagnosis could not be made, there would be a miss 
management to treat all the cases as that caused by PAH mutation. Linkage studies are 
based on accurate clinical diagnosis of PAH deficiency in the affected family and accurate 
understanding of the genetic relationships in the family. Prenatal diagnosis should be 
applied with a caution and linkage analysis should be performed with combined with 
mutation detection. 
Different families have different story: the mutation details, the linkage phase for the STR 
markers. So, it was required for cases asking for prenatal diagnosis, that gene analysis 
should be carried out prior to being pregnant, e.g., the differentiation diagnosis, especially 
when linkage analysis was employed, and DNA typing, either mutation detection or STR 
typing. In cases that probands deceased, it was still possible to perform prenatal diagnosis 
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In the beginning, linkage analysis with RFLP was tried. But unfortunately it was not as 
informative with RFLP markers as in the Caucasians, since 80% of the chromosomes were 
with haplotype 4 in Chinese [77]. Prenatal diagnosis got into service until mutation 
detection was carried out by PCR amplification and hybridized with ASO probes labeled 
with isotope [78]. The mutations of PAH gene could also be detected by methods of AS-
PCR[79], single strand conformation polymorphism(SSCP)[80], or RFLP[81] 
The limitation for all these procedures was that the two mutant alleles in the family must be 
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if the Guthrie card bloodspot was available, which might be kept in the newborn 
screening center. If differentiation diagnosis had been confirmed on the patient before 
death, linkage analysis can be done utilizing the remained genetic material. It would be 
better if mutations can be characterized using the DNA isolated from the bloodspots. The 
mutations in the family could be also identified by sequencing the parents’ DNAs if the 
proband’s DNA was not available, although the procedure was rather complicated in 
confirming the causal mutation. 
3.4 Spinal muscular atrophy (SMA) 
3.4.1 Molecular genetics of SMA  
Spinal muscular atrophy (SMA) is characterized by progressive muscle weakness resulting 
from degeneration and loss of the anterior horn cells in the spinal cord and the brain stem 
nuclei. Onset ranges from before birth to adolescence or young adulthood. 
Electromyography (EMG) reveals denervation and diminished motor action potential 
amplitude. 
SMA was classified into clinical subtypes according to the onset age and maximum function 
achieved. Infants of SMA 0, with prenatal onset and severe joint contractures, facial diplegia, 
and respiratory failure, died soon after birth. Children with SMA I (Werdnig-Hoffmann 
disease) manifest weakness before age six months and never be able to sit independently. 
The life expectancy for SMA I patients is less than two years. For SMA II (Dubowitz 
disease), with onset between age six and 12 months, the life expectancy is not known with 
certainty, some live into adolescence or as late as the third or fourth decade. The individuals 
with SMA III (Kugelberg-Welander disease) clinically manifest their weakness after age 12 
months and are able to walk independently. SMA IV is the adult onset type.  
SMA is inherited in an autosomal recessive manner. Two genes were considered related to 
SMA, SMN1 (survival motor neuron 1) and SMN2, which locate on 5q12.2-q13.3 head to 
head with SMN1. SMN1 is the primary disease-causing gene. Most people have one copy of 
SMN1 on each chromosome, and there are about 4% of the chromosomes have two copies of 
SMN1. The number of SMN2 copies ranges from zero to five in normal individuals, while 
there is at least one copy of SMN2 remains in SMA patients. SMN1 and SMN2 differ by five 
single base-pair, locate in introns 6(g/a) and 7(a/g and a/g), and exons 7(C/T) and 8(G/A). 
The C/T SNP at position 6 of exon 7 is critical, since this change causes skipping of exon 7 in 
the mRNA of SMN2 resulted in loss the function of SMN2, while the difference in exon 8 is a 
SNP in the 3’UTR of the genes. 
About 95%-98% of individuals with SMA are homozygous deletion and about 2%-5% are 
compound heterozygotes for an SMN1 deletion and an intragenic SMN1 mutation. Some of 
the deletion of SMN1 is caused by conversion between SMN1 and SMN2, with the 3’ portion 
of SMN2, not actually a real deletion.  
3.4.2 Advantages in genetic testing  
Prenatal gene diagnosis was carried out in China mainly on homozygous deletion cases, 
typically determined by lack of exon 7 of SMN1. Since there is at least on copy of SMN2 
remains in the SMA patients, Methods developed for deletion detection attempting to avoid 
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amplification of the SMN2 gene. In the beginning diagnosis of homozygous deletion of 
SMN1 was carried out by SSCP analysis [86]. Since the pattern of the SSCP bands was rather 
complicated, a PCR-RFLP protocol was then adapted to replace SSCP procedure[87]. The 
difference at position 6 of exons 7 between SMN1 and SMN2 was considered for primer 
design. An artificial restriction site of Dra I (TTTAAA) was created by introducing a 
mismatched T in the primer. The exons 7 of both SMN genes were amplified and the PCR 
products were cut with Dra I. Since the products of SMN2 has the restriction site while 
SMN1 fragment doesn’t, there would be no band corresponding to SMN1 and only a smaller 
band for SMN2 remained in homozygous deletion patients. For the PCR-RFLP procedure, 
there is a shortage of uncompleted digestion of the SMN2 fragment, which would be 
misinterpreted as the present of normal SMN1 copy. It was dangerous when it occurred in 
prenatal diagnosis. Other methods were investigated to overcome this limitation, such as 
DHPLC and MLPA to detect the copy numbers of SMNs[88]. For the purpose for detection 
of homozygous deletion, a more simplified approach was developed. SMNl gene was 
amplified specifically with double allele-specific PCR(AS-PCR)( e. g. both primers for SMN1 
amplification were SMN1 specific, utilizing SNPs at exon 7 and intron 7), coupled with a 
pair of primers for an irrelevant gene as internal control[89]. The products were separated 
by agarose gel electrophoresis or PAGE to determine whether the patients were of 
homozygous deletion of SMN1 gene. Comparing to PCR-RFLP and DHPLC used in the 
past, this approach can diagnose homozygous deletion of SMN1 much more accurate, easier 
and more convenient without the interference of SMN2.This approach could be further 
modified by keeping the PCR cycles by 25 and quantitatively determining the density of the 
bands by densitometer, or using fluorescent labeling primer for quantitative PCR.  
3.4.3 The feasibility of prenatal diagnosis for first pregnancy at risk for SMA 
With all the progress, it is possible to perform prenatal diagnosis for the family in which the 
proband deceased, the same story as in PKU. Deletion detection could be performed by 
dosage analysis if there were tissue samples available from the proband, such as bloodspots 
from newborn screening. If there is no DNA available, SMN1 dosage analysis may be 
performed on both parents to see if they were both with only one copy of SMN1. It is much 
easier to confirm the carrier status for the parents with real-time PCR or MLPA. But there 
might be a blind corner when the patient was a compound heterozygote or one of the 
parents has two SMN1 copies on one chromosome when dosage analysis was performed. 
It is reasonable to offer prenatal diagnosis for these family as a 50% exclusive diagnosis, in 
hope that the deceased proband was really homozygous deletion no mater that one of 
his/her parents had two copies of SMN1on one chromosome or he/she was resulted in a 
de novo mutation of deletion. In case of intragenic mutation, the mutation might be 
revealed by sequencing the SMN1 gene of the parent with two copies of SMN1. It is also 
feasible to detect carrier of deletion mutation in the population using this approach, at 
least for the relatives of the patient and his/her spouse. It was proposed to carry out 
population screening with the double AS-PCR procedure, since the rate of the carrier with 
deletion type was as high as 1 in 50[89]. It will make the prenatal diagnosis possible on 
the first pregnancy for the couples both with a single copy of SMN1, as doing on 
thalassemias in Southern China.  
It may be further increase the chance of prenatal diagnosis for the patients of non-
homozygous deletion by screening the possible intragenic mutation by sequence SMN1 
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if the Guthrie card bloodspot was available, which might be kept in the newborn 
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amplification of the SMN2 gene. In the beginning diagnosis of homozygous deletion of 
SMN1 was carried out by SSCP analysis [86]. Since the pattern of the SSCP bands was rather 
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difference at position 6 of exons 7 between SMN1 and SMN2 was considered for primer 
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there is a shortage of uncompleted digestion of the SMN2 fragment, which would be 
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from newborn screening. If there is no DNA available, SMN1 dosage analysis may be 
performed on both parents to see if they were both with only one copy of SMN1. It is much 
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de novo mutation of deletion. In case of intragenic mutation, the mutation might be 
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least for the relatives of the patient and his/her spouse. It was proposed to carry out 
population screening with the double AS-PCR procedure, since the rate of the carrier with 
deletion type was as high as 1 in 50[89]. It will make the prenatal diagnosis possible on 
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It may be further increase the chance of prenatal diagnosis for the patients of non-
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gene of the patient. But it should be offered with caution since the heterozygote frequency of 
SMN1 deletion is as high as 1 in 50, the diagnosis of SMA must be confirmed. For 
sequencing the SMN1 gene, it can be achieved by a method that facilitates SMN1-specific 
amplification. Since there were more copies of SMN2 than SMN1 at DNA level, and only 
15% of the SMN2 mRNA was full length (fl-mRNA), it may be easier to reveal the mutation 
by cDNA sequencing approach. Sequencing the full length mRNA of SMNs will increase the 
signal of the mutant allele since the ratio of fl-mRNA of SMN2 to that of SMN1 was reduced 
at the mRNA level. It has additional strength with cDNA sequencing strategy. The 
mutations affecting mRNA processing would be revealed much easier, no mater how deep 
it was hided within the intron. It will be able to detect the mutation responsible for 
transcription regulation if quantitative analysis of SMN1 mRNA was performed. There is 
also an alternative approach for characterizing the intragenic mutation, e.g., by long-range 
PCR protocol and subcloning. 
3.4.4 Be ware of contamination 
Prenatal diagnosis of SMA was relied on deletion detection. If there was no amplification 
the fetus would be considered as affected. It would be dangerous when contamination of 
maternal material occurred. The amplification of SMN1 exon 7 might be from the maternal 
DNA, since the mother had a normal SMN1 allele. To rule out the contamination of 
maternal material linkage analysis was performed routinely with STR markers on 
chromosome 21(section of quality control for prenatal diagnosis).  
3.5 Personalized service in rare disease 
Prenatal diagnosis was also offered to families with other genetic diseases as personalized 
services. In this case, mutation detection should be carried out in advance. There were more 
than 40 diseases available for this service in our center and more than 70 diseases were 
offered in other prenatal diagnosis center or department of medical genetics.  
4. Quality control on the prenatal diagnosis 
4.1 Be ware of heterogeneity 
In practice of prenatal diagnosis the accuracy is very important. Since there is heterogeneity 
for genetic diseases, it was critical to confirm the diagnosis of the disease in the family 
seeking prenatal diagnosis.  
4.2 Using different procedures to confirmed the output 
It would be helpful to use two different protocols to carry out prenatal diagnosis, mutation 
detection and linkage analysis. For deletion analysis, in addition to use internal control 
linkage analysis should be used, which can tell if there was a contamination occurred. 
4.3 Emphasis on pre-analysis in advance to prenatal diagnosis 
It is always happened that the pregnant women come for prenatal diagnosis at high 
gestation weeks without confirmation diagnosis of the proband or with no previous gene 
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analysis. Without genetic analysis in advance, it would be not sure if the prenatal diagnosis 
can be performed, since it might be uninformative with the commonly used polymorphic 
markers, or the mutations in the family can not be identified.  
4.4 Ensure the fetal material is really from fetus 
The maternal contamination was a serious risk, esprcially for deletion mutation. The mother 
always carried a normal allele which will give a positive amplification. We put an emphasis 
on sampling and sample processing: 1)CVS would be the first choice to get fetus material in 
our practice. When the sample received the chorionic villus would be carefully selected. 2)If 
amnion fluid had to be used the sample should be check for sure there was no blood 
contaminated. It can be told by sitting the fluid for a half hour to see if there was red cells 
precipitated. If it is so, cell culture will be set up. To avoid omission of the contamination, 
linkage analysis should be performed paralleling with mutation detection.  
4.4.1 Get three birds with one stone 
In our practice we performed linkage analysis first using two STRs on chromosome 21. By 
this procedure, we can get three answers: 1) whether the fetus was at risk for trisomy 21. If 
there is three alleles for the fetus or there were just two alleles but the density of one allele 
was nearly doubled, the fetus was affected with trisomy 21. Since we detected 2 markers, the 
chance for there was only one band, e. g. the parents were homozygous for two markers, 
was rare; 2) whether the fetal sample was taken from the fetus tissue. If the alleles were the 
same as the maternal ones and there is no paternal allele, it implied that the sample was not 
from the fetus but of maternal origin. It also showed whether there was a contamination 
with the maternal material, if there was an extra allele passed form the mother, and the 
density of the extra band was much weaker; 3) was the sample misplaced, if the genotypes 
of the parents and fetus were not matched.  
In our practice we have confronted with the situation 2, there were maternal contamination 
and even worse that the sample was taken from the mother, not from the fetus. To confirm 
the later situation, more marker, other than markers on chromosome 21, were used for 
personal identification as doing in paternity testing. We called this procedure as “get three 
birds with one stone”. If it implied the possibility for trisomy 21, markers on other 
chromosome would be tested. If there was no extra allele for the new markers, trisomy 21 
was suspected, and AF sampling would be suggested in order to rule out the confined 
trisomy 21 in the CVS. If there was maternal contamination, fetus sample should be 
collected again. If there was a trouble in sample preparation, DNA would be extracted from 
the back up material, which was reserved in the original sample tube. If the polymorphic 
marker didn’t give sufficient information, dosage analysis could be help. In our practice the 
contaminating band was always with a lower density, much less than 1 copy.  
4.4.2 Be aware of the maternal origin of the grown cells from AF culture 
When contamination of the maternal blood was suspected on AF sample, the routine way to 
get ride of the maternal white blood cells is to culture the amnion fluid cells. After several 
changes of the medium the blood cells would be washed away, leave the fetal cells grow up 
as fibroblast cells adhering on the culture flask. But in our practice in one case it turned to be 
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gene of the patient. But it should be offered with caution since the heterozygote frequency of 
SMN1 deletion is as high as 1 in 50, the diagnosis of SMA must be confirmed. For 
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analysis. Without genetic analysis in advance, it would be not sure if the prenatal diagnosis 
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amnion fluid had to be used the sample should be check for sure there was no blood 
contaminated. It can be told by sitting the fluid for a half hour to see if there was red cells 
precipitated. If it is so, cell culture will be set up. To avoid omission of the contamination, 
linkage analysis should be performed paralleling with mutation detection.  
4.4.1 Get three birds with one stone 
In our practice we performed linkage analysis first using two STRs on chromosome 21. By 
this procedure, we can get three answers: 1) whether the fetus was at risk for trisomy 21. If 
there is three alleles for the fetus or there were just two alleles but the density of one allele 
was nearly doubled, the fetus was affected with trisomy 21. Since we detected 2 markers, the 
chance for there was only one band, e. g. the parents were homozygous for two markers, 
was rare; 2) whether the fetal sample was taken from the fetus tissue. If the alleles were the 
same as the maternal ones and there is no paternal allele, it implied that the sample was not 
from the fetus but of maternal origin. It also showed whether there was a contamination 
with the maternal material, if there was an extra allele passed form the mother, and the 
density of the extra band was much weaker; 3) was the sample misplaced, if the genotypes 
of the parents and fetus were not matched.  
In our practice we have confronted with the situation 2, there were maternal contamination 
and even worse that the sample was taken from the mother, not from the fetus. To confirm 
the later situation, more marker, other than markers on chromosome 21, were used for 
personal identification as doing in paternity testing. We called this procedure as “get three 
birds with one stone”. If it implied the possibility for trisomy 21, markers on other 
chromosome would be tested. If there was no extra allele for the new markers, trisomy 21 
was suspected, and AF sampling would be suggested in order to rule out the confined 
trisomy 21 in the CVS. If there was maternal contamination, fetus sample should be 
collected again. If there was a trouble in sample preparation, DNA would be extracted from 
the back up material, which was reserved in the original sample tube. If the polymorphic 
marker didn’t give sufficient information, dosage analysis could be help. In our practice the 
contaminating band was always with a lower density, much less than 1 copy.  
4.4.2 Be aware of the maternal origin of the grown cells from AF culture 
When contamination of the maternal blood was suspected on AF sample, the routine way to 
get ride of the maternal white blood cells is to culture the amnion fluid cells. After several 
changes of the medium the blood cells would be washed away, leave the fetal cells grow up 
as fibroblast cells adhering on the culture flask. But in our practice in one case it turned to be 
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that the grown cells were maternal origin since all the markers tested gave the same 
genotype as the mother’s DNA did. Considering this situation, we added the STR testing 
procedure to all the prenatal diagnosis for monogenic diseases, such as for enzyme assay.  
5. References 
[1] Sun NH, et al. Intrauterine diagnosis for hereditary diseases, review on 78 cases. Chin J 
Ob & Gyn 1980; (1): 19-23 
[2] Zhou XT, et al. Prenatal diagnosis on hereditary disease I, culturing the amnion fluid 
cells and prenatal diagnosis, with report on 100 cases. Acta Genetica Sinica 1980 
(1):79-81 
[3] Sun Nianhu, et al. Apply fetoscope in prenatal diagnosis and intrauerne therapy. Chin J 
Ob & Gyn  (6): 356-358, 1986 
[4] Guo YP, Gao SF, Dai YY, Sun NH, Wang FY, Ning Y. Pseudohypertrophic muscular 
dystrophy, a case report on prenatal diagnosis with fetal muscle biopsy and 
pathology analysis. Chin J Neurol and Psychit 1990; 23(1): 35-37 
[5] Ye GL, Liao SX, Zhao XL, Xi HY, Liu Q, Cai XN. The possibility for maternal serum 
screening for fetal defects with AFP、β-HCG and UE3 in second trimester. J Xi’an 
Med. Univ. 16(4): 408-411, 1995 
[6] WuWenyan, et al. Intrauterine diagnosis of mucopolysaccharidosis tye Ⅵ. Chin J Obs & 
Gyn. 1985; (2): 117 
[7] Li Shanguo, Wang Peilan, Wu Wenyan. Two-dimentional electrophoresis of amnion 
fluid and its application in prenatal diagnosis of mucopolysaccharidosis. Shanghai 
Medicine 1989; 12(3): 153-156 
[8] Shi Huiping, et al. Postnatal and prenatal diagnosis for lysosomal diseases. Natl J Med 
Chin. 1988; (3): 124-127 
[9] Dept of Obstet & Gynocol. Fetal sex determination with chorionic villus sampling from 
cervix. Chin Med. J. 1(2):117-126, 1975 
[10] Sun Nianhu, et al. The study on prenatal diagnosis with chorionic villus in early 
pregnancy. Heredity and diseases 1985; (1): 1-4 
[11] Xiang Yang, Chang Xin, Wang Fengyun, Hao Na, Sun Nianhu. Prenatal diagnosis of 
genetic diseases at the early pregnancy by transabdominal chorionic vilus 
sampling. Chin J Obstet & Gynol 1997, 32(4): 253-254 
[12] Ye HY, Hu YZ, et al. The study in performance of abdominal cordocentesis and its 
clinical application. Chin J Obstet Gynecol. 1988:23: 218-20 
[13] Xu XM, Zhou YQ, Luo GX, Liao C, ZhouM, Chen PY, Lu JP, Jia SQ, Xiao GF, Shen X, Li 
J, Chen HP, Xia YY, Wen YX, MoQH, Li WD, Li YY, ZhuoLW, Wang ZQ, Chen YJ, 
Qin CH, Zhong M. et al. The prevalence and spectrum of alpha and beta 
thalassemia in Guangdong Province: implications for the future health burden and 
population screening. J Clin Pathol 57:517-522, 2004 
[14] Xiong F, Sun M, Zhang X, Cai R, Zhou Y, Lou J, Zeng L, Sun Q, Xiao Q, Shang X, Wei X, 
Zhang T, Xhen P, Xu X. Molecular epidemiological survey of 
haematoblobinopathies in the Guangxi Zhuang Autonomous Region of southern 
China. Clin Genet 2010. 78(2):139-48 
 
The Experiences of Prenatal Diagnosis in China 
 
187 
[15] Ou Caiying, Ming Jin, Xu Yunbi, Wang Chuanwen, and Huang Shangzhi. Study on the 
genotypes of α-thalassemia in 343 school children of the Li Nationality in Hainan. 
Hainan Med. J.  10(2): 112-113, 1999 
[16] Fu Xiong, Qiuying Huang, Xiaoyun Chen, Yuqiu Zhou, Xinhua Zhang, Ren Cai, Yajun 
Chen,_Jiansheng Xie, Shanwei Feng, Xiaofeng Wei, Qizhi Xiao, Tianlang Zhang, 
Shiqiang Luo, Xuehuang Yang,_ Ying Hao, Yanxia Qu, Qingge Li, and Xiangmin 
Xu. A Melting Curve Analysis–Based PCR Assay for One-Step Genotyping of β-
Thalassemia Mutations. J Mol Diagn 2011, 13:427–435 
[17] Zhang Junwu, Wu Guanyun, Xu Xiaoshi, et al. The organization of the α-globin gene in 
Hb H patients from Guangdong Province. Actae Academiae Medicinae Sinicae 
6:79-82, 1984 
[18] Zhou Yuqiu, Xhang Yongliang, Li Liyan, Li Wendian, Mo Qiuhua, Zheng Qing, Xu 
Xiangmin. Rapid detection of three common deletional α-thalassemias in Chinese 
by single-tube multiplex PCR. Chin J Med Genet 2005, 22(2):180-184 
[19] Li Liyan, MO Qiuhua, XU Xiangmin．Rapid diagnosis of non-deletion α-thalassemias 
by reverse dot blot. Chin J Med Genet 2003, 20(4):345-347 
[20] Haig H. Kazazian Jr., Carol E. Dowling, Pamela G. Waber, Shangzhi Huang and Wilson 
H. Y. Lo: The spectrum of βthalassemia genes in Chinas and Southeast Asia. Blood 
68: 964-966, 1986. 
[21] Shangzhi Huang, Haig H. Kazazian Jr., Pamela G. Waber, Wilson H. Y. Lo, Ruo-lian Cai 
and Mei-qi Wang: βthalassemia in Chinese. Analysis of polymorphic restriction site 
haplotype in the β-globin gene cluster. Chin Med J 98: 881-886, 1985. 
[22] Shangzhi Huang, Corinne Wong, Stylianos E. Antonarakis, Rolian Tsai, Wilson H. Y. Lo 
and Haig H. Kazazian Jr.: The same 'TATA' box β-thalassemia mutation in Chinese 
and U.S. blacks: another example of independent origins of mutation. Hum. Genet. 
74: 162-164, 1986. 
[23] Chen LC, Huang DA, Han JX, Chen LF, Huang S. The trial on population screening for 
β-thalassemia and mutation detection. Natural Science Journal of Hannan 
University 1993,11(1)：45-49; 
[24] Chen Luofu, Huang Dongai, Wen Zhongping, Chen Lichang, and Huang Shangzhi. 
Genotyping of β-thalassemia on 95 cases of Li Minority. Natural Science Journal of 
Hannan University 1993,11(2)：47-49 
[25] Liu Weipei, Zhang Luming, Zhang Yuhong, Ou Xiuyi, Liang Bo, Feng Shaoyan, Li 
Weiwen, Zhou Runtian, and Xing Tiehua. Six year practice in pre-marriage 
screening for thalassemia in Fushan City. Chinese J of Family Planning. 1999, 4: 
187-168 
[26] Xu Xiangmin, Liao Can, Liu Zhongying, Huang Yining, Zhang Jizeng, Li Jian, Peng 
Chaohui, Qiu Luoling, and Cai Xuheng. Antenatal screening and fetal diagnosis of 
β-thalassemia in the Chinese population. Chin J Med Genet 1996, 13(5):258-261 
[27] Zhou Yuqiu, Xhang Yongliang, Li Liyan, Li Wendian, Mo Qiuhua, Zheng Qing, Xu 
Xiangmin. Rapid detection of three common deletional α-thalassemias in Chinese 
by single-tube multiplex PCR. Chin J Med Genet 2005, 22(2):180-184 
[28] Li Liyan, MO Qiuhua,·XU Xiangmin．Rapid diagnosis of non-deletion α-thalassemias 
by reverse dot blot. Chin J Med Genet 2003, 20(4):345-347 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
186 
that the grown cells were maternal origin since all the markers tested gave the same 
genotype as the mother’s DNA did. Considering this situation, we added the STR testing 
procedure to all the prenatal diagnosis for monogenic diseases, such as for enzyme assay.  
5. References 
[1] Sun NH, et al. Intrauterine diagnosis for hereditary diseases, review on 78 cases. Chin J 
Ob & Gyn 1980; (1): 19-23 
[2] Zhou XT, et al. Prenatal diagnosis on hereditary disease I, culturing the amnion fluid 
cells and prenatal diagnosis, with report on 100 cases. Acta Genetica Sinica 1980 
(1):79-81 
[3] Sun Nianhu, et al. Apply fetoscope in prenatal diagnosis and intrauerne therapy. Chin J 
Ob & Gyn  (6): 356-358, 1986 
[4] Guo YP, Gao SF, Dai YY, Sun NH, Wang FY, Ning Y. Pseudohypertrophic muscular 
dystrophy, a case report on prenatal diagnosis with fetal muscle biopsy and 
pathology analysis. Chin J Neurol and Psychit 1990; 23(1): 35-37 
[5] Ye GL, Liao SX, Zhao XL, Xi HY, Liu Q, Cai XN. The possibility for maternal serum 
screening for fetal defects with AFP、β-HCG and UE3 in second trimester. J Xi’an 
Med. Univ. 16(4): 408-411, 1995 
[6] WuWenyan, et al. Intrauterine diagnosis of mucopolysaccharidosis tye Ⅵ. Chin J Obs & 
Gyn. 1985; (2): 117 
[7] Li Shanguo, Wang Peilan, Wu Wenyan. Two-dimentional electrophoresis of amnion 
fluid and its application in prenatal diagnosis of mucopolysaccharidosis. Shanghai 
Medicine 1989; 12(3): 153-156 
[8] Shi Huiping, et al. Postnatal and prenatal diagnosis for lysosomal diseases. Natl J Med 
Chin. 1988; (3): 124-127 
[9] Dept of Obstet & Gynocol. Fetal sex determination with chorionic villus sampling from 
cervix. Chin Med. J. 1(2):117-126, 1975 
[10] Sun Nianhu, et al. The study on prenatal diagnosis with chorionic villus in early 
pregnancy. Heredity and diseases 1985; (1): 1-4 
[11] Xiang Yang, Chang Xin, Wang Fengyun, Hao Na, Sun Nianhu. Prenatal diagnosis of 
genetic diseases at the early pregnancy by transabdominal chorionic vilus 
sampling. Chin J Obstet & Gynol 1997, 32(4): 253-254 
[12] Ye HY, Hu YZ, et al. The study in performance of abdominal cordocentesis and its 
clinical application. Chin J Obstet Gynecol. 1988:23: 218-20 
[13] Xu XM, Zhou YQ, Luo GX, Liao C, ZhouM, Chen PY, Lu JP, Jia SQ, Xiao GF, Shen X, Li 
J, Chen HP, Xia YY, Wen YX, MoQH, Li WD, Li YY, ZhuoLW, Wang ZQ, Chen YJ, 
Qin CH, Zhong M. et al. The prevalence and spectrum of alpha and beta 
thalassemia in Guangdong Province: implications for the future health burden and 
population screening. J Clin Pathol 57:517-522, 2004 
[14] Xiong F, Sun M, Zhang X, Cai R, Zhou Y, Lou J, Zeng L, Sun Q, Xiao Q, Shang X, Wei X, 
Zhang T, Xhen P, Xu X. Molecular epidemiological survey of 
haematoblobinopathies in the Guangxi Zhuang Autonomous Region of southern 
China. Clin Genet 2010. 78(2):139-48 
 
The Experiences of Prenatal Diagnosis in China 
 
187 
[15] Ou Caiying, Ming Jin, Xu Yunbi, Wang Chuanwen, and Huang Shangzhi. Study on the 
genotypes of α-thalassemia in 343 school children of the Li Nationality in Hainan. 
Hainan Med. J.  10(2): 112-113, 1999 
[16] Fu Xiong, Qiuying Huang, Xiaoyun Chen, Yuqiu Zhou, Xinhua Zhang, Ren Cai, Yajun 
Chen,_Jiansheng Xie, Shanwei Feng, Xiaofeng Wei, Qizhi Xiao, Tianlang Zhang, 
Shiqiang Luo, Xuehuang Yang,_ Ying Hao, Yanxia Qu, Qingge Li, and Xiangmin 
Xu. A Melting Curve Analysis–Based PCR Assay for One-Step Genotyping of β-
Thalassemia Mutations. J Mol Diagn 2011, 13:427–435 
[17] Zhang Junwu, Wu Guanyun, Xu Xiaoshi, et al. The organization of the α-globin gene in 
Hb H patients from Guangdong Province. Actae Academiae Medicinae Sinicae 
6:79-82, 1984 
[18] Zhou Yuqiu, Xhang Yongliang, Li Liyan, Li Wendian, Mo Qiuhua, Zheng Qing, Xu 
Xiangmin. Rapid detection of three common deletional α-thalassemias in Chinese 
by single-tube multiplex PCR. Chin J Med Genet 2005, 22(2):180-184 
[19] Li Liyan, MO Qiuhua, XU Xiangmin．Rapid diagnosis of non-deletion α-thalassemias 
by reverse dot blot. Chin J Med Genet 2003, 20(4):345-347 
[20] Haig H. Kazazian Jr., Carol E. Dowling, Pamela G. Waber, Shangzhi Huang and Wilson 
H. Y. Lo: The spectrum of βthalassemia genes in Chinas and Southeast Asia. Blood 
68: 964-966, 1986. 
[21] Shangzhi Huang, Haig H. Kazazian Jr., Pamela G. Waber, Wilson H. Y. Lo, Ruo-lian Cai 
and Mei-qi Wang: βthalassemia in Chinese. Analysis of polymorphic restriction site 
haplotype in the β-globin gene cluster. Chin Med J 98: 881-886, 1985. 
[22] Shangzhi Huang, Corinne Wong, Stylianos E. Antonarakis, Rolian Tsai, Wilson H. Y. Lo 
and Haig H. Kazazian Jr.: The same 'TATA' box β-thalassemia mutation in Chinese 
and U.S. blacks: another example of independent origins of mutation. Hum. Genet. 
74: 162-164, 1986. 
[23] Chen LC, Huang DA, Han JX, Chen LF, Huang S. The trial on population screening for 
β-thalassemia and mutation detection. Natural Science Journal of Hannan 
University 1993,11(1)：45-49; 
[24] Chen Luofu, Huang Dongai, Wen Zhongping, Chen Lichang, and Huang Shangzhi. 
Genotyping of β-thalassemia on 95 cases of Li Minority. Natural Science Journal of 
Hannan University 1993,11(2)：47-49 
[25] Liu Weipei, Zhang Luming, Zhang Yuhong, Ou Xiuyi, Liang Bo, Feng Shaoyan, Li 
Weiwen, Zhou Runtian, and Xing Tiehua. Six year practice in pre-marriage 
screening for thalassemia in Fushan City. Chinese J of Family Planning. 1999, 4: 
187-168 
[26] Xu Xiangmin, Liao Can, Liu Zhongying, Huang Yining, Zhang Jizeng, Li Jian, Peng 
Chaohui, Qiu Luoling, and Cai Xuheng. Antenatal screening and fetal diagnosis of 
β-thalassemia in the Chinese population. Chin J Med Genet 1996, 13(5):258-261 
[27] Zhou Yuqiu, Xhang Yongliang, Li Liyan, Li Wendian, Mo Qiuhua, Zheng Qing, Xu 
Xiangmin. Rapid detection of three common deletional α-thalassemias in Chinese 
by single-tube multiplex PCR. Chin J Med Genet 2005, 22(2):180-184 
[28] Li Liyan, MO Qiuhua,·XU Xiangmin．Rapid diagnosis of non-deletion α-thalassemias 
by reverse dot blot. Chin J Med Genet 2003, 20(4):345-347 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
188 
[29] Zhang JZ and Xu XM. Reverse dot blot, a quick approach for prenatal diagnosis of β-
thalassemia. Chin Sci Bulletin 1993, 38(24): 2285-2287 
[30] Wu Guanyun, Wang Limng, Zhang JunWu, Liang Xu, Zhou Peng, Long Guifang, Tang 
Zhining, Liang Rong, Fei Yongjun, Huang Youwen, Zhao Letian, Wang Rongxin, 
Su Jidong, Zhanlg Nijia. First-trimester fetal diagnosis for α-thalassemia. Actae 
Academiae Medicinae Sinicae 6(6):389-392, 1984 
[31] Zeng YT and Huang SZ. Alpha-globin gene organisation and prenatal diagnosis of 
alpha-thalassaemia in Chinese. Lancet. 1(8424):304-7, 1985 
[32] Zhang JZ, Cai SP, Huang DH, et al. Application of polymerase chain reaction in 
prenatal diagnosis of Bart’s. Natl J Med Chin 1988, 12(3): 183-187  
[33] Zhang Junwu, Zuo jin, Wu Guanyun, et al. Prenatal gene diagnosis on β-thalassemia in 
the first trimester(short report). Actae Academiae Medicinae Sinicae 7:180, 1985 
[34] Zeng YT, Huang SZ, Qiu XK, Chen MJ, Dong JH, Ku AL, Lu FQ, and Huang YZ. 
Prenatal diagnosis on β-thalassemia. Natl J Med China. 1985, 65(11): 690  
[35] Liu Jingzhong, Wu Guanyun, Gao Qingsheng, Jiang Zhe, Liang Zhiquan, Wilson HY 
Lo, Li Qi, Long Guifang, Zhang Jing, Deng Bing, Wang Rongxin, Huang Youwen, 
and Zeng Ruiping. Studies of β-thalassemia mutations and prenatal diagnosis in 
Guangxi, Guangdong and Sichuan Provinces of South China. Acta Academiae 
Medicinae Sinicae 1990, 12(2): 90-95 
[36] Cai SP, Zhang JZ, Huang DH, Wang ZX, Liao FP, and Kan JW. Prenatal gene diagnosis 
on β-thalassemia with nonradioactive allele-specific oligonucleotide probes. Chin J 
Hematol 1989. 10(11): 567-568 
[37] Liu JZ, Wu GY, Song F, and Wen XJ. Prenatal diagnosis of β-thalassemia with 3’ end 
specific primer PCR. Natl J Med Chin. 71(4):208-209, 1991 
[38] Mao Yaohua, Sun Qiong, Li Zheng, Sheng Min, Huang Shuzhen, and Zeng Yitao. 
Applicfication of multipex allele-specific PCR for molecular diagnosis of β-
thalassemia．J Med Genet. 1995, 12(4):209-211  
[39] G Chang, PH Chen, SS Chiou, LS Lee, LI Perng and TC Liu. Rapid Diagnosis of β-
Thalassemia Mutations in Chinese by Naturally and Amplified Created Restriction 
Sites. Blood, l80(8): pp 2092-2096, 1992 
[40] Bushby KM. The limb-girdle muscular dystrophies—multiple genes, multiple 
mechanisms. Hum Mol Genet. 1999;8: 1875–82.  
[41] Fanyi Zeng, Zhao-Rui Ren, Shang-Zhi Huang, Margot Kalf, Monique Mommersteeg, 
Maarten Smit, Stefan White, Chun-Lian Jin, Miao Xu, Da-Wen Zhou, Jing-Bin Yan, 
Mei-Jue Chen, Rinie van Beuningen, Shu-Zhen Huang, Johan den Dunnen, Yi-Tao 
Zeng, and Ying Wu. Array-MLPA: Comprehensive Detection of Deletions and 
Duplications and Its Application to DMD Patients. Hum Mutat. 2008 Jan;29(1):190-
197 
[42] Xiaozhu Wang, Zheng Wang, Ming Yan, Shangzhi Huang, Tian-Jian Chen and Nanbert 
Zhong. Similarity of DMD gene deletion and duplication in the Chinese patients 
compared to global populations. Behavioral and Brain Functions 2008, 4:20; 
[43] Peng Yuan-yuan，Meng Yan，Yao Feng-xia，Han Juan-juan，Huang Shang-zhi. New 
multiplex-PCR assays for deletion detection on the Chinese DMD patients. Chin J 
of 中Chin J Lab Med. 2010; 33:106-110  
 
The Experiences of Prenatal Diagnosis in China 
 
189 
[44] Zhang Junwu, Zhao Yanjun, Wu Guanyun, Chu Wenming, Liu Jingzhong, Wu 
Husheng, Zhao Shimin, and Sun Hianhu. Genetic analysis of 60 Duchenne 
muscular dystrophy(DMD) or Becker muscular dystrophy (BMD) patients using 
dystrophin cDNA. Actae Academiae Sinicae. 15(6):399-404, 1993 
[45] Beggs AH, Koenig M, Boyce FM, et a1. Detection of 98% of DMD/BMD gene deletions 
by polymerase chain reaction[J]. Hum Genet, 1990, 86:45-48;  
[46] Shenlin Ma, Guanyun Wu,Wenming Chu, et al.Two-step multiplex PCR amplification 
for quick detection of deletion mutations in Duchenne muscular dystrophy. Acta 
Academiae Medicinae Sinicae. 1993, 15:74-8. 
[47] Huang S and Zhang L, unpublished results  
[48] Chen Yanan, Zhou Xin, Jin Chunlian, et al. Scanning mutations of DMD gene in non-
deletion allele by DHPLC method. Chin J Pediatrics 45(6): 2007 
[49] Huang shangzhi. “Gene diagnosis and prenatal gene diagnosis”, in “Medical 
Genetics”.2ed ed. Li Pu et al eds, pp264-307 , Peking Union Medical College Press. 
Beijing, 2004 
[50] Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne 
muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res, 
16:11141-56, 1988. 
[51] Xu Shunbin, Huang Shangzhi, Lu Shan, and Wilson HY Lo. Assay of two microsatellite 
polymorphisms at the 5’ and 3’ ends of the dystrophin gene and its application to 
DMD carrier diagnosis. Chin J Med Genet  10(6):324-327. 1993 
[52] Huang Shangzh, Chu Haiying, Xu Shunbin, Zhou Yu, Wilson HY Lo. Amp-FLP 
analysis on MP1P site at the 3’ untranslated region of dystrophin gene and its 
application to linkage analysis in gene diagnosis of DMD. Chin J Med. Genet 
11(4):197-199, 1994 
[53] Xu Shunbin, Huang Shangzhi, and Wilson HY Lo. A new approach to gene diagnosis of 
Duchenne/Becker muscular dystrophy, Amplified fragment length 
polymorphisms. Chin Med Sci. J 9(3): 137-142, 1994  
[54] Chen Fan, Huang S, Pan XL,Fang B, Wu YY and Lo WHY. Molecular study of 
Duchenne muscular dystrophy, Carrier detection by means of RFLP linkage 
analysis .Natl J Med Chin 71: 339-341, 1991  
[55] Abbs S, Roberts RG, Mathew CG, Bentley DR, Bobrow M. Accurate assessment of 
intragenic recombination frequency within the Duchenne muscular dystrophy 
gene. Genomics. 1990;7:602–6.]  
[56] Huang Shangzhi.Gene diagnosis and prenatal diagnosis on Duchenne muscular 
dystrophy and spinal muscular atrophy. Chin J Neuroimmunol & Neurol 
15(4):317-320, 2008 
[57] Sun Nianhu, et al. Prenatal diagnosis on pseudohypertrophic muscular dystrophy, a 
case report on fetal muscle biopsy with the add of fetoscopy. Heredity and 
Diseases 4(2): 136-137, 1987 
[58] Wu Yinyu, Pan Xiaoli, Li Shuyi, Qu Lurong, Wang Fuwei, Zhou Zhuoran, Jin Chunlian, 
Lin Changkun, Jiang Li, and Sun Kailai. Clinical study on prenatal diagnosis of 
DMD by combined assay of aminion fluid CK, LDH, and Mb. Zhong Guo You 
Sheng Yu Yi Chuan Za Zhi 3(1):10-13, 1995 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
188 
[29] Zhang JZ and Xu XM. Reverse dot blot, a quick approach for prenatal diagnosis of β-
thalassemia. Chin Sci Bulletin 1993, 38(24): 2285-2287 
[30] Wu Guanyun, Wang Limng, Zhang JunWu, Liang Xu, Zhou Peng, Long Guifang, Tang 
Zhining, Liang Rong, Fei Yongjun, Huang Youwen, Zhao Letian, Wang Rongxin, 
Su Jidong, Zhanlg Nijia. First-trimester fetal diagnosis for α-thalassemia. Actae 
Academiae Medicinae Sinicae 6(6):389-392, 1984 
[31] Zeng YT and Huang SZ. Alpha-globin gene organisation and prenatal diagnosis of 
alpha-thalassaemia in Chinese. Lancet. 1(8424):304-7, 1985 
[32] Zhang JZ, Cai SP, Huang DH, et al. Application of polymerase chain reaction in 
prenatal diagnosis of Bart’s. Natl J Med Chin 1988, 12(3): 183-187  
[33] Zhang Junwu, Zuo jin, Wu Guanyun, et al. Prenatal gene diagnosis on β-thalassemia in 
the first trimester(short report). Actae Academiae Medicinae Sinicae 7:180, 1985 
[34] Zeng YT, Huang SZ, Qiu XK, Chen MJ, Dong JH, Ku AL, Lu FQ, and Huang YZ. 
Prenatal diagnosis on β-thalassemia. Natl J Med China. 1985, 65(11): 690  
[35] Liu Jingzhong, Wu Guanyun, Gao Qingsheng, Jiang Zhe, Liang Zhiquan, Wilson HY 
Lo, Li Qi, Long Guifang, Zhang Jing, Deng Bing, Wang Rongxin, Huang Youwen, 
and Zeng Ruiping. Studies of β-thalassemia mutations and prenatal diagnosis in 
Guangxi, Guangdong and Sichuan Provinces of South China. Acta Academiae 
Medicinae Sinicae 1990, 12(2): 90-95 
[36] Cai SP, Zhang JZ, Huang DH, Wang ZX, Liao FP, and Kan JW. Prenatal gene diagnosis 
on β-thalassemia with nonradioactive allele-specific oligonucleotide probes. Chin J 
Hematol 1989. 10(11): 567-568 
[37] Liu JZ, Wu GY, Song F, and Wen XJ. Prenatal diagnosis of β-thalassemia with 3’ end 
specific primer PCR. Natl J Med Chin. 71(4):208-209, 1991 
[38] Mao Yaohua, Sun Qiong, Li Zheng, Sheng Min, Huang Shuzhen, and Zeng Yitao. 
Applicfication of multipex allele-specific PCR for molecular diagnosis of β-
thalassemia．J Med Genet. 1995, 12(4):209-211  
[39] G Chang, PH Chen, SS Chiou, LS Lee, LI Perng and TC Liu. Rapid Diagnosis of β-
Thalassemia Mutations in Chinese by Naturally and Amplified Created Restriction 
Sites. Blood, l80(8): pp 2092-2096, 1992 
[40] Bushby KM. The limb-girdle muscular dystrophies—multiple genes, multiple 
mechanisms. Hum Mol Genet. 1999;8: 1875–82.  
[41] Fanyi Zeng, Zhao-Rui Ren, Shang-Zhi Huang, Margot Kalf, Monique Mommersteeg, 
Maarten Smit, Stefan White, Chun-Lian Jin, Miao Xu, Da-Wen Zhou, Jing-Bin Yan, 
Mei-Jue Chen, Rinie van Beuningen, Shu-Zhen Huang, Johan den Dunnen, Yi-Tao 
Zeng, and Ying Wu. Array-MLPA: Comprehensive Detection of Deletions and 
Duplications and Its Application to DMD Patients. Hum Mutat. 2008 Jan;29(1):190-
197 
[42] Xiaozhu Wang, Zheng Wang, Ming Yan, Shangzhi Huang, Tian-Jian Chen and Nanbert 
Zhong. Similarity of DMD gene deletion and duplication in the Chinese patients 
compared to global populations. Behavioral and Brain Functions 2008, 4:20; 
[43] Peng Yuan-yuan，Meng Yan，Yao Feng-xia，Han Juan-juan，Huang Shang-zhi. New 
multiplex-PCR assays for deletion detection on the Chinese DMD patients. Chin J 
of 中Chin J Lab Med. 2010; 33:106-110  
 
The Experiences of Prenatal Diagnosis in China 
 
189 
[44] Zhang Junwu, Zhao Yanjun, Wu Guanyun, Chu Wenming, Liu Jingzhong, Wu 
Husheng, Zhao Shimin, and Sun Hianhu. Genetic analysis of 60 Duchenne 
muscular dystrophy(DMD) or Becker muscular dystrophy (BMD) patients using 
dystrophin cDNA. Actae Academiae Sinicae. 15(6):399-404, 1993 
[45] Beggs AH, Koenig M, Boyce FM, et a1. Detection of 98% of DMD/BMD gene deletions 
by polymerase chain reaction[J]. Hum Genet, 1990, 86:45-48;  
[46] Shenlin Ma, Guanyun Wu,Wenming Chu, et al.Two-step multiplex PCR amplification 
for quick detection of deletion mutations in Duchenne muscular dystrophy. Acta 
Academiae Medicinae Sinicae. 1993, 15:74-8. 
[47] Huang S and Zhang L, unpublished results  
[48] Chen Yanan, Zhou Xin, Jin Chunlian, et al. Scanning mutations of DMD gene in non-
deletion allele by DHPLC method. Chin J Pediatrics 45(6): 2007 
[49] Huang shangzhi. “Gene diagnosis and prenatal gene diagnosis”, in “Medical 
Genetics”.2ed ed. Li Pu et al eds, pp264-307 , Peking Union Medical College Press. 
Beijing, 2004 
[50] Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne 
muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res, 
16:11141-56, 1988. 
[51] Xu Shunbin, Huang Shangzhi, Lu Shan, and Wilson HY Lo. Assay of two microsatellite 
polymorphisms at the 5’ and 3’ ends of the dystrophin gene and its application to 
DMD carrier diagnosis. Chin J Med Genet  10(6):324-327. 1993 
[52] Huang Shangzh, Chu Haiying, Xu Shunbin, Zhou Yu, Wilson HY Lo. Amp-FLP 
analysis on MP1P site at the 3’ untranslated region of dystrophin gene and its 
application to linkage analysis in gene diagnosis of DMD. Chin J Med. Genet 
11(4):197-199, 1994 
[53] Xu Shunbin, Huang Shangzhi, and Wilson HY Lo. A new approach to gene diagnosis of 
Duchenne/Becker muscular dystrophy, Amplified fragment length 
polymorphisms. Chin Med Sci. J 9(3): 137-142, 1994  
[54] Chen Fan, Huang S, Pan XL,Fang B, Wu YY and Lo WHY. Molecular study of 
Duchenne muscular dystrophy, Carrier detection by means of RFLP linkage 
analysis .Natl J Med Chin 71: 339-341, 1991  
[55] Abbs S, Roberts RG, Mathew CG, Bentley DR, Bobrow M. Accurate assessment of 
intragenic recombination frequency within the Duchenne muscular dystrophy 
gene. Genomics. 1990;7:602–6.]  
[56] Huang Shangzhi.Gene diagnosis and prenatal diagnosis on Duchenne muscular 
dystrophy and spinal muscular atrophy. Chin J Neuroimmunol & Neurol 
15(4):317-320, 2008 
[57] Sun Nianhu, et al. Prenatal diagnosis on pseudohypertrophic muscular dystrophy, a 
case report on fetal muscle biopsy with the add of fetoscopy. Heredity and 
Diseases 4(2): 136-137, 1987 
[58] Wu Yinyu, Pan Xiaoli, Li Shuyi, Qu Lurong, Wang Fuwei, Zhou Zhuoran, Jin Chunlian, 
Lin Changkun, Jiang Li, and Sun Kailai. Clinical study on prenatal diagnosis of 
DMD by combined assay of aminion fluid CK, LDH, and Mb. Zhong Guo You 
Sheng Yu Yi Chuan Za Zhi 3(1):10-13, 1995 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
190 
[59] Zeng Yitao, et al. Prenatal diagnosis on Duchenne muscular dystrophy using DNA 
restriction fragment length polymorphism. Natl J Med of China 68(10): 565-567, 
1988 
[60] Wu Yuanqing and Sun Nianhu, Prenatal gene diagnosis on DMD with multiplex PCR 
using 9 pairs of primers. Chin J Med. Genet. 10(1):28-29, 1993 
[61] Wu Yuanqing, Sun Nianhu, Wu Yuzhen, Wang Fengyun, and Ning Ynag. Prenatal gene 
diagnosis on psudohypertrophic muscular dystrophy with multiplex PCR using 14 
pairs of primers. Natl J Med. Chin. 73(9):532-534, 1993 
[62] Wu Yuanqing, Sun Nianhu, Huang Shangzhi, Xu Shunbin. Performing prenatal 
diagnosis and carrier detection in two families with high risk of DMD by STR 
markers linkage analysis. J. You Sheng You Yu. 6(1):1-4, 1995 
[63] Liu Yuge, Xie Bingdi, and Dai Zhihua. The prenatal diagnosis of Duchenne /Becker 
muscular dystrophy using STR haploid linkage analysis. Chin J Neurol. 31(5):296-
98, 1998 
[64] Qing LI，Shao-ying LI，Dong-gui HU，Xiao-fang SUN，Dun-jin CHEN，Cheng 
ZHANG，Wei-ying JIANG. Prenatal molecular diagnosis of Duchenne and Becker 
muscular dystrophy. J. Peking University (health Sci.) 38(1)53-56, 2006 
[65] GU Xuefan and WANG Zhiguo,Screening for phenylketonuria and congenital 
hypothyroidism in 518 million neonates in China. Chin J Prev Med. 2004, 38(2): 99-
102  
[66] Yan You-sheng, Wang Zheng, Hao Sheng-ju, et al. Mutation analysis of the PAH gene 
in patients with phenylketonuria in Gansu Province. Chin J Med Genet 2009, 26(4): 
419-422CHN)  
[67] Liu TT, Chiang SH, Wu SJ, Hsiao KJ. Tetrahydrobiopterin-deficient 
hyperphenylalaninemia in the Chinese.  Clin Chim Acta 2001;313:157-169 
[68] National consortium of newborn screening. The 5 years practice of newborn screening 
in eight cities. Chin J Pediatr, 1997, 35(12):255-256 
[69] T Wang, Y Okano, R Eisensmith, S Z Huang, Y T Zeng, W H Lo, and S L Woo. 
Molecular genetics of phenylketonuria in Orientals: linkage disequilibrium 
between a termination mutation and haplotype 4 of the phenylalanine hydroxylase 
gene. Am J Hum Genet. 45(5): 675–680, 1989 
[70] Song F, Qu YJ, Zhang T, Jin YW, Wang H, Zheng XY.Phenylketonuria mutations in 
Northern China. Mol Genet Metab. 86 Suppl 1:S107-18, 2005 
[71] Huang Shangzhi. unpublished data 
[72] Chen Ruiguan, Qian Dalong, Guo Hua, Feng Weijun, Gu Xuefan, Zhou Jiande, Zhang 
Yafen, Zhang Meihua, Pan Xinshi, Shen Yongnian, Lu Yongzhang. Treatment on 
patients of phenylketonuria with low phenylalanine dietary powder 
(BENTONG’AN) made in China. Chin J Pediat.. 28(5): 258-260, 1990 
[73] Zeng YT, Huang SZ, Ren ZR,et al.. Prenatal diagnosis of phenylketonuria. Natl Med. J 
of China. 1986, 66:193-194  
[74] Wang Tao, Yuan Lifang, Fang Bingliang, Huang Shangzhi, Wilson HY Luo, Sun 
Nianhu, Zhao Shimin, Liu Shenru, and Woo SLC. Prenatal diagnosis of 
phenylketonuria with polymerase chain reaction and oligonucleotide probes. Chin 
J Pediatrics 30(1): 30-31, 1992 
 
The Experiences of Prenatal Diagnosis in China 
 
191 
[75] Wang Mei, Fang Bingliang, Yuan Lifang, Huang Shangzhi, Ye Jue, Li Jia, Lu Shan, and 
Wilson HY Lo. Characterization of the mutaion spectrum of phenylalanine 
hydroxylase and prenatal gen diagnosis. Natl J Med China 72(11):670-673, 1992  
[76] Ye Jun, Gu Xuefan, zhang Yafen, Huang Xiaodong, Gao Xiaolan, Chen Ruiguan. 
Treatment of 769 cases with hyperphenylalanemia and gene study. Chin J of 
Pediatrics. 40(4):210-213, 2002 
[77] Daiger SP, Reed L, Huang S-S, Zeng Y-T, Wang T, Lo WHY, Okana Y, et al (1989) 
Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in 
Asian families with phenylketonuria (PKU). Am J Hum Genet 45: 319-324 
[78] Zeng YT, Xue JR, Zhang ML, et al. Prenatal diagnosis of phenylketonuria (10 cases 
report). Natl Med. J of China. 1988, 68:61-64 
[79] Song Fang, Wu Guanyun, Xu Guangzhi, Cai Weinian, and Ding Xiuyuan. Frequency of 
five point mutations of phenylalanine hydroxylase and prenatal gene diagnosis of 
phenylketonuria. Chin J Med Genet 12(6):321-324, 1995 
[80] Yang Tao, Yuan Lifang, Huang Shangzhi, Fang Bingliang, Wang Mei, Sun Nianhu, 
Zhao Shimin, and Wilson HY Lo. Detectton of the mutational gene in 
phenylketanuria and prenatal diagnoses by using single strand conformation 
polymorphism methods.Chin J Obst. and Gynol 31(7):401-403, 1996 
[81] Song Li, Xu Fengduo, Meng Yingtao, Shan Zhongmin. Prenatal gene diagnosis and 
synthetic analysis in high risk phenylketonurja. Tianjin Med J 31(2):82-84, 2003 
[82] Goltsov AA, Eisensmith RC, Naughton ER, Jin L, Chakraborty R, Woo SL. A single 
polymorphic STR system in the human phenylalanine hydroxylase gene permits 
rapid prenatal diagnosis and carrier screening for phenylketonuria. Hum Mol. 
Genet. 1993, 2(5):577-581; 
[83] Huang S, Fang BL, Chu HY, et al. Analysis of STR polymorphism in the PAH gene and 
its application to prenatal gene diagnosis of PKU. Natl Med. J. of China. 1995, 
75(1):22-24(CHN)  
[84] Huang S, Li H, Miao SR, Xu LT, Fang BL, Liu GY, and Luo HY. Analysis of the A/C 
polymorphic site within the phenylalanine hydroxylase gene. Acta Genetica Sinica 
1996, 23(3):169-173 
[85] Yao Feng-xia, Guo Hui, Han Juan-juan, Meng Yan, Sun Nian-hu, Huang Shang-zhi. The 
power of linkage analysis on PAH gene in prenatal gene diagnosis improved with 
three additional short tandem repeat markers. Chin J Med Genet. 2007, 24(4):382-
386 
[86] Yuan Lifang，Liu Tianci，Yang Tao, et a1. Gene diagnosis and prenatal diagnosis of 
spinal muscular atrophy in children. 1997.12.16; 35(12): 631-634  
[87] Zhang YJ，Ma HW，Wang Y，et al．Prenatal gene diagnosis of infantile spinal 
muscular atrophy．J Shanghai Tiedao Univ(Nat Sci ed.), 2000, 21: 319-320 
[88] Long Mei-juan, Wang Hong, Jin Yu-wei, et al. Quantitatice analysia of SMN1 and 
SMN2 genes based on DHPLC: a reliable method fro detection of non-
homozygous patients with spinal muscular atrophy. Natl Med J China. 2008, 
88(8): 1259-1263 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
190 
[59] Zeng Yitao, et al. Prenatal diagnosis on Duchenne muscular dystrophy using DNA 
restriction fragment length polymorphism. Natl J Med of China 68(10): 565-567, 
1988 
[60] Wu Yuanqing and Sun Nianhu, Prenatal gene diagnosis on DMD with multiplex PCR 
using 9 pairs of primers. Chin J Med. Genet. 10(1):28-29, 1993 
[61] Wu Yuanqing, Sun Nianhu, Wu Yuzhen, Wang Fengyun, and Ning Ynag. Prenatal gene 
diagnosis on psudohypertrophic muscular dystrophy with multiplex PCR using 14 
pairs of primers. Natl J Med. Chin. 73(9):532-534, 1993 
[62] Wu Yuanqing, Sun Nianhu, Huang Shangzhi, Xu Shunbin. Performing prenatal 
diagnosis and carrier detection in two families with high risk of DMD by STR 
markers linkage analysis. J. You Sheng You Yu. 6(1):1-4, 1995 
[63] Liu Yuge, Xie Bingdi, and Dai Zhihua. The prenatal diagnosis of Duchenne /Becker 
muscular dystrophy using STR haploid linkage analysis. Chin J Neurol. 31(5):296-
98, 1998 
[64] Qing LI，Shao-ying LI，Dong-gui HU，Xiao-fang SUN，Dun-jin CHEN，Cheng 
ZHANG，Wei-ying JIANG. Prenatal molecular diagnosis of Duchenne and Becker 
muscular dystrophy. J. Peking University (health Sci.) 38(1)53-56, 2006 
[65] GU Xuefan and WANG Zhiguo,Screening for phenylketonuria and congenital 
hypothyroidism in 518 million neonates in China. Chin J Prev Med. 2004, 38(2): 99-
102  
[66] Yan You-sheng, Wang Zheng, Hao Sheng-ju, et al. Mutation analysis of the PAH gene 
in patients with phenylketonuria in Gansu Province. Chin J Med Genet 2009, 26(4): 
419-422CHN)  
[67] Liu TT, Chiang SH, Wu SJ, Hsiao KJ. Tetrahydrobiopterin-deficient 
hyperphenylalaninemia in the Chinese.  Clin Chim Acta 2001;313:157-169 
[68] National consortium of newborn screening. The 5 years practice of newborn screening 
in eight cities. Chin J Pediatr, 1997, 35(12):255-256 
[69] T Wang, Y Okano, R Eisensmith, S Z Huang, Y T Zeng, W H Lo, and S L Woo. 
Molecular genetics of phenylketonuria in Orientals: linkage disequilibrium 
between a termination mutation and haplotype 4 of the phenylalanine hydroxylase 
gene. Am J Hum Genet. 45(5): 675–680, 1989 
[70] Song F, Qu YJ, Zhang T, Jin YW, Wang H, Zheng XY.Phenylketonuria mutations in 
Northern China. Mol Genet Metab. 86 Suppl 1:S107-18, 2005 
[71] Huang Shangzhi. unpublished data 
[72] Chen Ruiguan, Qian Dalong, Guo Hua, Feng Weijun, Gu Xuefan, Zhou Jiande, Zhang 
Yafen, Zhang Meihua, Pan Xinshi, Shen Yongnian, Lu Yongzhang. Treatment on 
patients of phenylketonuria with low phenylalanine dietary powder 
(BENTONG’AN) made in China. Chin J Pediat.. 28(5): 258-260, 1990 
[73] Zeng YT, Huang SZ, Ren ZR,et al.. Prenatal diagnosis of phenylketonuria. Natl Med. J 
of China. 1986, 66:193-194  
[74] Wang Tao, Yuan Lifang, Fang Bingliang, Huang Shangzhi, Wilson HY Luo, Sun 
Nianhu, Zhao Shimin, Liu Shenru, and Woo SLC. Prenatal diagnosis of 
phenylketonuria with polymerase chain reaction and oligonucleotide probes. Chin 
J Pediatrics 30(1): 30-31, 1992 
 
The Experiences of Prenatal Diagnosis in China 
 
191 
[75] Wang Mei, Fang Bingliang, Yuan Lifang, Huang Shangzhi, Ye Jue, Li Jia, Lu Shan, and 
Wilson HY Lo. Characterization of the mutaion spectrum of phenylalanine 
hydroxylase and prenatal gen diagnosis. Natl J Med China 72(11):670-673, 1992  
[76] Ye Jun, Gu Xuefan, zhang Yafen, Huang Xiaodong, Gao Xiaolan, Chen Ruiguan. 
Treatment of 769 cases with hyperphenylalanemia and gene study. Chin J of 
Pediatrics. 40(4):210-213, 2002 
[77] Daiger SP, Reed L, Huang S-S, Zeng Y-T, Wang T, Lo WHY, Okana Y, et al (1989) 
Polymorphic DNA haplotypes at the phenylalanine hydroxylase (PAH) locus in 
Asian families with phenylketonuria (PKU). Am J Hum Genet 45: 319-324 
[78] Zeng YT, Xue JR, Zhang ML, et al. Prenatal diagnosis of phenylketonuria (10 cases 
report). Natl Med. J of China. 1988, 68:61-64 
[79] Song Fang, Wu Guanyun, Xu Guangzhi, Cai Weinian, and Ding Xiuyuan. Frequency of 
five point mutations of phenylalanine hydroxylase and prenatal gene diagnosis of 
phenylketonuria. Chin J Med Genet 12(6):321-324, 1995 
[80] Yang Tao, Yuan Lifang, Huang Shangzhi, Fang Bingliang, Wang Mei, Sun Nianhu, 
Zhao Shimin, and Wilson HY Lo. Detectton of the mutational gene in 
phenylketanuria and prenatal diagnoses by using single strand conformation 
polymorphism methods.Chin J Obst. and Gynol 31(7):401-403, 1996 
[81] Song Li, Xu Fengduo, Meng Yingtao, Shan Zhongmin. Prenatal gene diagnosis and 
synthetic analysis in high risk phenylketonurja. Tianjin Med J 31(2):82-84, 2003 
[82] Goltsov AA, Eisensmith RC, Naughton ER, Jin L, Chakraborty R, Woo SL. A single 
polymorphic STR system in the human phenylalanine hydroxylase gene permits 
rapid prenatal diagnosis and carrier screening for phenylketonuria. Hum Mol. 
Genet. 1993, 2(5):577-581; 
[83] Huang S, Fang BL, Chu HY, et al. Analysis of STR polymorphism in the PAH gene and 
its application to prenatal gene diagnosis of PKU. Natl Med. J. of China. 1995, 
75(1):22-24(CHN)  
[84] Huang S, Li H, Miao SR, Xu LT, Fang BL, Liu GY, and Luo HY. Analysis of the A/C 
polymorphic site within the phenylalanine hydroxylase gene. Acta Genetica Sinica 
1996, 23(3):169-173 
[85] Yao Feng-xia, Guo Hui, Han Juan-juan, Meng Yan, Sun Nian-hu, Huang Shang-zhi. The 
power of linkage analysis on PAH gene in prenatal gene diagnosis improved with 
three additional short tandem repeat markers. Chin J Med Genet. 2007, 24(4):382-
386 
[86] Yuan Lifang，Liu Tianci，Yang Tao, et a1. Gene diagnosis and prenatal diagnosis of 
spinal muscular atrophy in children. 1997.12.16; 35(12): 631-634  
[87] Zhang YJ，Ma HW，Wang Y，et al．Prenatal gene diagnosis of infantile spinal 
muscular atrophy．J Shanghai Tiedao Univ(Nat Sci ed.), 2000, 21: 319-320 
[88] Long Mei-juan, Wang Hong, Jin Yu-wei, et al. Quantitatice analysia of SMN1 and 
SMN2 genes based on DHPLC: a reliable method fro detection of non-
homozygous patients with spinal muscular atrophy. Natl Med J China. 2008, 
88(8): 1259-1263 
 
Prenatal Diagnosis – Morphology Scan and Invasive Methods 
 
192 
[89] Li Xiaoqiao, Yao Fengxia, Su Liang, et al. A simplified approach for detecting 
homologous deletion of SMN1 gene in spinal muaeular atrophy. J Med Res 2009, 
38(5):29-32 
11 
Fetal Therapy: Where Do We Stand 
Sebastian Illanes and Javier Caradeux 
Fetal Medicine Unit, Department of Obstetrics & Gynaecology and  
Laboratory of Reproductive Biology, Universidad de los Andes 
Chile 
1. Introduction 
The last three decades have seen enormous scientific and technological advances, which 
have allowed the emergence of fetal medicine as a discipline and the possibility of fetal 
therapy. The development of different tools such as ultrasound, allows inspection and 
examination of the fetus, and a wide range of invasive procedures can be used for diagnostic 
and therapeutic purposes. 
The value of a fetal therapy relates to the balance between benefits and risks of the in-uterus 
intervention, contrasted with the natural history and prognosis of each pathological 
condition. Several studies have shown that any problem diagnosed prenatally, usually has a 
worse prognosis than when the diagnosis is made postnatally. This improvement of 
prognosis with time relates to the gestational age at diagnosis, because of early detection of 
the most severe cases. It also relates to complications occurring during the pregnancy such 
as the emergence of associated genetic syndromes resulting in the worst prognosis cases 
being excluded by for example miscarriage. Therefore we should be very cautious about 
counselling a pregnant woman based on neonatal data and we need to adjust the prognosis 
given depending on the gestational age of the pregnancy. 
We have classified the possible antenatal therapeutic interventions as transplacental 
treatment, invasive procedures, including transfusion and fetal surgery and future 
perspectives which we consider in an experimental stage but with clear possibilities of 
success. 
2. Transplacental therapy: Fetal pharmacotherapy 
Pharmacological therapy can be used to treat fetal disorders or improve the ability of the 
fetus to adapt to extra-uterine life. The transplacental route is the most commonly used 
way to administer drugs. However, transfer can be poor either because of the nature of 
the drug itself (e.g. digoxin) or if the condition requiring treatment reduces placental 
function (e.g. a hydropic placenta). Other approaches to drug therapy include direct fetal 
administration by the intra-amniotic route but these have a very limited role at present 
because of the invasive nature of the procedures and because very little is known 
regarding the effects of fetal physiology on fetal drug distribution and effects (Koren G. 
2002 - Thein AT. 1998). 
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2.1 Therapies to improve the ability of the fetus to adapt to extra-uterine life  
Several methods have been used to accelerate fetal maturation in fetuses at risk of preterm 
delivery, and the example most extensively studied and used is corticosteroids for lung 
maturity. Liggins was the first to describe this effect in 1969 (Liggins GC. 1969), and 40 years 
later the administration of these drugs remain the most important step to prevent 
respiratory distress syndrome and intraventricular haemorrhage in preterm infants (Crowley 
P. 2004 – Onland W 2011). The effect of treatment is optimal if the baby is delivered more 
than 24 hours and less than seven days after the start of treatment (Crowley. 2004 – 
Bronwnfoot FC. 2008). Use of repeat corticosteroid courses is at the moment under review. 
Some studies have shown a potential benefit of weekly repeat courses of antenatal 
corticosteroids in the occurrence and severity of neonatal respiratory disease but the short-
term benefits are associated with a reduction in weight and head circumference, by the 
moment weekly repeated courses of steroids are not recommended (Bevilacqua E. 2010 - 
ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7). More studies are needed to 
assess the long term effect of repeated steroid exposure on the developing human brain 
(Bevilacqua E. 2010 - ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7 – Lamer P. 
2002 – Crowther CA. 2004). Some authors have suggested a role for corticosteroids in elective 
term cesarean in order to reduce the higher incidence of respiratory distress presented by 
this group compared with vaginal term deliveries; however more studies are needed to 
recommend this approach (Sotiriadis A. 2009). 
2.2 Preventative therapies 
A number of modalities have been studied over the years to try to prevent fetal serious 
disease that can lead to fetal death or serious long-term sequel in the child. An example of 
this strategy is the prevention of neural tube defects (NTDs). These conditions include open 
spina bifida, anencephaly and encephalocele, and complicate 1 or 2 every 1000 pregnancies 
in the UK (Abramsky L. 1999), and can be prevented by the administration of folic acid 
during pregnancy (MRC. 1991 - Czeizel AE. 1992). This is the first congenital malformation to 
be primarily prevented by pharmacological fetal therapy (RCOG 2003). In 1996, the US Food 
and Drug Administration, initiated folic acid fortification of flour and mean folate levels in 
the population improved with substantial decrease in the risk of NTDs (Koren G. 2002), this 
policy have been implemented in many countries (RCOG 2003). Recent studies demonstrate 
this protective role of folate for NTDs, showing a protective effect of daily folic acid 
supplementation in preventing the disease (RR 0.28, 95% CI 0.15 to 0.52), with a significant 
protective effect for recurrence (RR 0.32, 95% CI 0.17 to 0.60) (De-Regil LM. 2010). 
Another successful strategy is the maternal administration of IVIg and/or corticosteroids to 
the mother to prevent severe fetomaternal alloimmune thrombocytopenia (FMAIT). This 
pathology occurs when a woman becomes alloimmunised against fetal platelet antigens 
inherited from the father of the baby which are absent from the maternal platelets. The most 
common of them is anti-HPA-1 (Kaplan C. 2002). This condition is more frequent than is 
often realised since it occurs in about 1 in 1200 births (Mueller EC. 1985 - Blanchette VS 1990 – 
Kaplan C. 1994). The main complication of this disease is bleeding which may have severe 
consequences such as fetal intracranial haemorrhage (ICH) resulting in death or long-term 
disability (Montemagno R. 1994). Unlike red cell alloimmunisation, this disease often affects 
the first pregnancy, possibly due to the presence of the antigens in the trophoblast. The risk 
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of recurrence in subsequent pregnancies with increasing severity is very high being 50-100% 
depending on the zygocity of the father for the relevant antigen (Murphy MF. 2000). Bussel 
(Bussel JB. 1996) demonstrated that treatment with IVIg produced an increase in the platelet 
count of fetuses with alloimmune thrombocytopenia and observational studies have 
suggested an improvement in clinical outcome and reduction in the risk for intracranial 
haemorrhage when IVIg is administered to the mother throughout pregnancy (Rayment R. 
2005). Maternal therapy with IVIg may result in a fetal platelet count exceeding 50 x 109/l in 
67% of pregnancies with a history of sibling affected by FMAIT (Birchall JE. 2003), reducing 
the need of FBS and transfusions avoiding the complications of this technique. Although, 
the optimal management of FMAIT remains unclear and further trials would be required to 
determine optimal treatment for this condition. (Rayment R.2011) 
In recent years, observational studies have indicated a relationship between antenatal 
treatment with magnesium sulfate in preeclampsia and preterm deliveries, and a 
consequent decrease in cerebral palsy in preterm infants with low birth weight (Nelson KB. 
1995 – Hirtz DG. 1998). Many randomized controlled trials have been conducted to examine 
this association. Recent meta-analysis conclude that the use of magnesium sulfate 
administered to patients at risk of preterm delivery before 34 weeks reduces the risk of 
cerebral palsy and gross motor dysfunction, without increase in pediatric mortality 
(Costantine M. 2009 - Conde-Agudelo A. 2009 - Doyle LW. 2009). 
2.3 Therapy for fetal disease 
Fetal arrhythmias are good examples of pathologies which can be treated by therapeutic 
fetal drug administration. Although tachycardia (fetal ventricular heart rate faster than 180 
bpm.) is sometimes intermittent, the chance of hemodynamic complications and 
development of fetal hydrops remains high (Yasuki M. 2009). The indications for therapy 
may depend on its etiology, fetal age and disease severity (McElhinney DB. 2010 - Strasburger 
JF 2010). For intermittent tachycardia, treatment is generally unnecessary, unless hydrops or 
cardiac dysfunction is evident. In preterm fetuses, sustained tachycardia should probably be 
treated regardless of cardiac dysfunction or hydrops, because these sequelae can develop 
rapidly (McElhinney DB. 2010). When the patient presents with hydrops most arrhythmias 
can often be controlled with transplacental treatment, but the mortality in this group 
remains quite high (Conde-Agudelo A. 2009).  
Over the years, most antiarrhythmic agents have been used to treat fetal supraventricular 
tachycardia (McElhinney DB. 2010) and most fetuses are successfully treated in utero by 
transplacental administration of antiarrhythmic drugs (Yasuki M. 2009). Digoxin is widely 
accepted as a first-line antiarrhythmic drug. Sotalol, flecainide and amiodarone are used as 
second-line drugs when digoxin fails to achieve conversion to sinus rhythm (Yasuki M. 2009 
- McElhinney DB. 2010). For fetuses with hydrops, digoxin is rarely effective (Yasuki M. 2009 
- McElhinney DB. 2010 - Strasburger JF 2010) because the placental transfer of the digoxin is 
limited. Hence, sotalol or flecainide, which have good placental transfer ability, should be 
used from the beginning of fetal treatment for hydrops. (Yasuki M. 2009 - McElhinney DB. 
2010 - Strasburger JF 2010) 
The safety of the mother is of great concern when managing fetal tachycardia, even after 
some studies did´nt find any serious effects in the mother (Simpson JM. 1998). 
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2.1 Therapies to improve the ability of the fetus to adapt to extra-uterine life  
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delivery, and the example most extensively studied and used is corticosteroids for lung 
maturity. Liggins was the first to describe this effect in 1969 (Liggins GC. 1969), and 40 years 
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P. 2004 – Onland W 2011). The effect of treatment is optimal if the baby is delivered more 
than 24 hours and less than seven days after the start of treatment (Crowley. 2004 – 
Bronwnfoot FC. 2008). Use of repeat corticosteroid courses is at the moment under review. 
Some studies have shown a potential benefit of weekly repeat courses of antenatal 
corticosteroids in the occurrence and severity of neonatal respiratory disease but the short-
term benefits are associated with a reduction in weight and head circumference, by the 
moment weekly repeated courses of steroids are not recommended (Bevilacqua E. 2010 - 
ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7). More studies are needed to 
assess the long term effect of repeated steroid exposure on the developing human brain 
(Bevilacqua E. 2010 - ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7 – Lamer P. 
2002 – Crowther CA. 2004). Some authors have suggested a role for corticosteroids in elective 
term cesarean in order to reduce the higher incidence of respiratory distress presented by 
this group compared with vaginal term deliveries; however more studies are needed to 
recommend this approach (Sotiriadis A. 2009). 
2.2 Preventative therapies 
A number of modalities have been studied over the years to try to prevent fetal serious 
disease that can lead to fetal death or serious long-term sequel in the child. An example of 
this strategy is the prevention of neural tube defects (NTDs). These conditions include open 
spina bifida, anencephaly and encephalocele, and complicate 1 or 2 every 1000 pregnancies 
in the UK (Abramsky L. 1999), and can be prevented by the administration of folic acid 
during pregnancy (MRC. 1991 - Czeizel AE. 1992). This is the first congenital malformation to 
be primarily prevented by pharmacological fetal therapy (RCOG 2003). In 1996, the US Food 
and Drug Administration, initiated folic acid fortification of flour and mean folate levels in 
the population improved with substantial decrease in the risk of NTDs (Koren G. 2002), this 
policy have been implemented in many countries (RCOG 2003). Recent studies demonstrate 
this protective role of folate for NTDs, showing a protective effect of daily folic acid 
supplementation in preventing the disease (RR 0.28, 95% CI 0.15 to 0.52), with a significant 
protective effect for recurrence (RR 0.32, 95% CI 0.17 to 0.60) (De-Regil LM. 2010). 
Another successful strategy is the maternal administration of IVIg and/or corticosteroids to 
the mother to prevent severe fetomaternal alloimmune thrombocytopenia (FMAIT). This 
pathology occurs when a woman becomes alloimmunised against fetal platelet antigens 
inherited from the father of the baby which are absent from the maternal platelets. The most 
common of them is anti-HPA-1 (Kaplan C. 2002). This condition is more frequent than is 
often realised since it occurs in about 1 in 1200 births (Mueller EC. 1985 - Blanchette VS 1990 – 
Kaplan C. 1994). The main complication of this disease is bleeding which may have severe 
consequences such as fetal intracranial haemorrhage (ICH) resulting in death or long-term 
disability (Montemagno R. 1994). Unlike red cell alloimmunisation, this disease often affects 
the first pregnancy, possibly due to the presence of the antigens in the trophoblast. The risk 
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of recurrence in subsequent pregnancies with increasing severity is very high being 50-100% 
depending on the zygocity of the father for the relevant antigen (Murphy MF. 2000). Bussel 
(Bussel JB. 1996) demonstrated that treatment with IVIg produced an increase in the platelet 
count of fetuses with alloimmune thrombocytopenia and observational studies have 
suggested an improvement in clinical outcome and reduction in the risk for intracranial 
haemorrhage when IVIg is administered to the mother throughout pregnancy (Rayment R. 
2005). Maternal therapy with IVIg may result in a fetal platelet count exceeding 50 x 109/l in 
67% of pregnancies with a history of sibling affected by FMAIT (Birchall JE. 2003), reducing 
the need of FBS and transfusions avoiding the complications of this technique. Although, 
the optimal management of FMAIT remains unclear and further trials would be required to 
determine optimal treatment for this condition. (Rayment R.2011) 
In recent years, observational studies have indicated a relationship between antenatal 
treatment with magnesium sulfate in preeclampsia and preterm deliveries, and a 
consequent decrease in cerebral palsy in preterm infants with low birth weight (Nelson KB. 
1995 – Hirtz DG. 1998). Many randomized controlled trials have been conducted to examine 
this association. Recent meta-analysis conclude that the use of magnesium sulfate 
administered to patients at risk of preterm delivery before 34 weeks reduces the risk of 
cerebral palsy and gross motor dysfunction, without increase in pediatric mortality 
(Costantine M. 2009 - Conde-Agudelo A. 2009 - Doyle LW. 2009). 
2.3 Therapy for fetal disease 
Fetal arrhythmias are good examples of pathologies which can be treated by therapeutic 
fetal drug administration. Although tachycardia (fetal ventricular heart rate faster than 180 
bpm.) is sometimes intermittent, the chance of hemodynamic complications and 
development of fetal hydrops remains high (Yasuki M. 2009). The indications for therapy 
may depend on its etiology, fetal age and disease severity (McElhinney DB. 2010 - Strasburger 
JF 2010). For intermittent tachycardia, treatment is generally unnecessary, unless hydrops or 
cardiac dysfunction is evident. In preterm fetuses, sustained tachycardia should probably be 
treated regardless of cardiac dysfunction or hydrops, because these sequelae can develop 
rapidly (McElhinney DB. 2010). When the patient presents with hydrops most arrhythmias 
can often be controlled with transplacental treatment, but the mortality in this group 
remains quite high (Conde-Agudelo A. 2009).  
Over the years, most antiarrhythmic agents have been used to treat fetal supraventricular 
tachycardia (McElhinney DB. 2010) and most fetuses are successfully treated in utero by 
transplacental administration of antiarrhythmic drugs (Yasuki M. 2009). Digoxin is widely 
accepted as a first-line antiarrhythmic drug. Sotalol, flecainide and amiodarone are used as 
second-line drugs when digoxin fails to achieve conversion to sinus rhythm (Yasuki M. 2009 
- McElhinney DB. 2010). For fetuses with hydrops, digoxin is rarely effective (Yasuki M. 2009 
- McElhinney DB. 2010 - Strasburger JF 2010) because the placental transfer of the digoxin is 
limited. Hence, sotalol or flecainide, which have good placental transfer ability, should be 
used from the beginning of fetal treatment for hydrops. (Yasuki M. 2009 - McElhinney DB. 
2010 - Strasburger JF 2010) 
The safety of the mother is of great concern when managing fetal tachycardia, even after 
some studies did´nt find any serious effects in the mother (Simpson JM. 1998). 
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Administration of antiarrhythmic drugs for intrauterine treatment may cause pro-
arrhythmia and threaten the mother. So ECG monitoring is recommended during dosage 
increase (Yasuki M. 2009). However, these complications are generally tolerable and 
reversible (Strasburger JF 2010). 
Although intrauterine treatment is very effective in fetuses with tachycardia, treatment after 
delivery is also very effective. Hence, decisions for which cases are treated in utero or 
postnatally is often difficult. So, it is important not to select postnatal treatment too quickly 
in premature gestation, even when the fetus has already developed hydrops (Yasuki M. 
2009). Once the tachycardia is converted to sinus rhythm, the hydrops will recover and the 
fetus can be delivered at term by vaginal birth. However, when the hydrops continues for 
more than 2 weeks without conversion of tachycardia, postnatal treatment is recommended 
(Yasuki M. 2009). 
The efficacy of prenatal treatment for fetal bradicardia (fetal ventricular heart rate is less 
than 100 bpm) is limited compared with treatment for fetal tachycardia. Approximately half 
of all cases are caused by associated congenital heart disease, and the remaining cases that 
have normal cardiac structure are often caused by maternal SS-A antibody (Yasuki M. 2009). 
Beta stimulants and steroids have been reported as effective transplacental treatments for 
fetal AV block (Yasuki M. 2009). But the utility of these drugs still controversial (McElhinney 
DB. 2010 - Strasburger JF 2010). Work is being done to develop leads and devices to improve 
fetal pacing (Strasburger JF 2010). 
3. Invasive procedure  
3.1 Transfusion therapy 
3.1.1 Red cell isoimmunisation 
Haemolytic disease of the fetus and newborn (HDFN) is due to maternal alloantibodies 
directed against paternally inherited antigens on fetal red cells and was a significant cause 
of fetal and neonatal morbidity and mortality until the introduction of anti- D 
immunoglobulin during pregnancy and shortly after delivery. However, it is still a major 
problem in affected pregnancies (Illanes S. 2008). 
Intrauterine blood transfusion of anaemic fetuses represents one of the great successes of 
fetal therapy. The first approach was intraperitoneal blood transfusion introduced in 1963 
by Liley (Liley AW. 1963). Subsequently Rodeck (Rodeck CH. 1981) described intravascular 
fetal blood transfusion (IVT) by needling of the chorionic plate or umbilical cord vessels 
under direct vision by fetoscopy. In 1982 Bang in Denmark (Bang J. 1982) started IVT by 
umbilical cord puncture under ultrasound guidance which is now widely used by an 
increasingly large number of centres. IVT has produced a marked improvement in survival 
of the anaemic hydropic fetus and can also prevent this complication from developing by 
treating anaemic non-hydropic fetuses where moderate or severe anaemia is detected 
noninvasively by Doppler ultrasonography on the basis of an increase in the peak velocity 
of systolic blood flow or time-averaged mean velocity in the middle cerebral artery (Mari G. 
2000 - Abdel-Fattah SA. 2002). 
The emphasis of current clinical management of HDFN is a non-invasive approach. This 
applies to the detection of fetuses at risk of HDFN with the use of cell-free fetal DNA in the 
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plasma of pregnant women for the determination of fetal RhD genotype which is now 
available as a service world-wide. In addition when a fetus is antigen positive, the follow-up 
of these fetuses is for the detection of moderate or severe anaemia non-invasively by 
Doppler ultrasonography. When anaemia is suspected, an invasive approach is required in 
order to perform an IVT which should only be attempted when the fetus needs transfusion. 
This approach reduces the iatrogenic conversion of mild to severe disease which occurred as 
a result of the previous management approaches and this change represents one of the 
genuine successes of fetal therapy (Illanes S. 2008). 
3.1.2 Transient aplastic anaemia (parvovirus) 
Parvovirus B19 accounts for about 25% of cases of nonimmune hydrops fetalis in 
anatomically normal fetuses (Hall J. 1994) as a result of fetal anaemia following tropism of 
B19 virus for erythroid precursor cells and the massive destruction of the infected erythroid 
cells and possibly myocarditis resulting in cardiac failure (Yaegashi N. 1999 - Von Kaisenberg 
CS. 2001). The mean gestational age of presentation of hydrops is 22 weeks but there are 
some reports of earlier presentation which might often be undiagnosed (Yaegashi N. 1998 - 
Sohan K. 2000).  
Also some have suggested it may be a cause of apparently unexplained late still birth 
(Norbeck O. 2002). The highest risk for a fetus developing hydrops is when maternal 
infection is before 20 weeks gestation probably due to the rapidly increasing red cell mass 
and short half-life of fetal red cells (Thein AT. 1998). Diagnostic techniques aim at detecting 
maternal antibodies or either viral particles or DNA by PCR in maternal serum, amniotic 
fluid or fetal blood (Von Kaisenberg CS. 2001). 
The fetal loss rate following maternal parvovirus infection is about 10% (PHLS. 1990) but 
this is much higher when hydrops develops, so management is by FBS for diagnosis of 
anaemia followed by transfusion if necessary (Soothill P. 1990). In fact, the rates of death 
among those who receive an intrauterine transfusion are significantly lower than among 
those who did not (Von Kaisenberg CS. 2001 - Fairley CK. 1995). However, consideration 
should be given to the high fetal loss rate in cases of hydrops after fetal blood sampling 
(Maxwell DJ. 1991). Fetal blood results in these cases show a negative Coomb’s test, anaemia, 
thrombocytopenia, and low reticulocyte count (Thein AT. 1998). If the reticulocyte count is 
high at the first transfusion this may indicate recovery already occurring and so a second 
transfusion may not be necessary. Usually FBS is repeated if hydrops returns or more 
recently when Doppler studies suggest worsening anaemia. 
In spite of some reports of hydrops due to fetal parvovirus infection resolving without 
treatment (Pryde PG. 1992 - Rodis JF. 1998), in our view if non-immune hydrops presents 
without obvious fetal malformations and anaemia is expected from the Doppler results, 
even if the mother does not give a clear history of parvovirus exposure, FBS should still be 
done urgently without waiting for maternal confirmatory tests and intra-uterine transfusion 
be done if there is evidence of severe fetal anaemia. 
In contrast with other causes of fetal anaemia and hydrops, fetal complications caused by 
hPV B19 have the potential to resolve as the fetus mounts its own immune response (Lamont 
R. 2011). So if other signs of fetal well-being are present, it might be possible to continue 
with conservative measurements (Lamont R. 2011). 
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Administration of antiarrhythmic drugs for intrauterine treatment may cause pro-
arrhythmia and threaten the mother. So ECG monitoring is recommended during dosage 
increase (Yasuki M. 2009). However, these complications are generally tolerable and 
reversible (Strasburger JF 2010). 
Although intrauterine treatment is very effective in fetuses with tachycardia, treatment after 
delivery is also very effective. Hence, decisions for which cases are treated in utero or 
postnatally is often difficult. So, it is important not to select postnatal treatment too quickly 
in premature gestation, even when the fetus has already developed hydrops (Yasuki M. 
2009). Once the tachycardia is converted to sinus rhythm, the hydrops will recover and the 
fetus can be delivered at term by vaginal birth. However, when the hydrops continues for 
more than 2 weeks without conversion of tachycardia, postnatal treatment is recommended 
(Yasuki M. 2009). 
The efficacy of prenatal treatment for fetal bradicardia (fetal ventricular heart rate is less 
than 100 bpm) is limited compared with treatment for fetal tachycardia. Approximately half 
of all cases are caused by associated congenital heart disease, and the remaining cases that 
have normal cardiac structure are often caused by maternal SS-A antibody (Yasuki M. 2009). 
Beta stimulants and steroids have been reported as effective transplacental treatments for 
fetal AV block (Yasuki M. 2009). But the utility of these drugs still controversial (McElhinney 
DB. 2010 - Strasburger JF 2010). Work is being done to develop leads and devices to improve 
fetal pacing (Strasburger JF 2010). 
3. Invasive procedure  
3.1 Transfusion therapy 
3.1.1 Red cell isoimmunisation 
Haemolytic disease of the fetus and newborn (HDFN) is due to maternal alloantibodies 
directed against paternally inherited antigens on fetal red cells and was a significant cause 
of fetal and neonatal morbidity and mortality until the introduction of anti- D 
immunoglobulin during pregnancy and shortly after delivery. However, it is still a major 
problem in affected pregnancies (Illanes S. 2008). 
Intrauterine blood transfusion of anaemic fetuses represents one of the great successes of 
fetal therapy. The first approach was intraperitoneal blood transfusion introduced in 1963 
by Liley (Liley AW. 1963). Subsequently Rodeck (Rodeck CH. 1981) described intravascular 
fetal blood transfusion (IVT) by needling of the chorionic plate or umbilical cord vessels 
under direct vision by fetoscopy. In 1982 Bang in Denmark (Bang J. 1982) started IVT by 
umbilical cord puncture under ultrasound guidance which is now widely used by an 
increasingly large number of centres. IVT has produced a marked improvement in survival 
of the anaemic hydropic fetus and can also prevent this complication from developing by 
treating anaemic non-hydropic fetuses where moderate or severe anaemia is detected 
noninvasively by Doppler ultrasonography on the basis of an increase in the peak velocity 
of systolic blood flow or time-averaged mean velocity in the middle cerebral artery (Mari G. 
2000 - Abdel-Fattah SA. 2002). 
The emphasis of current clinical management of HDFN is a non-invasive approach. This 
applies to the detection of fetuses at risk of HDFN with the use of cell-free fetal DNA in the 
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plasma of pregnant women for the determination of fetal RhD genotype which is now 
available as a service world-wide. In addition when a fetus is antigen positive, the follow-up 
of these fetuses is for the detection of moderate or severe anaemia non-invasively by 
Doppler ultrasonography. When anaemia is suspected, an invasive approach is required in 
order to perform an IVT which should only be attempted when the fetus needs transfusion. 
This approach reduces the iatrogenic conversion of mild to severe disease which occurred as 
a result of the previous management approaches and this change represents one of the 
genuine successes of fetal therapy (Illanes S. 2008). 
3.1.2 Transient aplastic anaemia (parvovirus) 
Parvovirus B19 accounts for about 25% of cases of nonimmune hydrops fetalis in 
anatomically normal fetuses (Hall J. 1994) as a result of fetal anaemia following tropism of 
B19 virus for erythroid precursor cells and the massive destruction of the infected erythroid 
cells and possibly myocarditis resulting in cardiac failure (Yaegashi N. 1999 - Von Kaisenberg 
CS. 2001). The mean gestational age of presentation of hydrops is 22 weeks but there are 
some reports of earlier presentation which might often be undiagnosed (Yaegashi N. 1998 - 
Sohan K. 2000).  
Also some have suggested it may be a cause of apparently unexplained late still birth 
(Norbeck O. 2002). The highest risk for a fetus developing hydrops is when maternal 
infection is before 20 weeks gestation probably due to the rapidly increasing red cell mass 
and short half-life of fetal red cells (Thein AT. 1998). Diagnostic techniques aim at detecting 
maternal antibodies or either viral particles or DNA by PCR in maternal serum, amniotic 
fluid or fetal blood (Von Kaisenberg CS. 2001). 
The fetal loss rate following maternal parvovirus infection is about 10% (PHLS. 1990) but 
this is much higher when hydrops develops, so management is by FBS for diagnosis of 
anaemia followed by transfusion if necessary (Soothill P. 1990). In fact, the rates of death 
among those who receive an intrauterine transfusion are significantly lower than among 
those who did not (Von Kaisenberg CS. 2001 - Fairley CK. 1995). However, consideration 
should be given to the high fetal loss rate in cases of hydrops after fetal blood sampling 
(Maxwell DJ. 1991). Fetal blood results in these cases show a negative Coomb’s test, anaemia, 
thrombocytopenia, and low reticulocyte count (Thein AT. 1998). If the reticulocyte count is 
high at the first transfusion this may indicate recovery already occurring and so a second 
transfusion may not be necessary. Usually FBS is repeated if hydrops returns or more 
recently when Doppler studies suggest worsening anaemia. 
In spite of some reports of hydrops due to fetal parvovirus infection resolving without 
treatment (Pryde PG. 1992 - Rodis JF. 1998), in our view if non-immune hydrops presents 
without obvious fetal malformations and anaemia is expected from the Doppler results, 
even if the mother does not give a clear history of parvovirus exposure, FBS should still be 
done urgently without waiting for maternal confirmatory tests and intra-uterine transfusion 
be done if there is evidence of severe fetal anaemia. 
In contrast with other causes of fetal anaemia and hydrops, fetal complications caused by 
hPV B19 have the potential to resolve as the fetus mounts its own immune response (Lamont 
R. 2011). So if other signs of fetal well-being are present, it might be possible to continue 
with conservative measurements (Lamont R. 2011). 
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3.2 Amniotic fluid management  
Amniotic fluid surrounds the fetus in intrauterine life providing a protected, low-resistance 
space suitable for fetal movements, growth and development. Disturbance of the balance 
between amniotic fluid production and consumption leads to oligo- or polyhydramnios, 
both of which are associated with poor perinatal outcome related to the degree of fluid 
volume change (Chamberlain PF. 1984). 
Severe polyhydroamnios can cause maternal abdominal discomfort, respiratory 
embarrassment and preterm delivery (Kyle PM. 1997 – Phelan JP. 1990). Amniotic fluid 
reduction can relieve maternal symptoms with severe polyhydramnios and prolong the 
gestation in both singleton and multiple pregnancies and is one of the possible treatments 
for TTTS (Kyle PM. 1997 - Wee LY. 2002). Abruption can be a complication of removal of 
large volumes of amniotic fluid and this risk has been estimated at about 3-4% (Leung WC. 
2004). Common criteria for amniotic fluid drainage are AFI > 40 cm or the deepest single 
pool of >12 cm but many prefer to make the decision mostly on maternal discomfort (Thein 
AT. 1998). Removal of a small volume can rapidly reduce amniotic fluid pressure but it 
usually re-accumulates quickly and approximately 1 litre needs to be removed for every 
10cm the AFI is elevated (Kyle PM. 1997 - Abdel-Fattah SA. 1999). The procedure often has to 
be repeated in order to prolong gestational age until maturity allows delivery. The insertion 
of a tube to achieve chronic long-term drainage has been tried in the past but there is a high 
risk of infection and no evidence supporting this approach. 
Oligohydramnios is found in 3-5% of pregnancies in the third trimester, but severe cases 
relating to impaired outcome are less common (Kyle PM. 1997). The significance of this 
finding relates mostly to the underlying cause, so the prognosis and the possibility of 
treatment depends on the aetiology. Attempts at therapy focus on restoring the amniotic 
fluid to allow continue development of the lungs during the canalicular phase. Quintero et 
al (Quintero RA. 1999) described effective resealing in cases of iatrogenic previable PPROM 
by intra-amniotic injection of platelets and cryoprecipitate although this approach has not 
been reported to work after spontaneous membrane rupture. Some reports have also shown 
that in pregnancies with preterm premature rupture of membranes (PPROM) with 
oligohydramnios at <26 weeks' gestation, serial amnioinfusions improve the perinatal 
outcome when compared to those with persistent oligohydramnios (Locatelli A. 2000 - De 
Santis M. 2003). Fisk et al have recently described an amnioinfusion test procedure to try 
and pre-select cases of midtrimester PPROM which may benefit from serial amnioinfusion. 
A quarter of patients who retained infused fluid went on to subsequent serial amnioinfusion 
and prolongation of pregnancy with decrease in the risk of pulmonary hypoplasia (Tan LK. 
2003). However, there are risks of procedure related complications such as chorioamnionitis, 
placental abruption and extreme prematurity, so ideally a large series in a prospectively 
randomised trial would be needed to assess the benefits. 
Amnioinfusion has also been used to prevent or relieve variable decelerations from 
umbilical cord compression in cases of rupture of membranes and to dilute meconium when 
present in the amniotic fluid and so reduce the risk of meconium aspiration during labour. 
A Cochrane review found that amnioinfusion for oligohydramnios helps when the baby 
shows signs of distress. If the baby shows no signs of distress from oligohydramnios, then 
amnioinfusion is not helpful. So there is no role for prophylactic amnioinfusion (Novikova N. 
1996). Another studies shows improvements in perinatal outcome when it is used to dilute 
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meconium, only in settings where facilities for perinatal surveillance are limited (Xu H. 2007 
- Hofmeyr GJ. 2010). 
3.3 Shunting 
3.3.1 Pleuro-amniotic shunting  
A pleural effusion may be an isolated finding or may occur in association with hydrops 
fetalis. When severe, this condition can produce hydrops, pulmonary hypoplasia by lung 
compression and polyhydramnios with secondary risks of preterm delivery (Phelan JP. 
1990). When due to a reversible cause such as chylothorax, the treatment of this condition by 
pleuro-amniotic shunting can be a very effective method (Sohan K. 2001) and can reverse the 
complications and prevent death. However, drainage does not help cases in which the 
pleural effusion is caused by an underlying progressive disease, or when the effusions are 
mild and so will not produce secondary effects or when the problem is diagnosed so late 
that pulmonary hypoplasia has already occurred and is irreversible.  
When making the difficult decision of whether or not to shunt, the risks of thoracoamniotic 
shunting must be considered. The recommendation is that large pleural effusions, especially 
those with hydropic changes, should be seen urgently in a center that can offer tertiary level 
ultrasound examination, aspiration and shunting because, with appropriate treatment, 50% 
of fetuses survive (Smith RP. 2005). Recently Yinon et al. conducted a retrospective study of 
88 fetuses with large pleural effusions who underwent pleuroamniotic shunting, to evaluate 
perinatal outcome associated to the procedure. They concluded that carefully selected 
fetuses with primary pleural effusions can benefit from pleuroamniotic shunting, allowing 
hydrops to resolve with a survival rate of almost 60% (Yinon Y. 2010). 
Another approach for management of fetal chylothorax that is under evaluation is the use of 
pleurodesis with OK-432. First case-reports about its utility where published in 2001 revealing 
rapid and effective control of pleural effusion (Tanemura M. 2001 – Okawa T 2001). A posterior 
review conducted by Chen et al. pooled a total of 9 cases, concluding that the success of the 
procedure depends on the complete aspiration of the pleural cavity and the demonstration of 
adhesions by ultrasonography following the procedure (Chen M. 2005). A recent report 
published last year, that included a total of 45 cases show that this treatment is only useful in 
those cases without hydrops, converting the use of OK-432 pleurodesis in a plausible 
alternative to the classic management with thoracoamniotic shunting (Yang YS. 2011). 
3.3.2 Vesico-amniotic shunting 
Lower urinary tract obstruction has a significant impact on perinatal morbidity and 
mortality, related principally to pulmonary hypoplasia and renal impairment that produce 
at least a 40% of mortality (Nakayama DK. 1986 - Freedman AL. 1996). Animal models of 
releasing obstruction have been very successful but these models are often different from 
human congenital urinary tract obstruction (Agarwal SK. 2001). The insertion of a double 
pig-tailed vesico-amniotic catheter is the most commonly used method to relieve this 
obstruction in vivo but complications are quite common, including failure of drainage or 
migration of the shunt, premature labour, urinary ascites, chorioamnionitis and iatrogenic 
gastroschisis (Coplen DE. 1997). The main concern about vesico-amniotic shunting is that by 
the time severe obstructive uropathy is detected, renal function may be already severely and 
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3.2 Amniotic fluid management  
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irreversibly damaged (Freedman AL. 1996). Needle drainage has been used to obtain an 
assessment of renal function and helping to identifying fetuses with potential to benefit 
from in uterus surgical intervention (Agarwal SK. 2001). Sometimes needle aspiration can 
appear to be therapeutic for megacystis in very early in the second trimester perhaps as a 
result of releasing urethral oedema secondary to pressure (Carroll SG. 2001).  
Recent data about antenatal bladder drainage appears to improve perinatal survival in cases 
of congenital lower urinary tract obstruction, but may confer a high residual risk of poor 
postnatal renal function, based on observational studies (Morris RK. 2010). Currently, a 
clinical trial (PLUTO trial) comparing conservative management to vesicoamniotic shunting 
in singleton fetuses below 28 weeks gestation with isolated bladder outflow obstruction is at 
development (PLUTO trial. 2007). 
3.4 Laser treatment 
Monochorionic (MC) twins account for 20% of spontaneous twin pregnancies and almost 5% 
occur as a result of medically assisted reproduction (Chalouhi GE. 2011). Twin-twin 
transfusion syndrome (TTTS) affects 10% to 15% of monozygous twin pregnancies with 
monochorionic placentation (Chalouhi GE. 2011 - Sebire NJ. 1997 - Carroll SG. 2002).  
Without treatment, there is a very high risk of perinatal mortality and perinatal morbidity 
due to preterm delivery but also as a result of acquired brain injury in utero (Denbow ML. 
1998). When TTTS is of early onset, the prognosis is even worse and interruption of the 
vascular anastomosis by fetoscopic laser ablation is a sensible treatment that has been 
used since the beginning of the 1990s (De Lia JE 1990). TTTS management has 
encompassed non-specific, sometimes symptomatic, treatments including 
amnioreduction, septostomy and even expectant management. To date, the only treatment 
addressing the pathophysiology of the syndrome is fetoscopic selective laser coagulation 
of placental vessels (SLCPV) (Chalouhi GE. 2011). 
With this treatment, in a third of pregnancies both twins survive, in another third one twin 
survives and in the remaining third both twins die (Ville Y. 1995). The recently published 
Eurofetus study showed that laser therapy is associated with improved perinatal outcome 
compared with amnioreduction in women presenting with TTTS before 26 weeks’ gestation 
(Senat MV. 2004). To improve these results we need better ways of identifying all arterial-
venous (A-V) anastomoses before ablation, which will enable a true rendering into a DC 
placenta with minimal destruction of viable placental territory. There have been some 
attempts of delineating placental vascular anatomy in utero with contrast agents and power 
Doppler but without clear success (Denbow ML. 2000). 
Laser ablation has also been used successfully to treat acardiac twin pregnancies that 
complicate 1% of monozygous twin pregnancies with monochorionic placentation (Moore 
TR. 1990) and are associated with congestive cardiac failure in the pump twin leading to 
polyhydramnios and preterm delivery with a reported perinatal mortality in untreated cases 
as high as 55% (Tan TY. 2003). Laser or diathermy ablation is used to occlude the cord or the 
pelvic vessels within the abdomen of the acardiac twin (Rodeck C. 1998 - Soothill P. 2002). A 
recent review suggests that intrafetal ablation is the treatment of choice for acardiac twins 
because it is simpler, safer and more effective when compared with the cord occlusion 
techniques (Soothill P. 2002). 
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3.5 Fetoscopic / Open fetal surgery 
Although most malformations diagnosed prenatally are best managed after birth, a few 
severe ones may be better treated before birth. The fetal malformations that warrant 
consideration for open surgical correction in uterus are those that interfere with normal 
growth, development and are life-threatening, so that correction of the defect may prevent 
these effects. At present, only a few malformations have been successfully corrected, 
including fetal myelomeningocele (MMC) and congenital diaphragmatic hernia (CDH). 
3.5.1 Hydrocephaly and neural tube defects 
Fetal MMC can produce (Johnson MP. 2003) obstructive hydrocephalus in up to 85% of cases 
requiring ventriculoperitoneal shunting. MMC can have other long term sequelae such as 
motor impairment of the legs and loss of bowel and bladder control.  The damage may be 
due to the defect in the bony spinal column exposing the spinal cord to the trauma from the 
amniotic fluid and the uterine environment (Evans MI. 2002) raising the possibility of 
covering the spinal cord in the uterus to avoid the damage. The accumulated experience 
with fetal MMC repair has been encouraging and suggests a decreased need for 
ventriculoperitoneal shunting, arrest or slowing of progressive ventriculomegaly, and 
consistent resolution of hindbrain herniation in the short term follow up (Johnson MP. 2003). 
However, further long-term follow-up is needed to evaluate neurodevelopment and bladder 
and bowel function. Since 2003 the MOMS trial is recruiting patients to assess the better 
management for these cases. So most centres still await for result before recommend the 
clinical intervention (Luks FI. 2011). 
3.5.2 Congenital diaphragmatic hernia 
Congenital diaphragmatic hernia has a high mortality rate, and many clinical and 
experimental efforts have been made in order to reduce it. Open fetal repair of the 
diaphragmatic defect was attempted but with an unacceptable high mortality rate and so 
has been abandoned (Evans MI. 2002). Fetoscopic temporary tracheal occlusion, have emerge 
as an alternative to open fetal surgery on the basis that the accumulation of lung fluid 
secretions can expand the lungs and so reduce the herniated viscera and avoid pulmonary 
hypoplasia. This approach may improve lung growth and development (Sydorak RM. 2003); 
however, complications related to tracheal dissection, premature delivery and late 
morbidity are significant (Deprest J. 2004). New techniques have been proven in 
experimental stage with less invasive approach but most studies have felt to prove any 
improvement of survival or morbidity rates when compared intrauterine fetal endoscopic 
tracheal occlusion approach with optimal postnatal care. However, there is a small group of 
extremely severe cases that could benefit from prenatal intervention (Luks FI. 2011). 
The exact definition of this subgroup of patients is still being debated. In 2003 Harrison et al. 
Correlated survival rates with lung-to-head ratio (LHR). Using this ratio good prognosis 
(100% survival) was associated with an LHR > 1.4. Poor prognosis (less than 30% survival) 
was associated with an LHR < 1.0 (Harrison MR. 2003). 
Actually, a RCT of Luks et al. is recruiting patients to evaluate the benefits of fetal tracheal 
occlusion with a detachable balloon for an LHR < 0.9 (Luks FI. 2008). 
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4. Interventions in experimental stages 
4.1 Ablation of tumours 
Some tumours may growth to massive proportion in uterus, inducing high-output failure 
leading to fetal hydrops that end most uniformly in fetal demise. Fetal sacrococcygeal 
teratoma is a good example of this and surgery may have a role before the onset of hydrops 
in order to avoid this complication or after in order to resolve it (Luks FI. 2011). Ablation of 
the majority of the tumour tissue is not usually necessary and perhaps only ligation or 
coagulation of the vascular steal can reverse or avoid the high-output fetal heart failure (Paek 
BW. 2001). Open fetal surgery with a high incidence of technique related complications has 
been moving to less invasive approach such as radiofrequency ablation and fetoscopic 
resection (Hirose S. 2003) but more studies are needed to assess the impact of these types of 
managements and what groups of fetus benefit from them. With cervical teratomas another 
possibility for tracheal obstruction can be the EXIT procedure where the fetus is partially 
delivered, maintaining the uteroplacental circulation in order to perform the surgery and 
achieve adequate ventilation (Murphy DJ. 2001). 
4.2 Stem cell transplantation 
At the present time, the most likely and eminent application of stem cell therapy to the 
fetus is in utero hematopoietic stem cell transplantation (Matthew T. 2009). Bone marrow 
transplantation of normal haematopoietic stem cells can sustain normal haemopoeisis and 
be an alternative in treatment of lethal haematological disease. In the case of congenital 
disease like haemoglobinopathies, immunodeficiency disorders and inborn errors of 
metabolism that can be diagnosed prenatally and cured or improved by the engraftment 
of normal stem cells are theoretically an attractive alternative for the in utero 
transplantation of stem cells (Evans MI. 2002). The unique characteristic of the 
hematologic and inmunologic system in the human fetus, could circumvent the postnatal 
problems of transplantation, such as graft-verus-host disease, and the remarkable ability 
of stem cells to proliferate, differentiate and become tolerant to host antigens are 
encouraging. However, most research on stem cell therapy to date has focused on 
disorders of old age that are not genetic. So, very little is known about the disorders that 
can occur in utero and how stem cells might be of benefit (Mummery C. 2011). Finally, 
there is a small amount of evidence about safety and effectiveness in animals for transfer 
of treatment to fetuses at the present time (Mummery C. 2011). 
4.3 Gene therapy  
The goal of gene therapy is to treat disease before damage secondary to the gene pathology 
is produce. Fetal gene therapy for many disorders already has been demonstrated in rodent 
and large animal models (Matthew T. 2009). Some reports show that using a percutaneous 
ultrasound-guided injection of gene transfers in the airway or in the amniotic cavity in 
animal, provided levels of gene expression in lung and intestine that could be relevant for a 
therapeutic application (David A. 2003 - Garrett DJ. 2003). In spite of the large amount of 
experimentation already made in this field, today we are still unsure whether or not this 
technique will provide the desired therapeutic effect and whether expression of the 
transferred genes will provide real clinical benefit (Matthew T. 2009). Safety concerns need to 
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be investigated extensively in appropriate preclinical animal models before application in 
humans. The ethics of fetal gene therapy also need to be considered. 
5. Conclusions 
Much has been achieved in the prevention, diagnosis and management of fetal pathology. 
This has allowed the development of interventions that have proven to be beneficial and 
safe for both fetus and mother. However, much remains to be investigated. The rapid 
progress in molecular and genetic research continues to be promising. However, the ethical 
and moral implications associated constitute a very important point that should not be 
omitted. 
This article is a review of the evidence available at the time of publication and at no stage 
intended to be the basis for decision making and behaviours in particular cases, were 
different variables have to be pondered that exceed the scope of this chapter. It is the duty of 
the specialists to inform their patients and taking into account all the edges and risk for each 
management.  
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technique will provide the desired therapeutic effect and whether expression of the 
transferred genes will provide real clinical benefit (Matthew T. 2009). Safety concerns need to 
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be investigated extensively in appropriate preclinical animal models before application in 
humans. The ethics of fetal gene therapy also need to be considered. 
5. Conclusions 
Much has been achieved in the prevention, diagnosis and management of fetal pathology. 
This has allowed the development of interventions that have proven to be beneficial and 
safe for both fetus and mother. However, much remains to be investigated. The rapid 
progress in molecular and genetic research continues to be promising. However, the ethical 
and moral implications associated constitute a very important point that should not be 
omitted. 
This article is a review of the evidence available at the time of publication and at no stage 
intended to be the basis for decision making and behaviours in particular cases, were 
different variables have to be pondered that exceed the scope of this chapter. It is the duty of 
the specialists to inform their patients and taking into account all the edges and risk for each 
management.  
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This book provides detailed and comprehensive coverage on various aspects of prenatal 
diagnosis-with particular emphasis on sonographic  and  molecular diagnostic issues. 
It features sections dedicated to fundamentals of clinical, ultrasound and genetics  
diagnosis of human diseases, as well as current and future health strategies related to 
prenatal diagnosis.  This book highlights the importance of utilizing fetal ultrasound/
clinical/genetics  knowledge to promote and achieve optimal health in fetal medicine. 
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